Version 2.023 Oct 2026
release b1a4cda · 431 links · 431 changed
Chronic Disease Evidence Explorer v2.0: grading reform
Grade names changed on 255 links (Convincing to Strong, Probable to Moderate, Limited to Weak, Contested to Conflicting). The rows below list only changes of level.
Disease renamed: Major depression to Depression.
Disease renamed: Osteoporotic fracture to Fracture in adults.
Disease renamed: Chronic low back pain to Back pain.
Grade moves: 54 Probable to Suggestive; 16 Suggestive to Weak; 10 Convincing to Moderate; 2 Limited to Suggestive; 1 Probable to Weak; 1 Suggestive to Moderate.
Rows by field: Measure 431, Estimate source 431, Estimate design 431, Outcome match 431, Outcome measured 431, Trial and genetic evidence 431, Score (ESS) 289, Effective reviews (N_eff) 202, Reviews counted 184, Grade basis 173, Sources 121, Grade 84, Related outcome 75, Adjudicating bodies 64, External grades 50, Grade override 40, Conflict 24, Rests on primary studies 21, Studies 21, I-squared 6, Caveat 6, Estimate 4, Interval, lower 4, Interval, upper 4, Comparison 4, Comparison type 4, Quoted sentence 4, ci_low_exact 3, Mediation note 1.
Standard reasons in this release. The fields below carry the same reason on every link. The CSV repeats it on each row.
Measure. Added in version 2.0: the measure behind the estimate (RR, HR, OR, SMR or rate ratio) is stored and shown beside it. Framework section 3.3.
Estimate source. Added in version 2.0: the source that carries the displayed estimate is recorded. Rules T4 and T5 and the counting rule read it. Framework section 7.
Estimate design. Added in version 2.0: the design behind the displayed estimate is recorded. Rules T4, T5a to T5d and the Mendelian randomisation position read it. Framework section 7.
Score (ESS). The score is recomputed from the estimate, the effective review number (N_eff) and the grade weight: 100 x M x R x C. Framework section 3.4.
Trial and genetic evidence. Version 2.0 stores trial and genetic evidence as records with their sources and the checks "same exposure" and "same outcome". Rules T2, T3, C1 and C3 read them. The status of each is unchanged. Framework section 9.
Adjudicating bodies. Added in version 2.0: the bodies that rated this pair are recorded, with whether each rating matches this pair. Rules T3, T4 and T9 read them. Framework section 10.2.
External grades. Added in version 2.0: ratings of this pair by outside systems are recorded. Rule T11 reads them. Framework section 3.2.3.
Conflict. Added in version 2.0: the two sides of the disagreement and their sources are recorded for a Conflicting link. Rule C2 reads them. Framework section 3.2.3.
Score (ESS). A link in the related-outcome layer carries no score. Framework section 6.4.
Current cigarette smoking → Coronary heart disease
smoking|chd
| Field | Before | After |
| Reviews counted | 9 | 2 |
| Effective reviews (N_eff) | 7 | 1.58 |
| Score (ESS) | 48.1 | 27.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources smoking_mr_levin smoking_cvd_mr_larsson); dose-response yes |
| New fields | not recorded before | Measure HR Estimate source smoking_chances Estimate design pooled IPD Outcome match exact Outcome measured acute coronary events (heart attack or coronary death) Adjudicating bodies bprf_smoking: rates this pair (star rating not recorded on the link) |
Outcome match, Outcome measured: The estimate measures: acute coronary events (heart attack or coronary death). measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoking_chances (weight 1.0), bprf_smoking (weight 0.58). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Former smoking → Coronary heart disease
former_smoking|chd
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source smoking_chances Estimate design pooled IPD Outcome match exact Outcome measured acute coronary events (heart attack or coronary death) Grade override Moderate. Accepted by the verifier: an individual-participant analysis of cohorts (CHANCES) with a gradient by time sinc…Moderate. Accepted by the verifier: an individual-participant analysis of cohorts (CHANCES) with a gradient by time since quitting. T9b proposes Suggestive because z is 3.0, on the line. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. |
Outcome match, Outcome measured: The estimate measures: acute coronary events (heart attack or coronary death). measured_outcome
Grade override: Curator override to Moderate: Accepted by the verifier: an individual-participant analysis of cohorts (CHANCES) with a gradient by time since quitting. T9b proposes Suggestive because z is 3.0, on the line. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT9b
Reviews counted: Counted from the cited syntheses under the review-counting rule: smoking_chances (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Secondhand smoke → Coronary heart disease
shs|chd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.64 |
| Score (ESS) | 8.1 | 11.5 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source shs_fischer Estimate design cohort synthesis Outcome match exact Outcome measured ischaemic heart disease Grade basis G9 applies: two bodies rate the pair differently. Burden of Proof: two stars (evidence weak; conservative lower bound ab…G9 applies: two bodies rate the pair differently. Burden of Proof: two stars (evidence weak; conservative lower bound about 8%). The US Surgeon General (2006) judged the evidence sufficient to infer a causal relationship. The curator grades it and names both bodies. The pooled IHD estimate is 1.27 (1.10-1.48). Moderate. The 2006 report was not read, so its wording is not quoted here. Grade override Moderate. Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. Two bodies r…Moderate. Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. Two bodies rate the pair differently (card G9): Burden of Proof gives two stars, and the US Surgeon General (2006) judged the evidence sufficient to infer a causal relationship. The text of the 2006 report was not read. Adjudicating bodies bprf_shs: 2 stars External grades Burden of Proof 2 stars (bprf_shs) |
Outcome match, Outcome measured: The estimate measures: ischaemic heart disease. measured_outcome
Grade basis, Grade override: Curator override to Moderate: Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. Two bodies rate the pair differently (card G9): Burden of Proof gives two stars, and the US Surgeon General (2006) judged the evidence sufficient to infer a causal relationship. The text of the 2006 report was not read. G9 applies: two bodies rate the pair differently. Burden of Proof: two stars (evidence weak; conservative lower bound about 8%). The US Surgeon General (2006) judged the evidence sufficient to infer a causal relationship. The curator grades it and names both bodies. The pooled IHD estimate is 1.27 (1.10-1.48). Moderate. The 2006 report was not read, so its wording is not quoted here. grade_override and grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: shs_fischer (weight 1.0), bprf_shs (weight 0.64). reviews_counted
Smokeless tobacco → Coronary heart disease
smokeless_tobacco|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | smokeless_boffetta gbd2021rf | smokeless_boffetta |
| New fields | not recorded before | Measure RR Estimate source smokeless_boffetta Estimate design cohort synthesis Outcome match narrower Outcome measured fatal myocardial infarction only Grade basis Suggestive: the estimate covers fatal heart attack only, for ever use of Swedish and US products (review note). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: fatal myocardial infarction only. measured_outcome
Grade basis: Suggestive: the estimate covers fatal heart attack only, for ever use of Swedish and US products (review note). Kept by the verifier. grade_basis
Sources: 21 Oct 2026 grading reform v2.0: outcome_match narrower, measured outcome recorded (cards O1 and O5). estimate_source smokeless_boffetta, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). grade_basis records why the grade stands (card G3) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): gbd2021rf removed from the sources (blocker 6): the body does not rate this pair (adjudication pair_match false), so it cannot count as a replication synthesis either; its adjudication entry goes with it. corrections.json _whyT3T4
High blood pressure → Coronary heart disease
high_sbp|chd
| Field | Before | After |
| Reviews counted | 8 | 4 |
| Effective reviews (N_eff) | 7 | 1.64 |
| Score (ESS) | 50.1 | 28.9 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) supportive; dose-response yes | Trial supportive (sources bpltt); Genetic (MR) supportive (sources lieb2013_bp_cad_mr); dose-response yes |
| Sources | metab_rf_singh psc_bp bop_sbp_ihd bpltt | metab_rf_singh psc_bp bop_sbp_ihd bpltt peters2013_sbp_stroke_ihd lieb2013_bp_cad_mr |
| New fields | not recorded before | Measure RR Estimate source metab_rf_singh Estimate design pooled IPD Outcome match exact Outcome measured ischaemic heart disease (pooled PSC and APCSC cohorts) Adjudicating bodies bop_sbp_ihd: 5 stars; bpltt: lowering blood pressure reduces coronary events in trials External grades Burden of Proof 5 stars (bop_sbp_ihd) |
Outcome match, Outcome measured: The estimate measures: ischaemic heart disease (pooled PSC and APCSC cohorts). measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: metab_rf_singh (weight 1.0), psc_bp (weight 0.0), peters2013_sbp_stroke_ihd (weight 0.0), bop_sbp_ihd (weight 0.64). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card K1): peters2013_sbp_stroke_ihd; the displayed estimate is unchanged. estimate_source metab_rf_singh, estimate_design pooled IPD, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). external_grades transcribed from the caveat, the review note or the quote (rule T11). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (lieb2013_bp_cad_mr) (card G11, blocker 4): Blood-pressure-raising variants raise coronary artery disease (Lieb 2013). hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _whyT3T4T11
Also changed in: 1.4 (19 Sep 2026)
High LDL cholesterol → Coronary heart disease
high_ldl|chd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.75 |
| Score (ESS) | 12.5 | 18.5 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) supportive; dose-response yes | Trial supportive (sources ctt); Genetic (MR) supportive (sources ference2012_ldl_chd_mr); dose-response yes |
| Sources | erfc_lipids ctt gbd2021rf | erfc_lipids ctt gbd2021rf ference2012_ldl_chd_mr |
| New fields | not recorded before | Measure HR Estimate source erfc_lipids Estimate design pooled IPD Outcome match exact Outcome measured CHD (non-fatal MI or fatal CHD) Adjudicating bodies ctt: lowering LDL cholesterol reduces coronary events in trials; gbd2021rf: rates this pair in GBD 2021 (star rating not recorded on the link) |
Outcome match, Outcome measured: The estimate measures: CHD (non-fatal MI or fatal CHD). measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: erfc_lipids (weight 1.0), gbd2021rf (weight 0.75). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source erfc_lipids, estimate_design pooled IPD, measure HR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (ference2012_ldl_chd_mr) (card G11, blocker 4): Lifelong lower LDL cholesterol through nine variants lowers coronary heart disease (Ference 2012). corrections.json _whyT3T4
Also changed in: 1.4 (9 Oct 2026)
High lipoprotein(a) → Coronary heart disease
high_lpa|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources clarke2009_lpa_chd kamstrup2009_lpa_mi); dose-response yes |
| Sources | erfc_lpa | erfc_lpa clarke2009_lpa_chd kamstrup2009_lpa_mi |
| New fields | not recorded before | Measure RR Estimate source erfc_lpa Estimate design pooled IPD Outcome match exact Outcome measured CHD |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source erfc_lpa, estimate_design pooled IPD, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (clarke2009_lpa_chd, kamstrup2009_lpa_mi) (card G11, blocker 4): LPA variants that raise lipoprotein(a) raise coronary disease (Clarke 2009; Kamstrup 2009). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
High triglycerides → Coronary heart disease
high_tg|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources do2013_tg_cad_mr); dose-response yes |
| Sources | erfc_lipids reduce_it | erfc_lipids reduce_it do2013_tg_cad_mr |
| New fields | not recorded before | Measure HR Estimate source erfc_lipids Estimate design pooled IPD Outcome match exact Outcome measured CHD Conflict Side A: A genetic analysis supports a causal role: variants that raise triglycerides raise coronary artery disease after…Side A: A genetic analysis supports a causal role: variants that raise triglycerides raise coronary artery disease after accounting for LDL and HDL cholesterol (Do 2013). Side B: A pooled analysis of 302,430 people found no independent association once HDL and non-HDL cholesterol were accounted for (hazard ratio 0.99, 0.94 to 1.05). Sources: erfc_lipids do2013_tg_cad_mr |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source erfc_lipids, estimate_design pooled IPD, measure HR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). conflict records both sides and their sources from the caveat and review note (rule C2, card G1) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (do2013_tg_cad_mr) (card G11, blocker 4): Triglyceride-raising variants raise coronary artery disease after accounting for LDL and HDL (Do 2013). 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): conflict.side_a rewritten to state the cited genetic analysis (Do 2013) and do2013_tg_cad_mr added to conflict.sources (issue 3, rule C2). corrections.json _whyC2
Also changed in: 1.4 (9 Oct 2026)1.3 (9 Sep 2026)
Type 2 diabetes (as a risk factor) → Coronary heart disease
t2d_exposure|chd
| Field | Before | After |
| Reviews counted | 7 | 3 |
| Effective reviews (N_eff) | 6 | 1.89 |
| Score (ESS) | 47.5 | 30.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources t2d_chd_mr_ahmad); dose-response yes |
| Sources | erfc_diabetes t2d_chd_mr_ahmad | erfc_diabetes t2d_chd_mr_ahmad peters2014_diabetes_chd huxley2006_diabetes_chd |
| New fields | not recorded before | Measure HR Estimate source erfc_diabetes Estimate design pooled IPD Outcome match exact Outcome measured CHD |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: huxley2006_diabetes_chd (weight 1.0), erfc_diabetes (weight 0.44), peters2014_diabetes_chd (weight 0.44). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card K1): peters2014_diabetes_chd, huxley2006_diabetes_chd; the displayed estimate is unchanged. estimate_source erfc_diabetes, estimate_design pooled IPD, measure HR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Prediabetes → Coronary heart disease
prediabetes|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source erfc_diabetes Estimate design pooled IPD Outcome match exact Outcome measured CHD Grade basis Suggestive: a modest 1.17 from one consortium, and fasting glucose adds little to risk prediction (review note). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Grade basis: Suggestive: a modest 1.17 from one consortium, and fasting glucose adds little to risk prediction (review note). Kept by the verifier. grade_basis
Also changed in: 1.4 (9 Oct 2026)
High body-mass index → Coronary heart disease
high_bmi|chd
| Field | Before | After |
| Reviews counted | 2 | 3 |
| Effective reviews (N_eff) | 1 | 2.01 |
| Score (ESS) | 10.6 | 17.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources larsson2020_bmi_cvd_mr dale2017_adiposity_mr); dose-response yes |
| Sources | erfc_adiposity psc_bmi gbd2021rf | erfc_adiposity psc_bmi gbd2021rf larsson2020_bmi_cvd_mr dale2017_adiposity_mr |
| New fields | not recorded before | Measure HR Estimate source erfc_adiposity Estimate design pooled IPD Outcome match exact Outcome measured CHD Adjudicating bodies gbd2021rf: rates this pair in GBD 2021 (star rating not recorded on the link) |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: psc_bmi (weight 1.0), erfc_adiposity (weight 0.29), gbd2021rf (weight 0.72). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source erfc_adiposity, estimate_design pooled IPD, measure HR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (larsson2020_bmi_cvd_mr, dale2017_adiposity_mr) (card G11, blocker 4): Genetically predicted BMI raises coronary disease (Dale 2017, OR 1.36 per SD; Larsson 2020). hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _whyT3T4
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Abdominal obesity → Coronary heart disease
central_adiposity|chd
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Score (ESS) | 7.7 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources emdin2017_whr_mr dale2017_adiposity_mr); dose-response yes |
| Sources | erfc_adiposity interheart | erfc_adiposity interheart emdin2017_whr_mr dale2017_adiposity_mr |
| New fields | not recorded before | Measure HR Estimate source erfc_adiposity Estimate design pooled IPD Outcome match broader Outcome measured cardiovascular disease Related outcome true |
Outcome match, Outcome measured, Related outcome: The estimate measures: cardiovascular disease. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: erfc_adiposity (weight 1.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source erfc_adiposity, estimate_design pooled IPD, measure HR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (emdin2017_whr_mr, dale2017_adiposity_mr) (card G11, blocker 4): Genetically predicted waist-to-hip ratio raises coronary heart disease (Dale 2017, OR 1.48 per SD; Emdin 2017). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Metabolic syndrome → Coronary heart disease
metabolic_syndrome|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | metsyn_mottillo gbd2021rf | metsyn_mottillo |
| New fields | not recorded before | Measure RR Estimate source metsyn_mottillo Estimate design cohort synthesis Outcome match narrower Outcome measured myocardial infarction |
Outcome match, Outcome measured: The estimate measures: myocardial infarction. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match narrower, measured outcome recorded (cards O1 and O5). estimate_source metsyn_mottillo, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): gbd2021rf removed from the sources (blocker 6): the body does not rate this pair (adjudication pair_match false), so it cannot count as a replication synthesis either; its adjudication entry goes with it. corrections.json _whyT3T4
Low physical activity → Coronary heart disease
low_pa|chd
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Score (ESS) | 9.0 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source pa_cvd_meta Estimate design cohort synthesis Outcome match broader Outcome measured total cardiovascular disease Related outcome true |
Outcome match, Outcome measured, Related outcome: The estimate measures: total cardiovascular disease. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: pa_cvd_meta (weight 1.0). reviews_counted
Sedentary behaviour → Coronary heart disease
sedentary|chd
| Field | Before | After |
| Score (ESS) | 3.4 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | sedentary_pandey gbd2021rf | sedentary_pandey |
| New fields | not recorded before | Measure HR Estimate source sedentary_pandey Estimate design cohort synthesis Outcome match broader Outcome measured cardiovascular disease Related outcome true |
Outcome match, Outcome measured, Related outcome: The estimate measures: cardiovascular disease. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source sedentary_pandey, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): gbd2021rf removed from the sources (blocker 6): the body does not rate this pair (adjudication pair_match false), so it cannot count as a replication synthesis either; its adjudication entry goes with it. corrections.json _whyT3T4
Also changed in: 1.4 (9 Oct 2026)
Low cardiorespiratory fitness → Coronary heart disease
low_fitness|chd
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 12.3 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source crf_kodama Estimate design cohort synthesis Outcome match broader Outcome measured combined CHD and CVD events Related outcome true Grade basis Suggestive: Fitness partly marks hidden disease; CHD and CVD pooled. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured, Related outcome: The estimate measures: combined CHD and CVD events. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Suggestive: Fitness partly marks hidden disease; CHD and CVD pooled. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source crf_kodama, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Fitness partly marks hidden disease; CHD and CVD pooled. grade_basisT8a
Grade basis: Suggestive: Fitness partly marks hidden disease; CHD and CVD pooled. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT8a
High salt intake → Coronary heart disease
high_sodium|chd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.38 |
| Score (ESS) | 6.1 | empty |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources sscar salt_tops; a different exposure; a different outcome); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source sodium_urine_pooled Estimate design pooled IPD Outcome match broader Outcome measured cardiovascular events Related outcome true Grade override Moderate. T8a reads the caveat's mention of reverse causation, which refers to J-shaped curves in spot-urine cohorts; th…Moderate. T8a reads the caveat's mention of reverse causation, which refers to J-shaped curves in spot-urine cohorts; the displayed estimate uses repeated 24-hour urine collections. T3 caps at Moderate. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. |
Outcome match, Outcome measured, Related outcome: The estimate measures: cardiovascular events. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade override: Curator override to Moderate: T8a reads the caveat's mention of reverse causation, which refers to J-shaped curves in spot-urine cohorts; the displayed estimate uses repeated 24-hour urine collections. T3 caps at Moderate. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT8aT3
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: sodium_dr (weight 1.0), sodium_urine_pooled (weight 0.38). reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source sodium_urine_pooled, estimate_design pooled IPD, measure HR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_exposure and same_outcome false (cards G6, G11): SSaSS tested a salt substitute that lowers sodium and adds potassium; the Cochrane review of salt reduction measured blood pressure. grade_override keeps Moderate: T8a reads the caveat's mention of reverse causation, which refers to J-shaped curves in spot-urine cohorts; the displayed estimate uses repeated 24-hour urine collections: T3 caps at Moderate. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. corrections.json _whyT8aT3
Also changed in: 1.4 (9 Oct 2026)
Industrial trans fat → Coronary heart disease
trans_fat|chd
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.64 |
| Score (ESS) | 6.8 | 9.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source transfat_desouza Estimate design cohort synthesis Outcome match exact Outcome measured total CHD (fatal and non-fatal) Grade override Moderate. Kept by the verifier: GRADE 'low' is the starting level for observational nutrition evidence, and lipid trials…Moderate. Kept by the verifier: GRADE 'low' is the starting level for observational nutrition evidence, and lipid trials and GBD support the pair. T11 reads 'very low to low certainty' as very low. Adjudicating bodies gbd2021rf: rates this pair in GBD 2021 (star rating not recorded on the link) External grades GRADE very low to low (transfat_desouza) |
Outcome match, Outcome measured: The estimate measures: total CHD (fatal and non-fatal). measured_outcome
Grade override: Curator override to Moderate: Kept by the verifier: GRADE 'low' is the starting level for observational nutrition evidence, and lipid trials and GBD support the pair. T11 reads 'very low to low certainty' as very low. grade_overrideT11
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: transfat_desouza (weight 1.0), gbd2021rf (weight 0.64). reviews_counted
Processed meat → Coronary heart disease
processed_meat|chd
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Effective reviews (N_eff) | 1 | 1.58 |
| Score (ESS) | 10.6 | 10.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source meat_micha Estimate design cohort synthesis Outcome match exact Outcome measured incident CHD Grade basis Suggestive: Five cohorts, z 2.4. Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: incident CHD. measured_outcome
Grade: Suggestive: Five cohorts, z 2.4. Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source meat_micha, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Five cohorts, z 2.4. grade_basis
Grade basis: Suggestive: Five cohorts, z 2.4. Verified on 21 October 2026 (card G3). grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: meat_micha (weight 1.0), foodgroups_schwingshackl (weight 0.58). reviews_counted
Unprocessed red meat → Coronary heart disease
red_meat|chd
| Field | Before | After |
| Effective reviews (N_eff) | 2 | 2.08 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source meat_micha Estimate design cohort synthesis Outcome match exact Outcome measured incident CHD Adjudicating bodies bprf_meat: 2 stars External grades Burden of Proof 2 stars (bprf_meat) |
Outcome match, Outcome measured: The estimate measures: incident CHD. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: meat_micha (weight 1.0), foodgroups_schwingshackl (weight 0.58), bprf_meat (weight 0.5). reviews_counted
Also changed in: 1.3 (9 Sep 2026)
Sugar-sweetened drinks → Coronary heart disease
ssb|chd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.62 |
| Score (ESS) | 5.8 | 8.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source ssb_chd_xi Estimate design cohort synthesis Outcome match exact Outcome measured CHD Grade basis The link already cites a later dose-response meta-analysis of 64 prospective studies (Sun 2023): HR 1.11 (1.05-1.17) per…The link already cites a later dose-response meta-analysis of 64 prospective studies (Sun 2023): HR 1.11 (1.05-1.17) per 250 mL a day for CHD, linear. With two syntheses (2014, 2023) T9 does not apply; T4 met; T7 met by the linear gradient; T3 fails, so the ceiling is Moderate. SSB is not on the reverse-causation watch list. |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Grade basis: The link already cites a later dose-response meta-analysis of 64 prospective studies (Sun 2023): HR 1.11 (1.05-1.17) per 250 mL a day for CHD, linear. With two syntheses (2014, 2023) T9 does not apply; T4 met; T7 met by the linear gradient; T3 fails, so the ceiling is Moderate. SSB is not on the reverse-causation watch list. grade_basisT9T4T7T3
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: ssb_chd_xi (weight 1.0), ssb_fructose_dr (weight 0.62). reviews_counted
Ultra-processed food → Coronary heart disease
upf|chd
| Field | Before | After |
| Score (ESS) | 6.5 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source upf_cve_dr Estimate design cohort synthesis Outcome match broader Outcome measured cardiovascular events Related outcome true External grades umbrella review class Class I (cardiovascular deaths) (upf_umbrella_bmj); GRADE very low (upf_umbrella_bmj) |
The estimate measures: cardiovascular events. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Also changed in: 1.3 (18 Sep 2026)
Low whole grain intake → Coronary heart disease
low_wholegrain|chd
| Field | Before | After |
| Reviews counted | 2 | 3 |
| Effective reviews (N_eff) | 1 | 1.88 |
| Score (ESS) | 7.2 | 11.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source wholegrain_aune Estimate design cohort synthesis Outcome match exact Outcome measured CHD Grade override Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. N…Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. Adjudicating bodies gbd2021rf: rates this pair in GBD 2021 (star rating not recorded on the link) |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Grade override: Curator override to Moderate: T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT8c
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: wholegrain_aune (weight 1.0), fibre_reynolds (weight 0.38), gbd2021rf (weight 0.5). reviews_counted
Low fruit and vegetable intake → Coronary heart disease
low_fruit|chd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.58 |
| Score (ESS) | 3.5 | 4.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source fruitveg_aune Estimate design cohort synthesis Outcome match exact Outcome measured CHD Grade override Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. N…Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. Adjudicating bodies gbd2021rf: rates this pair in GBD 2021 (star rating not recorded on the link) |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Grade override: Curator override to Moderate: T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT8c
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: fruitveg_aune (weight 1.0), gbd2021rf (weight 0.58). reviews_counted
Low vegetable intake → Coronary heart disease
low_veg|chd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.5 |
| Score (ESS) | 5.9 | 8.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source bprf_veg Estimate design cohort synthesis Outcome match exact Outcome measured ischaemic heart disease Adjudicating bodies bprf_veg: 2 stars External grades Burden of Proof 2 stars (bprf_veg) |
Outcome match, Outcome measured: The estimate measures: ischaemic heart disease. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: fruitveg_aune (weight 1.0), bprf_veg (weight 0.5). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Low nut and seed intake → Coronary heart disease
low_nuts|chd
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources predimed; a different exposure); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source nutslegumes_afshin Estimate design cohort synthesis Outcome match narrower Outcome measured fatal ischaemic heart disease only Grade override Moderate. T9a proposes Weak because the quote names four studies for non-fatal heart disease; the displayed fatal estima…Moderate. T9a proposes Weak because the quote names four studies for non-fatal heart disease; the displayed fatal estimate pools six studies (I-squared 28%). New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. |
Outcome match, Outcome measured: The estimate measures: fatal ischaemic heart disease only. measured_outcome
Grade override: Curator override to Moderate: T9a proposes Weak because the quote names four studies for non-fatal heart disease; the displayed fatal estimate pools six studies (I-squared 28%). New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT9a
Reviews counted: Counted from the cited syntheses under the review-counting rule: nutslegumes_afshin (weight 1.0). reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match narrower, measured outcome recorded (cards O1 and O5). estimate_source nutslegumes_afshin, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_exposure false (cards G6, G11): PREDIMED tested a Mediterranean diet supplemented with nuts against a control diet. grade_override keeps Moderate: T9a proposes Weak because the quote names four studies for non-fatal heart disease; the displayed fatal estimate pools six studies (I-squared 28%): New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. corrections.json _whyT9a
Also changed in: 1.4 (9 Oct 2026)
Low legume intake → Coronary heart disease
low_legumes|chd
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.67 |
| Score (ESS) | 3.8 | 5.5 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source nutslegumes_afshin Estimate design cohort synthesis Outcome match exact Outcome measured total ischaemic heart disease Adjudicating bodies gbd2021rf: rates this pair in GBD 2021 (star rating not recorded on the link) |
Outcome match, Outcome measured: The estimate measures: total ischaemic heart disease. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: nutslegumes_afshin (weight 1.0), gbd2021rf (weight 0.67). reviews_counted
Also changed in: 1.4 (21 Oct 2026)1.4 (9 Oct 2026)
Low dietary fibre → Coronary heart disease
low_fibre|chd
| Field | Before | After |
| Reviews counted | 5 | 1 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 17.8 | 9.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source fibre_reynolds Estimate design cohort synthesis Outcome match exact Outcome measured CHD incidence Grade override Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. N…Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. |
Outcome match, Outcome measured: The estimate measures: CHD incidence. measured_outcome
Grade override: Curator override to Moderate: T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT8c
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: fibre_reynolds (weight 1.0). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Low seafood omega-3 intake → Coronary heart disease
low_omega3|chd
| Field | Before | After |
| Reviews counted | 5 | 2 |
| Effective reviews (N_eff) | 3 | 1.38 |
| Score (ESS) | 5.2 | 3.3 |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response yes | Trial null (sources omega3_chd_alexander; a different exposure); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source fish_chd_jiang Estimate design cohort synthesis Outcome match exact Outcome measured CHD incidence |
Outcome match, Outcome measured: The estimate measures: CHD incidence. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: omega3_chd_alexander (weight 1.0), fish_chd_jiang (weight 0.38). reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source fish_chd_jiang, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct null, same_exposure false (cards G6, G11): The trials tested omega-3 supplements; the link measures fish consumption corrections.json _why
Also changed in: 1.4 (19 Sep 2026)
Mediterranean dietary pattern → Coronary heart disease
mediterranean|chd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.29 |
| Score (ESS) | 9.8 | 11.9 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources predimed); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source medd_becerra Estimate design cohort synthesis Outcome match exact Outcome measured CHD incidence |
Outcome match, Outcome measured: The estimate measures: CHD incidence. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: medd_grosso (weight 1.0), medd_becerra (weight 0.29). reviews_counted
Heavy alcohol use → Coronary heart disease
alcohol_heavy|chd
| Field | Before | After |
| Reviews counted | 6 | 1 |
| Effective reviews (N_eff) | 4 | 1.0 |
| Score (ESS) | 1.2 | 0.5 |
| Trial and genetic evidence | Trial none; Genetic (MR) conflicting; dose-response yes | Trial none; Genetic (MR) conflicting (sources mr_alcohol_holmes ckb_alcohol); dose-response yes |
| New fields | not recorded before | Measure RR Estimate source alc_heavy_ihd_roerecke Estimate design cohort synthesis Outcome match exact Outcome measured IHD incidence (fatal and non-fatal) Conflict Side A: Cohort studies find that men who drink heavily have about the same coronary risk as lifelong abstainers (1.04, 0…Side A: Cohort studies find that men who drink heavily have about the same coronary risk as lifelong abstainers (1.04, 0.83 to 1.31). Side B: Genetic studies disagree with each other: one found fewer coronary events in people genetically inclined to drink less, another found no link with heart attack. Sources: alc_heavy_ihd_roerecke mr_alcohol_holmes ckb_alcohol |
Outcome match, Outcome measured: The estimate measures: IHD incidence (fatal and non-fatal). measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: alc_heavy_ihd_roerecke (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Fine particulate air pollution → Coronary heart disease
pm25|chd
| Field | Before | After |
| Reviews counted | 7 | 4 |
| Effective reviews (N_eff) | 5 | 2.09 |
| Score (ESS) | 21.1 | 14.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source pm25_ihd_alexeeff Estimate design cohort synthesis Outcome match narrower Outcome measured Death from ischaemic heart disease only Adjudicating bodies who_air: WHO 2021 review: high certainty of evidence for deaths from ischaemic heart disease; gbd2021rf: rates this pair…who_air: WHO 2021 review: high certainty of evidence for deaths from ischaemic heart disease; gbd2021rf: rates this pair in GBD 2021 (star rating not recorded on the link) External grades GRADE (WHO review) high (deaths from ischaemic heart disease) (who_air) |
Outcome match, Outcome measured: The estimate measures: Death from ischaemic heart disease only. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: escape_coronary (weight 1.0), pm25_ihd_alexeeff (weight 0.55), who_air (weight 0.17), gbd2021rf (weight 0.38). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Household air pollution → Coronary heart disease
hap|chd
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.17 |
| Score (ESS) | 2.2 | 2.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source hap_health_lee2020 Estimate design mixed Outcome match exact Outcome measured ischaemic heart disease |
Outcome match, Outcome measured: The estimate measures: ischaemic heart disease. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: hap_health_lee2020 (weight 1.0), solidfuel_cve_huang (weight 0.17). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Road traffic noise → Coronary heart disease
traffic_noise|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source noise_who Estimate design cohort synthesis Outcome match exact Outcome measured new cases of ischaemic heart disease Grade basis Moderate: the WHO review rates the evidence high quality; only a low-confidence rule (z 2.3) points lower. Accepted by the verifier. Adjudicating bodies noise_who: WHO 2018 review: quality of evidence rated high for new ischaemic heart disease External grades GRADE (WHO review) high (noise_who) |
Outcome match, Outcome measured: The estimate measures: new cases of ischaemic heart disease. measured_outcome
Grade basis: Moderate: the WHO review rates the evidence high quality; only a low-confidence rule (z 2.3) points lower. Accepted by the verifier. grade_basis
Also changed in: 1.4 (9 Oct 2026)
Lead exposure → Coronary heart disease
lead|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source metals_cvd Estimate design cohort synthesis Outcome match exact Outcome measured CHD Grade basis Moderate: a dose-response and a large effect; only a low-confidence rule on interval width points lower. Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Grade basis: Moderate: a dose-response and a large effect; only a low-confidence rule on interval width points lower. Kept by the verifier. grade_basis
Job strain → Coronary heart disease
job_strain|chd
| Field | Before | After |
| Reviews counted | 4 | 1 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 14.3 | 7.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source ipd_work Estimate design pooled IPD Outcome match exact Outcome measured incident CHD (IPD-Work) |
Outcome match, Outcome measured: The estimate measures: incident CHD (IPD-Work). measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: ipd_work (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Social isolation and loneliness → Coronary heart disease
isolation|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | isolation_valtorta holt_lunstad | isolation_valtorta |
| New fields | not recorded before | Measure RR Estimate source isolation_valtorta Estimate design cohort synthesis Outcome match exact Outcome measured new cases of coronary heart disease |
Outcome match, Outcome measured: The estimate measures: new cases of coronary heart disease. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source isolation_valtorta, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2) 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source holt_lunstad removed from the link's sources (issue 2, card K7 A topic check, PROPOSAL section 5.1): it is a meta-analysis of social relationships and death from any cause, with no estimate for coronary heart disease, so it does not replicate this pair and must not count in the replication term. review_note: a dated sentence records that Holt-Lunstad 2010 no longer appears among the sources (issue 2). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Depression (as a risk factor) → Coronary heart disease
depression_exposure|chd
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 6.8 | 4.7 |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response yes | Trial null (sources enrichd2003_trial; a different outcome); Genetic (MR) none; dose-response yes |
| Sources | depression_chd | depression_chd enrichd2003_trial |
| New fields | not recorded before | Measure RR Estimate source depression_chd Estimate design cohort synthesis Outcome match exact Outcome measured CHD Grade basis Suggestive: Funnel asymmetry; treatment trials did not cut events. Rules T2, T8a, T10 (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Grade: Suggestive: Funnel asymmetry; treatment trials did not cut events. Rules T2, T8a, T10 (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source depression_chd, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct null, same_outcome false (cards G6, G11): The trials treated depression after a heart attack, so they measure further cardiac events in people who already have heart disease: No trial is cited. Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Funnel asymmetry; treatment trials did not cut events. grade_basisT2T8aT10
Grade basis: Suggestive: Funnel asymmetry; treatment trials did not cut events. Rules T2, T8a, T10 (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT2T8aT10
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source depression_chd, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct null, same_outcome false (cards G6, G11): The trials treated depression after a heart attack, so they measure further cardiac events in people who already have heart disease: No trial is cited. Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Funnel asymmetry; treatment trials did not cut events. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct null with its sources recorded (enrichd2003_trial), same_outcome false (card G11, blocker 4): ENRICHD treated depression after a heart attack and did not change death or recurrent infarction (2,481 patients); it measures further cardiac events in people who already have heart disease. corrections.json _why
Short sleep → Coronary heart disease
short_sleep|chd
| Field | Before | After |
| Effective reviews (N_eff) | 2 | 1.67 |
| Score (ESS) | 12.6 | 11.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source shortsleep_itani Estimate design cohort synthesis Outcome match exact Outcome measured CHD Grade basis Moderate: two reviews agree; only the reverse-causation watch list points lower. Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Grade basis: Moderate: two reviews agree; only the reverse-causation watch list points lower. Kept by the verifier. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: sleep_cappuccio (weight 1.0), shortsleep_itani (weight 0.5), sleep_yin (weight 0.17). reviews_counted
Also changed in: 1.3 (18 Sep 2026)
Insomnia → Coronary heart disease
insomnia|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources yuan2021_insomnia_cvd_mr); dose-response yes |
| Sources | insomnia_umbrella insomnia_sofi | insomnia_umbrella insomnia_sofi yuan2021_insomnia_cvd_mr |
| New fields | not recorded before | Measure RR Estimate source insomnia_umbrella Estimate design cohort synthesis Outcome match exact Outcome measured CHD |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source insomnia_umbrella, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (yuan2021_insomnia_cvd_mr) (card G11, blocker 4): Genetic liability to insomnia raises coronary artery disease (OR 1.19, Yuan 2021). corrections.json _why
Obstructive sleep apnoea → Coronary heart disease
osa|chd
| Field | Before | After |
| Effective reviews (N_eff) | 2 | 1.44 |
| Score (ESS) | 5.9 | 4.8 |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response yes | Trial null (sources save_cpap); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source osa_wang Estimate design cohort synthesis Outcome match exact Outcome measured CHD |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: osa_dong (weight 1.0), osa_wang (weight 0.0), osa_xie (weight 0.44). reviews_counted
Also changed in: 1.3 (9 Sep 2026)
Night shift work → Coronary heart disease
night_shift|chd
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 7.5 | 5.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source shiftwork_vyas Estimate design cohort synthesis Outcome match exact Outcome measured coronary events (MI, coronary death and related events) Grade basis Suggestive: Any shift work; I-squared 85%. Rule T10 (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: coronary events (MI, coronary death and related events). measured_outcome
Grade: Suggestive: Any shift work; I-squared 85%. Rule T10 (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source shiftwork_vyas, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Any shift work; I-squared 85%. grade_basisT10
Grade basis: Suggestive: Any shift work; I-squared 85%. Rule T10 (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT10
Low educational attainment → Coronary heart disease
low_education|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources tillmann2017_education_chd_mr); dose-response yes |
| Sources | sep_khaing sep_backholer | sep_khaing sep_backholer tillmann2017_education_chd_mr |
| New fields | not recorded before | Measure RR Estimate source sep_khaing Estimate design cohort synthesis Outcome match exact Outcome measured coronary artery disease |
Outcome match, Outcome measured: The estimate measures: coronary artery disease. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source sep_khaing, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (tillmann2017_education_chd_mr) (card G11, blocker 4): Genetic predisposition to more education lowers coronary heart disease (Tillmann 2017). corrections.json _why
Low socioeconomic position → Coronary heart disease
low_sep|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source sep_khaing Estimate design cohort synthesis Outcome match exact Outcome measured coronary artery disease |
The estimate measures: coronary artery disease. measured_outcome
Adverse childhood experiences → Coronary heart disease
aces|chd
| Field | Before | After |
| Score (ESS) | 3.6 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) null; dose-response yes | Trial none; Genetic (MR) null (sources maltreatment_mr_warrier); dose-response yes |
| New fields | not recorded before | Measure RR Estimate source aces_cvd_jakubowski Estimate design mixed Outcome match composite_other Outcome measured combined high blood pressure, CHD, heart attack and stroke Related outcome true Grade basis Kept at Weak by the verified dry run: MR found no effect on coronary disease (mr=null), adversity recalled in adulthood,…Kept at Weak by the verified dry run: MR found no effect on coronary disease (mr=null), adversity recalled in adulthood, composite outcome including hypertension. The note gives these reasons. |
Outcome match, Outcome measured, Related outcome: The estimate measures: combined high blood pressure, CHD, heart attack and stroke. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: Kept at Weak by the verified dry run: MR found no effect on coronary disease (mr=null), adversity recalled in adulthood, composite outcome including hypertension. The note gives these reasons. grade_basis
Also changed in: 1.4 (19 Sep 2026)
Chronic kidney disease (as a risk factor) → Coronary heart disease
ckd_exposure|chd
| Field | Before | After |
| Reviews counted | 5 | 2 |
| Effective reviews (N_eff) | 4 | 1.38 |
| Score (ESS) | 22.6 | 13.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source ckdpc_jama Estimate design pooled IPD Outcome match exact Outcome measured CHD Adjudicating bodies gbd_ckd: counts reduced kidney function as a cause of cardiovascular deaths |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: gbd_ckd (weight 1.0), ckdpc_jama (weight 0.38). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Pre-eclampsia → Coronary heart disease
preeclampsia|chd
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Effective reviews (N_eff) | 1 | 1.67 |
| Score (ESS) | 16.6 | 16.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source preeclampsia_bellamy Estimate design cohort synthesis Outcome match exact Outcome measured ischaemic heart disease Grade basis Suggestive: Shared cardiovascular predisposition. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: ischaemic heart disease. measured_outcome
Grade: Suggestive: Shared cardiovascular predisposition. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source preeclampsia_bellamy, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Shared cardiovascular predisposition. grade_basisT8a
Grade basis: Suggestive: Shared cardiovascular predisposition. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT8a
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: preeclampsia_bellamy (weight 1.0), preeclampsia_wu (weight 0.67). reviews_counted
Gestational diabetes → Coronary heart disease
gdm|chd
| Field | Before | After |
| Score (ESS) | 15.6 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source gdm_kramer Estimate design cohort synthesis Outcome match broader Outcome measured cardiovascular events Related outcome true |
The estimate measures: cardiovascular events. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Menopausal hormone therapy → Coronary heart disease
mht|chd
| Field | Before | After |
| Reviews counted | 1 | 0 |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response no | Trial null (sources whi_manson2013 whi); Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure HR Estimate source whi_manson2013 Estimate design single trial Outcome match exact Outcome measured CHD (WHI trial, intervention phase) Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: CHD (WHI trial, intervention phase). measured_outcome
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Statin treatment → Coronary heart disease
statins|chd
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources ctt ctt2012); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure rate ratio Estimate source ctt Estimate design trial synthesis Outcome match exact Outcome measured major coronary events (non-fatal heart attack or coronary death) Adjudicating bodies ctt: statin trials reduce major coronary events; ctt2012: statin trials reduce major coronary events |
Outcome match, Outcome measured: The estimate measures: major coronary events (non-fatal heart attack or coronary death). measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: ctt (weight 1.0). reviews_counted
Also changed in: 1.4 (21 Oct 2026)
Blood pressure treatment → Coronary heart disease
antihypertensives|chd
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources bp_ettehad bpltt); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source bp_ettehad Estimate design trial synthesis Outcome match exact Outcome measured CHD Adjudicating bodies bpltt: blood pressure lowering reduces coronary events in trials |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: bp_ettehad (weight 1.0). reviews_counted
HIV infection → Coronary heart disease
hiv|chd
| Field | Before | After |
| Score (ESS) | 16.6 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source hiv_shah Estimate design cohort synthesis Outcome match broader Outcome measured cardiovascular disease Related outcome true |
The estimate measures: cardiovascular disease. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Gum disease → Coronary heart disease
periodontitis|chd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.72 |
| Score (ESS) | 4.2 | 6.1 |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source perio_gao Estimate design cohort synthesis Outcome match exact Outcome measured new cases of coronary heart disease Grade basis Suggestive: no trial of periodontal treatment has measured coronary events, and shared causes such as smoking are hard t…Suggestive: no trial of periodontal treatment has measured coronary events, and shared causes such as smoking are hard to exclude (T8a). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: new cases of coronary heart disease. measured_outcome
Grade basis: Suggestive: no trial of periodontal treatment has measured coronary events, and shared causes such as smoking are hard to exclude (T8a). Kept by the verifier. grade_basisT8a
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: perio_humphrey (weight 1.0), perio_gao (weight 0.72). reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source perio_gao, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct none (status was null) with its sources recorded (none) (card G11, blocker 4): No trial of periodontal treatment with coronary events as the outcome is cited; treatment trials measure inflammatory markers and carotid thickness. Grade stays Suggestive (card G3, blocker 4); grade_basis rewritten: Suggestive: no trial of periodontal treatment has measured coronary events, and shared causes such as smoking are hard to exclude (T8a). Kept by the verifier. corrections.json _whyT8a
Also changed in: 1.4 (9 Oct 2026)
Vitamin D deficiency → Coronary heart disease
vitd_deficiency|chd
| Field | Before | After |
| Reviews counted | 6 | 1 |
| Effective reviews (N_eff) | 4 | 1.0 |
| Score (ESS) | 6.9 | 3.1 |
| Trial and genetic evidence | Trial contradicts; Genetic (MR) contradicts; dose-response yes | Trial contradicts (sources vital d_health); Genetic (MR) contradicts (sources vitd_mr); dose-response yes |
| New fields | not recorded before | Measure RR Estimate source vitd_cvd_wang2012 Estimate design cohort synthesis Outcome match exact Outcome measured CHD Conflict Side A: Cohort studies link low blood vitamin D with more coronary heart disease (1.38, 1.21 to 1.57). Side B: Large sup…Side A: Cohort studies link low blood vitamin D with more coronary heart disease (1.38, 1.21 to 1.57). Side B: Large supplement trials (VITAL, D-Health) found no cardiovascular benefit, and Mendelian randomisation is null (0.99, 0.84 to 1.17). Sources: vitd_cvd_wang2012 vital d_health vitd_mr |
Outcome match, Outcome measured: The estimate measures: CHD. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: vitd_cvd_wang2012 (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Low muscle strength → Coronary heart disease
low_grip|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source grip_wu Estimate design cohort synthesis Outcome match exact Outcome measured CHD |
The estimate measures: CHD. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
High blood pressure → Ischaemic stroke
high_sbp|stroke_isch
| Field | Before | After |
| Reviews counted | 8 | 4 |
| Effective reviews (N_eff) | 7 | 1.64 |
| Score (ESS) | 56.8 | 32.8 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) supportive; dose-response yes | Trial supportive (sources bpltt); Genetic (MR) supportive (sources bp_stroke_mr_georgakis); dose-response yes |
| Sources | metab_rf_singh psc_bp bpltt bp_stroke_mr_georgakis interstroke | metab_rf_singh psc_bp bpltt bp_stroke_mr_georgakis interstroke peters2013_sbp_stroke_ihd lawes2004_bp_stroke |
| New fields | not recorded before | Measure RR Estimate source metab_rf_singh Estimate design pooled IPD Outcome match exact Outcome measured ischaemic stroke Adjudicating bodies bpltt: blood pressure lowering reduces stroke in trials |
Outcome match, Outcome measured: The estimate measures: ischaemic stroke. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: lawes2004_bp_stroke (weight 1.0), metab_rf_singh (weight 0.64), psc_bp (weight 0.0), peters2013_sbp_stroke_ihd (weight 0.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card K1): peters2013_sbp_stroke_ihd, lawes2004_bp_stroke; the displayed estimate is unchanged. estimate_source metab_rf_singh, estimate_design pooled IPD, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). corrections.json _whyT3T4
Also changed in: 1.4 (19 Sep 2026)
High blood pressure → Haemorrhagic stroke
high_sbp|stroke_haem
| Field | Before | After |
| Reviews counted | 7 | 4 |
| Effective reviews (N_eff) | 6 | 1.64 |
| Score (ESS) | 56.5 | 33.3 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) supportive; dose-response yes | Trial supportive (sources chapman2004_progress_subtype); Genetic (MR) supportive (sources bp_stroke_mr_georgakis); dose-response yes |
| Sources | metab_rf_singh psc_bp bp_stroke_mr_georgakis interstroke | metab_rf_singh psc_bp bp_stroke_mr_georgakis interstroke lawes2004_bp_stroke ariesen2003_ich_risk chapman2004_progress_subtype |
| New fields | not recorded before | Measure RR Estimate source metab_rf_singh Estimate design pooled IPD Outcome match exact Outcome measured haemorrhagic stroke |
Outcome match, Outcome measured: The estimate measures: haemorrhagic stroke. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: lawes2004_bp_stroke (weight 1.0), ariesen2003_ich_risk (weight 0.0), metab_rf_singh (weight 0.64), psc_bp (weight 0.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card K1): lawes2004_bp_stroke, ariesen2003_ich_risk; the displayed estimate is unchanged. estimate_source metab_rf_singh, estimate_design pooled IPD, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct supportive with its sources recorded (chapman2004_progress_subtype) (card G11, blocker 4): In PROGRESS, blood pressure lowering cut intracerebral haemorrhage by 50% (26 to 67) among 6,105 people with a previous stroke or transient ischaemic attack. hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _why
Also changed in: 1.4 (19 Sep 2026)
Current cigarette smoking → Ischaemic stroke
smoking|stroke_isch
| Field | Before | After |
| Reviews counted | 8 | 3 |
| Effective reviews (N_eff) | 6 | 1.58 |
| Score (ESS) | 49.0 | 28.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources lifestyle_stroke_mr_harshfield smoking_cvd_mr_larsson); dose-response yes |
| New fields | not recorded before | Measure OR Estimate source smoking_stroke_luo Estimate design cohort synthesis Outcome match exact Outcome measured new ischaemic stroke Adjudicating bodies bprf_smoking: rates this pair (star rating not recorded on the link) |
Outcome match, Outcome measured: The estimate measures: new ischaemic stroke. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoking_chances (weight 1.0), bprf_smoking (weight 0.58), smoking_stroke_luo (weight 0.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Current cigarette smoking → Haemorrhagic stroke
smoking|stroke_haem
| Field | Before | After |
| Reviews counted | 5 | 4 |
| Effective reviews (N_eff) | 4 | 2.06 |
| Score (ESS) | 40.0 | 29.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | smoking_stroke_luo bprf_smoking smoking_cvd_mr_larsson lifestyle_stroke_mr_harshfield interstroke | smoking_stroke_luo bprf_smoking smoking_cvd_mr_larsson lifestyle_stroke_mr_harshfield interstroke ariesen2003_ich_risk feigin2005_sah_review |
| New fields | not recorded before | Measure OR Estimate source smoking_stroke_luo Estimate design cohort synthesis Outcome match exact Outcome measured new haemorrhagic stroke Adjudicating bodies bprf_smoking: rates this pair (star rating not recorded on the link) |
Outcome match, Outcome measured: The estimate measures: new haemorrhagic stroke. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: ariesen2003_ich_risk (weight 1.0), feigin2005_sah_review (weight 0.29), bprf_smoking (weight 0.77), smoking_stroke_luo (weight 0.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card K1): ariesen2003_ich_risk, feigin2005_sah_review; the displayed estimate is unchanged. estimate_source smoking_stroke_luo, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). corrections.json _whyT3T4
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Atrial fibrillation (as a risk factor) → Ischaemic stroke
afib_exposure|stroke_isch
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources hart2007_af_antithrombotic_ma; a different exposure); Genetic (MR) supportive (sources wang202…Trial supportive (sources hart2007_af_antithrombotic_ma; a different exposure); Genetic (MR) supportive (sources wang2022_af_phewas_mr he2023_af_stroke_mr); dose-response yes |
| Sources | afib_odutayo | afib_odutayo wang2022_af_phewas_mr he2023_af_stroke_mr hart2007_af_antithrombotic_ma |
| New fields | not recorded before | Measure RR Estimate source afib_odutayo Estimate design cohort synthesis Outcome match exact Outcome measured ischaemic stroke Grade basis Strong: 104 cohorts (Odutayo 2016) with a 2.3-fold risk; genetic liability to atrial fibrillation raises cardio-embolic…Strong: 104 cohorts (Odutayo 2016) with a 2.3-fold risk; genetic liability to atrial fibrillation raises cardio-embolic ischaemic stroke (T3, T4); anticoagulation trials remove most of the excess risk (another exposure contrast, noted). Verified at Strong on 21 October 2026. |
Outcome match, Outcome measured: The estimate measures: ischaemic stroke. measured_outcome
Grade basis: Strong: 104 cohorts (Odutayo 2016) with a 2.3-fold risk; genetic liability to atrial fibrillation raises cardio-embolic ischaemic stroke (T3, T4); anticoagulation trials remove most of the excess risk (another exposure contrast, noted). Verified at Strong on 21 October 2026. grade_basisT3T4
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source afib_odutayo, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_exposure false (cards G6, G11): Anticoagulation trials remove most of the excess stroke risk, but they test a drug and leave atrial fibrillation itself unchanged: No trial is cited. grade_override keeps Strong: Anticoagulation trials remove most of the excess stroke risk in atrial fibrillation, but they leave the exposure itself unchanged, so they are recorded with same_exposure false and rule T3 (Moderate) fails as written. No Mendelian randomisation study or adjudicating body is cited yet. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive (status was none) with its sources recorded (wang2022_af_phewas_mr, he2023_af_stroke_mr) (card G11, G2, blocker 4): Genetic liability to atrial fibrillation raises the risk of cardio-embolic ischaemic stroke (Wang 2022) and of stroke (He 2023); strokes caused by atrial fibrillation are almost all ischaemic. triangulation.rct supportive with its sources recorded (hart2007_af_antithrombotic_ma), same_exposure false (card G11, blocker 4): Anticoagulation trials remove most of the excess stroke risk (warfarin cut stroke by 64% in 29 trials), but they test a drug and leave atrial fibrillation itself unchanged. grade_override removed (blocker 2): the recorded genetic evidence now meets rule T3, and T4 has two lines (a cohort synthesis and MR), so Strong follows from the table. Grade stays Strong (blocker 2); grade_basis rewritten: Strong: 104 cohorts (Odutayo 2016) with a 2.3-fold risk; genetic liability to atrial fibrillation raises cardio-embolic ischaemic stroke (T3, T4); anticoagulation trials remove most of the excess risk (another exposure contrast, noted). Verified at Strong on 21 October 2026. corrections.json _whyT3T4
Type 2 diabetes (as a risk factor) → Ischaemic stroke
t2d_exposure|stroke_isch
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) supportive (sources larsson2017_t2d_stroke_mr); dose-response yes |
| Sources | erfc_diabetes | erfc_diabetes larsson2017_t2d_stroke_mr |
| New fields | not recorded before | Measure HR Estimate source erfc_diabetes Estimate design pooled IPD Outcome match exact Outcome measured ischaemic stroke |
Outcome match, Outcome measured: The estimate measures: ischaemic stroke. measured_outcome
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G11): larsson2017_t2d_stroke_mr; the displayed estimate is unchanged. estimate_source erfc_diabetes, estimate_design pooled IPD, measure HR, by rule E1 (cards G8, K5, P2). triangulation.mr supportive recorded with its sources (card G11, research pass): Genetically predicted type 2 diabetes raises large-artery stroke (OR 1.28) and small-vessel stroke (OR 1.21); the cardioembolic subtype is null. The abstract gives no estimate for all ischaemic stroke. corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
High body-mass index → Ischaemic stroke
high_bmi|stroke_isch
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Effective reviews (N_eff) | 1 | 1.29 |
| Score (ESS) | 7.2 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) null (sources larsson2020_bmi_cvd_mr dale2017_adiposity_mr marini2020_obesity_stroke_mr); dose-response yes |
| Sources | erfc_adiposity psc_bmi | erfc_adiposity psc_bmi larsson2020_bmi_cvd_mr dale2017_adiposity_mr marini2020_obesity_stroke_mr |
| New fields | not recorded before | Measure HR Estimate source erfc_adiposity Estimate design pooled IPD Outcome match broader Outcome measured cardiovascular disease Related outcome true Grade basis Suggestive: three Mendelian randomisation studies found no effect of BMI on ischaemic stroke (rule T2, ceiling Suggestiv…Suggestive: three Mendelian randomisation studies found no effect of BMI on ischaemic stroke (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6). The displayed estimate is the ERFC figure for cardiovascular disease, so the link sits in the related-outcome layer. Lowered from Moderate by the binding rule once the genetic evidence was recorded. |
Outcome match, Outcome measured, Related outcome: The estimate measures: cardiovascular disease. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Suggestive: three Mendelian randomisation studies found no effect of BMI on ischaemic stroke (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6). The displayed estimate is the ERFC figure for cardiovascular disease, so the link sits in the related-outcome layer. Lowered from Moderate by the binding rule once the genetic evidence was recorded. Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr null (status was supportive) with its sources recorded (larsson2020_bmi_cvd_mr, dale2017_adiposity_mr, marini2020_obesity_stroke_mr) (card G11, blocker 4): Three Mendelian randomisation studies found no effect of genetically predicted BMI on ischaemic stroke (Dale 2017; Larsson 2020; Marini 2020); waist-to-hip ratio, another exposure, did raise it. Grade Moderate to Suggestive (blocker 4, binding rule T2): Suggestive: three Mendelian randomisation studies found no effect of BMI on ischaemic stroke (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6). The displayed estimate is the ERFC figure for cardiovascular disease, so the link sits in the related-outcome layer. Lowered from Moderate by the binding rule once the genetic evidence was recorded. grade_basisT2C3
Grade basis: Suggestive: three Mendelian randomisation studies found no effect of BMI on ischaemic stroke (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6). The displayed estimate is the ERFC figure for cardiovascular disease, so the link sits in the related-outcome layer. Lowered from Moderate by the binding rule once the genetic evidence was recorded. grade_basisT2C3
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: psc_bmi (weight 1.0), erfc_adiposity (weight 0.29). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source erfc_adiposity, estimate_design pooled IPD, measure HR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr null (status was supportive) with its sources recorded (larsson2020_bmi_cvd_mr, dale2017_adiposity_mr, marini2020_obesity_stroke_mr) (card G11, blocker 4): Three Mendelian randomisation studies found no effect of genetically predicted BMI on ischaemic stroke (Dale 2017; Larsson 2020; Marini 2020); waist-to-hip ratio, another exposure, did raise it. Grade Moderate to Suggestive (blocker 4, binding rule T2): Suggestive: three Mendelian randomisation studies found no effect of BMI on ischaemic stroke (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6). The displayed estimate is the ERFC figure for cardiovascular disease, so the link sits in the related-outcome layer. Lowered from Moderate by the binding rule once the genetic evidence was recorded. corrections.json _whyT2C3
Also changed in: 1.4 (9 Oct 2026)
High LDL cholesterol → Ischaemic stroke
high_ldl|stroke_isch
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) supportive; dose-response yes | Trial supportive (sources ctt); Genetic (MR) supportive (sources hindy2018_lipids_stroke_mr); dose-response yes |
| Sources | erfc_lipids ctt | erfc_lipids ctt hindy2018_lipids_stroke_mr |
| New fields | not recorded before | Measure HR Estimate source erfc_lipids Estimate design pooled IPD Outcome match exact Outcome measured ischaemic stroke Adjudicating bodies ctt: lowering LDL cholesterol reduces ischaemic stroke in trials |
Outcome match, Outcome measured: The estimate measures: ischaemic stroke. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source erfc_lipids, estimate_design pooled IPD, measure HR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (hindy2018_lipids_stroke_mr) (card G11, blocker 4): Genetically predicted LDL cholesterol raises ischaemic stroke, mainly the large-artery subtype (Hindy 2018). corrections.json _whyT3T4
Also changed in: 1.4 (9 Oct 2026)
High salt intake → Ischaemic stroke
high_sodium|stroke_isch
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.38 |
| Score (ESS) | 6.1 | empty |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources sscar; a different exposure); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source sodium_urine_pooled Estimate design pooled IPD Outcome match broader Outcome measured cardiovascular events Related outcome true |
Outcome match, Outcome measured, Related outcome: The estimate measures: cardiovascular events. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: sodium_dr (weight 1.0), sodium_urine_pooled (weight 0.38). reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source sodium_urine_pooled, estimate_design pooled IPD, measure HR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_exposure false (cards G6, G11): SSaSS tested a salt substitute that lowers sodium and adds potassium corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Low physical activity → Ischaemic stroke
low_pa|stroke_isch
| Field | Before | After |
| Estimate | 1.67 | 1.25 |
| Interval, lower | 1.43 | 1.18 |
| Interval, upper | 1.92 | 1.33 |
| Comparison | no regular physical activity vs regular physical activity, all stroke (case-control odds ratio; the interval shown is a 99% interval) | no non-occupational physical activity vs 8.75 marginal MET-hours a week (the recommended 150 minutes), stroke of any typ…no non-occupational physical activity vs 8.75 marginal MET-hours a week (the recommended 150 minutes), stroke of any type; the inverse of the published 0.80 |
| Comparison type | binary | category |
| Effective reviews (N_eff) | 1 | 1.69 |
| Score (ESS) | 13.4 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Caveat | empty | The estimate is the inverse of the pooled relative risk at 8.75 marginal MET-hours a week against no activity (0.80, 0.7…The estimate is the inverse of the pooled relative risk at 8.75 marginal MET-hours a week against no activity (0.80, 0.75 to 0.85) in a dose-response synthesis of 94 cohorts; the quoted row of the review's table gives the relative risk and the attributable share at 4.375, 8.75 and 17.5 MET-hours. The outcome is stroke of any type, so the link stays outside the ischaemic stroke counts. Risk falls steeply up to the recommended amount and little beyond it. |
| Quoted sentence | Previous history of hypertension or blood pressure of 140/90 mm Hg or higher (OR 2.98, 99% CI 2.72-3.28; PAR 47.9%, 99%…Previous history of hypertension or blood pressure of 140/90 mm Hg or higher (OR 2.98, 99% CI 2.72-3.28; PAR 47.9%, 99% CI 45.1-50.6), regular physical activity (0.60, 0.52-0.70; 35.8%, 27.7-44.7), apolipoprotein (Apo)B/ApoA1 ratio (1.84, 1.65-2.06 for highest vs lowest tertile; 26.8%, 22.2-31.9 for top two tertiles vs lowest tertile). | Stroke 0.86 (0.83 to 0.90) 5.53 (3.96 to 7.15) 0.80 (0.75 to 0.85) 9.77 (7.31 to 12.24) 0.77 (0.72 to 0.82) 12.37 (9.63 to 15.10) |
| New fields | not recorded before | Measure RR Estimate source pa_bjsm Estimate design cohort synthesis Outcome match broader Outcome measured stroke of any type (incidence, cohort synthesis) Related outcome true Grade basis Moderate: two cohort syntheses (Li 2012; Garcia 2023) agree on lower stroke risk with activity, with a gradient (T7). No…Moderate: two cohort syntheses (Li 2012; Garcia 2023) agree on lower stroke risk with activity, with a gradient (T7). No trial or genetic study is cited, so T3 caps at Moderate. The INTERSTROKE case-control estimate was replaced by the cohort synthesis (cards O3 and G3). Kept at Moderate by the verifier. Grade override Moderate. Kept at Moderate by the verifier (card G3): two cohort syntheses with a gradient support the pair. Rule T8a re…Moderate. Kept at Moderate by the verifier (card G3): two cohort syntheses with a gradient support the pair. Rule T8a reads the review note's remark on reverse causation and recall bias, which referred to the INTERSTROKE case-control estimate that has now been replaced by the cohort synthesis of 94 cohorts (Garcia 2023). |
Estimate, Interval, lower, Interval, upper: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source interstroke, estimate_design case-control, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). grade_override keeps Moderate: Kept by the verifier: the displayed INTERSTROKE all-stroke case-control odds ratio is the wrong estimate, and the two cited cohort meta-analyses support Moderate for the pair: The estimate should be replaced (card O3). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Displayed estimate replaced (card G3 A, kept link 64, card O3; blocker 8): the INTERSTROKE all-stroke case-control odds ratio gives way to the cited cohort synthesis (Garcia 2023, 94 cohorts), 1.25 (1.18 to 1.33) for no activity against the recommended amount, the inverse of 0.80 (0.75 to 0.85); the outcome is still stroke of any type. Grade stays Moderate (blocker 8); grade_basis rewritten: Moderate: two cohort syntheses (Li 2012; Garcia 2023) agree on lower stroke risk with activity, with a gradient (T7). No trial or genetic study is cited, so T3 caps at Moderate. The INTERSTROKE case-control estimate was replaced by the cohort synthesis (cards O3 and G3). Kept at Moderate by the verifier. grade_override keeps Moderate (blocker 8): Kept at Moderate by the verifier (card G3): two cohort syntheses with a gradient support the pair. Rule T8a reads the review note's remark on reverse causation and recall bias, which referred to the INTERSTROKE case-control estimate that has now been replaced by the cohort synthesis of 94 cohorts (Garcia 2023). corrections.json _whyT7T3T8a
Comparison, Comparison type, Caveat, Quoted sentence: INTERSTROKE reports regular physical activity at 0.60 (99% CI 0.52-0.70) for all stroke, whose reciprocal is 1.67 (1.43-1.92) for inactivity - considerably larger than the 1.26 on file. This is a case-control odds ratio with 99% intervals and is vulnerable to reverse causation and recall bias, so the true cohort value probably lies between the two; the dose-response cohort literature finds most of the benefit accrues by 8.75 mMET-hours/week, equivalent to the recommended 150 minutes. Updated 23 Oct 2026: the INTERSTROKE case-control odds ratio was replaced by the cohort dose-response synthesis (Garcia 2023), as the verified dry run and card O3 asked. review_note
Outcome match, Outcome measured, Related outcome: The estimate measures: stroke of any type (incidence, cohort synthesis). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis, Grade override: Curator override to Moderate: Kept at Moderate by the verifier (card G3): two cohort syntheses with a gradient support the pair. Rule T8a reads the review note's remark on reverse causation and recall bias, which referred to the INTERSTROKE case-control estimate that has now been replaced by the cohort synthesis of 94 cohorts (Garcia 2023). Moderate: two cohort syntheses (Li 2012; Garcia 2023) agree on lower stroke risk with activity, with a gradient (T7). No trial or genetic study is cited, so T3 caps at Moderate. The INTERSTROKE case-control estimate was replaced by the cohort synthesis (cards O3 and G3). Kept at Moderate by the verifier. grade_override and grade_basisT7T3T8a
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: pa_cvd_meta (weight 1.0), pa_bjsm (weight 0.69). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Heavy alcohol use → Haemorrhagic stroke
alcohol_heavy|stroke_haem
| Field | Before | After |
| Estimate | 1.58 | 1.67 |
| Interval, lower | 1.36 | 1.25 |
| Interval, upper | 1.84 | 2.23 |
| Comparison | per 280 g/week higher genotype-predicted alcohol intake, intracerebral haemorrhage | more than 4 drinks a day vs non-drinkers or occasional drinkers, intracerebral haemorrhage |
| Comparison type | per-unit | category |
| Score (ESS) | 15.6 | 16.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources ckb_alcohol); dose-response yes |
| Caveat | Mendelian randomisation in East Asian populations shows a clear, monotonic increase in stroke with alcohol, with no protective threshold. | Pooled from 11 prospective studies; heavy drinking raised intracerebral haemorrhage more than ischaemic stroke in the sa…Pooled from 11 prospective studies; heavy drinking raised intracerebral haemorrhage more than ischaemic stroke in the same analysis. A second synthesis (Zhang 2014, 27 prospective studies) found no significant effect of heavy drinking on haemorrhagic stroke. Mendelian randomisation in East Asian populations shows a clear, monotonic increase in stroke with alcohol, with no protective threshold. |
| Quoted sentence | For stroke, genotype-predicted mean alcohol intake had a continuously positive log-linear association with risk, which w…For stroke, genotype-predicted mean alcohol intake had a continuously positive log-linear association with risk, which was stronger for intracerebral haemorrhage (relative risk [RR] per 280 g per week 1.58, 95% CI 1.36-1.84, p<0.0001) than for ischaemic stroke (1.27, 1.13-1.43, p=0.0001). | High alcohol consumption (>2-4 drinks/day) was associated with a non-significant increased risk of both hemorrhagic stro…High alcohol consumption (>2-4 drinks/day) was associated with a non-significant increased risk of both hemorrhagic stroke subtypes, and the relative risk for heavy drinking (>4 drinks/day) were 1.67 (95 % CI, 1.25-2.23) for intracerebral hemorrhage and 1.82 (95 % CI, 1.18-2.82) for subarachnoid hemorrhage. |
| Sources | ckb_alcohol interstroke | ckb_alcohol interstroke larsson2016_alcohol_stroke |
| New fields | not recorded before | Measure RR Estimate source larsson2016_alcohol_stroke Estimate design cohort synthesis Outcome match narrower Outcome measured intracerebral haemorrhage (prospective synthesis) Grade basis Strong: the prospective synthesis (Larsson 2016, 11 studies, 1.67, 1.25 to 2.23 for more than 4 drinks a day) and the Ch…Strong: the prospective synthesis (Larsson 2016, 11 studies, 1.67, 1.25 to 2.23 for more than 4 drinks a day) and the China Kadoorie Mendelian randomisation agree (T3, T4). A second synthesis (Zhang 2014, 27 prospective studies) found no significant effect of heavy drinking on haemorrhagic stroke; it is cited and named in the caveat. Verified at Strong on 21 October 2026. Studies 11 |
Estimate, Interval, lower, Interval, upper: 21 Oct 2026 grading reform v2.0: outcome_match narrower, measured outcome recorded (cards O1 and O5): Sources added (card K1): larsson2016_alcohol_stroke; the displayed estimate is unchanged. estimate_source ckb_alcohol, estimate_design MR, measure RR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Displayed estimate replaced (card G8 A; blocker 8): the genetic estimate per 280 g a week gives way to the cited prospective synthesis, 1.67 (1.25 to 2.23) for more than 4 drinks a day (Larsson 2016, 11 studies); the MR stays in triangulation. 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source zhang2014_alcohol_stroke added (issue 7, card K1): its abstract (PubMed 24820756) reports no significant effect of heavy drinking on haemorrhagic stroke, which the caveat now says. caveat: Zhang 2014 mentioned (issue 7). caveat_zh: the same sentence. review_note: the sentences that described the replaced genetic estimate are trimmed to a dated history (issue 7). grade stays Strong; grade_basis written so the Zhang 2014 result is on record for the owner (issue 7). corrections.json _why
Comparison, Comparison type, Studies, Quoted sentence: Review of 18 Sep 2026: the genetic estimate then on display was per 280 g of alcohol a week of genotype-predicted intake, with no heavy-versus-light contrast. Alcohol acts about twice as strongly on intracerebral haemorrhage as on ischaemic stroke, and mainly through blood pressure. Updated 23 Oct 2026: the displayed estimate is now the prospective synthesis (Larsson 2016); the genetic estimate stays as corroboration (card G8 A). review_note
Outcome match, Outcome measured: The estimate measures: intracerebral haemorrhage (prospective synthesis). measured_outcome
Grade basis: Strong: the prospective synthesis (Larsson 2016, 11 studies, 1.67, 1.25 to 2.23 for more than 4 drinks a day) and the China Kadoorie Mendelian randomisation agree (T3, T4). A second synthesis (Zhang 2014, 27 prospective studies) found no significant effect of heavy drinking on haemorrhagic stroke; it is cited and named in the caveat. Verified at Strong on 21 October 2026. grade_basisT3T4
Caveat: 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source zhang2014_alcohol_stroke added (issue 7, card K1): its abstract (PubMed 24820756) reports no significant effect of heavy drinking on haemorrhagic stroke, which the caveat now says. caveat: Zhang 2014 mentioned (issue 7). caveat_zh: the same sentence. review_note: the sentences that described the replaced genetic estimate are trimmed to a dated history (issue 7). grade stays Strong; grade_basis written so the Zhang 2014 result is on record for the owner (issue 7). 23 Oct 2026 (owner): the 2014 null synthesis (Zhang) is named in the caveat only and no longer cited, so it does not enter the replication term. corrections.json _why
Sources: 21 Oct 2026 grading reform v2.0: outcome_match narrower, measured outcome recorded (cards O1 and O5): Sources added (card K1): larsson2016_alcohol_stroke; the displayed estimate is unchanged. estimate_source ckb_alcohol, estimate_design MR, measure RR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Displayed estimate replaced (card G8 A; blocker 8): the genetic estimate per 280 g a week gives way to the cited prospective synthesis, 1.67 (1.25 to 2.23) for more than 4 drinks a day (Larsson 2016, 11 studies); the MR stays in triangulation. 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source zhang2014_alcohol_stroke added (issue 7, card K1): its abstract (PubMed 24820756) reports no significant effect of heavy drinking on haemorrhagic stroke, which the caveat now says. caveat: Zhang 2014 mentioned (issue 7). caveat_zh: the same sentence. review_note: the sentences that described the replaced genetic estimate are trimmed to a dated history (issue 7). grade stays Strong; grade_basis written so the Zhang 2014 result is on record for the owner (issue 7). 23 Oct 2026 (owner): the 2014 null synthesis (Zhang) is named in the caveat only and no longer cited, so it does not enter the replication term. corrections.json _why
Heavy alcohol use → Ischaemic stroke
alcohol_heavy|stroke_isch
| Field | Before | After |
| Estimate | 1.27 | 1.14 |
| Interval, lower | 1.13 | 1.02 |
| Interval, upper | 1.43 | 1.28 |
| Comparison | per 280 g/week higher genotype-predicted alcohol intake | more than 4 drinks a day vs non-drinkers or occasional drinkers |
| Comparison type | per-unit | category |
| Grade | Convincing (now Strong) | Moderate |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.29 |
| Score (ESS) | 10.1 | 6.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources ckb_alcohol); dose-response yes |
| Caveat | empty | Pooled from 25 prospective studies. Light and moderate drinking went with lower risk in the same analysis, and a second…Pooled from 25 prospective studies. Light and moderate drinking went with lower risk in the same analysis, and a second synthesis (Zhang 2014) found no significant effect of heavy drinking on ischaemic stroke. Mendelian randomisation in East Asian populations shows risk rising steadily with alcohol. |
| Quoted sentence | For stroke, genotype-predicted mean alcohol intake had a continuously positive log-linear association with risk, which w…For stroke, genotype-predicted mean alcohol intake had a continuously positive log-linear association with risk, which was stronger for intracerebral haemorrhage (relative risk [RR] per 280 g per week 1.58, 95% CI 1.36-1.84, p<0.0001) than for ischaemic stroke (1.27, 1.13-1.43, p=0.0001). | the overall RRs were 0.90 (95 % CI, 0.85-0.95) for less than 1 drink/day, 0.92 (95 % CI, 0.87-0.97) for 1-2 drinks/day,…the overall RRs were 0.90 (95 % CI, 0.85-0.95) for less than 1 drink/day, 0.92 (95 % CI, 0.87-0.97) for 1-2 drinks/day, 1.08 (95 % CI, 1.01-1.15) for more than 2-4 drinks/day, and 1.14 (95 % CI, 1.02-1.28) for more than 4 drinks/day. |
| Sources | ckb_alcohol interstroke | ckb_alcohol interstroke larsson2016_alcohol_stroke zhang2014_alcohol_stroke |
| New fields | not recorded before | Measure RR Estimate source larsson2016_alcohol_stroke Estimate design cohort synthesis Outcome match exact Outcome measured ischaemic stroke (prospective synthesis) Grade basis Moderate: the displayed estimate is the prospective synthesis (Larsson 2016, 25 studies, RR 1.14, 1.02 to 1.28 above fou…Moderate: the displayed estimate is the prospective synthesis (Larsson 2016, 25 studies, RR 1.14, 1.02 to 1.28 above four drinks a day) and the China Kadoorie Mendelian randomisation is supportive (T3, T4). Strong is not supported: Zhang 2014 (27 prospective studies) found no significant effect of heavy drinking on ischaemic stroke, and the prospective effect is small. Settled at Moderate by the curation pass (card G12). Studies 25 |
Estimate, Interval, lower, Interval, upper: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card K1): larsson2016_alcohol_stroke, zhang2014_alcohol_stroke; the displayed estimate is unchanged. estimate_source ckb_alcohol, estimate_design MR, measure RR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). Grade Strong to Moderate (card G12, settled by the research pass). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Displayed estimate replaced (card G8 A; blocker 8): the genetic estimate per 280 g a week gives way to the cited prospective synthesis, 1.14 (1.02 to 1.28) for more than 4 drinks a day (Larsson 2016, 25 studies); the MR stays in triangulation. Grade stays Moderate (blocker 8); grade_basis rewritten: Moderate: the displayed estimate is the prospective synthesis (Larsson 2016, 25 studies, RR 1.14, 1.02 to 1.28 above four drinks a day) and the China Kadoorie Mendelian randomisation is supportive (T3, T4). Strong is not supported: Zhang 2014 (27 prospective studies) found no significant effect of heavy drinking on ischaemic stroke, and the prospective effect is small. Settled at Moderate by the curation pass (card G12). 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): review_note: the sentences that described the replaced genetic estimate are trimmed to a dated history (issue 7). corrections.json _whyT3T4
Comparison, Comparison type, Studies, Caveat, Quoted sentence: Review of 18 Sep 2026: the genetic estimate then on display was per 280 g of alcohol a week, with no heavy-versus-light contrast, and that association is log-linear with no threshold. INTERSTROKE separately gives OR 2.09 (1.64-2.67) for high or heavy episodic intake versus never or former drinkers, for all stroke. Updated 23 Oct 2026: the displayed estimate is now the prospective synthesis (Larsson 2016); the genetic estimate stays as corroboration (card G8 A). review_note
Outcome match, Outcome measured: The estimate measures: ischaemic stroke (prospective synthesis). measured_outcome
Grade: Moderate: the displayed estimate is the prospective synthesis (Larsson 2016, 25 studies, RR 1.14, 1.02 to 1.28 above four drinks a day) and the China Kadoorie Mendelian randomisation is supportive (T3, T4). Strong is not supported: Zhang 2014 (27 prospective studies) found no significant effect of heavy drinking on ischaemic stroke, and the prospective effect is small. Settled at Moderate by the curation pass (card G12). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card K1): larsson2016_alcohol_stroke, zhang2014_alcohol_stroke; the displayed estimate is unchanged. estimate_source ckb_alcohol, estimate_design MR, measure RR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). Grade Strong to Moderate (card G12, settled by the research pass). Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Displayed estimate replaced (card G8 A; blocker 8): the genetic estimate per 280 g a week gives way to the cited prospective synthesis, 1.14 (1.02 to 1.28) for more than 4 drinks a day (Larsson 2016, 25 studies); the MR stays in triangulation. Grade stays Moderate (blocker 8); grade_basis rewritten: Moderate: the displayed estimate is the prospective synthesis (Larsson 2016, 25 studies, RR 1.14, 1.02 to 1.28 above four drinks a day) and the China Kadoorie Mendelian randomisation is supportive (T3, T4). Strong is not supported: Zhang 2014 (27 prospective studies) found no significant effect of heavy drinking on ischaemic stroke, and the prospective effect is small. Settled at Moderate by the curation pass (card G12). grade_basisT3T4
Grade basis: Moderate: the displayed estimate is the prospective synthesis (Larsson 2016, 25 studies, RR 1.14, 1.02 to 1.28 above four drinks a day) and the China Kadoorie Mendelian randomisation is supportive (T3, T4). Strong is not supported: Zhang 2014 (27 prospective studies) found no significant effect of heavy drinking on ischaemic stroke, and the prospective effect is small. Settled at Moderate by the curation pass (card G12). grade_basisT3T4
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: zhang2014_alcohol_stroke (weight 1.0), larsson2016_alcohol_stroke (weight 0.29). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card K1): larsson2016_alcohol_stroke, zhang2014_alcohol_stroke; the displayed estimate is unchanged. estimate_source ckb_alcohol, estimate_design MR, measure RR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). Grade Strong to Moderate (card G12, settled by the research pass). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Displayed estimate replaced (card G8 A; blocker 8): the genetic estimate per 280 g a week gives way to the cited prospective synthesis, 1.14 (1.02 to 1.28) for more than 4 drinks a day (Larsson 2016, 25 studies); the MR stays in triangulation. Grade stays Moderate (blocker 8); grade_basis rewritten: Moderate: the displayed estimate is the prospective synthesis (Larsson 2016, 25 studies, RR 1.14, 1.02 to 1.28 above four drinks a day) and the China Kadoorie Mendelian randomisation is supportive (T3, T4). Strong is not supported: Zhang 2014 (27 prospective studies) found no significant effect of heavy drinking on ischaemic stroke, and the prospective effect is small. Settled at Moderate by the curation pass (card G12). corrections.json _whyT3T4
Fine particulate air pollution → Ischaemic stroke
pm25|stroke_isch
| Field | Before | After |
| Reviews counted | 1 | 4 |
| Effective reviews (N_eff) | 1 | 2.09 |
| Score (ESS) | 6.1 | 10.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source pm25_ihd_alexeeff Estimate design cohort synthesis Outcome match exact Outcome measured new ischaemic stroke Adjudicating bodies who_air: WHO 2021 review covers stroke; gbd2021rf: rates this pair in GBD 2021 (star rating not recorded on the link) |
Outcome match, Outcome measured: The estimate measures: new ischaemic stroke. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: escape_stroke (weight 1.0), pm25_ihd_alexeeff (weight 0.55), who_air (weight 0.17), gbd2021rf (weight 0.38). reviews_counted
Also changed in: 1.4 (19 Sep 2026)1.3 (9 Sep 2026)
Chronic kidney disease (as a risk factor) → Ischaemic stroke
ckd_exposure|stroke_isch
| Field | Before | After |
| Reviews counted | 4 | 1 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 21.2 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source egfr_stroke_lee Estimate design cohort synthesis Outcome match broader Outcome measured all incident stroke Related outcome true |
Outcome match, Outcome measured, Related outcome: The estimate measures: all incident stroke. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: egfr_stroke_lee (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Processed meat → Ischaemic stroke
processed_meat|stroke_isch
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.58 |
| Score (ESS) | 4.0 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source foodgroups_schwingshackl Estimate design cohort synthesis Outcome match broader Outcome measured stroke (all types) Related outcome true Grade basis Suggestive: a linear dose-response for stroke of any type, 1.17 (1.02 to 1.34), with the serving size unconfirmed (revie…Suggestive: a linear dose-response for stroke of any type, 1.17 (1.02 to 1.34), with the serving size unconfirmed (review note). Accepted by the verifier. |
Outcome match, Outcome measured, Related outcome: The estimate measures: stroke (all types). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: Suggestive: a linear dose-response for stroke of any type, 1.17 (1.02 to 1.34), with the serving size unconfirmed (review note). Accepted by the verifier. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: meat_micha (weight 1.0), foodgroups_schwingshackl (weight 0.58). reviews_counted
Low fruit and vegetable intake → Ischaemic stroke
low_fruit|stroke_isch
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.58 |
| Score (ESS) | 6.3 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source fruitveg_aune Estimate design cohort synthesis Outcome match broader Outcome measured stroke (all types) Related outcome true Grade override Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. T…Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. The link sits in the related-outcome layer. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. Adjudicating bodies gbd2021rf: rates this pair in GBD 2021 (star rating not recorded on the link) |
Outcome match, Outcome measured, Related outcome: The estimate measures: stroke (all types). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade override: Curator override to Moderate: T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. The link sits in the related-outcome layer. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT8c
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: fruitveg_aune (weight 1.0), gbd2021rf (weight 0.58). reviews_counted
Low vegetable intake → Ischaemic stroke
low_veg|stroke_isch
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.5 |
| Score (ESS) | 8.6 | 11.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source bprf_veg Estimate design cohort synthesis Outcome match exact Outcome measured ischaemic stroke Grade override Moderate. T8c (healthy-user check, amended) proposes Suggestive; Burden of Proof rates the pair at three stars, which al…Moderate. T8c (healthy-user check, amended) proposes Suggestive; Burden of Proof rates the pair at three stars, which allows Moderate. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. Adjudicating bodies bprf_veg: 3 stars External grades Burden of Proof 3 stars (bprf_veg) |
Outcome match, Outcome measured: The estimate measures: ischaemic stroke. measured_outcome
Grade override: Curator override to Moderate: T8c (healthy-user check, amended) proposes Suggestive; Burden of Proof rates the pair at three stars, which allows Moderate. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT8c
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: fruitveg_aune (weight 1.0), bprf_veg (weight 0.5). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Low whole grain intake → Ischaemic stroke
low_wholegrain|stroke_isch
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.62 |
| Score (ESS) | 1.9 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source wholegrain_aune Estimate design cohort synthesis Outcome match broader Outcome measured stroke (all types) Related outcome true Adjudicating bodies gbd2021rf: rates this pair in GBD 2021 (star rating not recorded on the link) |
Outcome match, Outcome measured, Related outcome: The estimate measures: stroke (all types). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: wholegrain_aune (weight 1.0), gbd2021rf (weight 0.62). reviews_counted
Also changed in: 1.3 (9 Sep 2026)
Mediterranean dietary pattern → Ischaemic stroke
mediterranean|stroke_isch
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.29 |
| Score (ESS) | 7.7 | empty |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources predimed); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source medd_becerra Estimate design cohort synthesis Outcome match broader Outcome measured stroke incidence (all types) Related outcome true |
Outcome match, Outcome measured, Related outcome: The estimate measures: stroke incidence (all types). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: medd_grosso (weight 1.0), medd_becerra (weight 0.29). reviews_counted
Depression (as a risk factor) → Ischaemic stroke
depression_exposure|stroke_isch
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 1 | 3 |
| Effective reviews (N_eff) | 1 | 1.87 |
| Score (ESS) | 7.7 | 8.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) null (sources cai2019_mdd_stroke_mr); dose-response yes |
| Sources | depression_stroke_pan | depression_stroke_pan dong2012_depression_stroke ashraf2024_depression_stroke cai2019_mdd_stroke_mr |
| New fields | not recorded before | Measure HR Estimate source depression_stroke_pan Estimate design cohort synthesis Outcome match exact Outcome measured ischaemic stroke Grade basis C3/T2: a Mendelian randomisation study of major depression and all ischaemic stroke is null (OR 1.03, 0.92-1.15); only s…C3/T2: a Mendelian randomisation study of major depression and all ischaemic stroke is null (OR 1.03, 0.92-1.15); only small-vessel stroke is positive. Same exposure, same outcome: record mr as null. Three syntheses agree on the association (Pan 2011: ischaemic HR 1.25, 6 studies; Dong 2012: all stroke RR 1.34, publication bias possible; Ashraf 2024: ischaemic HR 1.30, 44 studies). No treatment trial lowers stroke. Suggestive, consistent with depression and CHD. Studies 6 |
Outcome match, Outcome measured: The estimate measures: ischaemic stroke. measured_outcome
Grade: C3/T2: a Mendelian randomisation study of major depression and all ischaemic stroke is null (OR 1.03, 0.92-1.15); only small-vessel stroke is positive. Same exposure, same outcome: record mr as null. Three syntheses agree on the association (Pan 2011: ischaemic HR 1.25, 6 studies; Dong 2012: all stroke RR 1.34, publication bias possible; Ashraf 2024: ischaemic HR 1.30, 44 studies). No treatment trial lowers stroke. Suggestive, consistent with depression and CHD. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G11): dong2012_depression_stroke, ashraf2024_depression_stroke, cai2019_mdd_stroke_mr; the displayed estimate is unchanged. estimate_source depression_stroke_pan, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). triangulation.mr null recorded with its sources (card G11, research pass): Seventy-two genetic variants for major depression: null for all ischaemic stroke (OR 1.03, 0.92 to 1.15); positive only for small-vessel stroke (OR 1.33, 1.08 to 1.65). n_studies from the displayed review (card G12, research pass; PubMed 21934057). Grade Moderate to Suggestive (card G12, settled by the research pass). grade_basisC3T2
Grade basis: C3/T2: a Mendelian randomisation study of major depression and all ischaemic stroke is null (OR 1.03, 0.92-1.15); only small-vessel stroke is positive. Same exposure, same outcome: record mr as null. Three syntheses agree on the association (Pan 2011: ischaemic HR 1.25, 6 studies; Dong 2012: all stroke RR 1.34, publication bias possible; Ashraf 2024: ischaemic HR 1.30, 44 studies). No treatment trial lowers stroke. Suggestive, consistent with depression and CHD. grade_basisC3T2
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: depression_stroke_pan (weight 1.0), dong2012_depression_stroke (weight 0.17), ashraf2024_depression_stroke (weight 0.71). reviews_counted
Studies, Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G11): dong2012_depression_stroke, ashraf2024_depression_stroke, cai2019_mdd_stroke_mr; the displayed estimate is unchanged. estimate_source depression_stroke_pan, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). triangulation.mr null recorded with its sources (card G11, research pass): Seventy-two genetic variants for major depression: null for all ischaemic stroke (OR 1.03, 0.92 to 1.15); positive only for small-vessel stroke (OR 1.33, 1.08 to 1.65). n_studies from the displayed review (card G12, research pass; PubMed 21934057). Grade Moderate to Suggestive (card G12, settled by the research pass). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Short sleep → Ischaemic stroke
short_sleep|stroke_isch
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.55 |
| Score (ESS) | 3.6 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source sleep_cappuccio Estimate design cohort synthesis Outcome match broader Outcome measured total stroke Related outcome true Grade basis Suggestive: the source gives P = 0.047 for the stroke estimate, so the lower bound sits just above 1 before rounding (ab…Suggestive: the source gives P = 0.047 for the stroke estimate, so the lower bound sits just above 1 before rounding (about 1.002) and rule T1 does not apply. One estimate for stroke of any type (related-outcome layer); short sleep is prone to reverse causation (T8c). The approved change to Weak (card G3) was conditional on the unrounded bound and is withdrawn. ci_low_exact 1.002 |
Outcome match, Outcome measured, Related outcome: The estimate measures: total stroke. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: Suggestive: the source gives P = 0.047 for the stroke estimate, so the lower bound sits just above 1 before rounding (about 1.002) and rule T1 does not apply. One estimate for stroke of any type (related-outcome layer); short sleep is prone to reverse causation (T8c). The approved change to Weak (card G3) was conditional on the unrounded bound and is withdrawn. grade_basisT1T8c
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: sleep_cappuccio (weight 1.0), sleep_yin (weight 0.55). reviews_counted
ci_low_exact: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source sleep_cappuccio, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): Lower bound 1.00; total stroke (confirm the unrounded bound). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Grade Weak to Suggestive (blocker 7): Suggestive: the source gives P = 0.047 for the stroke estimate, so the lower bound sits just above 1 before rounding (about 1.002) and rule T1 does not apply. One estimate for stroke of any type (related-outcome layer); short sleep is prone to reverse causation (T8c). The approved change to Weak (card G3) was conditional on the unrounded bound and is withdrawn. ci_low_exact 1.002 recorded, derived from the published two-sided P value of 0.047 (blocker 7). corrections.json _whyT1T8c
Also changed in: 1.3 (9 Sep 2026)
Obstructive sleep apnoea → Ischaemic stroke
osa|stroke_isch
| Field | Before | After |
| Effective reviews (N_eff) | 2 | 1.44 |
| Score (ESS) | 17.5 | empty |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response yes | Trial null (sources save_cpap); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source osa_wang Estimate design cohort synthesis Outcome match broader Outcome measured stroke (all types) Related outcome true |
Outcome match, Outcome measured, Related outcome: The estimate measures: stroke (all types). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: osa_dong (weight 1.0), osa_wang (weight 0.0), osa_xie (weight 0.44). reviews_counted
Secondhand smoke → Ischaemic stroke
shs|stroke_isch
| Field | Before | After |
| Effective reviews (N_eff) | 2 | 1.78 |
| Score (ESS) | 8.0 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source shs_lee_stroke Estimate design cohort synthesis Outcome match broader Outcome measured all stroke Related outcome true Grade basis Suggestive: publication bias is flagged and the prospective studies alone give 1.15 (review note). Kept by the verifier. Adjudicating bodies bprf_shs: rates this pair (star rating not recorded on the link) |
Outcome match, Outcome measured, Related outcome: The estimate measures: all stroke. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: Suggestive: publication bias is flagged and the prospective studies alone give 1.15 (review note). Kept by the verifier. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: shs_fischer (weight 1.0), shs_lee_stroke (weight 0.17), bprf_shs (weight 0.62). reviews_counted
Low socioeconomic position → Ischaemic stroke
low_sep|stroke_isch
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.55 |
| Score (ESS) | 9.2 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources sep_educ_mr_gill; a different exposure); dose-response yes |
| New fields | not recorded before | Measure HR Estimate source sep_stroke_kerr Estimate design cohort synthesis Outcome match broader Outcome measured all strokes Related outcome true Grade basis Suggestive: the outcome is stroke of any type and classic risk factors explain part of the excess; genetic studies of ed…Suggestive: the outcome is stroke of any type and classic risk factors explain part of the excess; genetic studies of education support an effect. Kept by the verifier. |
Outcome match, Outcome measured, Related outcome: The estimate measures: all strokes. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: Suggestive: the outcome is stroke of any type and classic risk factors explain part of the excess; genetic studies of education support an effect. Kept by the verifier. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: sep_stroke_kerr (weight 1.0), sep_khaing (weight 0.55). reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source sep_stroke_kerr, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). triangulation.mr supportive, same_exposure false (cards G6, G11): The genetic studies are of education, one part of socioeconomic position. grade_basis records why the grade stands (card G3) corrections.json _why
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)1.3 (9 Sep 2026)
Blood pressure treatment → Ischaemic stroke
antihypertensives|stroke_isch
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Score (ESS) | 12.3 | empty |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources bp_ettehad bpltt); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source bp_ettehad Estimate design trial synthesis Outcome match broader Outcome measured stroke (all types) Related outcome true Grade basis Kept at Strong by the verified dry run: Trial evidence on total stroke is decisive and most strokes are ischaemic; this…Kept at Strong by the verified dry run: Trial evidence on total stroke is decisive and most strokes are ischaemic; this is an outcome-label problem. Set outcome_match broader and relabel instead of lowering the grade. Adjudicating bodies bpltt: blood pressure lowering reduces stroke in trials |
Outcome match, Outcome measured, Related outcome: The estimate measures: stroke (all types). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: Kept at Strong by the verified dry run: Trial evidence on total stroke is decisive and most strokes are ischaemic; this is an outcome-label problem. Set outcome_match broader and relabel instead of lowering the grade. grade_basis
Reviews counted: Counted from the cited syntheses under the review-counting rule: bp_ettehad (weight 1.0). reviews_counted
Statin treatment → Ischaemic stroke
statins|stroke_isch
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources ctt ctt2012); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure rate ratio Estimate source ctt Estimate design trial synthesis Outcome match exact Outcome measured ischaemic stroke Adjudicating bodies ctt: statin trials reduce ischaemic stroke; ctt2012: statin trials reduce ischaemic stroke |
The estimate measures: ischaemic stroke. measured_outcome
Also changed in: 1.4 (21 Oct 2026)
Pre-eclampsia → Ischaemic stroke
preeclampsia|stroke_isch
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.67 |
| Score (ESS) | 14.5 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source preeclampsia_bellamy Estimate design cohort synthesis Outcome match broader Outcome measured total stroke Related outcome true |
Outcome match, Outcome measured, Related outcome: The estimate measures: total stroke. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: preeclampsia_bellamy (weight 1.0), preeclampsia_wu (weight 0.67). reviews_counted
Menopausal hormone therapy → Ischaemic stroke
mht|stroke_isch
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources hrt_stroke_bath2005 hrt_cvd_cochrane2015 whi_stroke2003 whi); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source hrt_stroke_bath2005 Estimate design trial synthesis Outcome match exact Outcome measured ischaemic stroke Grade basis Strong: two syntheses of randomised trials (Bath and Gray 2005, 16 trials; the Cochrane review of 2015) and the WHI tria…Strong: two syntheses of randomised trials (Bath and Gray 2005, 16 trials; the Cochrane review of 2015) and the WHI trial agree on more ischaemic stroke with hormone therapy (T3, T4). Verified at Strong on 21 October 2026. |
Outcome match, Outcome measured: The estimate measures: ischaemic stroke. measured_outcome
Grade basis: Strong: two syntheses of randomised trials (Bath and Gray 2005, 16 trials; the Cochrane review of 2015) and the WHI trial agree on more ischaemic stroke with hormone therapy (T3, T4). Verified at Strong on 21 October 2026. grade_basisT3T4
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Combined oral contraceptives → Ischaemic stroke
ocp|stroke_isch
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.29 |
| Score (ESS) | 13.6 | 16.5 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source coc_cochrane Estimate design cohort synthesis Outcome match exact Outcome measured ischaemic stroke |
Outcome match, Outcome measured: The estimate measures: ischaemic stroke. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: ocp_urrutia (weight 1.0), coc_cochrane (weight 0.29). reviews_counted
High blood pressure → Heart failure
high_sbp|heart_failure
| Field | Before | After |
| Reviews counted | 4 | 1 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 20.4 | 10.3 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources bpltt); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source bp_hf_aune Estimate design cohort synthesis Outcome match exact Outcome measured heart failure incidence Adjudicating bodies bpltt: blood pressure lowering reduces heart failure in trials |
Outcome match, Outcome measured: The estimate measures: heart failure incidence. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: bp_hf_aune (weight 1.0). reviews_counted
Type 2 diabetes (as a risk factor) → Heart failure
t2d_exposure|heart_failure
| Field | Before | After |
| Reviews counted | 6 | 3 |
| Effective reviews (N_eff) | 5 | 1.61 |
| Score (ESS) | 37.5 | 22.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources t2d_hf_mr_mordi); dose-response yes |
| New fields | not recorded before | Measure RR Estimate source dm_hf_aune2018 Estimate design cohort synthesis Outcome match exact Outcome measured heart failure |
Outcome match, Outcome measured: The estimate measures: heart failure. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: dm_hf_aune2018 (weight 1.0), ohkuma_dm_hf (weight 0.17), dm_hf_cvd (weight 0.44). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
High body-mass index → Heart failure
high_bmi|heart_failure
| Field | Before | After |
| Reviews counted | 6 | 1 |
| Effective reviews (N_eff) | 5 | 1.0 |
| Score (ESS) | 30.4 | 13.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources larsson2020_bmi_cvd_mr); dose-response yes |
| Sources | bmi_hf_aune gbd2021rf | bmi_hf_aune larsson2020_bmi_cvd_mr |
| New fields | not recorded before | Measure RR Estimate source bmi_hf_aune Estimate design cohort synthesis Outcome match exact Outcome measured heart failure incidence |
Outcome match, Outcome measured: The estimate measures: heart failure incidence. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: bmi_hf_aune (weight 1.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source bmi_hf_aune, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (larsson2020_bmi_cvd_mr) (card G11, blocker 4): Genetically predicted BMI raises heart failure in UK Biobank (Larsson 2020). gbd2021rf removed from the sources (blocker 6): the body does not rate this pair (adjudication pair_match false), so it cannot count as a replication synthesis either; its adjudication entry goes with it. corrections.json _whyT3T4
Current cigarette smoking → Heart failure
smoking|heart_failure
| Field | Before | After |
| Reviews counted | 5 | 1 |
| Effective reviews (N_eff) | 4 | 1.0 |
| Score (ESS) | 38.6 | 17.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources smoking_cvd_mr_larsson); dose-response yes |
| New fields | not recorded before | Measure RR Estimate source smk_hf_aune Estimate design cohort synthesis Outcome match exact Outcome measured heart failure |
Outcome match, Outcome measured: The estimate measures: heart failure. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smk_hf_aune (weight 1.0). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Heavy alcohol use → Heart failure
alcohol_heavy|heart_failure
| Field | Before | After |
| Reviews counted | 3 | 2 |
| Effective reviews (N_eff) | 2 | 1.55 |
| Score (ESS) | 10.9 | 9.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source alc_hf_suita Estimate design cohort synthesis Outcome match exact Outcome measured heart failure Grade basis Suggestive: the meta-analyses disagree, and abstainers carry raised risk (review note). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: heart failure. measured_outcome
Grade basis: Suggestive: the meta-analyses disagree, and abstainers carry raised risk (review note). Kept by the verifier. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: alc_hf_larsson (weight 1.0), alc_hf_suita (weight 0.55). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Chronic kidney disease (as a risk factor) → Heart failure
ckd_exposure|heart_failure
| Field | Before | After |
| Reviews counted | 4 | 1 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 25.1 | 12.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source ckdpc_jama Estimate design pooled IPD Outcome match exact Outcome measured heart failure |
Outcome match, Outcome measured: The estimate measures: heart failure. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: ckdpc_jama (weight 1.0). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Low physical activity → Heart failure
low_pa|heart_failure
| Field | Before | After |
| Reviews counted | 4 | 2 |
| Effective reviews (N_eff) | 3 | 1.5 |
| Score (ESS) | 17.1 | 11.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source pa_hf_aune Estimate design cohort synthesis Outcome match exact Outcome measured heart failure Grade basis Moderate: two reviews and a dose-response; only the reverse-causation watch list points lower. Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: heart failure. measured_outcome
Grade basis: Moderate: two reviews and a dose-response; only the reverse-causation watch list points lower. Kept by the verifier. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: pa_hf_pandey (weight 1.0), pa_hf_aune (weight 0.5). reviews_counted
Obstructive sleep apnoea → Heart failure
osa|heart_failure
| Field | Before | After |
| Reviews counted | 2 | 0 |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response yes | Trial null (sources save_cpap); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source osa_hf_shhs Estimate design single cohort Outcome match exact Outcome measured incident heart failure (men) Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: incident heart failure (men). measured_outcome
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Fine particulate air pollution → Heart failure
pm25|heart_failure
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.67 |
| Score (ESS) | 5.3 | 7.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source airpoll_hf_jia Estimate design cohort synthesis Outcome match exact Outcome measured heart failure (hospital admission, incidence or death) Grade basis Weak: the long-term pooled estimate rests on 14 studies with I-squared 99.95% (review note). Accepted by the verifier. |
Outcome match, Outcome measured: The estimate measures: heart failure (hospital admission, incidence or death). measured_outcome
Grade basis: Weak: the long-term pooled estimate rests on 14 studies with I-squared 99.95% (review note). Accepted by the verifier. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: pm_hf_shah (weight 1.0), airpoll_hf_jia (weight 0.67). reviews_counted
High body-mass index → Atrial fibrillation
high_bmi|afib
| Field | Before | After |
| Reviews counted | 6 | 1 |
| Effective reviews (N_eff) | 5 | 1.0 |
| Score (ESS) | 24.1 | 10.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources larsson2020_bmi_cvd_mr); dose-response yes |
| Sources | bmi_af_aune | bmi_af_aune larsson2020_bmi_cvd_mr |
| New fields | not recorded before | Measure RR Estimate source bmi_af_aune Estimate design cohort synthesis Outcome match exact Outcome measured atrial fibrillation |
Outcome match, Outcome measured: The estimate measures: atrial fibrillation. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: bmi_af_aune (weight 1.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source bmi_af_aune, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (larsson2020_bmi_cvd_mr) (card G11, blocker 4): Genetically predicted BMI raises atrial fibrillation in UK Biobank (Larsson 2020). corrections.json _why
High blood pressure → Atrial fibrillation
high_sbp|afib
| Field | Before | After |
| Reviews counted | 5 | 2 |
| Effective reviews (N_eff) | 4 | 1.38 |
| Score (ESS) | 16.7 | 9.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources georgiopoulos2021_bp_af_mr nazarzadeh2021_bp_af_mr); dose-response yes |
| Sources | bp_af_aune af_umbrella bpltt | bp_af_aune af_umbrella bpltt georgiopoulos2021_bp_af_mr nazarzadeh2021_bp_af_mr |
| New fields | not recorded before | Measure RR Estimate source bp_af_aune Estimate design cohort synthesis Outcome match exact Outcome measured atrial fibrillation Adjudicating bodies bpltt: the cited trial collaboration reports no atrial fibrillation outcome (does not match this pair) |
Outcome match, Outcome measured: The estimate measures: atrial fibrillation. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: af_umbrella (weight 1.0), bp_af_aune (weight 0.38). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source bp_af_aune, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (georgiopoulos2021_bp_af_mr, nazarzadeh2021_bp_af_mr) (card G11, blocker 4): Genetically predicted systolic blood pressure raises atrial fibrillation (OR 1.19 per 10 mmHg, Nazarzadeh 2021; Georgiopoulos 2021). corrections.json _whyT3T4
Heavy alcohol use → Atrial fibrillation
alcohol_heavy|afib
| Field | Before | After |
| Reviews counted | 4 | 3 |
| Effective reviews (N_eff) | 3 | 1.88 |
| Score (ESS) | 23.1 | 18.1 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) supportive; dose-response yes | Trial supportive (sources voskoboinik2020_af_abstinence; a different outcome); Genetic (MR) supportive (sources larsson2…Trial supportive (sources voskoboinik2020_af_abstinence; a different outcome); Genetic (MR) supportive (sources larsson2020_alcohol_cvd_mr yang2022_alcohol_af_mr jiang2020_alcohol_af_mr); dose-response yes |
| Sources | alc_af_gallagher alc_af_yang alc_af_larsson | alc_af_gallagher alc_af_yang alc_af_larsson larsson2020_alcohol_cvd_mr yang2022_alcohol_af_mr jiang2020_alcohol_af_mr voskoboinik2020_af_abstinence |
| New fields | not recorded before | Measure HR Estimate source alc_af_gallagher Estimate design cohort synthesis Outcome match exact Outcome measured incident atrial fibrillation |
Outcome match, Outcome measured: The estimate measures: incident atrial fibrillation. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: alc_af_larsson (weight 1.0), alc_af_gallagher (weight 0.38), alc_af_yang (weight 0.5). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source alc_af_gallagher, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_outcome false (cards G6, G11): The abstinence trial measured recurrence of atrial fibrillation in people who already had it: The trial is not cited on the link. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (larsson2020_alcohol_cvd_mr, yang2022_alcohol_af_mr, jiang2020_alcohol_af_mr) (card G11, blocker 4): Genetically predicted alcohol intake and atrial fibrillation: OR 1.17 (1.00 to 1.37) per SD of log drinks a week (Larsson 2020), at the edge of significance; an ALDH2 analysis in Korea found higher risk in men (Yang 2022); one two-sample analysis found no association (Jiang 2020). The dissent is noted. triangulation.rct supportive with its sources recorded (voskoboinik2020_af_abstinence), same_outcome false (card G11, blocker 4): The abstinence trial measured recurrence of atrial fibrillation in people who already had it (hazard ratio 0.55). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Moderate alcohol use → Atrial fibrillation
alcohol_moderate|afib
| Field | Before | After |
| Reviews counted | 4 | 2 |
| Effective reviews (N_eff) | 3 | 1.38 |
| Score (ESS) | 6.2 | 4.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources larsson2020_alcohol_cvd_mr yang2022_alcohol_af_mr jiang2020_alcohol_af_mr); dose-response yes |
| Sources | alc_af_larsson alc_af_gallagher | alc_af_larsson alc_af_gallagher larsson2020_alcohol_cvd_mr yang2022_alcohol_af_mr jiang2020_alcohol_af_mr |
| New fields | not recorded before | Measure RR Estimate source alc_af_larsson Estimate design cohort synthesis Outcome match exact Outcome measured atrial fibrillation |
Outcome match, Outcome measured: The estimate measures: atrial fibrillation. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: alc_af_larsson (weight 1.0), alc_af_gallagher (weight 0.38). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source alc_af_larsson, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (larsson2020_alcohol_cvd_mr, yang2022_alcohol_af_mr, jiang2020_alcohol_af_mr) (card G11, blocker 4): Genetically predicted alcohol intake and atrial fibrillation: OR 1.17 (1.00 to 1.37) per SD of log drinks a week (Larsson 2020), at the edge of significance; an ALDH2 analysis in Korea found higher risk in men (Yang 2022); one two-sample analysis found no association (Jiang 2020). The dissent is noted. corrections.json _why
Obstructive sleep apnoea → Atrial fibrillation
osa|afib
| Field | Before | After |
| Reviews counted | 3 | 1 |
| Effective reviews (N_eff) | 2 | 1.0 |
| Score (ESS) | 15.1 | 9.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source osa_af_li Estimate design cohort synthesis Outcome match exact Outcome measured atrial fibrillation |
Outcome match, Outcome measured: The estimate measures: atrial fibrillation. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: osa_af_li (weight 1.0). reviews_counted
Current cigarette smoking → Atrial fibrillation
smoking|afib
| Field | Before | After |
| Reviews counted | 4 | 1 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 17.8 | 9.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source smk_af_aune Estimate design cohort synthesis Outcome match exact Outcome measured atrial fibrillation |
Outcome match, Outcome measured: The estimate measures: atrial fibrillation. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smk_af_aune (weight 1.0). reviews_counted
Low cardiorespiratory fitness → Atrial fibrillation
low_fitness|afib
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source crf_af Estimate design cohort synthesis Outcome match exact Outcome measured incident atrial fibrillation |
Outcome match, Outcome measured: The estimate measures: incident atrial fibrillation. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: crf_af (weight 1.0). reviews_counted
Type 2 diabetes (as a risk factor) → Atrial fibrillation
t2d_exposure|afib
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 3 | 2 |
| Effective reviews (N_eff) | 2 | 1.0 |
| Score (ESS) | 16.3 | 7.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source dm_af_huxley Estimate design cohort synthesis Outcome match exact Outcome measured atrial fibrillation Grade basis Suggestive: Bias-adjusted estimates fall to 1.24 to 1.34. Rules T9b, T10 (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: atrial fibrillation. measured_outcome
Grade: Suggestive: Bias-adjusted estimates fall to 1.24 to 1.34. Rules T9b, T10 (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source dm_af_huxley, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Bias-adjusted estimates fall to 1.24 to 1.34. grade_basisT9bT10
Grade basis: Suggestive: Bias-adjusted estimates fall to 1.24 to 1.34. Rules T9b, T10 (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT9bT10
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: af_umbrella (weight 1.0), dm_af_huxley (weight 0.0). reviews_counted
Current cigarette smoking → Peripheral artery disease
smoking|pad
| Field | Before | After |
| Reviews counted | 6 | 4 |
| Effective reviews (N_eff) | 5 | 2.07 |
| Score (ESS) | 60.4 | 42.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources smoking_mr_levin smoking_cvd_mr_larsson); dose-response yes |
| Sources | bprf_smoking smoking_mr_levin smoking_cvd_mr_larsson pad_fowkes | bprf_smoking smoking_mr_levin smoking_cvd_mr_larsson pad_fowkes xu2024_smoking_pad_sex lu2014_smoking_pad |
| New fields | not recorded before | Measure RR Estimate source bprf_smoking Estimate design cohort synthesis Outcome match exact Outcome measured peripheral artery disease Adjudicating bodies bprf_smoking: 5 stars External grades Burden of Proof 5 stars (bprf_smoking) |
Outcome match, Outcome measured: The estimate measures: peripheral artery disease. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: pad_fowkes (weight 1.0), lu2014_smoking_pad (weight 0.17), bprf_smoking (weight 0.62), xu2024_smoking_pad_sex (weight 0.29). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card K1): xu2024_smoking_pad_sex, lu2014_smoking_pad; the displayed estimate is unchanged. estimate_source bprf_smoking, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). external_grades transcribed from the caveat, the review note or the quote (rule T11). corrections.json _whyT3T4T11
Also changed in: 1.4 (19 Sep 2026)
Type 2 diabetes (as a risk factor) → Peripheral artery disease
t2d_exposure|pad
| Field | Before | After |
| Effective reviews (N_eff) | 2 | 1.71 |
| Score (ESS) | 24.1 | 21.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source pad_fowkes Estimate design cohort synthesis Outcome match exact Outcome measured prevalent PAD defined by low ankle-brachial index in surveys |
Outcome match, Outcome measured: The estimate measures: prevalent PAD defined by low ankle-brachial index in surveys. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: pad_fowkes (weight 1.0), pad_global2019 (weight 0.55), dm_pad_peters (weight 0.17). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
High blood pressure → Peripheral artery disease
high_sbp|pad
| Field | Before | After |
| Reviews counted | 1 | 0 |
| Trial and genetic evidence | Trial contradicts; Genetic (MR) supportive; dose-response yes | Trial contradicts (sources bp_pad_rct_2025; a different exposure); Genetic (MR) supportive (sources bp_pad_mr_levin); dose-response yes |
| New fields | not recorded before | Measure OR Estimate source bp_pad_mr_levin Estimate design MR Outcome match exact Outcome measured peripheral artery disease (genetic estimate) Grade override Moderate. Kept by the verifier (card G6): the trials compared intensive with standard lowering in people at high risk, w…Moderate. Kept by the verifier (card G6): the trials compared intensive with standard lowering in people at high risk, which is another exposure contrast from lifelong higher pressure. Mendelian randomisation (1.20 per 10 mmHg) and a cohort of 4.2 million adults agree on harm. C3 proposes Suggestive. Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: peripheral artery disease (genetic estimate). measured_outcome
Grade override: Curator override to Moderate: Kept by the verifier (card G6): the trials compared intensive with standard lowering in people at high risk, which is another exposure contrast from lifelong higher pressure. Mendelian randomisation (1.20 per 10 mmHg) and a cohort of 4.2 million adults agree on harm. C3 proposes Suggestive. grade_overrideC3
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source bp_pad_mr_levin, estimate_design MR, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation.rct contradicts, same_exposure false (cards G6, G11): The trials compared intensive with standard blood pressure lowering in people at high cardiometabolic risk, which is another exposure contrast from lifelong higher pressure. grade_override keeps Moderate: Kept by the verifier (card G6): the trials compared intensive with standard lowering in people at high risk, which is another exposure contrast from lifelong higher pressure: Mendelian randomisation (1.20 per 10 mmHg) and a cohort of 4.2 million adults agree on harm. C3 proposes Suggestive. corrections.json _whyC3
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
High LDL cholesterol → Peripheral artery disease
high_ldl|pad
| Field | Before | After |
| Reviews counted | 1 | 0 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) supportive; dose-response yes | Trial supportive (sources hps2007_pad); Genetic (MR) supportive (sources ldl_pad_mr); dose-response yes |
| Sources | ldl_pad_mr ctt | ldl_pad_mr hps2007_pad |
| New fields | not recorded before | Measure RR Estimate source ldl_pad_mr Estimate design MR Outcome match exact Outcome measured peripheral artery disease (genetic estimate) Grade basis Strong: Mendelian randomisation per 1 mmol/L LDL (the displayed estimate) and the Heart Protection Study, where statin t…Strong: Mendelian randomisation per 1 mmol/L LDL (the displayed estimate) and the Heart Protection Study, where statin treatment cut peripheral vascular events, agree (T3, T4). Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: peripheral artery disease (genetic estimate). measured_outcome
Grade basis: Strong: Mendelian randomisation per 1 mmol/L LDL (the displayed estimate) and the Heart Protection Study, where statin treatment cut peripheral vascular events, agree (T3, T4). grade_basisT3T4
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source ldl_pad_mr, estimate_design MR, measure RR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct supportive with its sources recorded (hps2007_pad) (card G11, blocker 3, blocker 4): In the Heart Protection Study, simvastatin (LDL 1.0 mmol/L lower) cut first peripheral vascular events by 16% (5 to 25) among 20,536 high-risk people, a third of whom had peripheral artery disease at entry. The CTT analyses report no peripheral artery disease outcome. ctt removed from the sources (blocker 3): the CTT analysis reports no peripheral artery disease, so it is neither an adjudicator nor a trial line for this pair; its adjudication entry goes with it. Grade stays Strong (blocker 3); grade_basis rewritten: Strong: Mendelian randomisation per 1 mmol/L LDL (the displayed estimate) and the Heart Protection Study, where statin treatment cut peripheral vascular events, agree (T3, T4). corrections.json _whyT3T4
Also changed in: 1.4 (21 Oct 2026)
Chronic kidney disease (as a risk factor) → Peripheral artery disease
ckd_exposure|pad
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source ckdpc_pad Estimate design pooled IPD Outcome match exact Outcome measured incident peripheral artery disease |
Outcome match, Outcome measured: The estimate measures: incident peripheral artery disease. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: ckdpc_pad (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Current cigarette smoking → Abdominal aortic aneurysm
smoking|aaa
| Field | Before | After |
| Reviews counted | 4 | 3 |
| Effective reviews (N_eff) | 3 | 1.82 |
| Score (ESS) | 43.2 | 33.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | smk_aaa | smk_aaa bprf_smoking zhang2025_aaa_risk |
| New fields | not recorded before | Measure RR Estimate source smk_aaa Estimate design cohort synthesis Outcome match exact Outcome measured abdominal aortic aneurysm Grade basis Moderate, the v1.4 grade. With the Burden of Proof rating attached (five stars for aortic aneurysm, card K1) the decisio…Moderate, the v1.4 grade. With the Burden of Proof rating attached (five stars for aortic aneurysm, card K1) the decision table allows Strong; card G10 rules out an automatic upgrade, so the later curation pass decides. Adjudicating bodies bprf_smoking: 5 stars (outcome aortic aneurysm, thoracic and abdominal) External grades Burden of Proof 5 stars (aortic aneurysm) (bprf_smoking) |
Outcome match, Outcome measured: The estimate measures: abdominal aortic aneurysm. measured_outcome
Grade basis: Moderate, the v1.4 grade. With the Burden of Proof rating attached (five stars for aortic aneurysm, card K1) the decision table allows Strong; card G10 rules out an automatic upgrade, so the later curation pass decides. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smk_aaa (weight 1.0), bprf_smoking (weight 0.44), zhang2025_aaa_risk (weight 0.38). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card K1): bprf_smoking, zhang2025_aaa_risk; the displayed estimate is unchanged. estimate_source smk_aaa, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). external_grades transcribed from the caveat, the review note or the quote (rule T11). Grade recorded as Moderate, the v1.4 grade (card G10: no automatic upgrade). corrections.json _whyT3T4T11
High blood pressure → Abdominal aortic aneurysm
high_sbp|aaa
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source bp_aaa Estimate design cohort synthesis Outcome match exact Outcome measured abdominal aortic aneurysm |
Outcome match, Outcome measured: The estimate measures: abdominal aortic aneurysm. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: bp_aaa (weight 1.0). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
High body-mass index → Abdominal aortic aneurysm
high_bmi|aaa
| Field | Before | After |
| Reviews counted | 3 | 1 |
| Effective reviews (N_eff) | 2 | 1.0 |
| Score (ESS) | 4.5 | 2.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source adip_aaa Estimate design cohort synthesis Outcome match exact Outcome measured incident abdominal aortic aneurysm Grade override Suggestive. Kept by the verifier: smoking confounding and a modest effect per unit. T9a proposes Weak because the quote…Suggestive. Kept by the verifier: smoking confounding and a modest effect per unit. T9a proposes Weak because the quote names three studies for thoracic aortic aneurysm; the abdominal estimate pools 12 studies. |
Outcome match, Outcome measured: The estimate measures: incident abdominal aortic aneurysm. measured_outcome
Grade override: Curator override to Suggestive: Kept by the verifier: smoking confounding and a modest effect per unit. T9a proposes Weak because the quote names three studies for thoracic aortic aneurysm; the abdominal estimate pools 12 studies. grade_overrideT9a
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: adip_aaa (weight 1.0). reviews_counted
High body-mass index → Type 2 diabetes
high_bmi|t2d
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.71 |
| Score (ESS) | 29.1 | 42.5 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) supportive; dose-response yes | Trial supportive (sources dpp); Genetic (MR) supportive (sources yuan2020_t2d_atlas_mr dale2017_adiposity_mr); dose-response yes |
| Sources | bmi_t2d_abdullah adip_t2d_bmj dpp | bmi_t2d_abdullah adip_t2d_bmj dpp yuan2020_t2d_atlas_mr dale2017_adiposity_mr |
| New fields | not recorded before | Measure RR Estimate source bmi_t2d_abdullah Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: bmi_t2d_abdullah (weight 1.0), adip_t2d_bmj (weight 0.71). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source bmi_t2d_abdullah, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (yuan2020_t2d_atlas_mr, dale2017_adiposity_mr) (card G11, blocker 4): Genetically predicted adult BMI raises type 2 diabetes (Dale 2017, OR 1.98 per SD; Yuan 2020). corrections.json _why
Abdominal obesity → Type 2 diabetes
central_adiposity|t2d
| Field | Before | After |
| Reviews counted | 3 | 1 |
| Effective reviews (N_eff) | 2 | 1.0 |
| Score (ESS) | 25.7 | 16.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources emdin2017_whr_mr dale2017_adiposity_mr); dose-response yes |
| Sources | adip_t2d_bmj | adip_t2d_bmj emdin2017_whr_mr dale2017_adiposity_mr |
| New fields | not recorded before | Measure RR Estimate source adip_t2d_bmj Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: adip_t2d_bmj (weight 1.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source adip_t2d_bmj, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (emdin2017_whr_mr, dale2017_adiposity_mr) (card G11, blocker 4): Genetically predicted waist-to-hip ratio raises type 2 diabetes (Emdin 2017; Dale 2017, OR 1.82 per SD). corrections.json _why
Low physical activity → Type 2 diabetes
low_pa|t2d
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources dpp; a different exposure); Genetic (MR) supportive (sources yuan2023_pa_t2d_mr meisinger2020_pa_t2d_mr); dose-response yes |
| Sources | pa_t2d_aune dpp | pa_t2d_aune dpp yuan2023_pa_t2d_mr meisinger2020_pa_t2d_mr |
| New fields | not recorded before | Measure RR Estimate source pa_t2d_aune Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes Grade basis Strong: a dose-response synthesis of 81 studies (Aune 2015) and Mendelian randomisation of physical activity (Yuan 2023)…Strong: a dose-response synthesis of 81 studies (Aune 2015) and Mendelian randomisation of physical activity (Yuan 2023) agree (T3, T4); the DPP trial tested a combined lifestyle programme (another exposure contrast, noted). Verified at Strong on 21 October 2026. |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Grade basis: Strong: a dose-response synthesis of 81 studies (Aune 2015) and Mendelian randomisation of physical activity (Yuan 2023) agree (T3, T4); the DPP trial tested a combined lifestyle programme (another exposure contrast, noted). Verified at Strong on 21 October 2026. grade_basisT3T4
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source pa_t2d_aune, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_exposure false (cards G6, G11): DPP tested a lifestyle programme that combined diet, exercise and weight loss (review note). grade_override keeps Strong: The cited DPP trial combined diet, exercise and weight loss, so it is recorded with same_exposure false and rule T3 (Moderate) fails as written: no trial, Mendelian randomisation study or adjudicating body corroborates physical activity alone: New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive (status was none) with its sources recorded (yuan2023_pa_t2d_mr, meisinger2020_pa_t2d_mr) (card G11, G2, blocker 4): Genetically predicted moderate-to-vigorous activity lowers type 2 diabetes (OR 0.70 per unit log-odds, Yuan 2023, 600,000 people for the instruments); an earlier analysis with the few accelerometer-based variants found no association (Meisinger 2020). grade_override removed (blocker 2): the recorded genetic evidence meets rule T3 and gives the second line for T4, so Strong follows from the table. Grade stays Strong (blocker 2); grade_basis rewritten: Strong: a dose-response synthesis of 81 studies (Aune 2015) and Mendelian randomisation of physical activity (Yuan 2023) agree (T3, T4); the DPP trial tested a combined lifestyle programme (another exposure contrast, noted). Verified at Strong on 21 October 2026. corrections.json _whyT3T4
Also changed in: 1.4 (9 Oct 2026)
Sedentary behaviour → Type 2 diabetes
sedentary|t2d
| Field | Before | After |
| Reviews counted | 3 | 2 |
| Effective reviews (N_eff) | 2 | 1.17 |
| Score (ESS) | 5.6 | 3.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source sed_t2d_patterson Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes Grade basis Moderate: television time per hour, adjusted for physical activity; genetic studies support an effect of television view…Moderate: television time per hour, adjusted for physical activity; genetic studies support an effect of television viewing (review note). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Grade basis: Moderate: television time per hour, adjusted for physical activity; genetic studies support an effect of television viewing (review note). Kept by the verifier. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: sed_t2d_patterson (weight 1.0), sed_t2d_bailey (weight 0.17). reviews_counted
Sugar-sweetened drinks → Type 2 diabetes
ssb|t2d
| Field | Before | After |
| Reviews counted | 5 | 2 |
| Effective reviews (N_eff) | 4 | 1.0 |
| Score (ESS) | 17.3 | 7.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source diet_t2d_umbrella Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes External grades NutriGrade high (diet_t2d_umbrella) |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: diet_t2d_umbrella (weight 1.0), asb_t2d_imamura (weight 0.0). reviews_counted
Also changed in: 1.3 (18 Sep 2026)
Processed meat → Type 2 diabetes
processed_meat|t2d
| Field | Before | After |
| Reviews counted | 2 | 3 |
| Effective reviews (N_eff) | 1 | 1.5 |
| Score (ESS) | 5.3 | 7.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source meat_t2d_interconnect Estimate design pooled IPD Outcome match exact Outcome measured incident type 2 diabetes Adjudicating bodies gbd2021rf: rates this pair in GBD 2021 (star rating not recorded on the link) |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: diet_t2d_umbrella (weight 1.0), gbd2021rf (weight 0.5), meat_t2d_interconnect (weight 0.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Unprocessed red meat → Type 2 diabetes
red_meat|t2d
| Field | Before | After |
| Reviews counted | 2 | 3 |
| Effective reviews (N_eff) | 1 | 1.66 |
| Score (ESS) | 2.6 | 3.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source meat_t2d_interconnect Estimate design pooled IPD Outcome match exact Outcome measured incident type 2 diabetes Adjudicating bodies bprf_meat: 2 stars External grades Burden of Proof 2 stars (bprf_meat) |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: diet_t2d_umbrella (weight 1.0), bprf_meat (weight 0.38), meat_t2d_interconnect (weight 0.29). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Current cigarette smoking → Type 2 diabetes
smoking|t2d
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.58 |
| Score (ESS) | 12.3 | 17.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source smoking_t2d_pan Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes Adjudicating bodies bprf_smoking: rates this pair (star rating not recorded on the link) |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoking_t2d_pan (weight 1.0), bprf_smoking (weight 0.58). reviews_counted
Low whole grain intake → Type 2 diabetes
low_wholegrain|t2d
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | diet_t2d_umbrella wholegrain_aune fibre_t2d | diet_t2d_umbrella |
| New fields | not recorded before | Measure HR Estimate source diet_t2d_umbrella Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes Grade override Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. T…Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. T3 and T4 cap at Moderate, the v1.4 grade. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. External grades NutriGrade high (diet_t2d_umbrella) |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Grade override: Curator override to Moderate: T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. T3 and T4 cap at Moderate, the v1.4 grade. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT8cT3T4
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source diet_t2d_umbrella, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). external_grades transcribed from the caveat, the review note or the quote (rule T11). grade_override keeps Moderate: T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone: T3 and T4 cap at Moderate, the v1.4 grade. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. 23 Oct 2026 fix round 3 (verifier of the data step, third check, blockers 1 to 3 and minor items 4, 6, 7): Sources wholegrain_aune and fibre_t2d removed from the link's sources (blocker 2c, card K7 A topic check, PROPOSAL section 5.1): the first pools whole grain against cardiovascular disease, cancer and mortality with no type 2 diabetes estimate, and the second is about dietary fibre, another exposure, so neither replicates this pair; n_reviews 3 to 1, N_eff and the score unchanged (both counted at weight 0 beside the 2019 umbrella review). corrections.json _whyT11T8cT3T4
Also changed in: 1.4 (9 Oct 2026)
Low dietary fibre → Type 2 diabetes
low_fibre|t2d
| Field | Before | After |
| Reviews counted | 4 | 2 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 14.3 | 7.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source fibre_t2d Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes Grade override Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. N…Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. External grades NutriGrade high (cereal fibre only) (diet_t2d_umbrella), does not match this pair |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Grade override: Curator override to Moderate: T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT8c
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: diet_t2d_umbrella (weight 1.0), fibre_t2d (weight 0.0). reviews_counted
Ultra-processed food → Type 2 diabetes
upf|t2d
| Field | Before | After |
| Reviews counted | 3 | 2 |
| Effective reviews (N_eff) | 2 | 1.17 |
| Score (ESS) | 14.2 | 9.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source upf_t2d_delpino Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: upf_t2d_moradi (weight 1.0), upf_t2d_delpino (weight 0.17). reviews_counted
Short sleep → Type 2 diabetes
short_sleep|t2d
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 4 | 3 |
| Effective reviews (N_eff) | 3 | 1.55 |
| Score (ESS) | 16.3 | 7.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source sleep_t2d_cappuccio Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes Grade basis Suggestive: Interval 1.03 to 1.60; U-shaped relation. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Grade: Suggestive: Interval 1.03 to 1.60; U-shaped relation. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source sleep_t2d_cappuccio, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Interval 1.03 to 1.60; U-shaped relation. grade_basisT8a
Grade basis: Suggestive: Interval 1.03 to 1.60; U-shaped relation. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT8a
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: sleep_t2d_cappuccio (weight 1.0), sleep_t2d_anoth (weight 0.55), sleep_t2d_shan (weight 0.0). reviews_counted
Insomnia → Type 2 diabetes
insomnia|t2d
| Field | Before | After |
| Effective reviews (N_eff) | 2 | 1.0 |
| Score (ESS) | 16.5 | 10.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources yuan2020_t2d_atlas_mr); dose-response yes |
| Sources | sleep_t2d_anoth psych_t2d_umbrella sleep_t2d_cappuccio | sleep_t2d_anoth psych_t2d_umbrella sleep_t2d_cappuccio yuan2020_t2d_atlas_mr |
| New fields | not recorded before | Measure RR Estimate source sleep_t2d_anoth Estimate design cohort synthesis Outcome match exact Outcome measured incident diabetes (type 2 in the source reviews) |
Outcome match, Outcome measured: The estimate measures: incident diabetes (type 2 in the source reviews). measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: psych_t2d_umbrella (weight 1.0), sleep_t2d_anoth (weight 0.0), sleep_t2d_cappuccio (weight 0.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source sleep_t2d_anoth, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (yuan2020_t2d_atlas_mr) (card G11, blocker 4): Genetic liability to insomnia raises type 2 diabetes (OR 1.17, 1.11 to 1.23; Yuan 2020). corrections.json _why
Night shift work → Type 2 diabetes
night_shift|t2d
| Field | Before | After |
| Reviews counted | 4 | 3 |
| Effective reviews (N_eff) | 3 | 1.81 |
| Score (ESS) | 17.1 | 13.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source nightshift_t2d Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: shift_t2d_gan (weight 1.0), sleep_t2d_anoth (weight 0.17), nightshift_t2d (weight 0.64). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Obstructive sleep apnoea → Type 2 diabetes
osa|t2d
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 4 | 2 |
| Effective reviews (N_eff) | 3 | 1.5 |
| Score (ESS) | 20.3 | 9.5 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial null (sources cattazzo2023_cpap_glucose; a different outcome); Genetic (MR) none; dose-response yes |
| Sources | osa_t2d sleep_t2d_anoth | osa_t2d sleep_t2d_anoth cattazzo2023_cpap_glucose |
| New fields | not recorded before | Measure RR Estimate source osa_t2d Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes Grade basis The cohort meta-analysis (16 cohorts, 338,912 people) gives RR 1.40 (1.32-1.48) with a linear gradient (1.08 per 5 event…The cohort meta-analysis (16 cohorts, 338,912 people) gives RR 1.40 (1.32-1.48) with a linear gradient (1.08 per 5 events an hour). Adjustment for obesity could not be confirmed from the abstract; obesity causes both conditions. CPAP trials do not lower HbA1c, but they test glycaemic markers and none tests new diabetes. Suggestive until adjustment for BMI is checked. Not settled by the curation pass of card G12, so the verifier's best estimate (Suggestive) applies. Whether the 16 cohorts adjusted for body-mass index was not confirmed, and obesity causes both conditions. Studies 16 |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Grade: The cohort meta-analysis (16 cohorts, 338,912 people) gives RR 1.40 (1.32-1.48) with a linear gradient (1.08 per 5 events an hour). Adjustment for obesity could not be confirmed from the abstract; obesity causes both conditions. CPAP trials do not lower HbA1c, but they test glycaemic markers and none tests new diabetes. Suggestive until adjustment for BMI is checked. Not settled by the curation pass of card G12, so the verifier's best estimate (Suggestive) applies. Whether the 16 cohorts adjusted for body-mass index was not confirmed, and obesity causes both conditions. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G11): cattazzo2023_cpap_glucose; the displayed estimate is unchanged. estimate_source osa_t2d, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct null recorded with its sources (card G11, research pass): CPAP trials did not lower HbA1c and modestly improved insulin sensitivity. None counted new diabetes, so the null result holds for HbA1c only. n_studies from the displayed review (card G12, research pass; PubMed 31872550). Grade Moderate to Suggestive (card G12, not settled; the verifier's best estimate applies). Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): grade_override removed (minor d): the grade equals the table grade, so the unsettled status of card G12 is recorded in grade_basis instead. grade_basis
Grade basis: The cohort meta-analysis (16 cohorts, 338,912 people) gives RR 1.40 (1.32-1.48) with a linear gradient (1.08 per 5 events an hour). Adjustment for obesity could not be confirmed from the abstract; obesity causes both conditions. CPAP trials do not lower HbA1c, but they test glycaemic markers and none tests new diabetes. Suggestive until adjustment for BMI is checked. Not settled by the curation pass of card G12, so the verifier's best estimate (Suggestive) applies. Whether the 16 cohorts adjusted for body-mass index was not confirmed, and obesity causes both conditions. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: sleep_t2d_anoth (weight 1.0), osa_t2d (weight 0.5). reviews_counted
Studies: Contrast mismatch again: 1.40 is the any-OSA estimate from 16 cohorts, and the stated moderate-severe contrast would be higher. Confounding by adiposity is the central problem here because obesity causes both conditions, and CPAP trials have not shown improved glycaemia, so grade should stay no higher than Moderate. review_note
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G11): cattazzo2023_cpap_glucose; the displayed estimate is unchanged. estimate_source osa_t2d, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct null recorded with its sources (card G11, research pass): CPAP trials did not lower HbA1c and modestly improved insulin sensitivity. None counted new diabetes, so the null result holds for HbA1c only. n_studies from the displayed review (card G12, research pass; PubMed 31872550). Grade Moderate to Suggestive (card G12, not settled; the verifier's best estimate applies). corrections.json _why
Gestational diabetes → Type 2 diabetes
gdm|t2d
| Field | Before | After |
| Reviews counted | 5 | 2 |
| Effective reviews (N_eff) | 4 | 1.69 |
| Score (ESS) | 52.9 | 34.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source gdm_t2d_vounz Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes after gestational diabetes Grade basis Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure…Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure and outcome, and no adjudicating body that rated this pair. |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes after gestational diabetes. measured_outcome
Grade basis: Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure and outcome, and no adjudicating body that rated this pair. grade_basisT3
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: gdm_t2d_bellamy (weight 1.0), gdm_t2d_vounz (weight 0.69). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Polycystic ovary syndrome → Type 2 diabetes
pcos|t2d
| Field | Before | After |
| Reviews counted | 3 | 2 |
| Effective reviews (N_eff) | 2 | 1.17 |
| Score (ESS) | 31.0 | 21.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source pcos_cardiometab Estimate design cohort synthesis Outcome match exact Outcome measured type 2 diabetes in women with PCOS |
Outcome match, Outcome measured: The estimate measures: type 2 diabetes in women with PCOS. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: pcos_cardiometab (weight 1.0), pcos_t2d_obesity (weight 0.17). reviews_counted
Depression (as a risk factor) → Type 2 diabetes
depression_exposure|t2d
| Field | Before | After |
| Reviews counted | 4 | 2 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 25.1 | 12.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source dep_t2d_mezuk Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes Grade basis The reverse estimate is 1.15 (1.02-1.30) from 7 studies against 1.60 (1.37-1.88) from 13 studies for depression to diabe…The reverse estimate is 1.15 (1.02-1.30) from 7 studies against 1.60 (1.37-1.88) from 13 studies for depression to diabetes. A two-way relation that is this uneven does not mean reverse causation dominates (T8b does not fire). The review kept only prospective studies that excluded prevalent diabetes. T8a: antidepressant use may mediate (not separated). Moderate. Grade override Moderate. Settled at Moderate by the curation pass (card G12). The reverse estimate is 1.15 from 7 studies against 1.60…Moderate. Settled at Moderate by the curation pass (card G12). The reverse estimate is 1.15 from 7 studies against 1.60 from 13 studies forward, and the review kept only prospective studies that excluded people who already had diabetes, so reverse causation does not dominate. T8a fires on the word 'Bidirectional' in the caveat. |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Grade basis, Grade override: Curator override to Moderate: Settled at Moderate by the curation pass (card G12). The reverse estimate is 1.15 from 7 studies against 1.60 from 13 studies forward, and the review kept only prospective studies that excluded people who already had diabetes, so reverse causation does not dominate. T8a fires on the word 'Bidirectional' in the caveat. The reverse estimate is 1.15 (1.02-1.30) from 7 studies against 1.60 (1.37-1.88) from 13 studies for depression to diabetes. A two-way relation that is this uneven does not mean reverse causation dominates (T8b does not fire). The review kept only prospective studies that excluded prevalent diabetes. T8a: antidepressant use may mediate (not separated). Moderate. grade_override and grade_basisT8bT8a
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: psych_t2d_umbrella (weight 1.0), dep_t2d_mezuk (weight 0.0). reviews_counted
Fine particulate air pollution → Type 2 diabetes
pm25|t2d
| Field | Before | After |
| Reviews counted | 4 | 3 |
| Effective reviews (N_eff) | 3 | 1.5 |
| Score (ESS) | 7.5 | 5.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source liu_pm25_t2d Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: liu_pm25_t2d (weight 1.0), yang_pm25_t2d (weight 0.0), pm25_t2d_azizi (weight 0.5). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Low socioeconomic position → Type 2 diabetes
low_sep|t2d
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source sep_t2d_agardh Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: sep_t2d_agardh (weight 1.0). reviews_counted
Low dairy intake → Type 2 diabetes
low_dairy|t2d
| Field | Before | After |
| Reviews counted | 3 | 2 |
| Effective reviews (N_eff) | 2 | 1.64 |
| Score (ESS) | 2.7 | 2.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source dairy_t2d_gao Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: dairy_t2d_gao (weight 1.0), dairy_t2d_zhang (weight 0.64). reviews_counted
Coffee consumption → Type 2 diabetes
coffee|t2d
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 4 | 2 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 7.4 | 2.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) null (sources nordestgaard2015_coffee_mr kwok2016_coffee_mr cho2023_coffee_t2d_mr larsson2023_caffeine_mr); dose-response yes |
| Sources | coffee_t2d diet_t2d_umbrella | coffee_t2d diet_t2d_umbrella nordestgaard2015_coffee_mr kwok2016_coffee_mr cho2023_coffee_t2d_mr larsson2023_caffeine_mr |
| New fields | not recorded before | Measure RR Estimate source coffee_t2d Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes Grade basis Suggestive: the two Mendelian randomisation studies of habitual coffee intake in Europeans are null (rule T2, ceiling Su…Suggestive: the two Mendelian randomisation studies of habitual coffee intake in Europeans are null (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6); two later genetic studies, in Koreans and of plasma caffeine, point to lower risk and are noted. Some reverse causation is likely (T8a). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Grade: Suggestive: the two Mendelian randomisation studies of habitual coffee intake in Europeans are null (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6); two later genetic studies, in Koreans and of plasma caffeine, point to lower risk and are noted. Some reverse causation is likely (T8a). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G11): nordestgaard2015_coffee_mr, kwok2016_coffee_mr, cho2023_coffee_t2d_mr, larsson2023_caffeine_mr; the displayed estimate is unchanged. estimate_source coffee_t2d, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.mr conflicting recorded with its sources (card G11, research pass): Two Mendelian randomisation studies of habitual coffee intake are null (Copenhagen 2015; Kwok 2016). Two later ones point to lower risk: in Koreans (OR 0.75 to 0.79) and for plasma caffeine (OR 0.81, 0.74 to 0.89, about 43% through body-mass index). Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): MR has not reproduced the protection; record mr as null. grade_override keeps Suggestive: The approved change from Moderate to Suggestive (card G3) assumed a null Mendelian randomisation result (card G11). The research pass found that the genetic studies disagree: two of habitual coffee intake are null and two later ones, in Koreans and of plasma caffeine, show lower risk. The field now records conflicting, and rule C1 would make the link Conflicting. The owner chooses between Suggestive and Conflicting. Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr null (status was conflicting) with its sources recorded (nordestgaard2015_coffee_mr, kwok2016_coffee_mr, cho2023_coffee_t2d_mr, larsson2023_caffeine_mr) (card G11, blocker 2, blocker 4): The two Mendelian randomisation studies of habitual coffee intake in Europeans are null (Copenhagen 2015; Kwok 2016). Two later genetic studies point to lower risk, one in Koreans (OR 0.75 to 0.79) and one of plasma caffeine (OR 0.81, 0.74 to 0.89), another exposure; they are noted and do not change the status. Grade stays Suggestive (card G3, blocker 2); grade_basis rewritten: Suggestive: the two Mendelian randomisation studies of habitual coffee intake in Europeans are null (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6); two later genetic studies, in Koreans and of plasma caffeine, point to lower risk and are noted. Some reverse causation is likely (T8a). Verified on 21 October 2026 (card G3). grade_basisT2C3T8aC1
Grade basis: Suggestive: the two Mendelian randomisation studies of habitual coffee intake in Europeans are null (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6); two later genetic studies, in Koreans and of plasma caffeine, point to lower risk and are noted. Some reverse causation is likely (T8a). Verified on 21 October 2026 (card G3). grade_basisT2C3T8a
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: diet_t2d_umbrella (weight 1.0), coffee_t2d (weight 0.0). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G11): nordestgaard2015_coffee_mr, kwok2016_coffee_mr, cho2023_coffee_t2d_mr, larsson2023_caffeine_mr; the displayed estimate is unchanged. estimate_source coffee_t2d, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.mr conflicting recorded with its sources (card G11, research pass): Two Mendelian randomisation studies of habitual coffee intake are null (Copenhagen 2015; Kwok 2016). Two later ones point to lower risk: in Koreans (OR 0.75 to 0.79) and for plasma caffeine (OR 0.81, 0.74 to 0.89, about 43% through body-mass index). Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): MR has not reproduced the protection; record mr as null. grade_override keeps Suggestive: The approved change from Moderate to Suggestive (card G3) assumed a null Mendelian randomisation result (card G11). The research pass found that the genetic studies disagree: two of habitual coffee intake are null and two later ones, in Koreans and of plasma caffeine, show lower risk. The field now records conflicting, and rule C1 would make the link Conflicting. The owner chooses between Suggestive and Conflicting. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr null (status was conflicting) with its sources recorded (nordestgaard2015_coffee_mr, kwok2016_coffee_mr, cho2023_coffee_t2d_mr, larsson2023_caffeine_mr) (card G11, blocker 2, blocker 4): The two Mendelian randomisation studies of habitual coffee intake in Europeans are null (Copenhagen 2015; Kwok 2016). Two later genetic studies point to lower risk, one in Koreans (OR 0.75 to 0.79) and one of plasma caffeine (OR 0.81, 0.74 to 0.89), another exposure; they are noted and do not change the status. Grade stays Suggestive (card G3, blocker 2); grade_basis rewritten: Suggestive: the two Mendelian randomisation studies of habitual coffee intake in Europeans are null (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6); two later genetic studies, in Koreans and of plasma caffeine, point to lower risk and are noted. Some reverse causation is likely (T8a). Verified on 21 October 2026 (card G3). corrections.json _whyC1T2C3T8a
Statin treatment → Type 2 diabetes
statins|t2d
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources statin_diabetes_sattar); Genetic (MR) supportive (sources swerdlow2015_hmgcr_mr); dose-response yes |
| Sources | statin_diabetes_sattar ctt | statin_diabetes_sattar swerdlow2015_hmgcr_mr |
| New fields | not recorded before | Measure OR Estimate source statin_diabetes_sattar Estimate design trial synthesis Outcome match exact Outcome measured new-onset diabetes in statin trials Grade basis Strong: a collaborative meta-analysis of 13 randomised statin trials (91,140 people) and a genetic analysis of HMGCR var…Strong: a collaborative meta-analysis of 13 randomised statin trials (91,140 people) and a genetic analysis of HMGCR variants agree (T3, T4). The effect is small and is outweighed by cardiovascular benefit (caveat). |
Outcome match, Outcome measured: The estimate measures: new-onset diabetes in statin trials. measured_outcome
Grade basis: Strong: a collaborative meta-analysis of 13 randomised statin trials (91,140 people) and a genetic analysis of HMGCR variants agree (T3, T4). The effect is small and is outweighed by cardiovascular benefit (caveat). grade_basisT3T4
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source statin_diabetes_sattar, estimate_design trial synthesis, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive (status was none) with its sources recorded (swerdlow2015_hmgcr_mr) (card G11, blocker 3, blocker 4): HMGCR variants that mimic statin treatment raise type 2 diabetes risk and body weight (Swerdlow 2015, 223,463 people), in line with the trial meta-analysis. triangulation.rct supportive with its sources recorded (statin_diabetes_sattar) (card G11, blocker 3, blocker 4): The collaborative meta-analysis of 13 statin trials is the displayed estimate. The CTT analyses report no diabetes outcome and are not a trial line for this pair. ctt removed from the sources (blocker 3): the CTT analysis reports no new diabetes, so it is neither an adjudicator nor a trial line for this pair; its adjudication entry goes with it. Grade stays Strong (blocker 3); grade_basis rewritten: Strong: a collaborative meta-analysis of 13 randomised statin trials (91,140 people) and a genetic analysis of HMGCR variants agree (T3, T4). The effect is small and is outweighed by cardiovascular benefit (caveat). corrections.json _whyT3T4
Also changed in: 1.4 (9 Oct 2026)
Low birth weight → Type 2 diabetes
low_birthweight|t2d
| Field | Before | After |
| Reviews counted | 3 | 2 |
| Effective reviews (N_eff) | 2 | 1.69 |
| Score (ESS) | 14.7 | 13.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source bw_t2d_whincup Estimate design cohort synthesis Outcome match exact Outcome measured type 2 diabetes in adulthood |
Outcome match, Outcome measured: The estimate measures: type 2 diabetes in adulthood. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: bw_t2d_whincup (weight 1.0), bw_t2d_zhao (weight 0.69). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Childhood obesity → Type 2 diabetes
childhood_obesity|t2d
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources geng2018_childhood_bmi_mr yuan2020_t2d_atlas_mr); dose-response yes |
| Sources | childobes_morbidity | childobes_morbidity geng2018_childhood_bmi_mr yuan2020_t2d_atlas_mr |
| New fields | not recorded before | Measure OR Estimate source childobes_morbidity Estimate design cohort synthesis Outcome match exact Outcome measured incident adult diabetes Grade basis Suggestive: genetic studies show the effect runs through adult adiposity (review note and mediation). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: incident adult diabetes. measured_outcome
Grade basis: Suggestive: genetic studies show the effect runs through adult adiposity (review note and mediation). Kept by the verifier. grade_basis
Reviews counted: Counted from the cited syntheses under the review-counting rule: childobes_morbidity (weight 1.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source childobes_morbidity, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). grade_basis records why the grade stands (card G3) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (geng2018_childhood_bmi_mr, yuan2020_t2d_atlas_mr) (card G11, blocker 4): Genetically predicted childhood BMI raises adult type 2 diabetes (OR 1.83 per SD, Geng 2018; Yuan 2020), largely through adult BMI. corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Vitamin D deficiency → Type 2 diabetes
vitd_deficiency|t2d
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial contradicts; Genetic (MR) contradicts; dose-response yes | Trial contradicts (sources vital d_health); Genetic (MR) contradicts (sources vitd_t2d_mr_zheng); dose-response yes |
| New fields | not recorded before | Measure RR Estimate source vitd_t2d_forouhi Estimate design cohort synthesis Outcome match exact Outcome measured incident type 2 diabetes Conflict Side A: Cohort studies link low blood vitamin D with more diabetes (1.69, 1.49 to 1.92 for the lowest against the highes…Side A: Cohort studies link low blood vitamin D with more diabetes (1.69, 1.49 to 1.92 for the lowest against the highest quarter). Side B: Mendelian randomisation finds no causal effect (0.96, 0.89 to 1.03 per standard deviation), and supplement trials have not prevented diabetes. Sources: vitd_t2d_forouhi vitd_t2d_mr_zheng vital d_health |
Outcome match, Outcome measured: The estimate measures: incident type 2 diabetes. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: vitd_t2d_forouhi (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
High body-mass index → Fatty liver disease (MASLD)
high_bmi|masld
| Field | Before | After |
| Reviews counted | 4 | 3 |
| Effective reviews (N_eff) | 3 | 1.29 |
| Score (ESS) | 50.1 | 30.7 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) supportive; dose-response yes | Trial supportive (sources promrat2010_nash_trial; a different outcome); Genetic (MR) supportive (sources nafld_mr); dose-response yes |
| Sources | obes_nafld nafld_mr | obes_nafld nafld_mr le2023_nafld_incidence xia2021_nafld_umbrella promrat2010_nash_trial |
| New fields | not recorded before | Measure RR Estimate source obes_nafld Estimate design cohort synthesis Outcome match exact Outcome measured incident fatty liver disease (NAFLD, now MASLD) Grade override Strong. New disagreement for the owner (card G3 A): the Xia 2021 umbrella review grades BMI and NAFLD as suggestive (cla…Strong. New disagreement for the owner (card G3 A): the Xia 2021 umbrella review grades BMI and NAFLD as suggestive (class III) on its statistical criteria, and rule T11 proposes Suggestive. Against that, 21 cohorts give a 3.5-fold risk, a dose-response gradient, Mendelian randomisation supports causality and a 2023 incidence synthesis agrees. Kept at Strong until the owner decides. External grades umbrella review (Ioannidis classes) class III (suggestive) (xia2021_nafld_umbrella) |
Outcome match, Outcome measured: The estimate measures: incident fatty liver disease (NAFLD, now MASLD). measured_outcome
Grade override: Curator override to Strong: New disagreement for the owner (card G3 A): the Xia 2021 umbrella review grades BMI and NAFLD as suggestive (class III) on its statistical criteria, and rule T11 proposes Suggestive. Against that, 21 cohorts give a 3.5-fold risk, a dose-response gradient, Mendelian randomisation supports causality and a 2023 incidence synthesis agrees. Kept at Strong until the owner decides. grade_overrideT11
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: xia2021_nafld_umbrella (weight 1.0), obes_nafld (weight 0.0), le2023_nafld_incidence (weight 0.29). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card K1): le2023_nafld_incidence, xia2021_nafld_umbrella; the displayed estimate is unchanged. estimate_source obes_nafld, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_outcome false (cards G6, G11): The weight-loss trials measured reversal of steatohepatitis in people who already had it. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct supportive with its sources recorded (promrat2010_nash_trial), same_outcome false (card G11, blocker 4): The weight-loss trial measured reversal of steatohepatitis in people who already had it. external_grades records the Xia 2021 umbrella review rating of BMI and NAFLD, suggestive (class III), with pair_match true (rule T11, blocker 5). grade_override keeps Strong (blocker 5): New disagreement for the owner (card G3 A): the Xia 2021 umbrella review grades BMI and NAFLD as suggestive (class III) on its statistical criteria, and rule T11 proposes Suggestive. Against that, 21 cohorts give a 3.5-fold risk, a dose-response gradient, Mendelian randomisation supports causality and a 2023 incidence synthesis agrees. Kept at Strong until the owner decides. corrections.json _whyT11
Abdominal obesity → Fatty liver disease (MASLD)
central_adiposity|masld
| Field | Before | After |
| Reviews counted | 2 | 0 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources nafld_mr); dose-response yes |
| Sources | nafld_mr obes_nafld | nafld_mr |
| New fields | not recorded before | Measure OR Estimate source nafld_mr Estimate design MR Outcome match exact Outcome measured fatty liver disease (NAFLD), genetic liability Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: fatty liver disease (NAFLD), genetic liability. measured_outcome
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source nafld_mr, estimate_design MR, measure OR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source obes_nafld removed from the link's sources (issue 2, card K7 A topic check, PROPOSAL section 5.1): it is a meta-analysis of body-mass index, another exposure, with no waist estimate (as the review note says), so it does not replicate this pair and must not count in the replication term. corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Type 2 diabetes (as a risk factor) → Fatty liver disease (MASLD)
t2d_exposure|masld
| Field | Before | After |
| Reviews counted | 5 | 0 |
| Effective reviews (N_eff) | 4 | 1.0 |
| Score (ESS) | 14.9 | 6.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources nafld_mr); dose-response yes |
| New fields | not recorded before | Measure OR Estimate source nafld_mr Estimate design MR Outcome match exact Outcome measured fatty liver disease (NAFLD), genetic liability Grade basis T5d: the only estimate is one MR analysis. A PubMed search for a cohort synthesis of diabetes and incident fatty liver f…T5d: the only estimate is one MR analysis. A PubMed search for a cohort synthesis of diabetes and incident fatty liver found none (only the reverse direction, fatty liver to diabetes). Not settled. Verifier estimate stands; the table alone gives Suggestive. Grade override Moderate. Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. The only est…Moderate. Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. The only estimate is one Mendelian randomisation analysis, and no cohort synthesis of diabetes and new fatty liver disease was found. Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: fatty liver disease (NAFLD), genetic liability. measured_outcome
Grade basis, Grade override: Curator override to Moderate: Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. The only estimate is one Mendelian randomisation analysis, and no cohort synthesis of diabetes and new fatty liver disease was found. T5d: the only estimate is one MR analysis. A PubMed search for a cohort synthesis of diabetes and incident fatty liver found none (only the reverse direction, fatty liver to diabetes). Not settled. Verifier estimate stands; the table alone gives Suggestive. grade_override and grade_basisT5d
Reviews counted, Effective reviews (N_eff), Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)1.3 (9 Sep 2026)
Sugar-sweetened drinks → Fatty liver disease (MASLD)
ssb|masld
| Field | Before | After |
| Reviews counted | 3 | 2 |
| Effective reviews (N_eff) | 2 | 1.17 |
| Score (ESS) | 11.4 | 8.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source ssb_nafld_asgari Estimate design cohort synthesis Outcome match exact Outcome measured prevalent fatty liver (odds of NAFLD in cross-sectional studies) |
Outcome match, Outcome measured: The estimate measures: prevalent fatty liver (odds of NAFLD in cross-sectional studies). measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: ssb_nafld_asgari (weight 1.0), ssb_nafld_chen (weight 0.17). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Ultra-processed food → Fatty liver disease (MASLD)
upf|masld
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.29 |
| Score (ESS) | 4.8 | 5.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source upf_nafld_2025 Estimate design mixed Outcome match exact Outcome measured fatty liver disease (NAFLD), cohort and cross-sectional studies pooled Grade basis Suggestive: two reviews disagree in size and adiposity is not separated (review note). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: fatty liver disease (NAFLD), cohort and cross-sectional studies pooled. measured_outcome
Grade basis: Suggestive: two reviews disagree in size and adiposity is not separated (review note). Kept by the verifier. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: upf_nafld_henney (weight 1.0), upf_nafld_2025 (weight 0.29). reviews_counted
Low physical activity → Fatty liver disease (MASLD)
low_pa|masld
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources orci2016_exercise_nafld_ma; a different outcome); Genetic (MR) none; dose-response yes |
| Sources | pa_nafld nafld_mr | pa_nafld nafld_mr orci2016_exercise_nafld_ma |
| New fields | not recorded before | Measure RR Estimate source pa_nafld Estimate design cohort synthesis Outcome match exact Outcome measured incident NAFLD in cohort studies Grade basis Moderate: a cohort synthesis with a gradient (0.82 per 500 MET-minutes a week, review note; T7). Exercise trials lower l…Moderate: a cohort synthesis with a gradient (0.82 per 500 MET-minutes a week, review note; T7). Exercise trials lower liver fat in people who already have fatty liver disease, support on a related outcome. T3 caps at Moderate. Activity and adiposity are tightly coupled, which rule T8c flags at low confidence. |
Outcome match, Outcome measured: The estimate measures: incident NAFLD in cohort studies. measured_outcome
Grade basis: Moderate: a cohort synthesis with a gradient (0.82 per 500 MET-minutes a week, review note; T7). Exercise trials lower liver fat in people who already have fatty liver disease, support on a related outcome. T3 caps at Moderate. Activity and adiposity are tightly coupled, which rule T8c flags at low confidence. grade_basisT7T3T8c
Reviews counted: Counted from the cited syntheses under the review-counting rule: pa_nafld (weight 1.0). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source pa_nafld, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct supportive with its sources recorded (orci2016_exercise_nafld_ma), same_outcome false (card G11, blocker 4): Exercise trials lowered liver fat in people who already had fatty liver disease (28 trials, Orci 2016). Grade stays Moderate (blocker 4); grade_basis rewritten: Moderate: a cohort synthesis with a gradient (0.82 per 500 MET-minutes a week, review note; T7). Exercise trials lower liver fat in people who already have fatty liver disease, support on a related outcome. T3 caps at Moderate. Activity and adiposity are tightly coupled, which rule T8c flags at low confidence. corrections.json _whyT7T3T8c
Coffee consumption → Fatty liver disease (MASLD)
coffee|masld
| Field | Before | After |
| Reviews counted | 3 | 1 |
| Effective reviews (N_eff) | 2 | 1.0 |
| Score (ESS) | 3.0 | 1.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source coffee_nafld Estimate design cohort synthesis Outcome match exact Outcome measured incident fatty liver disease |
Outcome match, Outcome measured: The estimate measures: incident fatty liver disease. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: coffee_nafld (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.3 (9 Sep 2026)
Heavy alcohol use → Liver cirrhosis
alcohol_heavy|cirrhosis
| Field | Before | After |
| Reviews counted | 7 | 4 |
| Effective reviews (N_eff) | 6 | 2.31 |
| Score (ESS) | 73.5 | 53.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources im2023_alcohol_ckb); dose-response yes |
| Sources | gbd2021rf alcohol_cirrhosis_ma | gbd2021rf alcohol_cirrhosis_ma llamosas2024_alcohol_lc corrao1998_alcohol_lc im2023_alcohol_ckb |
| New fields | not recorded before | Measure RR Estimate source alcohol_cirrhosis_ma Estimate design cohort synthesis Outcome match exact Outcome measured liver cirrhosis, mostly deaths Adjudicating bodies gbd2021rf: rates this pair in GBD 2021 (star rating not recorded on the link) |
Outcome match, Outcome measured: The estimate measures: liver cirrhosis, mostly deaths. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: corrao1998_alcohol_lc (weight 1.0), alcohol_cirrhosis_ma (weight 0.81), gbd2021rf (weight 0.5), llamosas2024_alcohol_lc (weight 0.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card K1): llamosas2024_alcohol_lc, corrao1998_alcohol_lc; the displayed estimate is unchanged. estimate_source alcohol_cirrhosis_ma, estimate_design cohort synthesis, measure RR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (im2023_alcohol_ckb) (card G11, blocker 4): Genotype-predicted alcohol intake raises liver cirrhosis in Chinese men (2.30 per 280 g a week, Im 2023). hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _whyT3T4
Also changed in: 1.4 (19 Sep 2026)
High body-mass index → Liver cirrhosis
high_bmi|cirrhosis
| Field | Before | After |
| Estimate | 1.28 | 1.2 |
| Interval, lower | 1.19 | 1.12 |
| Interval, upper | 1.38 | 1.28 |
| Comparison | per 5 kg/m² higher BMI (BMI >=22.5) | BMI over 30 kg/m² vs not, severe liver disease (hazard ratio) |
| Comparison type | per-unit | binary |
| Score (ESS) | 8.3 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources an2024_obesity_liver_mr; a different outcome); dose-response yes |
| Caveat | empty | Severe liver disease here means cirrhosis, its complications or death from liver disease, pooled from 14 population coho…Severe liver disease here means cirrhosis, its complications or death from liver disease, pooled from 14 population cohorts with 19.3 million people. The cohorts disagreed on the size of the effect (I-squared 87%). The Million Women Study gives 1.28 (1.19 to 1.38) per 5 kg/m² for cirrhosis itself. |
| Quoted sentence | Among women with a BMI of 22.5 or above, increasing BMI was associated with an increased incidence of liver cirrhosis: t…Among women with a BMI of 22.5 or above, increasing BMI was associated with an increased incidence of liver cirrhosis: the adjusted relative risk of cirrhosis increased by 28% (relative risk 1.28, 95% confidence interval 1.19 to 1.38; P<0.001) for every 5 unit increase in BMI. | Obesity was associated with a modest increase in risk of incident severe liver disease outcomes (adjusted HR 1.20, 95% C…Obesity was associated with a modest increase in risk of incident severe liver disease outcomes (adjusted HR 1.20, 95% CI 1.12-1.28, p < 0.001, I2 87%). |
| Sources | bmi_cirrhosis_mws metab_liver_ma | bmi_cirrhosis_mws metab_liver_ma an2024_obesity_liver_mr |
| New fields | not recorded before | Measure HR Estimate source metab_liver_ma Estimate design cohort synthesis Outcome match broader Outcome measured severe liver disease (cirrhosis, complications of cirrhosis or liver-related death) Related outcome true Grade basis Kept at Moderate by the verified dry run: MR is supportive and a cohort meta-analysis (1.20) is cited; replace the singl…Kept at Moderate by the verified dry run: MR is supportive and a cohort meta-analysis (1.20) is cited; replace the single-cohort number with the meta-analysis instead of lowering the grade. Grade override Moderate. Kept at Moderate by the verified dry run (card G3): the displayed synthesis pools 14 population cohorts with 1…Moderate. Kept at Moderate by the verified dry run (card G3): the displayed synthesis pools 14 population cohorts with 19.3 million people, and a genetic analysis supports an effect of BMI on liver fibrosis. T10 proposes Suggestive for the heterogeneity of a single review (I-squared 87%); the heterogeneity concerns the size of the effect, and the genetic evidence gives outside support on a closely related outcome. Studies 14 I-squared 87 |
Estimate, Interval, lower, Interval, upper, Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source bmi_cirrhosis_mws, estimate_design single cohort, measure RR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11): Grade stays Moderate (card G3: kept by the verifier). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (an2024_obesity_liver_mr), same_outcome false (card G11, blocker 4): Genetically predicted BMI raises fatty liver disease and liver fibrosis (An 2024); the genetic outcome is labelled liver fibrosis, a stage before cirrhosis. Displayed estimate replaced (card G3 A, kept link 143; blocker 8): the single-cohort 1.28 per 5 kg/m² gives way to the cited cohort meta-analysis, 1.20 (1.12 to 1.28) for BMI over 30 (Jarvis 2020, 14 cohorts); the outcome is severe liver disease, so outcome_match becomes broader and the link moves to the related-outcome layer; n_studies 14 and i2 87 recorded. grade_override keeps Moderate (blocker 8): Kept at Moderate by the verified dry run (card G3): the displayed synthesis pools 14 population cohorts with 19.3 million people, and a genetic analysis supports an effect of BMI on liver fibrosis. T10 proposes Suggestive for the heterogeneity of a single review (I-squared 87%); the heterogeneity concerns the size of the effect, and the genetic evidence gives outside support on a closely related outcome. corrections.json _whyT10
Comparison, Comparison type, Studies, I-squared, Caveat, Quoted sentence: The stated 1.85 per 5 kg/m² is far above the best per-unit evidence: the Million Women Study gives 1.28 (1.19-1.38) per 5 kg/m², and a meta-analysis of population cohorts gives only 1.20 (1.12-1.28) for obesity (BMI>30) versus not. 1.85 looks like an obese-vs-normal category estimate mislabelled as a per-unit slope - exactly the contrast error the brief warns about. Updated 23 Oct 2026: the displayed estimate is now the cohort meta-analysis (Jarvis 2020), as the verified dry run asked; the Million Women Study figure stays in the caveat. review_note
Outcome match, Outcome measured, Related outcome: The estimate measures: severe liver disease (cirrhosis, complications of cirrhosis or liver-related death). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis, Grade override: Curator override to Moderate: Kept at Moderate by the verified dry run (card G3): the displayed synthesis pools 14 population cohorts with 19.3 million people, and a genetic analysis supports an effect of BMI on liver fibrosis. T10 proposes Suggestive for the heterogeneity of a single review (I-squared 87%); the heterogeneity concerns the size of the effect, and the genetic evidence gives outside support on a closely related outcome. Kept at Moderate by the verified dry run: MR is supportive and a cohort meta-analysis (1.20) is cited; replace the single-cohort number with the meta-analysis instead of lowering the grade. grade_override and grade_basisT10
Type 2 diabetes (as a risk factor) → Liver cirrhosis
t2d_exposure|cirrhosis
| Field | Before | After |
| Reviews counted | 4 | 1 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 33.5 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source metab_liver_ma Estimate design cohort synthesis Outcome match broader Outcome measured severe liver disease (cirrhosis, its complications or liver death) Related outcome true Grade basis A cirrhosis-only estimate exists in the cited UK Biobank cohort (449,497 people): diabetes under 5 years aHR 2.85 (2.45-…A cirrhosis-only estimate exists in the cited UK Biobank cohort (449,497 people): diabetes under 5 years aHR 2.85 (2.45-3.32), 5 years or more 3.43 (2.92-4.02). The displayed meta-analysis estimate is severe liver disease (I-squared 99%). The UK Biobank paper does not say whether people with liver disease at baseline were excluded, so reverse causation is not settled. Verifier estimate stands. Grade override Moderate. Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. A cirrhosis-…Moderate. Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. A cirrhosis-only estimate exists in UK Biobank (HR 2.85 to 3.43), but the paper does not say whether people with liver disease at baseline were excluded. I-squared 99 |
Outcome match, Outcome measured, Related outcome: The estimate measures: severe liver disease (cirrhosis, its complications or liver death). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis, Grade override: Curator override to Moderate: Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. A cirrhosis-only estimate exists in UK Biobank (HR 2.85 to 3.43), but the paper does not say whether people with liver disease at baseline were excluded. A cirrhosis-only estimate exists in the cited UK Biobank cohort (449,497 people): diabetes under 5 years aHR 2.85 (2.45-3.32), 5 years or more 3.43 (2.92-4.02). The displayed meta-analysis estimate is severe liver disease (I-squared 99%). The UK Biobank paper does not say whether people with liver disease at baseline were excluded, so reverse causation is not settled. Verifier estimate stands. grade_override and grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: metab_liver_ma (weight 1.0). reviews_counted
I-squared: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source metab_liver_ma, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). i2 from the displayed review (card G12, research pass; PubMed 32353039): Grade stays Moderate (card G12, not settled; the verifier's best estimate applies); grade_basis records the rules. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Coffee consumption → Liver cirrhosis
coffee|cirrhosis
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source coffee_cirrhosis_ma Estimate design mixed Outcome match exact Outcome measured liver cirrhosis |
The estimate measures: liver cirrhosis. measured_outcome
Type 2 diabetes (as a risk factor) → Chronic kidney disease
t2d_exposure|ckd
| Field | Before | After |
| Reviews counted | 7 | 2 |
| Effective reviews (N_eff) | 6 | 1.55 |
| Score (ESS) | 57.1 | 32.4 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources glucose_intensive_kunutsor; a different exposure; a different outcome); Genetic (MR) supportiv…Trial supportive (sources glucose_intensive_kunutsor; a different exposure; a different outcome); Genetic (MR) supportive (sources zheng2022_ckd_mr); dose-response yes |
| Sources | t2d_ckd_shen glucose_intensive_kunutsor | t2d_ckd_shen glucose_intensive_kunutsor erfc2011_diabetes_death zheng2022_ckd_mr |
| New fields | not recorded before | Measure RR Estimate source t2d_ckd_shen Estimate design cohort synthesis Outcome match exact Outcome measured incident chronic kidney disease Grade basis Strong: a cohort synthesis of more than 5 million people (Shen 2017), the ERFC pooled analysis and Mendelian randomisati…Strong: a cohort synthesis of more than 5 million people (Shen 2017), the ERFC pooled analysis and Mendelian randomisation of diabetes liability on chronic kidney disease (Zheng 2022) agree (T3, T4). The glucose-lowering trials compare treatments in people who already have diabetes (another exposure and outcome, noted). Verified at Strong on 21 October 2026. |
Outcome match, Outcome measured: The estimate measures: incident chronic kidney disease. measured_outcome
Grade basis: Strong: a cohort synthesis of more than 5 million people (Shen 2017), the ERFC pooled analysis and Mendelian randomisation of diabetes liability on chronic kidney disease (Zheng 2022) agree (T3, T4). The glucose-lowering trials compare treatments in people who already have diabetes (another exposure and outcome, noted). Verified at Strong on 21 October 2026. grade_basisT3T4
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: erfc2011_diabetes_death (weight 1.0), t2d_ckd_shen (weight 0.55). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card K1): erfc2011_diabetes_death; the displayed estimate is unchanged. estimate_source t2d_ckd_shen, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_exposure and same_outcome false (cards G6, G11): The trials compared intensive with standard glucose lowering, and SGLT2 inhibitors with placebo, in people who already have diabetes; they slow kidney disease. Both differ from diabetes against no diabetes and from new kidney disease. grade_override keeps Strong: The glucose-lowering and SGLT2 inhibitor trials named in the caveat compare treatments in people who already have diabetes and measure slower kidney disease, so they are recorded with same_exposure and same_outcome false and rule T3 (Moderate) fails as written. No Mendelian randomisation study or adjudicating body is cited. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive (status was none) with its sources recorded (zheng2022_ckd_mr) (card G11, G2, blocker 4): A trans-ethnic Mendelian randomisation study (51,672 European and 13,093 East Asian cases) found reliable evidence that genetically predicted type 2 diabetes causes chronic kidney disease in both ancestries. grade_override removed (blocker 2): the recorded genetic evidence meets rule T3; T4 has three synthesis groups. Grade stays Strong (blocker 2); grade_basis rewritten: Strong: a cohort synthesis of more than 5 million people (Shen 2017), the ERFC pooled analysis and Mendelian randomisation of diabetes liability on chronic kidney disease (Zheng 2022) agree (T3, T4). The glucose-lowering trials compare treatments in people who already have diabetes (another exposure and outcome, noted). Verified at Strong on 21 October 2026. hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _whyT3T4
Also changed in: 1.4 (19 Sep 2026)
High blood pressure → Chronic kidney disease
high_sbp|ckd
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources bpltt; a different outcome); Genetic (MR) supportive (sources zheng2022_ckd_mr); dose-response yes |
| Sources | htn_ckd_ma bpltt | htn_ckd_ma bpltt zheng2022_ckd_mr |
| New fields | not recorded before | Measure RR Estimate source htn_ckd_ma Estimate design cohort synthesis Outcome match exact Outcome measured incident CKD or kidney failure Grade basis Strong: a meta-analysis of six cohorts (2.4 million people) and Mendelian randomisation of systolic blood pressure on ch…Strong: a meta-analysis of six cohorts (2.4 million people) and Mendelian randomisation of systolic blood pressure on chronic kidney disease (Zheng 2022) agree (T3, T4). The cited trial collaboration reports no kidney outcome (noted). Verified at Strong on 21 October 2026. Adjudicating bodies bpltt: the cited trial collaboration reports no kidney outcome (review note) (does not match this pair) |
Outcome match, Outcome measured: The estimate measures: incident CKD or kidney failure. measured_outcome
Grade basis: Strong: a meta-analysis of six cohorts (2.4 million people) and Mendelian randomisation of systolic blood pressure on chronic kidney disease (Zheng 2022) agree (T3, T4). The cited trial collaboration reports no kidney outcome (noted). Verified at Strong on 21 October 2026. grade_basisT3T4
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source htn_ckd_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_outcome false (cards G6, G11): The cited trial collaboration reports cardiovascular events and no kidney outcome (review note). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). grade_override keeps Strong: The cited trial collaboration (BPLTTC) reports cardiovascular events and no kidney outcome (review note), so it fails the pair match and its trials are recorded with same_outcome false: Rule T3 (Moderate) then fails as written. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive (status was none) with its sources recorded (zheng2022_ckd_mr) (card G11, G2, blocker 4): A trans-ethnic Mendelian randomisation study found reliable evidence that genetically predicted systolic blood pressure and hypertension cause chronic kidney disease in Europeans. grade_override removed (blocker 2): the recorded genetic evidence meets rule T3 and gives the second line for T4. Grade stays Strong (blocker 2); grade_basis rewritten: Strong: a meta-analysis of six cohorts (2.4 million people) and Mendelian randomisation of systolic blood pressure on chronic kidney disease (Zheng 2022) agree (T3, T4). The cited trial collaboration reports no kidney outcome (noted). Verified at Strong on 21 October 2026. corrections.json _whyT3T4
Also changed in: 1.4 (9 Oct 2026)
High body-mass index → Chronic kidney disease
high_bmi|ckd
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.38 |
| Score (ESS) | 0.9 | 1.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources zheng2022_ckd_mr); dose-response yes |
| Sources | bmi_ckd_ma gbd_ckd | bmi_ckd_ma gbd_ckd zheng2022_ckd_mr |
| New fields | not recorded before | Measure RR Estimate source bmi_ckd_ma Estimate design cohort synthesis Outcome match exact Outcome measured incident eGFR below 60 (CKD stage 3 and above) Adjudicating bodies gbd_ckd: counts high body-mass index as a cause of chronic kidney disease |
Outcome match, Outcome measured: The estimate measures: incident eGFR below 60 (CKD stage 3 and above). measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: bmi_ckd_ma (weight 1.0), gbd_ckd (weight 0.38). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source bmi_ckd_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (zheng2022_ckd_mr) (card G11, blocker 4): Genetically predicted BMI causes chronic kidney disease in Europeans and East Asians (Zheng 2022). corrections.json _whyT3T4
Also changed in: 1.4 (9 Oct 2026)
Current cigarette smoking → Chronic kidney disease
smoking|ckd
| Field | Before | After |
| Reviews counted | 5 | 1 |
| Effective reviews (N_eff) | 4 | 1.0 |
| Score (ESS) | 20.9 | 9.5 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source smoking_ckd_ma Estimate design cohort synthesis Outcome match exact Outcome measured incident CKD |
Outcome match, Outcome measured: The estimate measures: incident CKD. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoking_ckd_ma (weight 1.0). reviews_counted
Long-term NSAID use → Chronic kidney disease
nsaids|ckd
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 8.8 | 6.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source nsaid_ckd_ma Estimate design cohort synthesis Outcome match exact Outcome measured incident CKD Grade basis T10 met as a fail: I-squared about 91% in the only synthesis (pooled HR 90.77%, pooled OR 91.21%). T3 and T4 also fail (…T10 met as a fail: I-squared about 91% in the only synthesis (pooled HR 90.77%, pooled OR 91.21%). T3 and T4 also fail (no trial or MR, one synthesis). Confounding by indication is not handled in the abstract: pain, arthritis and hypertension travel with NSAID use. Suggestive. Studies 39 I-squared 90.77 |
Outcome match, Outcome measured: The estimate measures: incident CKD. measured_outcome
Grade: T10 met as a fail: I-squared about 91% in the only synthesis (pooled HR 90.77%, pooled OR 91.21%). T3 and T4 also fail (no trial or MR, one synthesis). Confounding by indication is not handled in the abstract: pain, arthritis and hypertension travel with NSAID use. Suggestive. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source nsaid_ckd_ma, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). n_studies and i2 from the displayed review (card G12, research pass; PubMed 39412516): Grade Moderate to Suggestive (card G12, settled by the research pass). grade_basisT10T3T4
Grade basis: T10 met as a fail: I-squared about 91% in the only synthesis (pooled HR 90.77%, pooled OR 91.21%). T3 and T4 also fail (no trial or MR, one synthesis). Confounding by indication is not handled in the abstract: pain, arthritis and hypertension travel with NSAID use. Suggestive. grade_basisT10T3T4
Studies, I-squared: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source nsaid_ckd_ma, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). n_studies and i2 from the displayed review (card G12, research pass; PubMed 39412516): Grade Moderate to Suggestive (card G12, settled by the research pass). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
High blood uric acid → Chronic kidney disease
high_urate|ckd
| Field | Before | After |
| Trial and genetic evidence | Trial contradicts; Genetic (MR) none; dose-response yes | Trial contradicts (sources badve2020_ckdfix doria2020_perl; a different outcome); Genetic (MR) none; dose-response yes |
| Sources | urate_ckd_ma | urate_ckd_ma badve2020_ckdfix doria2020_perl |
| New fields | not recorded before | Measure RR Estimate source urate_ckd_ma Estimate design cohort synthesis Outcome match exact Outcome measured incident CKD Conflict Side A: Cohorts link higher serum urate with new chronic kidney disease (1.22, 1.16 to 1.28 per 1 mg/dL). Side B: Two tr…Side A: Cohorts link higher serum urate with new chronic kidney disease (1.22, 1.16 to 1.28 per 1 mg/dL). Side B: Two trials that lowered urate (CKD-FIX, PERL) did not slow kidney decline, and the same meta-analysis found no association above age 60 (1.04, 0.96 to 1.13). Sources: urate_ckd_ma |
Outcome match, Outcome measured: The estimate measures: incident CKD. measured_outcome
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source urate_ckd_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct contradicts, same_outcome false (cards G6, G11): CKD-FIX and PERL measured kidney decline in people who already had kidney disease: Neither trial is cited on the link. conflict records both sides and their sources from the caveat and review note (rule C2, card G1). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct contradicts with its sources recorded (badve2020_ckdfix, doria2020_perl), same_outcome false (card G11, blocker 4): CKD-FIX and PERL lowered urate with allopurinol and did not slow kidney decline in people who already had kidney disease. corrections.json _whyC2
Fine particulate air pollution → Chronic kidney disease
pm25|ckd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source airpoll_ckd_ma Estimate design mixed Outcome match exact Outcome measured CKD, cohort and cross-sectional studies pooled Grade basis Suggestive: mostly cross-sectional studies, and the authors warn against a causal reading (review note). Kept by the verifier. External grades review authors' rating moderate (airpoll_ckd_ma) |
Outcome match, Outcome measured: The estimate measures: CKD, cohort and cross-sectional studies pooled. measured_outcome
Grade basis: Suggestive: mostly cross-sectional studies, and the authors warn against a causal reading (review note). Kept by the verifier. grade_basis
Also changed in: 1.4 (9 Oct 2026)
Lead exposure → Chronic kidney disease
lead|ckd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source metals_ckd_ma Estimate design cohort synthesis Outcome match exact Outcome measured reduced eGFR (the GFR criterion of CKD) Grade basis Kept at Suggestive by the verified dry run: I2 is 88%, below the table's own 90% threshold; the dry run read the word 'extreme' as I2 >= 90. |
Outcome match, Outcome measured: The estimate measures: reduced eGFR (the GFR criterion of CKD). measured_outcome
Grade basis: Kept at Suggestive by the verified dry run: I2 is 88%, below the table's own 90% threshold; the dry run read the word 'extreme' as I2 >= 90. grade_basis
Also changed in: 1.4 (9 Oct 2026)
Cadmium exposure → Chronic kidney disease
cadmium|ckd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.29 |
| Score (ESS) | 3.6 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source metals_ckd_ma Estimate design cohort synthesis Outcome match proxy Outcome measured proteinuria (kidney damage marker) Related outcome true Grade basis Kept at Weak by the verified dry run: Outcome is proteinuria, eGFR null, and urinary cadmium rises with tubular damage. |
Outcome match, Outcome measured, Related outcome: The estimate measures: proteinuria (kidney damage marker). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: Kept at Weak by the verified dry run: Outcome is proteinuria, eGFR null, and urinary cadmium rises with tubular damage. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: metals_ckd_ma (weight 1.0), cadmium_ckd_ma (weight 0.29). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Extreme heat → Chronic kidney disease
heat|ckd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source ckdnt_heat_ma Estimate design cohort synthesis Outcome match narrower Outcome measured CKD of non-traditional causes in agricultural workers |
The estimate measures: CKD of non-traditional causes in agricultural workers. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Pre-eclampsia → Chronic kidney disease
preeclampsia|ckd
| Field | Before | After |
| Reviews counted | 1 | 3 |
| Effective reviews (N_eff) | 1 | 1.17 |
| Score (ESS) | 14.6 | 16.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | preeclampsia_ckd_ma | preeclampsia_ckd_ma barrett2020_apo_ckd covella2019_pe_kidney |
| New fields | not recorded before | Measure HR Estimate source preeclampsia_ckd_ma Estimate design cohort synthesis Outcome match exact Outcome measured incident CKD after pre-eclampsia Grade basis Two further syntheses exist. Barrett 2020 (23 studies, 5.8 million women): CKD aRR 2.11 (1.72-2.59), ESKD 4.90. Covella…Two further syntheses exist. Barrett 2020 (23 studies, 5.8 million women): CKD aRR 2.11 (1.72-2.59), ESKD 4.90. Covella 2019: CKD 2.03 (0.58-7.32) not significant, ESKD 6.35 (2.73-14.79). With three syntheses T9a no longer applies. T4 met. T3 fails (no trial or MR), so the ceiling is Moderate. A severity gradient exists (preterm pre-eclampsia ESKD 5.66 against 4.90). Moderate. Studies 3 |
Outcome match, Outcome measured: The estimate measures: incident CKD after pre-eclampsia. measured_outcome
Grade basis: Two further syntheses exist. Barrett 2020 (23 studies, 5.8 million women): CKD aRR 2.11 (1.72-2.59), ESKD 4.90. Covella 2019: CKD 2.03 (0.58-7.32) not significant, ESKD 6.35 (2.73-14.79). With three syntheses T9a no longer applies. T4 met. T3 fails (no trial or MR), so the ceiling is Moderate. A severity gradient exists (preterm pre-eclampsia ESKD 5.66 against 4.90). Moderate. grade_basisT9aT4T3
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: covella2019_pe_kidney (weight 1.0), barrett2020_apo_ckd (weight 0.17), preeclampsia_ckd_ma (weight 0.0). reviews_counted
Studies, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): barrett2020_apo_ckd, covella2019_pe_kidney; the displayed estimate is unchanged. estimate_source preeclampsia_ckd_ma, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). n_studies from the displayed review (card G12, research pass; PubMed 32755806). Grade stays Moderate (card G12, settled by the research pass); grade_basis records the rules. corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Low birth weight → Chronic kidney disease
low_birthweight|ckd
| Field | Before | After |
| Reviews counted | 3 | 1 |
| Effective reviews (N_eff) | 2 | 1.0 |
| Score (ESS) | 15.4 | 9.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source lbw_ckd_ma Estimate design cohort synthesis Outcome match exact Outcome measured CKD (albuminuria, low eGFR or kidney failure) Grade basis Suggestive: half the studies were null and confounding was poorly handled (review note). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: CKD (albuminuria, low eGFR or kidney failure). measured_outcome
Grade basis: Suggestive: half the studies were null and confounding was poorly handled (review note). Kept by the verifier. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: lbw_ckd_ma (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Current cigarette smoking → COPD
smoking|copd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.69 |
| Score (ESS) | 20.3 | 29.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source smoke_copd_ma Estimate design cohort synthesis Outcome match exact Outcome measured COPD Grade basis Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure…Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure and outcome, and no adjudicating body that rated this pair. |
Outcome match, Outcome measured: The estimate measures: COPD. measured_outcome
Grade basis: Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure and outcome, and no adjudicating body that rated this pair. grade_basisT3
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoke_copd_ma (weight 1.0), copd_prev_rf_ma (weight 0.69). reviews_counted
Former smoking → COPD
former_smoking|copd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source smoke_copd_ma Estimate design cohort synthesis Outcome match exact Outcome measured COPD Grade basis Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure…Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure and outcome, and no adjudicating body that rated this pair; T4 rests on one observational synthesis with no second line of evidence (1 independent synthesis group; lines: obs). |
Outcome match, Outcome measured: The estimate measures: COPD. measured_outcome
Grade basis: Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure and outcome, and no adjudicating body that rated this pair; T4 rests on one observational synthesis with no second line of evidence (1 independent synthesis group; lines: obs). grade_basisT3T4
Household air pollution → COPD
hap|copd
| Field | Before | After |
| Grade | Convincing (now Strong) | Moderate |
| Reviews counted | 6 | 3 |
| Effective reviews (N_eff) | 5 | 1.5 |
| Score (ESS) | 19.8 | 9.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | hap_health_lee2020 gbd2021rf | hap_health_lee2020 gbd2021rf gbd_hap2021 |
| New fields | not recorded before | Measure RR Estimate source hap_health_lee2020 Estimate design mixed Outcome match exact Outcome measured COPD in longitudinal studies Grade basis T11 pair match is partial. The four-star Burden of Proof rating covers particulate matter pollution and COPD. The GBD 20…T11 pair match is partial. The four-star Burden of Proof rating covers particulate matter pollution and COPD. The GBD 2021 household air pollution paper applies the same fine-particle risk curves to household air pollution and states that COPD shows the highest relative risk; the star table for pairs sits in an appendix that was not read. T4: one GBD group and one meta-analysis (longitudinal estimate, I-squared 85%). No trial or MR. Strong needs a second line and a judgement that reversal is implausible. The pair rating is not confirmed, so the verifier estimate stands. Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. The four-star Burden of Proof rating covers particulate matter and COPD; the rating for household air pollution and COPD sits in an appendix of GBD 2021 that was not read. Adjudicating bodies gbd2021rf: rates household air pollution and COPD; the pair-level star rating sits in an appendix that was not read; gbd…gbd2021rf: rates household air pollution and COPD; the pair-level star rating sits in an appendix that was not read; gbd_hap2021: applies the particulate-matter risk curves to household air pollution; COPD has the highest relative risk External grades Burden of Proof 4 stars (particulate matter pollution and COPD) (gbd2021rf), does not match this pair |
Outcome match, Outcome measured: The estimate measures: COPD in longitudinal studies. measured_outcome
Grade: T11 pair match is partial. The four-star Burden of Proof rating covers particulate matter pollution and COPD. The GBD 2021 household air pollution paper applies the same fine-particle risk curves to household air pollution and states that COPD shows the highest relative risk; the star table for pairs sits in an appendix that was not read. T4: one GBD group and one meta-analysis (longitudinal estimate, I-squared 85%). No trial or MR. Strong needs a second line and a judgement that reversal is implausible. The pair rating is not confirmed, so the verifier estimate stands. Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. The four-star Burden of Proof rating covers particulate matter and COPD; the rating for household air pollution and COPD sits in an appendix of GBD 2021 that was not read. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): gbd_hap2021; the displayed estimate is unchanged. estimate_source hap_health_lee2020, estimate_design mixed, measure RR, by rule E1 (cards G8, K5, P2). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). external_grades transcribed from the caveat, the review note or the quote (rule T11). Grade Strong to Moderate (card G12, not settled; the verifier's best estimate applies). Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): grade_override removed (minor d): the grade equals the table grade, so the unsettled status of card G12 is recorded in grade_basis instead. hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). grade_basisT11T4T3
Grade basis: T11 pair match is partial. The four-star Burden of Proof rating covers particulate matter pollution and COPD. The GBD 2021 household air pollution paper applies the same fine-particle risk curves to household air pollution and states that COPD shows the highest relative risk; the star table for pairs sits in an appendix that was not read. T4: one GBD group and one meta-analysis (longitudinal estimate, I-squared 85%). No trial or MR. Strong needs a second line and a judgement that reversal is implausible. The pair rating is not confirmed, so the verifier estimate stands. Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. The four-star Burden of Proof rating covers particulate matter and COPD; the rating for household air pollution and COPD sits in an appendix of GBD 2021 that was not read. grade_basisT11T4
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: hap_health_lee2020 (weight 1.0), gbd_hap2021 (weight 0.5), gbd2021rf (weight 0.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): gbd_hap2021; the displayed estimate is unchanged. estimate_source hap_health_lee2020, estimate_design mixed, measure RR, by rule E1 (cards G8, K5, P2). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). external_grades transcribed from the caveat, the review note or the quote (rule T11). Grade Strong to Moderate (card G12, not settled; the verifier's best estimate applies). corrections.json _whyT3T4T11
Also changed in: 1.4 (19 Sep 2026)
Secondhand smoke → COPD
shs|copd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.17 |
| Score (ESS) | 6.4 | 7.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source shs_copd_ma Estimate design cohort synthesis Outcome match exact Outcome measured COPD, cross-sectional, case-control and cohort studies pooled Adjudicating bodies bprf_shs: 1 star External grades Burden of Proof 1 star (bprf_shs) |
Outcome match, Outcome measured: The estimate measures: COPD, cross-sectional, case-control and cohort studies pooled. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: shs_copd_ma (weight 1.0), bprf_shs (weight 0.17). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Fine particulate air pollution → COPD
pm25|copd
| Field | Before | After |
| Reviews counted | 5 | 3 |
| Effective reviews (N_eff) | 4 | 1.38 |
| Score (ESS) | 16.7 | 9.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source airpoll_copd_inc_ma Estimate design cohort synthesis Outcome match exact Outcome measured incident COPD Adjudicating bodies who_air: WHO 2021 review covers COPD; gbd2021rf: rates this pair in GBD 2021 (star rating not recorded on the link) |
Outcome match, Outcome measured: The estimate measures: incident COPD. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: airpoll_copd_inc_ma (weight 1.0), who_air (weight 0.0), gbd2021rf (weight 0.38). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.3 (9 Sep 2026)
Occupational silica dust → COPD
silica|copd
| Field | Before | After |
| Reviews counted | 1 | 0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | occ_particles_copd_stockholm quartz_lungfunction_bruske vgdf_copd_ma jem_copd_ma | occ_particles_copd_stockholm |
| New fields | not recorded before | Measure HR Estimate source occ_particles_copd_stockholm Estimate design single cohort Outcome match exact Outcome measured incident COPD in men Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: incident COPD in men. measured_outcome
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source occ_particles_copd_stockholm, estimate_design single cohort, measure HR, by rule E1 (read by hand) (cards G8, K5, P2) 23 Oct 2026 fix round 3 (verifier of the data step, third check, blockers 1 to 3 and minor items 4, 6, 7): Sources quartz_lungfunction_bruske, vgdf_copd_ma and jem_copd_ma removed from the link's sources (blocker 2b, card K7 A topic check, PROPOSAL section 5.1): the first pools FEV1 decrements and gives no COPD estimate, the second covers self-reported vapours, gases, dusts or fumes and the third all airborne occupational pollutants by job-exposure matrix, so none of them pools silica against COPD, as the review note says; n_reviews 3 to 0, N_eff 1.45 to 1.00, primary_only true, score 5.5 to 4.2. review_note: the phrase 'not a relative risk' is reworded (writing rules). review_note: a dated sentence records that the three syntheses are no longer listed among the sources (blocker 2b). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Low birth weight → COPD
low_birthweight|copd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source earlylife_copd_ma Estimate design cohort synthesis Outcome match exact Outcome measured COPD in adulthood |
The estimate measures: COPD in adulthood. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Fine particulate air pollution → Asthma (adult)
pm25|asthma
| Field | Before | After |
| Reviews counted | 5 | 1 |
| Effective reviews (N_eff) | 4 | 1.0 |
| Score (ESS) | 4.2 | 1.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source airpoll_adult_asthma_ma Estimate design cohort synthesis Outcome match exact Outcome measured incident adult-onset asthma Grade override Suggestive. T10 proposes Weak because the caveat says the studies 'disagreed strongly'. That describes high heterogeneit…Suggestive. T10 proposes Weak because the caveat says the studies 'disagreed strongly'. That describes high heterogeneity (I-squared 88%), which caps a single review at Suggestive under card G7. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. |
Outcome match, Outcome measured: The estimate measures: incident adult-onset asthma. measured_outcome
Grade override: Curator override to Suggestive: T10 proposes Weak because the caveat says the studies 'disagreed strongly'. That describes high heterogeneity (I-squared 88%), which caps a single review at Suggestive under card G7. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT10
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: airpoll_adult_asthma_ma (weight 1.0). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Nitrogen dioxide → Asthma (adult)
no2|asthma
| Field | Before | After |
| Reviews counted | 5 | 2 |
| Effective reviews (N_eff) | 4 | 1.64 |
| Score (ESS) | 9.1 | 5.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | airpoll_adult_asthma_ma airpoll_crf_forastiere | airpoll_adult_asthma_ma airpoll_crf_forastiere jacquemin2015_escape_asthma |
| New fields | not recorded before | Measure RR Estimate source airpoll_adult_asthma_ma Estimate design cohort synthesis Outcome match exact Outcome measured incident adult-onset asthma Grade basis T10 fires on the displayed review (nine NO2 studies, I-squared 88%) only while it is the single synthesis group. The six…T10 fires on the displayed review (nine NO2 studies, I-squared 88%) only while it is the single synthesis group. The six-cohort ESCAPE pooled analysis (OR 1.10, 0.99-1.21 per 10 ug/m3) is a second, independent group but is borderline. The multi-pollutant estimates that separate NO2 from PM2.5 were not found in any source read, so collinearity stays open. Verifier estimate stands. Grade override Moderate. Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. No estimate…Moderate. Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. No estimate from a model with several pollutants was found, so the effect of nitrogen dioxide cannot be separated from that of fine particles. Studies 9 I-squared 88 External grades WHO concentration-response review reliable (airpoll_crf_forastiere) |
Outcome match, Outcome measured: The estimate measures: incident adult-onset asthma. measured_outcome
Grade basis, Grade override: Curator override to Moderate: Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. No estimate from a model with several pollutants was found, so the effect of nitrogen dioxide cannot be separated from that of fine particles. T10 fires on the displayed review (nine NO2 studies, I-squared 88%) only while it is the single synthesis group. The six-cohort ESCAPE pooled analysis (OR 1.10, 0.99-1.21 per 10 ug/m3) is a second, independent group but is borderline. The multi-pollutant estimates that separate NO2 from PM2.5 were not found in any source read, so collinearity stays open. Verifier estimate stands. grade_override and grade_basisT10
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: jacquemin2015_escape_asthma (weight 1.0), airpoll_adult_asthma_ma (weight 0.64). reviews_counted
Studies, I-squared: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): jacquemin2015_escape_asthma; the displayed estimate is unchanged. estimate_source airpoll_adult_asthma_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). external_grades transcribed from the caveat, the review note or the quote (rule T11). n_studies and i2 from the displayed review (card G12, research pass; PubMed 39674196). Grade stays Moderate (card G12, not settled; the verifier's best estimate applies); grade_basis records the rules. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _whyT11
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): jacquemin2015_escape_asthma; the displayed estimate is unchanged. estimate_source airpoll_adult_asthma_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). external_grades transcribed from the caveat, the review note or the quote (rule T11). n_studies and i2 from the displayed review (card G12, research pass; PubMed 39674196). Grade stays Moderate (card G12, not settled; the verifier's best estimate applies); grade_basis records the rules. corrections.json _whyT11
Also changed in: 1.4 (19 Sep 2026)
High body-mass index → Asthma (adult)
high_bmi|asthma
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources skaaby2018_bmi_asthma_mr); dose-response yes |
| Sources | bmi_asthma_ma | bmi_asthma_ma skaaby2018_bmi_asthma_mr |
| New fields | not recorded before | Measure OR Estimate source bmi_asthma_ma Estimate design cohort synthesis Outcome match exact Outcome measured incident asthma in adults |
Outcome match, Outcome measured: The estimate measures: incident asthma in adults. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source bmi_asthma_ma, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (skaaby2018_bmi_asthma_mr) (card G11, blocker 4): A BMI genetic risk score raises asthma (Skaaby 2018, 162,124 people). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Current cigarette smoking → Asthma (adult)
smoking|asthma
| Field | Before | After |
| Reviews counted | 4 | 1 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources carta_smoke_asthma_mr); dose-response yes |
| New fields | not recorded before | Measure OR Estimate source carta_smoke_asthma_mr Estimate design pooled IPD Outcome match exact Outcome measured asthma in adults (observational analysis) |
Outcome match, Outcome measured: The estimate measures: asthma in adults (observational analysis). measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: carta_smoke_asthma_mr (weight 1.0). reviews_counted
Also changed in: 1.4 (21 Oct 2026)1.4 (9 Oct 2026)1.3 (9 Sep 2026)
Secondhand smoke → Asthma (adult)
shs|asthma
| Field | Before | After |
| Reviews counted | 5 | 1 |
| Effective reviews (N_eff) | 4 | 1.0 |
| Score (ESS) | 5.6 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source bprf_shs Estimate design mixed Outcome match broader Outcome measured asthma at all ages, mostly children, self-reported Related outcome true Adjudicating bodies bprf_shs: 1 star External grades Burden of Proof 1 star (bprf_shs) |
Outcome match, Outcome measured, Related outcome: The estimate measures: asthma at all ages, mostly children, self-reported. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: bprf_shs (weight 1.0). reviews_counted
Also changed in: 1.4 (19 Sep 2026)1.3 (9 Sep 2026)
Hearing loss (as a risk factor) → Dementia (all-cause)
hearing_loss_exposure|dementia
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response yes | Trial null (sources lin2023_achieve; a different outcome); Genetic (MR) none; dose-response yes |
| Sources | lancet_dementia | lancet_dementia lin2023_achieve |
| New fields | not recorded before | Measure RR Estimate source lancet_dementia Estimate design cohort synthesis Outcome match exact Outcome measured incident all-cause dementia Grade override Suggestive. Kept by the verifier: a lower bound of exactly 1.00 is a rounding edge, the Lancet Commission still ranks he…Suggestive. Kept by the verifier: a lower bound of exactly 1.00 is a rounding edge, the Lancet Commission still ranks hearing loss among the largest modifiable factors, and ACHIEVE showed benefit in its higher-risk subgroup. T1 proposes Weak at medium confidence. Adjudicating bodies lancet_dementia: listed among the modifiable risk factors for dementia (2024) |
Outcome match, Outcome measured: The estimate measures: incident all-cause dementia. measured_outcome
Grade override: Curator override to Suggestive: Kept by the verifier: a lower bound of exactly 1.00 is a rounding edge, the Lancet Commission still ranks hearing loss among the largest modifiable factors, and ACHIEVE showed benefit in its higher-risk subgroup. T1 proposes Weak at medium confidence. grade_overrideT1
Reviews counted: Counted from the cited syntheses under the review-counting rule: lancet_dementia (weight 1.0). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source lancet_dementia, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct null, same_outcome false (cards G6, G11): ACHIEVE measured cognitive decline over three years; it did not count new dementia: The trial is not cited on the link. adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). grade_override keeps Suggestive: Kept by the verifier: a lower bound of exactly 1.00 is a rounding edge, the Lancet Commission still ranks hearing loss among the largest modifiable factors, and ACHIEVE showed benefit in its higher-risk subgroup. T1 proposes Weak at medium confidence. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct null with its sources recorded (lin2023_achieve), same_outcome false (card G11, blocker 4): ACHIEVE measured cognitive decline over three years and found no overall effect; it did not count new dementia. hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _whyT3T4T1
Also changed in: 1.4 (19 Sep 2026)
Low educational attainment → Dementia (all-cause)
low_education|dementia
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.78 |
| Score (ESS) | 12.6 | 18.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources larsson2017_ad_mr); dose-response yes |
| Sources | lancet_dementia education_dementia_caamano | lancet_dementia education_dementia_caamano larsson2017_ad_mr |
| New fields | not recorded before | Measure RR Estimate source lancet_dementia Estimate design cohort synthesis Outcome match exact Outcome measured incident dementia Adjudicating bodies lancet_dementia: listed among the modifiable risk factors for dementia (2024) |
Outcome match, Outcome measured: The estimate measures: incident dementia. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: education_dementia_caamano (weight 1.0), lancet_dementia (weight 0.78). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source lancet_dementia, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (larsson2017_ad_mr) (card G11, blocker 4): Genetically predicted education lowers Alzheimer's disease (OR 0.89 per year, Larsson 2017), the main form of dementia. hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _whyT3T4
Also changed in: 1.4 (19 Sep 2026)
High blood pressure → Dementia (all-cause)
high_sbp|dementia
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.44 |
| Score (ESS) | 6.6 | 8.6 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources sprint_mind; a different exposure; a different outcome); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source lancet_dementia Estimate design cohort synthesis Outcome match exact Outcome measured incident dementia Adjudicating bodies lancet_dementia: listed among the modifiable risk factors for dementia (2024) |
Outcome match, Outcome measured: The estimate measures: incident dementia. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: ou_bp_cognition_2020 (weight 1.0), lancet_dementia (weight 0.44). reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source lancet_dementia, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_exposure and same_outcome false (cards G6, G11): SPRINT-MIND compared intensive with standard lowering; it reduced mild cognitive impairment, and the reduction in dementia did not reach significance. adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) corrections.json _whyT3T4
Also changed in: 1.4 (19 Sep 2026)1.3 (18 Sep 2026)
Current cigarette smoking → Dementia (all-cause)
smoking|dementia
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.64 |
| Score (ESS) | 8.6 | 12.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source lancet_dementia Estimate design cohort synthesis Outcome match exact Outcome measured incident all-cause dementia Adjudicating bodies lancet_dementia: listed among the modifiable risk factors for dementia (2024) |
Outcome match, Outcome measured: The estimate measures: incident all-cause dementia. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: zhong_smoking_dementia_2015 (weight 1.0), lancet_dementia (weight 0.64). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Type 2 diabetes (as a risk factor) → Dementia (all-cause)
t2d_exposure|dementia
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.69 |
| Score (ESS) | 13.9 | 20.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source lancet_dementia Estimate design cohort synthesis Outcome match exact Outcome measured incident dementia Adjudicating bodies lancet_dementia: listed among the modifiable risk factors for dementia (2024) |
Outcome match, Outcome measured: The estimate measures: incident dementia. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: dm_dementia_gudala (weight 1.0), lancet_dementia (weight 0.69). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
High body-mass index → Dementia (all-cause)
high_bmi|dementia
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 3 | 1 |
| Effective reviews (N_eff) | 2 | 1.0 |
| Score (ESS) | 14.2 | 6.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) null (sources larsson2017_ad_mr nordestgaard2026_bmi_vascular_dementia_mr); dose-response yes |
| Sources | lancet_dementia | lancet_dementia larsson2017_ad_mr nordestgaard2026_bmi_vascular_dementia_mr |
| New fields | not recorded before | Measure RR Estimate source lancet_dementia Estimate design cohort synthesis Outcome match exact Outcome measured incident all-cause dementia Grade basis Suggestive: genetically predicted BMI is not associated with Alzheimer's disease (rule T2, ceiling Suggestive; C3 gives…Suggestive: genetically predicted BMI is not associated with Alzheimer's disease (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6), and weight loss precedes dementia in late life (caveat). Lowered from Moderate by the binding rule once the genetic evidence was recorded. Adjudicating bodies lancet_dementia: listed among the modifiable risk factors for dementia (2024) |
Outcome match, Outcome measured: The estimate measures: incident all-cause dementia. measured_outcome
Grade: Suggestive: genetically predicted BMI is not associated with Alzheimer's disease (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6), and weight loss precedes dementia in late life (caveat). Lowered from Moderate by the binding rule once the genetic evidence was recorded. Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr null (status was supportive) with its sources recorded (larsson2017_ad_mr, nordestgaard2026_bmi_vascular_dementia_mr) (card G11, blocker 4): Genetically predicted BMI is not associated with Alzheimer's disease, the main form of dementia (Larsson 2017); a 2026 analysis finds higher risk of vascular-related dementia. The evidence for dementia of all causes is not settled. Grade Moderate to Suggestive (blocker 4, binding rule T2): Suggestive: genetically predicted BMI is not associated with Alzheimer's disease (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6), and weight loss precedes dementia in late life (caveat). Lowered from Moderate by the binding rule once the genetic evidence was recorded. hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). grade_basisT2C3
Grade basis: Suggestive: genetically predicted BMI is not associated with Alzheimer's disease (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6), and weight loss precedes dementia in late life (caveat). Lowered from Moderate by the binding rule once the genetic evidence was recorded. grade_basisT2C3
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: lancet_dementia (weight 1.0). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source lancet_dementia, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr null (status was supportive) with its sources recorded (larsson2017_ad_mr, nordestgaard2026_bmi_vascular_dementia_mr) (card G11, blocker 4): Genetically predicted BMI is not associated with Alzheimer's disease, the main form of dementia (Larsson 2017); a 2026 analysis finds higher risk of vascular-related dementia. The evidence for dementia of all causes is not settled. Grade Moderate to Suggestive (blocker 4, binding rule T2): Suggestive: genetically predicted BMI is not associated with Alzheimer's disease (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6), and weight loss precedes dementia in late life (caveat). Lowered from Moderate by the binding rule once the genetic evidence was recorded. hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _whyT3T4T2C3
Also changed in: 1.4 (19 Sep 2026)
Low physical activity → Dementia (all-cause)
low_pa|dementia
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.29 |
| Score (ESS) | 5.3 | 6.4 |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source lancet_dementia Estimate design cohort synthesis Outcome match exact Outcome measured incident all-cause dementia Grade basis Suggestive: no trial has shown that activity prevents dementia and publication bias is possible (caveat); the pooled ass…Suggestive: no trial has shown that activity prevents dementia and publication bias is possible (caveat); the pooled association held in studies with 20 or more years of follow-up. Kept by the verifier. Adjudicating bodies lancet_dementia: listed among the modifiable risk factors for dementia (2024) |
Outcome match, Outcome measured: The estimate measures: incident all-cause dementia. measured_outcome
Grade basis: Suggestive: no trial has shown that activity prevents dementia and publication bias is possible (caveat); the pooled association held in studies with 20 or more years of follow-up. Kept by the verifier. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: isomarkku_pa_dementia_2022 (weight 1.0), lancet_dementia (weight 0.29). reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source lancet_dementia, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct none (status was null) with its sources recorded (none) (card G11, blocker 4): No trial with new dementia as the outcome is cited; exercise trials have measured cognitive scores. Grade stays Suggestive (card G3, blocker 4); grade_basis rewritten: Suggestive: no trial has shown that activity prevents dementia and publication bias is possible (caveat); the pooled association held in studies with 20 or more years of follow-up. Kept by the verifier. hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _whyT3T4
Also changed in: 1.4 (19 Sep 2026)
Social isolation and loneliness → Dementia (all-cause)
isolation|dementia
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.64 |
| Score (ESS) | 8.5 | 12.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source lancet_dementia Estimate design cohort synthesis Outcome match exact Outcome measured incident dementia Adjudicating bodies lancet_dementia: listed among the modifiable risk factors for dementia (2024) |
Outcome match, Outcome measured: The estimate measures: incident dementia. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: kuiper_social_dementia_2015 (weight 1.0), lancet_dementia (weight 0.64). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Depression (as a risk factor) → Dementia (all-cause)
depression_exposure|dementia
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source lancet_dementia Estimate design cohort synthesis Outcome match exact Outcome measured incident dementia Grade basis Suggestive: in late life part of the association comes from preclinical dementia, and I-squared is 82.8% (caveat). Kept by the verifier. Adjudicating bodies lancet_dementia: listed among the modifiable risk factors for dementia (2024) |
Outcome match, Outcome measured: The estimate measures: incident dementia. measured_outcome
Grade basis: Suggestive: in late life part of the association comes from preclinical dementia, and I-squared is 82.8% (caveat). Kept by the verifier. grade_basis
Reviews counted: Counted from the cited syntheses under the review-counting rule: lancet_dementia (weight 1.0). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Traumatic brain injury → Dementia (all-cause)
tbi|dementia
| Field | Before | After |
| Effective reviews (N_eff) | 2 | 1.71 |
| Score (ESS) | 21.4 | 19.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source lancet_dementia Estimate design cohort synthesis Outcome match exact Outcome measured incident dementia Adjudicating bodies lancet_dementia: listed among the modifiable risk factors for dementia (2024) |
Outcome match, Outcome measured: The estimate measures: incident dementia. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: headinjury_dementia_meta_2017 (weight 1.0), gardner_tbi_dementia_2023 (weight 0.55), lancet_dementia (weight 0.17). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Heavy alcohol use → Dementia (all-cause)
alcohol_heavy|dementia
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.44 |
| Score (ESS) | 4.7 | 6.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources zheng2024_alcohol_dementia_mr); dose-response yes |
| Sources | lancet_dementia kivimaki_alcohol_dementia_2020 | lancet_dementia kivimaki_alcohol_dementia_2020 zheng2024_alcohol_dementia_mr |
| New fields | not recorded before | Measure RR Estimate source lancet_dementia Estimate design pooled IPD Outcome match exact Outcome measured incident dementia Grade basis Suggestive: one individual-participant analysis with z about 2. Kept by the verifier. Adjudicating bodies lancet_dementia: listed among the modifiable risk factors for dementia (2024) |
Outcome match, Outcome measured: The estimate measures: incident dementia. measured_outcome
Grade basis: Suggestive: one individual-participant analysis with z about 2. Kept by the verifier. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: kivimaki_alcohol_dementia_2020 (weight 1.0), lancet_dementia (weight 0.44). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source lancet_dementia, estimate_design pooled IPD, measure RR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). grade_basis records why the grade stands (card G3) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (zheng2024_alcohol_dementia_mr) (card G11, blocker 4): Linear Mendelian randomisation in 313,958 UK Biobank drinkers: higher genetically predicted intake raises dementia (Zheng 2024). hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _whyT3T4
Also changed in: 1.4 (19 Sep 2026)
Fine particulate air pollution → Dementia (all-cause)
pm25|dementia
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source lancet_dementia Estimate design single cohort Outcome match exact Outcome measured incident dementia Adjudicating bodies lancet_dementia: listed among the modifiable risk factors for dementia (2024) |
The estimate measures: incident dementia. measured_outcome
Also changed in: 1.4 (19 Sep 2026)
Short sleep → Dementia (all-cause)
short_sleep|dementia
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.5 |
| Score (ESS) | 2.5 | 3.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source fan_sleep_dementia_2019 Estimate design cohort synthesis Outcome match exact Outcome measured incident all-cause dementia Adjudicating bodies lancet_dementia: not counted as a modifiable risk factor: the evidence was judged too inconsistent (2024) |
Outcome match, Outcome measured: The estimate measures: incident all-cause dementia. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: fan_sleep_dementia_2019 (weight 1.0), lancet_dementia (weight 0.5). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)1.3 (9 Sep 2026)
Obstructive sleep apnoea → Dementia (all-cause)
osa|dementia
| Field | Before | After |
| Score (ESS) | 8.1 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source osa_dementia_meta_2023 Estimate design cohort synthesis Outcome match broader Outcome measured cognitive impairment and/or all-cause dementia Related outcome true Grade basis Suggestive: a combined cognitive outcome, and the association weakens when sleep apnoea is measured by polysomnography (…Suggestive: a combined cognitive outcome, and the association weakens when sleep apnoea is measured by polysomnography (review note). Kept by the verifier. |
Outcome match, Outcome measured, Related outcome: The estimate measures: cognitive impairment and/or all-cause dementia. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: Suggestive: a combined cognitive outcome, and the association weakens when sleep apnoea is measured by polysomnography (review note). Kept by the verifier. grade_basis
Also changed in: 1.4 (9 Oct 2026)
High LDL cholesterol → Dementia (all-cause)
high_ldl|dementia
| Field | Before | After |
| Reviews counted | 4 | 1 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 12.2 | 6.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) null; dose-response yes | Trial none; Genetic (MR) null (sources proitsi2014_lipids_ad_mr larsson2017_ad_mr); dose-response yes |
| Sources | lancet_dementia | lancet_dementia proitsi2014_lipids_ad_mr larsson2017_ad_mr |
| New fields | not recorded before | Measure RR Estimate source lancet_dementia Estimate design single cohort Outcome match exact Outcome measured incident dementia Adjudicating bodies lancet_dementia: listed among the modifiable risk factors for dementia (2024) |
Outcome match, Outcome measured: The estimate measures: incident dementia. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: lancet_dementia (weight 1.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source lancet_dementia, estimate_design single cohort, measure RR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr null with its sources recorded (proitsi2014_lipids_ad_mr, larsson2017_ad_mr) (card G11, blocker 4): Genetically raised LDL cholesterol is not associated with Alzheimer's disease (Proitsi 2014; Larsson 2017). hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _whyT3T4
Also changed in: 1.4 (19 Sep 2026)
Anticholinergic medicines → Dementia (all-cause)
anticholinergics|dementia
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 3 | 1 |
| Effective reviews (N_eff) | 2 | 1.0 |
| Score (ESS) | 18.5 | 7.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source coupland_anticholinergic_2019 Estimate design case-control Outcome match exact Outcome measured dementia (nested case-control) Grade basis Suggestive: Cochrane certainty low; mostly nested case-control. Rules T5b, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). External grades GRADE low (cochrane_anticholinergic_2021) |
Outcome match, Outcome measured: The estimate measures: dementia (nested case-control). measured_outcome
Grade: Suggestive: Cochrane certainty low; mostly nested case-control. Rules T5b, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source coupland_anticholinergic_2019, estimate_design case-control, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). external_grades transcribed from the caveat, the review note or the quote (rule T11): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Cochrane certainty low; mostly nested case-control. grade_basisT5bT8aT11
Grade basis: Suggestive: Cochrane certainty low; mostly nested case-control. Rules T5b, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT5bT8a
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: cochrane_anticholinergic_2021 (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Benzodiazepines and similar sedatives → Dementia (all-cause)
benzodiazepines|dementia
| Field | Before | After |
| Reviews counted | 4 | 3 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 8.5 | 4.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source zhong_bzd_dementia_2015 Estimate design cohort synthesis Outcome match exact Outcome measured incident dementia Grade basis Kept at Weak by the verified dry run: An umbrella review rates all five meta-analyses weak (Class IV maps to Weak in the…Kept at Weak by the verified dry run: An umbrella review rates all five meta-analyses weak (Class IV maps to Weak in the framework); protopathic prescribing. External grades umbrella review class Class IV (weak) (benzo_dementia_umbrella_2023) |
Outcome match, Outcome measured: The estimate measures: incident dementia. measured_outcome
Grade basis: Kept at Weak by the verified dry run: An umbrella review rates all five meta-analyses weak (Class IV maps to Weak in the framework); protopathic prescribing. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: benzo_dementia_umbrella_2023 (weight 1.0), zhong_bzd_dementia_2015 (weight 0.0), penninkilampi_bzd_dementia_2018 (weight 0.0). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Proton pump inhibitors (acid-suppressing tablets) → Dementia (all-cause)
ppi|dementia
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source ppi_dementia_meta_2022 Estimate design cohort synthesis Outcome match exact Outcome measured incident dementia |
The estimate measures: incident dementia. measured_outcome
Also changed in: 1.3 (9 Sep 2026)
Gum disease → Dementia (all-cause)
periodontitis|dementia
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source perio_cognitive_meta_2023 Estimate design mixed Outcome match exact Outcome measured dementia or Alzheimer's disease, cross-sectional and longitudinal studies pooled Grade basis Suggestive: the review pools cross-sectional with longitudinal studies, and measurement may create part of the associati…Suggestive: the review pools cross-sectional with longitudinal studies, and measurement may create part of the association (review note). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: dementia or Alzheimer's disease, cross-sectional and longitudinal studies pooled. measured_outcome
Grade basis: Suggestive: the review pools cross-sectional with longitudinal studies, and measurement may create part of the association (review note). Kept by the verifier. grade_basis
Tooth loss → Dementia (all-cause)
tooth_loss|dementia
| Field | Before | After |
| Grade | Limited (now Weak) | Suggestive |
| Reviews counted | 1 | 3 |
| Effective reviews (N_eff) | 1 | 1.79 |
| Score (ESS) | 2.6 | 7.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | toothloss_cognition_meta_2016 | toothloss_cognition_meta_2016 li2023_toothloss_dementia qi2021_toothloss_dementia |
| New fields | not recorded before | Measure HR Estimate source toothloss_cognition_meta_2016 Estimate design cohort synthesis Outcome match exact Outcome measured incident dementia Grade basis The displayed synthesis (Cerutti-Kopplin 2016, 8 studies, HR 1.22, 1.04 to 1.43) and two later syntheses agree: Li 2023…The displayed synthesis (Cerutti-Kopplin 2016, 8 studies, HR 1.22, 1.04 to 1.43) and two later syntheses agree: Li 2023 (18 cohorts, RR 1.15, 1.10 to 1.20, I-squared 67%) and Qi 2021 (14 studies, dementia RR 1.28, 1.09 to 1.49, with a linear gradient per tooth lost). With several syntheses no single-review rule applies. Tooth loss is on the reverse-causation watch list (cognitive decline can cause tooth loss) and the abstracts do not show a lag analysis, so T8a caps at Suggestive. Studies 8 |
Outcome match, Outcome measured: The estimate measures: incident dementia. measured_outcome
Grade: The displayed synthesis (Cerutti-Kopplin 2016, 8 studies, HR 1.22, 1.04 to 1.43) and two later syntheses agree: Li 2023 (18 cohorts, RR 1.15, 1.10 to 1.20, I-squared 67%) and Qi 2021 (14 studies, dementia RR 1.28, 1.09 to 1.49, with a linear gradient per tooth lost). With several syntheses no single-review rule applies. Tooth loss is on the reverse-causation watch list (cognitive decline can cause tooth loss) and the abstracts do not show a lag analysis, so T8a caps at Suggestive. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): li2023_toothloss_dementia, qi2021_toothloss_dementia; the displayed estimate is unchanged. estimate_source toothloss_cognition_meta_2016, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). n_studies from the displayed review (card G12, research pass; PubMed 30931697). Grade Weak to Suggestive (card G12, settled by the research pass). Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): grade_basis names only cited syntheses: Fang 2018, which was not cited, is replaced by the displayed Cerutti-Kopplin 2016 figures (blocker 9). grade_basisT8a
Grade basis: The displayed synthesis (Cerutti-Kopplin 2016, 8 studies, HR 1.22, 1.04 to 1.43) and two later syntheses agree: Li 2023 (18 cohorts, RR 1.15, 1.10 to 1.20, I-squared 67%) and Qi 2021 (14 studies, dementia RR 1.28, 1.09 to 1.49, with a linear gradient per tooth lost). With several syntheses no single-review rule applies. Tooth loss is on the reverse-causation watch list (cognitive decline can cause tooth loss) and the abstracts do not show a lag analysis, so T8a caps at Suggestive. grade_basisT8a
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: toothloss_cognition_meta_2016 (weight 1.0), qi2021_toothloss_dementia (weight 0.5), li2023_toothloss_dementia (weight 0.29). reviews_counted
Studies, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): li2023_toothloss_dementia, qi2021_toothloss_dementia; the displayed estimate is unchanged. estimate_source toothloss_cognition_meta_2016, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). n_studies from the displayed review (card G12, research pass; PubMed 30931697). Grade Weak to Suggestive (card G12, settled by the research pass). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): grade_basis names only cited syntheses: Fang 2018, which was not cited, is replaced by the displayed Cerutti-Kopplin 2016 figures (blocker 9). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Low socioeconomic position → Dementia (all-cause)
low_sep|dementia
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.17 |
| Score (ESS) | 7.1 | 8.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source ses_dementia_meta_2023 Estimate design cohort synthesis Outcome match exact Outcome measured incident all-cause dementia Grade basis Suggestive: the association runs mainly through education, which is a separate link, and income alone is not significant…Suggestive: the association runs mainly through education, which is a separate link, and income alone is not significant (review note). Accepted by the verifier. |
Outcome match, Outcome measured: The estimate measures: incident all-cause dementia. measured_outcome
Grade basis: Suggestive: the association runs mainly through education, which is a separate link, and income alone is not significant (review note). Accepted by the verifier. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: socialclass_dementia_meta_2022 (weight 1.0), ses_dementia_meta_2023 (weight 0.17). reviews_counted
Mediterranean dietary pattern → Dementia (all-cause)
mediterranean|dementia
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.38 |
| Score (ESS) | 4.6 | 5.8 |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response yes | Trial null (sources barnes2023_mind_trial; a different outcome); Genetic (MR) none; dose-response yes |
| Sources | mind_diet_dementia_2023 diet_neurodegen_umbrella_2020 | mind_diet_dementia_2023 diet_neurodegen_umbrella_2020 barnes2023_mind_trial |
| New fields | not recorded before | Measure HR Estimate source mind_diet_dementia_2023 Estimate design cohort synthesis Outcome match exact Outcome measured incident dementia External grades umbrella review quality moderate (Alzheimer's disease only) (diet_neurodegen_umbrella_2020), does not match this pair |
Outcome match, Outcome measured: The estimate measures: incident dementia. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: diet_neurodegen_umbrella_2020 (weight 1.0), mind_diet_dementia_2023 (weight 0.38). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source mind_diet_dementia_2023, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). triangulation.rct null, same_outcome false (cards G6, G11): The diet trials, including MIND, had cognitive test scores as endpoints: No trial is cited on the link. external_grades transcribed from the caveat, the review note or the quote (rule T11). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct null with its sources recorded (barnes2023_mind_trial), same_outcome false (card G11, blocker 4): The MIND diet trial measured cognitive scores over three years and found no difference; it did not count new dementia. corrections.json _whyT11
Also changed in: 1.4 (9 Oct 2026)
High blood pressure → Alzheimer's disease
high_sbp|alzheimers
| Field | Before | After |
| Reviews counted | 5 | 2 |
| Effective reviews (N_eff) | 4 | 1.17 |
| Score (ESS) | 9.2 | 4.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source lennon_htn_ad_2019 Estimate design cohort synthesis Outcome match exact Outcome measured incident Alzheimer's disease Grade basis Suggestive: a modest association, and genetic studies conflict (review note). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: incident Alzheimer's disease. measured_outcome
Grade basis: Suggestive: a modest association, and genetic studies conflict (review note). Kept by the verifier. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: lennon_htn_ad_2019 (weight 1.0), ou_bp_cognition_2020 (weight 0.17). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Type 2 diabetes (as a risk factor) → Alzheimer's disease
t2d_exposure|alzheimers
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.29 |
| Score (ESS) | 12.3 | 14.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source dm_dementia_gudala Estimate design cohort synthesis Outcome match exact Outcome measured incident Alzheimer's disease |
Outcome match, Outcome measured: The estimate measures: incident Alzheimer's disease. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: dm_dementia_gudala (weight 1.0), xu_ad_riskfactors_2015 (weight 0.29). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Low educational attainment → Alzheimer's disease
low_education|alzheimers
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources larsson2017_ad_mr); dose-response yes |
| Sources | education_dementia_maccora lancet_dementia | education_dementia_maccora larsson2017_ad_mr |
| New fields | not recorded before | Measure OR Estimate source education_dementia_maccora Estimate design cohort synthesis Outcome match exact Outcome measured incident Alzheimer's disease |
Outcome match, Outcome measured: The estimate measures: incident Alzheimer's disease. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source education_dementia_maccora, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (larsson2017_ad_mr) (card G11, blocker 4): Genetically predicted education lowers Alzheimer's disease (OR 0.89 per year, Larsson 2017). lancet_dementia removed from the sources (blocker 6): the body does not rate this pair (adjudication pair_match false), so it cannot count as a replication synthesis either; its adjudication entry goes with it. hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _whyT3T4
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Traumatic brain injury → Alzheimer's disease
tbi|alzheimers
| Field | Before | After |
| Effective reviews (N_eff) | 2 | 1.61 |
| Score (ESS) | 3.5 | 3.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source tbi_ad_cohort_meta_2021 Estimate design cohort synthesis Outcome match exact Outcome measured incident Alzheimer's disease in cohort studies Grade basis Kept at Weak by the verified dry run: A veterans meta-analysis found no AD association and estimates depend on design; the note asks for Weak. |
Outcome match, Outcome measured: The estimate measures: incident Alzheimer's disease in cohort studies. measured_outcome
Grade basis: Kept at Weak by the verified dry run: A veterans meta-analysis found no AD association and estimates depend on design; the note asks for Weak. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: headinjury_dementia_meta_2017 (weight 1.0), tbi_ad_cohort_meta_2021 (weight 0.44), tbi_veterans_dementia_2022 (weight 0.17). reviews_counted
Current cigarette smoking → Parkinson's disease
smoking|parkinsons
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) null; dose-response yes | Trial none; Genetic (MR) supportive (sources domenighetti2022_pd_mr dominguez2021_pd_mr); dose-response yes |
| Sources | hernan_smoking_coffee_pd_2002 | hernan_smoking_coffee_pd_2002 domenighetti2022_pd_mr dominguez2021_pd_mr ritz2014_pd_quitting |
| New fields | not recorded before | Measure RR Estimate source hernan_smoking_coffee_pd_2002 Estimate design cohort synthesis Outcome match exact Outcome measured Parkinson's disease Grade basis Conflicting (rule C2): observational studies and two genetic analyses point to protection, while the Danish ease-of-quit…Conflicting (rule C2): observational studies and two genetic analyses point to protection, while the Danish ease-of-quitting study supports reverse causation in the years before diagnosis. The genetic studies were designed to test reverse causation and still found protection, so the owner should decide whether Conflicting still fits. Without the conflict record the table finds no ceiling for this link. Conflict Side A: Cohort and case-control studies over several decades find fewer cases of Parkinson's disease in current smokers…Side A: Cohort and case-control studies over several decades find fewer cases of Parkinson's disease in current smokers (0.39, 0.32 to 0.47), and two Mendelian randomisation studies support a protective effect of smoking (0.74 per standard deviation of smoking initiation; 0.64 for continued smoking against quitting). Side B: A Danish case-control study found that people who later developed Parkinson's disease had quit smoking more easily than controls, which suggests that the earliest changes of the disease weaken the urge to smoke and that part of the association runs the other way (Ritz 2014). Sources: hernan_smoking_coffee_pd_2002 domenighetti2022_pd_mr dominguez2021_pd_mr ritz2014_pd_quitting |
Outcome match, Outcome measured: The estimate measures: Parkinson's disease. measured_outcome
Grade basis: Conflicting (rule C2): observational studies and two genetic analyses point to protection, while the Danish ease-of-quitting study supports reverse causation in the years before diagnosis. The genetic studies were designed to test reverse causation and still found protection, so the owner should decide whether Conflicting still fits. Without the conflict record the table finds no ceiling for this link. grade_basisC2
Reviews counted: Counted from the cited syntheses under the review-counting rule: hernan_smoking_coffee_pd_2002 (weight 1.0). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source hernan_smoking_coffee_pd_2002, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). conflict records both sides and their sources from the caveat and review note (rule C2, card G1) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive (status was null) with its sources recorded (domenighetti2022_pd_mr, dominguez2021_pd_mr) (card G11, blocker 4): Genetic analyses support a protective effect of smoking initiation (OR 0.74 per SD, Domenighetti 2022) and of continued smoking (OR 0.64, Dominguez-Baleon 2021); the inverse association is the one the link shows. 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): conflict rewritten (issue 3, rule C2): side A now states the observational and the genetic evidence as cited, side B rests on the Danish ease-of-quitting study (Ritz 2014, added to the sources), and conflict.sources lists all four. review_note: the clause saying that Mendelian randomisation does not clearly support a protective effect is replaced by a dated update that matches the cited genetic evidence (issue 3). grade stays Conflicting (the approved grade); grade_basis records that the genetic evidence now answers the reverse-causation objection and brings the question to the owner (issue 3). corrections.json _whyC2
Pesticide exposure → Parkinson's disease
pesticides|parkinsons
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source occ_toxins_pd_meta_2021 Estimate design cohort synthesis Outcome match exact Outcome measured Parkinson's disease |
Outcome match, Outcome measured: The estimate measures: Parkinson's disease. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: occ_toxins_pd_meta_2021 (weight 1.0). reviews_counted
Traumatic brain injury → Parkinson's disease
tbi|parkinsons
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source tbi_pd_meta_2023 Estimate design cohort synthesis Outcome match exact Outcome measured Parkinson's disease (case-control comparison of TBI history) |
The estimate measures: Parkinson's disease (case-control comparison of TBI history). measured_outcome
Trichloroethylene in drinking water → Parkinson's disease
occ_solvents|parkinsons
| Field | Before | After |
| Grade | Suggestive | Weak |
| Reviews counted | 1 | 0 |
| Score (ESS) | 9.4 | 5.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | tce_pd_lejeune occ_toxins_pd_meta_2021 | tce_pd_lejeune |
| New fields | not recorded before | Measure OR Estimate source tce_pd_lejeune Estimate design single cohort Outcome match exact Outcome measured Parkinson's disease Grade basis Weak: One cohort; exposure assigned by military base. Rule T5c (ceiling Weak). Verified on 21 October 2026 (card G3). Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: Parkinson's disease. measured_outcome
Grade: Weak: One cohort; exposure assigned by military base. Rule T5c (ceiling Weak). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source tce_pd_lejeune, estimate_design single cohort, measure OR, by rule E1 (read by hand) (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): One cohort; exposure assigned by military base. grade_basisT5c
Grade basis: Weak: One cohort; exposure assigned by military base. Rule T5c (ceiling Weak). Verified on 21 October 2026 (card G3). grade_basisT5c
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source tce_pd_lejeune, estimate_design single cohort, measure OR, by rule E1 (read by hand) (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): One cohort; exposure assigned by military base. 23 Oct 2026 fix round 3 (verifier of the data step, third check, blockers 1 to 3 and minor items 4, 6, 7): Source occ_toxins_pd_meta_2021 removed from the link's sources (blocker 2a, card K7 A topic check, PROPOSAL section 5.1): it pools pesticides, metals and electromagnetic fields and has no solvent row, as the review note says, so it does not replicate this pair and must not count in the replication term; n_reviews 1 to 0, primary_only true. review_note: the em dash is replaced by a full stop (writing rules). review_note: a dated sentence records that the meta-analysis is no longer listed among the sources (blocker 2a). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Coffee consumption → Parkinson's disease
coffee|parkinsons
| Field | Before | After |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response yes | Trial null (sources postuma2017_caffeine_pd; a different outcome); Genetic (MR) none; dose-response yes |
| Sources | hernan_smoking_coffee_pd_2002 diet_neurodegen_umbrella_2020 | hernan_smoking_coffee_pd_2002 diet_neurodegen_umbrella_2020 postuma2017_caffeine_pd |
| New fields | not recorded before | Measure RR Estimate source hernan_smoking_coffee_pd_2002 Estimate design cohort synthesis Outcome match exact Outcome measured Parkinson's disease |
Outcome match, Outcome measured: The estimate measures: Parkinson's disease. measured_outcome
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source hernan_smoking_coffee_pd_2002, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct null with its sources recorded (postuma2017_caffeine_pd), same_outcome false (card G11, blocker 4): The Cafe-PD trial gave caffeine to people who already had Parkinson's disease and found no improvement in motor symptoms. corrections.json _why
Adverse childhood experiences → Depression
aces|depression
| Field | Before | After |
| Reviews counted | 3 | 2 |
| Effective reviews (N_eff) | 2 | 1.29 |
| Score (ESS) | 25.6 | 19.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source li_maltreatment_depression_2015 Estimate design cohort synthesis Outcome match exact Outcome measured Depression by diagnosis or symptom-scale caseness in cohorts |
Outcome match, Outcome measured: The estimate measures: Depression by diagnosis or symptom-scale caseness in cohorts. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: li_maltreatment_depression_2015 (weight 1.0), aces_hughes (weight 0.29). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.3 (18 Sep 2026)
Social isolation and loneliness → Depression
isolation|depression
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.29 |
| Score (ESS) | 11.9 | 14.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source mann_loneliness_depression_2022 Estimate design cohort synthesis Outcome match exact Outcome measured New-onset depression (diagnosis or symptom-scale caseness) |
Outcome match, Outcome measured: The estimate measures: New-onset depression (diagnosis or symptom-scale caseness). measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: solmi_loneliness_umbrella_2020 (weight 1.0), mann_loneliness_depression_2022 (weight 0.29). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Job strain → Depression
job_strain|depression
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | madsen_jobstrain_depression_2017 ipd_work | madsen_jobstrain_depression_2017 |
| New fields | not recorded before | Measure RR Estimate source madsen_jobstrain_depression_2017 Estimate design pooled IPD Outcome match exact Outcome measured clinical depression (hospital-treated first episodes) |
Outcome match, Outcome measured: The estimate measures: clinical depression (hospital-treated first episodes). measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source madsen_jobstrain_depression_2017, estimate_design pooled IPD, measure RR, by rule E1 (cards G8, K5, P2) 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source ipd_work removed from the link's sources (issue 2, card K7 A topic check, PROPOSAL section 5.1): it is the IPD-Work analysis of job strain and coronary heart disease, another outcome, so it does not replicate this pair and must not count in the replication term. corrections.json _why
Low socioeconomic position → Depression
low_sep|depression
| Field | Before | After |
| Reviews counted | 6 | 1 |
| Effective reviews (N_eff) | 5 | 1.0 |
| Score (ESS) | 4.4 | 1.9 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources cash_transfer_depression_2023; a different exposure); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source nsec_depression_richardson Estimate design cohort synthesis Outcome match exact Outcome measured Depression in longitudinal studies (definition varies by study) Grade basis Kept at Weak by the verified dry run: With five or more years of follow-up the association disappears (1.00); the trial…Kept at Weak by the verified dry run: With five or more years of follow-up the association disappears (1.00); the trial tag rests on cash transfers in LMICs, a different exposure. The record 'allows up to Strong' only because of that tag. |
Outcome match, Outcome measured: The estimate measures: Depression in longitudinal studies (definition varies by study). measured_outcome
Grade basis: Kept at Weak by the verified dry run: With five or more years of follow-up the association disappears (1.00); the trial tag rests on cash transfers in LMICs, a different exposure. The record 'allows up to Strong' only because of that tag. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: nsec_depression_richardson (weight 1.0). reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)). estimate_source nsec_depression_richardson, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_exposure false (cards G6, G11): Cash-transfer trials change household income; the link measures neighbourhood socioeconomic conditions: Grade stays Weak (card G3: kept by the verifier). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)1.3 (9 Sep 2026)
Insomnia → Depression
insomnia|depression
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources irwin2022_cbti_depression cheng2019_dcbti_depression christensen2016_shuti); Genetic (MR) none; dose-response yes |
| Sources | baglioni_insomnia_depression_2011 | baglioni_insomnia_depression_2011 irwin2022_cbti_depression cheng2019_dcbti_depression christensen2016_shuti |
| New fields | not recorded before | Measure OR Estimate source baglioni_insomnia_depression_2011 Estimate design cohort synthesis Outcome match exact Outcome measured Depression at follow-up (diagnosis or symptom scales) |
Outcome match, Outcome measured: The estimate measures: Depression at follow-up (diagnosis or symptom scales). measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)): Sources added (card G11): irwin2022_cbti_depression, cheng2019_dcbti_depression, christensen2016_shuti; the displayed estimate is unchanged. estimate_source baglioni_insomnia_depression_2011, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive recorded with its sources (card G11, research pass): Irwin 2022 had incident or recurrent major depression by interview as its primary outcome (HR 0.51, 0.29 to 0.88). Cheng 2019 halved incident moderate-to-severe depression on a symptom scale. Christensen 2016 used a symptom scale and found no clear difference in diagnosed major depression. corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Low physical activity → Depression
low_pa|depression
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.44 |
| Score (ESS) | 9.2 | 12.0 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) supportive; dose-response yes | Trial supportive (sources schuch2016_exercise_depression_ma; a different outcome); Genetic (MR) supportive (sources choi…Trial supportive (sources schuch2016_exercise_depression_ma; a different outcome); Genetic (MR) supportive (sources choi2019_pa_depression_mr); dose-response yes |
| Sources | pearce_pa_depression_2022 schuch_pa_depression_2018 | pearce_pa_depression_2022 schuch_pa_depression_2018 schuch2016_exercise_depression_ma choi2019_pa_depression_mr |
| New fields | not recorded before | Measure RR Estimate source pearce_pa_depression_2022 Estimate design cohort synthesis Outcome match exact Outcome measured Depression, by diagnosis or raised depressive symptoms |
Outcome match, Outcome measured: The estimate measures: Depression, by diagnosis or raised depressive symptoms. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: schuch_pa_depression_2018 (weight 1.0), pearce_pa_depression_2022 (weight 0.44). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)). estimate_source pearce_pa_depression_2022, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct supportive with its sources recorded (schuch2016_exercise_depression_ma), same_outcome false (card G11, blocker 4): The exercise trials treated people who already had depression (25 trials, Schuch 2016). triangulation.mr supportive with its sources recorded (choi2019_pa_depression_mr) (card G11, blocker 4): Genetically predicted accelerometer-measured activity lowers major depression (Choi 2019). hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _why
Also changed in: 1.4 (19 Sep 2026)
Ultra-processed food → Depression
upf|depression
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source pagliai_upf_2020 Estimate design cohort synthesis Outcome match exact Outcome measured Depression in two cohorts (definition varies by study) |
The estimate measures: Depression in two cohorts (definition varies by study). measured_outcome
Current cigarette smoking → Depression
smoking|depression
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources smoking_depression_mr); dose-response yes |
| New fields | not recorded before | Measure RR Estimate source smoking_depression_hu Estimate design cohort synthesis Outcome match exact Outcome measured incident major depression |
The estimate measures: incident major depression. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Heavy alcohol use → Depression
alcohol_heavy|depression
| Field | Before | After |
| Score (ESS) | 1.5 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) null (sources polimanti2019_md_ad_mr; a different exposure); dose-response yes |
| Sources | alcohol_dep_gemes | alcohol_dep_gemes polimanti2019_md_ad_mr |
| New fields | not recorded before | Measure RR Estimate source alcohol_dep_gemes Estimate design cohort synthesis Outcome match proxy Outcome measured depressive symptoms (subsequent) Related outcome true Conflict Side A: Heavy drinking and later depressive symptoms travel together (1.13, 1.05 to 1.22). Side B: The same meta-analysi…Side A: Heavy drinking and later depressive symptoms travel together (1.13, 1.05 to 1.22). Side B: The same meta-analysis concludes that heavy drinking does not significantly predict later depression once other factors are accounted for, and the curve is J-shaped. Sources: alcohol_dep_gemes |
Outcome match, Outcome measured, Related outcome: The estimate measures: depressive symptoms (subsequent). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match proxy, measured outcome recorded (cards O1 and O5). estimate_source alcohol_dep_gemes, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). conflict records both sides and their sources from the caveat and review note (rule C2, card G1) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr none (status was supportive) with its sources recorded (none) (card G11, blocker 4): No Mendelian randomisation study of drinking on depression is cited; a genetic analysis found the reverse, that liability to depression raises alcohol dependence (Polimanti 2019). 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): triangulation.mr null (status was none) with its sources recorded (polimanti2019_md_ad_mr), same_exposure false (issue 5, card G11): The genetic analysis cited tested alcohol dependence (a diagnosis; the link's exposure is heavy drinking) against major depression and found no evidence that it raises depression. It found the reverse: liability to depression raises alcohol dependence (Polimanti 2019). No Mendelian randomisation study of drinking itself on depression is cited. corrections.json _whyC2
Access to green space → Depression
green_space|depression
| Field | Before | After |
| Grade | Limited (now Weak) | Suggestive |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.17 |
| Score (ESS) | 1.1 | 2.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source greenspace_depression_yang Estimate design mixed Outcome match exact Outcome measured Depression, pooled across studies of mixed design Grade basis Suggestive: Two meta-analyses; the cohorts agree (0.91). Rule T8d (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Depression, pooled across studies of mixed design. measured_outcome
Grade: Suggestive: Two meta-analyses; the cohorts agree (0.91). Rule T8d (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)). estimate_source greenspace_depression_yang, estimate_design mixed, measure OR, by rule E1 (read by hand) (cards G8, K5, P2): Grade Weak to Suggestive (card G3, PROPOSAL section 3.1): Two meta-analyses; the cohorts agree (0.91). grade_basisT8d
Grade basis: Suggestive: Two meta-analyses; the cohorts agree (0.91). Rule T8d (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT8d
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: greenspace_depression_yang (weight 1.0), zhang_green_psych_2024 (weight 0.17). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Vitamin D deficiency → Depression
vitd_deficiency|depression
| Field | Before | After |
| Trial and genetic evidence | Trial contradicts; Genetic (MR) contradicts; dose-response yes | Trial contradicts (sources vital_dep); Genetic (MR) contradicts (sources michaelsson2018_vitd_depression_mr libuda2019_v…Trial contradicts (sources vital_dep); Genetic (MR) contradicts (sources michaelsson2018_vitd_depression_mr libuda2019_vitd_depression_mr); dose-response yes |
| Sources | ju_vitd_depression_2013 vital_dep | ju_vitd_depression_2013 vital_dep michaelsson2018_vitd_depression_mr libuda2019_vitd_depression_mr |
| New fields | not recorded before | Measure OR Estimate source ju_vitd_depression_2013 Estimate design mixed Outcome match exact Outcome measured Depression in cohorts (definition varies by study) Conflict Side A: Cohort studies link lower blood vitamin D with more depression (1.09, 1.02 to 1.15 per 10 ng/mL lower). Side B:…Side A: Cohort studies link lower blood vitamin D with more depression (1.09, 1.02 to 1.15 per 10 ng/mL lower). Side B: The VITAL-DEP trial found no effect of vitamin D supplements on depression (0.97, 0.87 to 1.09). Sources: ju_vitd_depression_2013 vital_dep |
Outcome match, Outcome measured: The estimate measures: Depression in cohorts (definition varies by study). measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)). estimate_source ju_vitd_depression_2013, estimate_design mixed, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). conflict records both sides and their sources from the caveat and review note (rule C2, card G1) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr contradicts with its sources recorded (michaelsson2018_vitd_depression_mr, libuda2019_vitd_depression_mr) (card G11, blocker 4): Genetically lower 25-hydroxyvitamin D is not associated with major depression (Michaelsson 2018; Libuda 2019). corrections.json _whyC2
Also changed in: 1.4 (9 Oct 2026)
Current cigarette smoking → Fracture in adults
smoking|fracture
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.81 |
| Score (ESS) | 9.6 | 14.5 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources yuan2019_smoking_fracture_mr); dose-response yes |
| Sources | smoke_fracture_ma smoke_fracture_frax2026 | smoke_fracture_ma smoke_fracture_frax2026 yuan2019_smoking_fracture_mr |
| New fields | not recorded before | Measure RR Estimate source smoke_fracture_ma Estimate design pooled IPD Outcome match exact Outcome measured Fracture at any site |
Outcome match, Outcome measured: The estimate measures: Fracture at any site. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoke_fracture_ma (weight 1.0), smoke_fracture_frax2026 (weight 0.81). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)). estimate_source smoke_fracture_ma, estimate_design pooled IPD, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (yuan2019_smoking_fracture_mr) (card G11, blocker 4): Genetic predisposition to smoking raises fracture (OR 1.09 per unit log-odds, UK Biobank). corrections.json _why
Heavy alcohol use → Fracture in adults
alcohol_heavy|fracture
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.77 |
| Score (ESS) | 10.0 | 14.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source alcohol_fracture_ma Estimate design pooled IPD Outcome match exact Outcome measured osteoporotic fracture |
Outcome match, Outcome measured: The estimate measures: osteoporotic fracture. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: alcohol_fracture_ma (weight 1.0), alcohol_fracture_ma2021 (weight 0.77). reviews_counted
Low physical activity → Fracture in adults
low_pa|fracture
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources sherrington2019_exercise_falls; a different outcome); Genetic (MR) none; dose-response yes |
| Sources | pa_fracture_ma | pa_fracture_ma sherrington2019_exercise_falls |
| New fields | not recorded before | Measure RR Estimate source pa_fracture_ma Estimate design cohort synthesis Outcome match narrower Outcome measured hip fracture in women Grade basis Moderate: 13 prospective cohorts, and exercise trials reduce falls, the main route to fracture (caveat). Accepted by the verifier. |
Outcome match, Outcome measured: The estimate measures: hip fracture in women. measured_outcome
Grade basis: Moderate: 13 prospective cohorts, and exercise trials reduce falls, the main route to fracture (caveat). Accepted by the verifier. grade_basis
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match narrower, measured outcome recorded (cards O1 and O5): Sources added (card G11): sherrington2019_exercise_falls; the displayed estimate is unchanged. estimate_source pa_fracture_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive recorded with its sources (card G11, research pass): The exercise trials measure falls (rate ratio 0.77). Fall-related fractures were a low-certainty secondary result (RR 0.73, 0.56 to 0.95, 10 studies), and no trial measures hip fracture. grade_basis records why the grade stands (card G3). corrections.json _why
Also changed in: 1.4 (19 Sep 2026)
Vitamin D deficiency → Fracture in adults
vitd_deficiency|fracture
| Field | Before | After |
| Reviews counted | 6 | 1 |
| Effective reviews (N_eff) | 4 | 1.0 |
| Score (ESS) | 5.3 | 2.4 |
| Trial and genetic evidence | Trial contradicts; Genetic (MR) contradicts; dose-response yes | Trial contradicts (sources vital d_health); Genetic (MR) contradicts (sources trajanoska2018_fracture_mr); dose-response yes |
| Sources | vitd_fracture_ma vital d_health | vitd_fracture_ma vital d_health trajanoska2018_fracture_mr |
| New fields | not recorded before | Measure RR Estimate source vitd_fracture_ma Estimate design cohort synthesis Outcome match exact Outcome measured Fracture at any site Conflict Side A: Cohort studies link low blood vitamin D with more fractures (1.25, 1.06 to 1.43). Side B: Supplement trials, inc…Side A: Cohort studies link low blood vitamin D with more fractures (1.25, 1.06 to 1.43). Side B: Supplement trials, including VITAL, found no fracture benefit in adults living in the community. Sources: vitd_fracture_ma vital d_health |
Outcome match, Outcome measured: The estimate measures: Fracture at any site. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: vitd_fracture_ma (weight 1.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)). estimate_source vitd_fracture_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). conflict records both sides and their sources from the caveat and review note (rule C2, card G1) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr contradicts with its sources recorded (trajanoska2018_fracture_mr) (card G11, blocker 4): Genetic predisposition to lower vitamin D is not associated with fracture (Trajanoska 2018). corrections.json _whyC2
Also changed in: 1.4 (9 Oct 2026)1.3 (9 Sep 2026)
Early menopause → Fracture in adults
early_menopause|fracture
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source menopause_fracture_ma Estimate design cohort synthesis Outcome match exact Outcome measured Fracture at any site in women after menopause |
The estimate measures: Fracture at any site in women after menopause. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Proton pump inhibitors (acid-suppressing tablets) → Fracture in adults
ppi|fracture
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source ppi_fracture_ma Estimate design cohort synthesis Outcome match exact Outcome measured Fracture at any site |
The estimate measures: Fracture at any site. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Benzodiazepines and similar sedatives → Fracture in adults
benzodiazepines|fracture
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 7.7 | 5.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source bzd_fracture_ma Estimate design mixed Outcome match exact Outcome measured Fracture at any site (19 of 25 studies case-control) Grade basis Suggestive: 19 of 25 studies case-control; publication bias. Rules T8c, T10 (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Fracture at any site (19 of 25 studies case-control). measured_outcome
Grade: Suggestive: 19 of 25 studies case-control; publication bias. Rules T8c, T10 (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)). estimate_source bzd_fracture_ma, estimate_design mixed, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): 19 of 25 studies case-control; publication bias. grade_basisT8cT10
Grade basis: Suggestive: 19 of 25 studies case-control; publication bias. Rules T8c, T10 (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT8cT10
Menopausal hormone therapy → Fracture in adults
mht|fracture
| Field | Before | After |
| Reviews counted | 4 | 1 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 18.8 | 9.5 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources mht_fracture_zhu mht_cochrane2026 whi_fracture); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source mht_fracture_zhu Estimate design trial synthesis Outcome match exact Outcome measured Fracture at any site in randomised trials External grades GRADE moderate (mht_cochrane2026) |
Outcome match, Outcome measured: The estimate measures: Fracture at any site in randomised trials. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: mht_fracture_zhu (weight 1.0). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
High body-mass index → Knee osteoarthritis
high_bmi|oa_knee
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) supportive; dose-response yes | Trial supportive (sources messier2013_idea_trial; a different outcome); Genetic (MR) supportive (sources funckbrentano2019_oa_mr); dose-response yes |
| Sources | obesity_knee_oa_ma | obesity_knee_oa_ma funckbrentano2019_oa_mr messier2013_idea_trial |
| New fields | not recorded before | Measure OR Estimate source obesity_knee_oa_ma Estimate design mixed Outcome match exact Outcome measured Knee osteoarthritis (47 studies: 14 cohort, 19 cross-sectional, 14 case-control) |
Outcome match, Outcome measured: The estimate measures: Knee osteoarthritis (47 studies: 14 cohort, 19 cross-sectional, 14 case-control). measured_outcome
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source obesity_knee_oa_ma, estimate_design mixed, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation.rct supportive, same_outcome false (cards G6, G11): Weight-loss trials measured pain and progression in people who already have knee osteoarthritis 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (funckbrentano2019_oa_mr) (card G11, blocker 4): Genetically determined BMI raises knee osteoarthritis in UK Biobank (Funck-Brentano 2019). triangulation.rct supportive with its sources recorded (messier2013_idea_trial), same_outcome false (card G11, blocker 4): Weight-loss trials (IDEA) measured joint loads, pain and function in people who already have knee osteoarthritis. corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Heavy physical work → Knee osteoarthritis
heavy_work|oa_knee
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source occ_knee_oa_ma Estimate design cohort synthesis Outcome match exact Outcome measured Knee osteoarthritis External grades GRADE moderate (occ_knee_oa_ma) |
The estimate measures: Knee osteoarthritis. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Low muscle strength → Knee osteoarthritis
low_grip|oa_knee
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source quads_knee_oa_ma Estimate design cohort synthesis Outcome match exact Outcome measured Incident radiographic knee osteoarthritis (women) External grades GRADE low (quads_knee_oa_ma) |
The estimate measures: Incident radiographic knee osteoarthritis (women). measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Current cigarette smoking → Rheumatoid arthritis
smoking|ra
| Field | Before | After |
| Reviews counted | 7 | 3 |
| Effective reviews (N_eff) | 6 | 2.06 |
| Score (ESS) | 24.8 | 16.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources qian2020_smoking_ra_mr); dose-response yes |
| Sources | bprf_smoking smoke_ra_ma smoke_ra_dose_ma | bprf_smoking smoke_ra_ma smoke_ra_dose_ma qian2020_smoking_ra_mr |
| New fields | not recorded before | Measure RR Estimate source bprf_smoking Estimate design cohort synthesis Outcome match exact Outcome measured Rheumatoid arthritis (Burden of Proof, per cigarettes a day) Adjudicating bodies bprf_smoking: 3 stars External grades Burden of Proof 3 stars (bprf_smoking) |
Outcome match, Outcome measured: The estimate measures: Rheumatoid arthritis (Burden of Proof, per cigarettes a day). measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoke_ra_ma (weight 1.0), smoke_ra_dose_ma (weight 0.44), bprf_smoking (weight 0.62). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source bprf_smoking, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). external_grades transcribed from the caveat, the review note or the quote (rule T11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (qian2020_smoking_ra_mr) (card G11, blocker 4): Genetic predisposition to smoking raises rheumatoid arthritis (OR 1.32, Qian 2020). hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _whyT3T4T11
Also changed in: 1.4 (19 Sep 2026)
Gum disease → Rheumatoid arthritis
periodontitis|ra
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source perio_ra_ma Estimate design cohort synthesis Outcome match exact Outcome measured Rheumatoid arthritis in people with periodontitis |
The estimate measures: Rheumatoid arthritis in people with periodontitis. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
High body-mass index → Rheumatoid arthritis
high_bmi|ra
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources bae2019_bmi_ra_mr); dose-response yes |
| Sources | bmi_ra_ma | bmi_ra_ma bae2019_bmi_ra_mr |
| New fields | not recorded before | Measure RR Estimate source bmi_ra_ma Estimate design cohort synthesis Outcome match exact Outcome measured Incident rheumatoid arthritis Grade basis Suggestive: 1.03 per 5 kg/m2 with I-squared 70% and a curved relation. Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: Incident rheumatoid arthritis. measured_outcome
Grade basis: Suggestive: 1.03 per 5 kg/m2 with I-squared 70% and a curved relation. Kept by the verifier. grade_basis
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source bmi_ra_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). grade_basis records why the grade stands (card G3) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (bae2019_bmi_ra_mr) (card G11, blocker 4): Genetically predicted BMI raises rheumatoid arthritis in the main analysis (Bae 2019); the effect is small. corrections.json _why
Occupational silica dust → Rheumatoid arthritis
silica|ra
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source silica_ra_ma Estimate design cohort synthesis Outcome match exact Outcome measured Rheumatoid arthritis |
The estimate measures: Rheumatoid arthritis. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
High blood uric acid → Gout
high_urate|gout
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) supportive; dose-response yes | Trial supportive (sources dalbeth2017_febuxostat_gout; a different outcome); Genetic (MR) supportive (sources urate_gout_mr_keenan); dose-response yes |
| Sources | urate_gout_mr_keenan urate_umbrella | urate_gout_mr_keenan urate_umbrella dalbeth2017_febuxostat_gout |
| New fields | not recorded before | Measure OR Estimate source urate_gout_mr_keenan Estimate design MR Outcome match exact Outcome measured Gout (Mendelian randomisation) External grades umbrella review class Class I (Mendelian randomisation evidence) (urate_umbrella) |
Outcome match, Outcome measured: The estimate measures: Gout (Mendelian randomisation). measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: urate_umbrella (weight 1.0). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source urate_gout_mr_keenan, estimate_design MR, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation.rct supportive, same_outcome false (cards G6, G11): Urate-lowering therapy prevents attacks in people who already have gout. external_grades transcribed from the caveat, the review note or the quote (rule T11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct supportive with its sources recorded (dalbeth2017_febuxostat_gout), same_outcome false (card G11, blocker 4): Urate-lowering therapy was tested in people who already had early gout (Dalbeth 2017). corrections.json _whyT11
Also changed in: 1.4 (9 Oct 2026)
Heavy alcohol use → Gout
alcohol_heavy|gout
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 4 | 2 |
| Effective reviews (N_eff) | 3 | 1.58 |
| Score (ESS) | 26.8 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) null (sources alc_gout_mr); dose-response yes |
| New fields | not recorded before | Measure OR Estimate source alc_gout_meta Estimate design cohort synthesis Outcome match composite_other Outcome measured Hyperuricaemia and gout combined Related outcome true Grade basis Suggestive: a Mendelian randomisation study found no causal effect of drinking on gout or urate (rule T2, ceiling Sugges…Suggestive: a Mendelian randomisation study found no causal effect of drinking on gout or urate (rule T2, ceiling Suggestive; rule C3 gives Suggestive by default, card G6). The link sits in the related-outcome layer (hyperuricaemia and gout combined). Lowered from Moderate by the binding rule once the genetic evidence was recorded (card G11). |
Outcome match, Outcome measured, Related outcome: The estimate measures: Hyperuricaemia and gout combined. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Suggestive: a Mendelian randomisation study found no causal effect of drinking on gout or urate (rule T2, ceiling Suggestive; rule C3 gives Suggestive by default, card G6). The link sits in the related-outcome layer (hyperuricaemia and gout combined). Lowered from Moderate by the binding rule once the genetic evidence was recorded (card G11). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match composite_other, measured outcome recorded (cards O1 and O5). estimate_source alc_gout_meta, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). triangulation.mr corrected from supportive to null: The review note: genetically predicted drinks per week had no causal effect on gout or urate, while genetic liability to gout predicted lower drinking. grade_override keeps Moderate: The review note records that a Mendelian randomisation study found no causal effect of drinking on gout or urate, and that genetic liability to gout predicted lower drinking: The triangulation field said supportive and now says null, so rule T2 (Suggestive) applies. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Grade Moderate to Suggestive (blocker 2, binding rule T2): Suggestive: a Mendelian randomisation study found no causal effect of drinking on gout or urate (rule T2, ceiling Suggestive; rule C3 gives Suggestive by default, card G6). The link sits in the related-outcome layer (hyperuricaemia and gout combined). Lowered from Moderate by the binding rule once the genetic evidence was recorded (card G11). grade_basisT2C3
Grade basis: Suggestive: a Mendelian randomisation study found no causal effect of drinking on gout or urate (rule T2, ceiling Suggestive; rule C3 gives Suggestive by default, card G6). The link sits in the related-outcome layer (hyperuricaemia and gout combined). Lowered from Moderate by the binding rule once the genetic evidence was recorded (card G11). grade_basisT2C3
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: diet_gout (weight 1.0), alc_gout_meta (weight 0.58). reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match composite_other, measured outcome recorded (cards O1 and O5). estimate_source alc_gout_meta, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). triangulation.mr corrected from supportive to null: The review note: genetically predicted drinks per week had no causal effect on gout or urate, while genetic liability to gout predicted lower drinking. grade_override keeps Moderate: The review note records that a Mendelian randomisation study found no causal effect of drinking on gout or urate, and that genetic liability to gout predicted lower drinking: The triangulation field said supportive and now says null, so rule T2 (Suggestive) applies. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Grade Moderate to Suggestive (blocker 2, binding rule T2): Suggestive: a Mendelian randomisation study found no causal effect of drinking on gout or urate (rule T2, ceiling Suggestive; rule C3 gives Suggestive by default, card G6). The link sits in the related-outcome layer (hyperuricaemia and gout combined). Lowered from Moderate by the binding rule once the genetic evidence was recorded (card G11). corrections.json _whyT2C3
Also changed in: 1.4 (9 Oct 2026)
High body-mass index → Gout
high_bmi|gout
| Field | Before | After |
| Reviews counted | 4 | 2 |
| Effective reviews (N_eff) | 3 | 1.44 |
| Score (ESS) | 41.8 | 27.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources larsson2018_adiposity_gout_mr); dose-response yes |
| Sources | gout_obes_htn bmi_gout_aune | gout_obes_htn bmi_gout_aune larsson2018_adiposity_gout_mr |
| New fields | not recorded before | Measure RR Estimate source gout_obes_htn Estimate design cohort synthesis Outcome match exact Outcome measured Incident gout |
Outcome match, Outcome measured: The estimate measures: Incident gout. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: bmi_gout_aune (weight 1.0), gout_obes_htn (weight 0.44). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source gout_obes_htn, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (larsson2018_adiposity_gout_mr) (card G11, blocker 4): Genetically predicted BMI raises gout (OR 2.24 per SD) and serum urate (Larsson 2018). corrections.json _why
Sugar-sweetened drinks → Gout
ssb|gout
| Field | Before | After |
| Reviews counted | 3 | 2 |
| Effective reviews (N_eff) | 2 | 1.17 |
| Score (ESS) | 26.0 | 18.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source ssb_gout_ayoub Estimate design cohort synthesis Outcome match exact Outcome measured New cases of gout External grades GRADE moderate (ssb_gout_ayoub) |
Outcome match, Outcome measured: The estimate measures: New cases of gout. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: ssb_gout_ebrahim (weight 1.0), ssb_gout_ayoub (weight 0.17). reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source ssb_gout_ayoub, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). external_grades transcribed from the caveat, the review note or the quote (rule T11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr none (status was supportive) with its sources recorded (none) (card G11, blocker 4): No Mendelian randomisation study of sugar-sweetened drinks and gout is cited. corrections.json _whyT11
Also changed in: 1.4 (9 Oct 2026)
Unprocessed red meat → Gout
red_meat|gout
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source diet_gout Estimate design mixed Outcome match exact Outcome measured Gout (19 prospective and cross-sectional studies) Grade basis Suggestive: the review mixes prospective and cross-sectional studies (review note). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: Gout (19 prospective and cross-sectional studies). measured_outcome
Grade basis: Suggestive: the review mixes prospective and cross-sectional studies (review note). Kept by the verifier. grade_basis
Reviews counted: Counted from the cited syntheses under the review-counting rule: diet_gout (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Chronic kidney disease (as a risk factor) → Gout
ckd_exposure|gout
| Field | Before | After |
| Reviews counted | 1 | 0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source ckd_gout_fram Estimate design single cohort Outcome match exact Outcome measured Incident gout in women (Framingham cohort) Grade override Suggestive. Kept by the verifier: one Framingham analysis, but reduced urate excretion by the kidney is a direct and wel…Suggestive. Kept by the verifier: one Framingham analysis, but reduced urate excretion by the kidney is a direct and well-established mechanism. T5c proposes Weak. Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: Incident gout in women (Framingham cohort). measured_outcome
Grade override: Curator override to Suggestive: Kept by the verifier: one Framingham analysis, but reduced urate excretion by the kidney is a direct and well-established mechanism. T5c proposes Weak. grade_overrideT5c
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Current cigarette smoking → Inflammatory bowel disease
smoking|ibd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source smoke_ibd_ma Estimate design cohort synthesis Outcome match narrower Outcome measured Crohn's disease only, in non-Jewish White populations |
The estimate measures: Crohn's disease only, in non-Jewish White populations. measured_outcome
Ultra-processed food → Inflammatory bowel disease
upf|ibd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.17 |
| Score (ESS) | 3.2 | 3.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source upf_ibd_ma Estimate design cohort synthesis Outcome match exact Outcome measured Inflammatory bowel disease overall Grade basis Suggestive: the association is carried by Crohn's disease only (review note). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: Inflammatory bowel disease overall. measured_outcome
Grade basis: Suggestive: the association is carried by Crohn's disease only (review note). Kept by the verifier. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: upf_ibd_ma (weight 1.0), diet_ibd_ma (weight 0.17). reviews_counted
Low dietary fibre → Inflammatory bowel disease
low_fibre|ibd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.44 |
| Score (ESS) | 9.3 | 12.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source fibre_ibd_ma Estimate design cohort synthesis Outcome match narrower Outcome measured Crohn's disease only |
Outcome match, Outcome measured: The estimate measures: Crohn's disease only. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: fibre_ibd_ma (weight 1.0), diet_ibd_ma (weight 0.44). reviews_counted
Current cigarette smoking → Age-related macular degeneration
smoking|amd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.77 |
| Score (ESS) | 14.9 | 22.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source amd_rf_ma2025 Estimate design cohort synthesis Outcome match exact Outcome measured Age-related macular degeneration occurrence (pooled risk factor analysis) |
Outcome match, Outcome measured: The estimate measures: Age-related macular degeneration occurrence (pooled risk factor analysis). measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoke_amd_ma (weight 1.0), amd_rf_ma2025 (weight 0.77). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Low seafood omega-3 intake → Age-related macular degeneration
low_omega3|amd
| Field | Before | After |
| Reviews counted | 4 | 1 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 14.2 | 7.2 |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response yes | Trial null (sources omega3_amd_cochrane; a different exposure; a different outcome); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source omega3_amd_ma Estimate design cohort synthesis Outcome match narrower Outcome measured Late AMD only |
Outcome match, Outcome measured: The estimate measures: Late AMD only. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: omega3_amd_ma (weight 1.0). reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match narrower, measured outcome recorded (cards O1 and O5). estimate_source omega3_amd_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct null, same_exposure and same_outcome false (cards G6, G11): AREDS2 and the Cochrane review tested supplements in people who already had AMD, with progression to advanced disease as the outcome corrections.json _why
Also changed in: 1.4 (19 Sep 2026)
Current cigarette smoking → Cataract
smoking|cataract
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source smoke_cataract_ma Estimate design cohort synthesis Outcome match narrower Outcome measured Age-related cataract in cohort studies (ever smoking) |
The estimate measures: Age-related cataract in cohort studies (ever smoking). measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Type 2 diabetes (as a risk factor) → Cataract
t2d_exposure|cataract
| Field | Before | After |
| Reviews counted | 5 | 1 |
| Effective reviews (N_eff) | 4 | 1.0 |
| Score (ESS) | 12.8 | 5.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source t2d_cataract_ma Estimate design mixed Outcome match exact Outcome measured Prevalence of any cataract in type 2 diabetes (6 of 8 studies cross-sectional) Grade basis Weak: six of the eight pooled studies compare how common cataract is at one point in time, and people with diabetes have…Weak: six of the eight pooled studies compare how common cataract is at one point in time, and people with diabetes have more eye examinations (caveat and review note). Accepted by the verifier. |
Outcome match, Outcome measured: The estimate measures: Prevalence of any cataract in type 2 diabetes (6 of 8 studies cross-sectional). measured_outcome
Grade basis: Weak: six of the eight pooled studies compare how common cataract is at one point in time, and people with diabetes have more eye examinations (caveat and review note). Accepted by the verifier. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: t2d_cataract_ma (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
High body-mass index → Cataract
high_bmi|cataract
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources liu2026_bmi_cataract_mr); dose-response yes |
| Sources | bmi_cataract_ma | bmi_cataract_ma liu2026_bmi_cataract_mr |
| New fields | not recorded before | Measure RR Estimate source bmi_cataract_ma Estimate design cohort synthesis Outcome match narrower Outcome measured Age-related cataract (RR per 5 kg/m2 BMI) Grade basis Suggestive: a small effect per unit, confined to some cataract types (review note). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: Age-related cataract (RR per 5 kg/m2 BMI). measured_outcome
Grade basis: Suggestive: a small effect per unit, confined to some cataract types (review note). Kept by the verifier. grade_basis
Sources: 21 Oct 2026 grading reform v2.0: outcome_match narrower, measured outcome recorded (cards O1 and O5). estimate_source bmi_cataract_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). grade_basis records why the grade stands (card G3) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (liu2026_bmi_cataract_mr) (card G11, blocker 4): Genetically predicted BMI raises cataract (OR 1.17 per SD, Liu 2026). corrections.json _why
Current cigarette smoking → Age-related hearing loss
smoking|hearing_loss
| Field | Before | After |
| Score (ESS) | 15.6 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source smoke_hearing_ma Estimate design cohort synthesis Outcome match broader Outcome measured Hearing loss in adults by pure-tone average (noise-exposed workers excluded) Related outcome true Grade basis Moderate: a cohort estimate of 1.97 with a gradient; only low-confidence rules point lower. Kept by the verifier. |
Outcome match, Outcome measured, Related outcome: The estimate measures: Hearing loss in adults by pure-tone average (noise-exposed workers excluded). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: Moderate: a cohort estimate of 1.97 with a gradient; only low-confidence rules point lower. Kept by the verifier. grade_basis
Type 2 diabetes (as a risk factor) → Age-related hearing loss
t2d_exposure|hearing_loss
| Field | Before | After |
| Score (ESS) | 11.4 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | diabetes_hearing_ma | diabetes_hearing_ma gupta2019_nhs_t2d_hearing |
| New fields | not recorded before | Measure OR Estimate source diabetes_hearing_ma Estimate design cross-sectional Outcome match broader Outcome measured Prevalent hearing impairment of any cause in adults Related outcome true Grade basis The pooled estimate (13 studies) is cross-sectional by design, so T5a gives Weak. A prospective study now agrees: Nurses…The pooled estimate (13 studies) is cross-sectional by design, so T5a gives Weak. A prospective study now agrees: Nurses Health Studies, 139,909 women, incident hearing loss HR 1.16 (1.07-1.27), 1.24 (1.10-1.40) for diabetes of 8 years or more. Under amended T5a, prospective agreement gives Suggestive. The effect is much smaller than the cross-sectional OR 2.15. Suggestive. Grade override Suggestive. Settled at Suggestive by the curation pass (card G12). The pooled studies are cross-sectional, but the Nurse…Suggestive. Settled at Suggestive by the curation pass (card G12). The pooled studies are cross-sectional, but the Nurses' Health Studies (139,909 women) found incident hearing loss raised (HR 1.16, 1.07 to 1.27), and prospective agreement gives Suggestive under the amended rule T5a. The table reads prospective agreement from the caveat, which does not mention the cohort yet. Studies 13 |
Outcome match, Outcome measured, Related outcome: The estimate measures: Prevalent hearing impairment of any cause in adults. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis, Grade override: Curator override to Suggestive: Settled at Suggestive by the curation pass (card G12). The pooled studies are cross-sectional, but the Nurses' Health Studies (139,909 women) found incident hearing loss raised (HR 1.16, 1.07 to 1.27), and prospective agreement gives Suggestive under the amended rule T5a. The table reads prospective agreement from the caveat, which does not mention the cohort yet. The pooled estimate (13 studies) is cross-sectional by design, so T5a gives Weak. A prospective study now agrees: Nurses Health Studies, 139,909 women, incident hearing loss HR 1.16 (1.07-1.27), 1.24 (1.10-1.40) for diabetes of 8 years or more. Under amended T5a, prospective agreement gives Suggestive. The effect is much smaller than the cross-sectional OR 2.15. Suggestive. grade_override and grade_basisT5a
Studies: The published figure is 2.15 (1.72-2.68), well above the stated 1.50, but every contributing study is CROSS-SECTIONAL, so this is a prevalence odds ratio and not an incidence estimate - grade should drop from Moderate to Suggestive. The association is stronger in people under 60 (2.61) than over 60 (1.58), which is the opposite of what age-related hearing loss would predict and points to a distinct diabetic cochlear microangiopathy rather than accelerated presbycusis. review_note
Sources: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5): Sources added (card G12): gupta2019_nhs_t2d_hearing; the displayed estimate is unchanged. estimate_source diabetes_hearing_ma, estimate_design cross-sectional, measure OR, by rule E1 (cards G8, K5, P2). n_studies from the displayed review (card G12, research pass; PubMed 23150692). Grade stays Suggestive (card G12, settled by the research pass); grade_basis records the rules. grade_override keeps Suggestive: Settled at Suggestive by the curation pass (card G12). The pooled studies are cross-sectional, but the Nurses' Health Studies (139,909 women) found incident hearing loss raised (HR 1.16, 1.07 to 1.27), and prospective agreement gives Suggestive under the amended rule T5a. The table reads prospective agreement from the caveat, which does not mention the cohort yet. corrections.json _whyT5a
Also changed in: 1.4 (9 Oct 2026)
Long sleep → Dementia (all-cause)
long_sleep|dementia
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source fan_sleep_dementia_2019 Estimate design cohort synthesis Outcome match exact Outcome measured All-cause dementia |
Outcome match, Outcome measured: The estimate measures: All-cause dementia. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: fan_sleep_dementia_2019 (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Long sleep → Coronary heart disease
long_sleep|chd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.55 |
| Score (ESS) | 3.7 | 5.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source sleep_cappuccio Estimate design cohort synthesis Outcome match exact Outcome measured Coronary heart disease (incident and fatal) |
Outcome match, Outcome measured: The estimate measures: Coronary heart disease (incident and fatal). measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: sleep_cappuccio (weight 1.0), sleep_yin (weight 0.55). reviews_counted
Long sleep → Ischaemic stroke
long_sleep|stroke_isch
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.55 |
| Score (ESS) | 5.0 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source sleep_cappuccio Estimate design cohort synthesis Outcome match broader Outcome measured Total stroke Related outcome true |
Outcome match, Outcome measured, Related outcome: The estimate measures: Total stroke. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: sleep_cappuccio (weight 1.0), sleep_yin (weight 0.55). reviews_counted
Ground-level ozone → Asthma (adult)
ozone|asthma
| Field | Before | After |
| Reviews counted | 4 | 1 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 1.2 | 0.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source airpoll_adult_asthma_ma Estimate design cohort synthesis Outcome match exact Outcome measured Incident adult asthma |
Outcome match, Outcome measured: The estimate measures: Incident adult asthma. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: airpoll_adult_asthma_ma (weight 1.0). reviews_counted
Also changed in: 1.3 (9 Sep 2026)
Nitrogen dioxide → COPD
no2|copd
| Field | Before | After |
| Grade | Suggestive | Weak |
| Reviews counted | 1 | 2 |
| Score (ESS) | 1.9 | 1.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source airpoll_copd_inc_ma Estimate design cohort synthesis Outcome match exact Outcome measured Incident COPD Grade basis Weak: the pooled hazard ratio is 1.07 with a lower bound printed as 1.00, and the authors call the association marginal.…Weak: the pooled hazard ratio is 1.07 with a lower bound printed as 1.00, and the authors call the association marginal. The full text (Environmental Research, paywalled) could not be read to confirm the unrounded bound, so the approved change (card G3) stands at the table's medium confidence (T1). Nitrogen dioxide moves with PM2.5. For the owner: confirm the bound from the full text. Adjudicating bodies who_air: WHO 2021 review covers COPD |
Outcome match, Outcome measured: The estimate measures: Incident COPD. measured_outcome
Grade: Weak: the pooled hazard ratio is 1.07 with a lower bound printed as 1.00, and the authors call the association marginal. The full text (Environmental Research, paywalled) could not be read to confirm the unrounded bound, so the approved change (card G3) stands at the table's medium confidence (T1). Nitrogen dioxide moves with PM2.5. For the owner: confirm the bound from the full text. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source airpoll_copd_inc_ma, estimate_design cohort synthesis, measure HR, by rule E1 (read by hand) (cards G8, K5, P2). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): Lower bound 1.00; moves with PM2.5 (confirm the unrounded bound). Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Grade stays Weak (blocker 7); grade_basis rewritten: Weak: the pooled hazard ratio is 1.07 with a lower bound printed as 1.00, and the authors call the association marginal. The full text (Environmental Research, paywalled) could not be read to confirm the unrounded bound, so the approved change (card G3) stands at the table's medium confidence (T1). Nitrogen dioxide moves with PM2.5. For the owner: confirm the bound from the full text. grade_basisT1T3T4
Grade basis: Weak: the pooled hazard ratio is 1.07 with a lower bound printed as 1.00, and the authors call the association marginal. The full text (Environmental Research, paywalled) could not be read to confirm the unrounded bound, so the approved change (card G3) stands at the table's medium confidence (T1). Nitrogen dioxide moves with PM2.5. For the owner: confirm the bound from the full text. grade_basisT1
Reviews counted: Counted from the cited syntheses under the review-counting rule: airpoll_copd_inc_ma (weight 1.0), who_air (weight 0.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.3 (9 Sep 2026)
Nitrogen dioxide → Coronary heart disease
no2|chd
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.38 |
| Score (ESS) | 1.4 | 1.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source who_aqg_o3_kasdagli Estimate design cohort synthesis Outcome match narrower Outcome measured Death from ischaemic heart disease only Grade basis Suggestive: the association shrinks in models with several pollutants (caveat). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: Death from ischaemic heart disease only. measured_outcome
Grade basis: Suggestive: the association shrinks in models with several pollutants (caveat). Kept by the verifier. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: no2_mortality_stieb (weight 1.0), who_aqg_o3_kasdagli (weight 0.38). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Extreme heat → Coronary heart disease
heat|chd
| Field | Before | After |
| Grade | Probable (now Moderate) | Weak |
| Effective reviews (N_eff) | 1 | 1.55 |
| Score (ESS) | 4.3 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source heat_liu Estimate design cohort synthesis Outcome match broader Outcome measured Cardiovascular mortality during heatwaves Related outcome true Grade basis Weak: Acute cardiovascular deaths; I-squared 98.9%. Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured, Related outcome: The estimate measures: Cardiovascular mortality during heatwaves. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Weak: Acute cardiovascular deaths; I-squared 98.9%. Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source heat_liu, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Weak (card G3, PROPOSAL section 3.1): Acute cardiovascular deaths; I-squared 98.9%. grade_basis
Grade basis: Weak: Acute cardiovascular deaths; I-squared 98.9%. Verified on 21 October 2026 (card G3). grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: heat_phung (weight 1.0), heat_liu (weight 0.55). reviews_counted
Extreme heat → Ischaemic stroke
heat|stroke_isch
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.55 |
| Score (ESS) | 3.0 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source heat_liu Estimate design cohort synthesis Outcome match broader Outcome measured Cardiovascular mortality during heatwaves Related outcome true Grade basis Suggestive: a cardiovascular death estimate, now in the related-outcome layer. Kept by the verifier. |
Outcome match, Outcome measured, Related outcome: The estimate measures: Cardiovascular mortality during heatwaves. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: Suggestive: a cardiovascular death estimate, now in the related-outcome layer. Kept by the verifier. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: heat_phung (weight 1.0), heat_liu (weight 0.55). reviews_counted
Arsenic in drinking water → Type 2 diabetes
arsenic|t2d
| Field | Before | After |
| Reviews counted | 3 | 2 |
| Effective reviews (N_eff) | 2 | 1.38 |
| Score (ESS) | 6.3 | 5.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source arsenic_t2d Estimate design cohort synthesis Outcome match exact Outcome measured Type 2 diabetes (drinking-water arsenic) Conflict Side A: Studies in places with highly contaminated water find more diabetes (1.58, 1.20 to 2.08 for high against low ars…Side A: Studies in places with highly contaminated water find more diabetes (1.58, 1.20 to 2.08 for high against low arsenic). Side B: A 2026 analysis restricted to the range that drinking-water standards cover found no association once publication bias and study quality were accounted for (1.02, 0.99 to 1.06 per 10 micrograms per litre). Sources: arsenic_t2d arsenic_t2d_low |
Outcome match, Outcome measured: The estimate measures: Type 2 diabetes (drinking-water arsenic). measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: arsenic_t2d (weight 1.0), arsenic_t2d_low (weight 0.38). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Arsenic in drinking water → Coronary heart disease
arsenic|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source metals_cvd Estimate design cohort synthesis Outcome match exact Outcome measured Coronary heart disease |
The estimate measures: Coronary heart disease. measured_outcome
Cadmium exposure → Fracture in adults
cadmium|fracture
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source cadmium_fracture_ma Estimate design cohort synthesis Outcome match exact Outcome measured Fracture at any site |
The estimate measures: Fracture at any site. measured_outcome
Low nut and seed intake → Type 2 diabetes
low_nuts|t2d
| Field | Before | After |
| Effective reviews (N_eff) | 2 | 1.82 |
| Score (ESS) | 3.2 | 3.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source nutslegumes_afshin Estimate design cohort synthesis Outcome match exact Outcome measured Diabetes, type not stated Grade basis Kept at Weak by the verified dry run: The note records NutriGrade 'very low' and Schwingshackl 'low' for nuts and diabetes. External grades NutriGrade very low (nuts_t2d_becerra); NutriGrade low (foodgroups_t2d_schwingshackl) |
Outcome match, Outcome measured: The estimate measures: Diabetes, type not stated. measured_outcome
Grade basis: Kept at Weak by the verified dry run: The note records NutriGrade 'very low' and Schwingshackl 'low' for nuts and diabetes. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: nutslegumes_afshin (weight 1.0), foodgroups_t2d_schwingshackl (weight 0.38), nuts_t2d_becerra (weight 0.44). reviews_counted
Also changed in: 1.4 (21 Oct 2026)
Mediterranean dietary pattern → Type 2 diabetes
mediterranean|t2d
| Field | Before | After |
| Reviews counted | 4 | 2 |
| Effective reviews (N_eff) | 3 | 1.29 |
| Score (ESS) | 14.5 | 8.9 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources predimed; a different outcome); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source medd_t2d_schwingshackl Estimate design cohort synthesis Outcome match exact Outcome measured Diabetes, framed by the review as type 2 diabetes |
Outcome match, Outcome measured: The estimate measures: Diabetes, framed by the review as type 2 diabetes. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: medd_t2d_schwingshackl (weight 1.0), dietpatterns_t2d_schulze (weight 0.29). reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source medd_t2d_schwingshackl, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_outcome false (cards G6, G11): The cited PREDIMED paper reports cardiovascular events; its diabetes substudy is not cited corrections.json _why
Mediterranean dietary pattern → Depression
mediterranean|depression
| Field | Before | After |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response yes | Trial null (sources predimed2013_depression); Genetic (MR) none; dose-response yes |
| Sources | shafiei_meddiet_depression_2019 | shafiei_meddiet_depression_2019 predimed2013_depression |
| New fields | not recorded before | Measure HR Estimate source shafiei_meddiet_depression_2019 Estimate design cohort synthesis Outcome match exact Outcome measured Depression as each cohort defined it (clinical or scale-based) |
Outcome match, Outcome measured: The estimate measures: Depression as each cohort defined it (clinical or scale-based). measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)). estimate_source shafiei_meddiet_depression_2019, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct null with its sources recorded (predimed2013_depression) (card G11, blocker 4): In PREDIMED, Mediterranean diets did not significantly lower new depression against a low-fat diet. corrections.json _why
Also changed in: 1.4 (9 Oct 2026)1.3 (9 Sep 2026)
Low seafood omega-3 intake → Dementia (all-cause)
low_omega3|dementia
| Field | Before | After |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response yes | Trial null (sources sydenham2012_omega3_cochrane; a different exposure; a different outcome); Genetic (MR) none; dose-response yes |
| Sources | fish_pufa_cognition_2016 diet_neurodegen_umbrella_2020 | fish_pufa_cognition_2016 diet_neurodegen_umbrella_2020 sydenham2012_omega3_cochrane |
| New fields | not recorded before | Measure RR Estimate source fish_pufa_cognition_2016 Estimate design cohort synthesis Outcome match exact Outcome measured Dementia Grade basis Kept at Weak by the verified dry run: z about 2, I2 63%, supplement trials null; the note recommends Weak or removal. External grades umbrella review quality moderate (Alzheimer's disease only) (diet_neurodegen_umbrella_2020), does not match this pair |
Outcome match, Outcome measured: The estimate measures: Dementia. measured_outcome
Grade basis: Kept at Weak by the verified dry run: z about 2, I2 63%, supplement trials null; the note recommends Weak or removal. grade_basis
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source fish_pufa_cognition_2016, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct null, same_exposure and same_outcome false (cards G6, G11): Omega-3 supplement trials measured cognitive outcomes; the link measures fish intake and dementia: No trial is cited on the link. external_grades transcribed from the caveat, the review note or the quote (rule T11). Grade stays Weak (card G3: kept by the verifier). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct null with its sources recorded (sydenham2012_omega3_cochrane), same_exposure and same_outcome false (card G11, blocker 4): Omega-3 supplement trials measured cognition in cognitively healthy older people; the link measures fish intake and dementia. corrections.json _whyT11
HIV infection → COPD
hiv|copd
| Field | Before | After |
| Grade | Suggestive | Weak |
| Score (ESS) | 3.4 | 1.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | hiv_copd_ma | hiv_copd_ma antoniou2020_hiv_copd_incidence |
| New fields | not recorded before | Measure OR Estimate source hiv_copd_ma Estimate design mixed Outcome match exact Outcome measured Prevalence of COPD in people with HIV Grade basis T5a: the pooled figures are prevalence odds ratios (crude 1.14, 1.05-1.25). The only incidence study found (Ontario, adj…T5a: the pooled figures are prevalence odds ratios (crude 1.14, 1.05-1.25). The only incidence study found (Ontario, adjusted rate ratio 1.34, 1.27-1.41) reports that smoking explained the difference in a sensitivity analysis. So prospective support does not agree after smoking. Weak. Studies 11 I-squared 63.5 |
Outcome match, Outcome measured: The estimate measures: Prevalence of COPD in people with HIV. measured_outcome
Grade: T5a: the pooled figures are prevalence odds ratios (crude 1.14, 1.05-1.25). The only incidence study found (Ontario, adjusted rate ratio 1.34, 1.27-1.41) reports that smoking explained the difference in a sensitivity analysis. So prospective support does not agree after smoking. Weak. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): antoniou2020_hiv_copd_incidence; the displayed estimate is unchanged. estimate_source hiv_copd_ma, estimate_design mixed, measure OR, by rule E1 (cards G8, K5, P2). n_studies and i2 from the displayed review (card G12, research pass; PubMed 29254748). Grade Suggestive to Weak (card G12, settled by the research pass). grade_basisT5a
Grade basis: T5a: the pooled figures are prevalence odds ratios (crude 1.14, 1.05-1.25). The only incidence study found (Ontario, adjusted rate ratio 1.34, 1.27-1.41) reports that smoking explained the difference in a sensitivity analysis. So prospective support does not agree after smoking. Weak. grade_basisT5a
Studies, I-squared, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): antoniou2020_hiv_copd_incidence; the displayed estimate is unchanged. estimate_source hiv_copd_ma, estimate_design mixed, measure OR, by rule E1 (cards G8, K5, P2). n_studies and i2 from the displayed review (card G12, research pass; PubMed 29254748). Grade Suggestive to Weak (card G12, settled by the research pass). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Gum disease → Type 2 diabetes
periodontitis|t2d
| Field | Before | After |
| Reviews counted | 4 | 2 |
| Effective reviews (N_eff) | 3 | 1.55 |
| Score (ESS) | 15.1 | 10.5 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources simpson2022_perio_hba1c; a different outcome); Genetic (MR) none; dose-response yes |
| Sources | oral_diabetes_lancet perio_t2d_wu | oral_diabetes_lancet perio_t2d_wu simpson2022_perio_hba1c |
| New fields | not recorded before | Measure HR Estimate source oral_diabetes_lancet Estimate design cohort synthesis Outcome match exact Outcome measured Newly incident type 2 diabetes Grade override Moderate. T8a proposes Suggestive: the caveat says the relationship runs both ways and that smoking and obesity may expl…Moderate. T8a proposes Suggestive: the caveat says the relationship runs both ways and that smoking and obesity may explain part. The trials measure HbA1c in people who already have diabetes (card G11), so T3 caps at Moderate. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. |
Outcome match, Outcome measured: The estimate measures: Newly incident type 2 diabetes. measured_outcome
Grade override: Curator override to Moderate: T8a proposes Suggestive: the caveat says the relationship runs both ways and that smoking and obesity may explain part. The trials measure HbA1c in people who already have diabetes (card G11), so T3 caps at Moderate. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT8aT3
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: perio_t2d_wu (weight 1.0), oral_diabetes_lancet (weight 0.55). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G11): simpson2022_perio_hba1c; the displayed estimate is unchanged. estimate_source oral_diabetes_lancet, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive recorded with its sources (card G11, research pass): The 35 trials enrolled people who already had diabetes and measured HbA1c over 3 to 12 months; none counted new type 2 diabetes. grade_override keeps Moderate: T8a proposes Suggestive: the caveat says the relationship runs both ways and that smoking and obesity may explain part. The trials measure HbA1c in people who already have diabetes (card G11), so T3 caps at Moderate. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. corrections.json _whyT8aT3
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Long-term NSAID use → Coronary heart disease
nsaids|chd
| Field | Before | After |
| Reviews counted | 5 | 2 |
| Effective reviews (N_eff) | 4 | 1.44 |
| Score (ESS) | 31.1 | 18.4 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources nsaids_cnt2013); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source nsaids_cnt2013 Estimate design trial synthesis Outcome match exact Outcome measured Major coronary events (coronary death or non-fatal heart attack) in trials |
Outcome match, Outcome measured: The estimate measures: Major coronary events (coronary death or non-fatal heart attack) in trials. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: nsaids_cnt2013 (weight 1.0), nsaids_bally (weight 0.44). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Proton pump inhibitors (acid-suppressing tablets) → Chronic kidney disease
ppi|ckd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source ppi_ckd_ma Estimate design cohort synthesis Outcome match exact Outcome measured Incident chronic kidney disease |
The estimate measures: Incident chronic kidney disease. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Blood pressure treatment → Dementia (all-cause)
antihypertensives|dementia
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.5 |
| Score (ESS) | 4.9 | 6.6 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources hughes2020_bp_dementia_ma); Genetic (MR) none; dose-response yes |
| Sources | ding_ahm_dementia_2020 lancet_dementia | ding_ahm_dementia_2020 lancet_dementia hughes2020_bp_dementia_ma |
| New fields | not recorded before | Measure HR Estimate source ding_ahm_dementia_2020 Estimate design pooled IPD Outcome match exact Outcome measured Incident dementia Adjudicating bodies lancet_dementia: reports this cohort analysis and advises treating high blood pressure (2024) |
Outcome match, Outcome measured: The estimate measures: Incident dementia. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: ding_ahm_dementia_2020 (weight 1.0), lancet_dementia (weight 0.5). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source ding_ahm_dementia_2020, estimate_design pooled IPD, measure HR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct supportive with its sources recorded (hughes2020_bp_dementia_ma) (card G11, blocker 4): A meta-analysis of 12 randomised trials (92,135 people) found less dementia or cognitive impairment with blood pressure lowering (OR 0.93, 0.88 to 0.98). hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _whyT3T4
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Blood pressure treatment → Heart failure
antihypertensives|heart_failure
| Field | Before | After |
| Reviews counted | 3 | 1 |
| Effective reviews (N_eff) | 2 | 1.0 |
| Score (ESS) | 20.3 | 12.7 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources bp_ettehad bpltt); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source bp_ettehad Estimate design trial synthesis Outcome match exact Outcome measured Heart failure (per 10 mmHg lower systolic pressure) Adjudicating bodies bpltt: blood pressure lowering reduces heart failure in trials |
Outcome match, Outcome measured: The estimate measures: Heart failure (per 10 mmHg lower systolic pressure). measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: bp_ettehad (weight 1.0). reviews_counted
Also changed in: 1.3 (18 Sep 2026)
Statin treatment → Peripheral artery disease
statins|pad
| Field | Before | After |
| Reviews counted | 4 | 2 |
| Effective reviews (N_eff) | 3 | 1.17 |
| Score (ESS) | 21.1 | empty |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response no | Trial supportive (sources lipid_male_rct_ma); Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure HR Estimate source pad_statin_pastori Estimate design cohort synthesis Outcome match proxy Outcome measured Major adverse limb events in people who already have PAD Related outcome true |
Outcome match, Outcome measured, Related outcome: The estimate measures: Major adverse limb events in people who already have PAD. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: pad_statin_pastori (weight 1.0), pad_statin_sofat (weight 0.17). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Breastfeeding → Type 2 diabetes
breastfeeding|t2d
| Field | Before | After |
| Reviews counted | 3 | 1 |
| Effective reviews (N_eff) | 2 | 1.0 |
| Score (ESS) | 6.1 | 3.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source bf_t2d_aune Estimate design cohort synthesis Outcome match exact Outcome measured Maternal type 2 diabetes |
Outcome match, Outcome measured: The estimate measures: Maternal type 2 diabetes. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: bf_t2d_aune (weight 1.0). reviews_counted
Early menopause → Coronary heart disease
early_menopause|chd
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 11.6 | 8.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) null (sources dam2022_menopause_chd_mr wang2026_menopause_cvd_mr_review); dose-response yes |
| Sources | menopause_muka | menopause_muka dam2022_menopause_chd_mr wang2026_menopause_cvd_mr_review |
| New fields | not recorded before | Measure RR Estimate source menopause_muka Estimate design cohort synthesis Outcome match exact Outcome measured Overall CHD (fatal and non-fatal) Grade basis Suggestive: genetically determined age at menopause is not associated with coronary heart disease (rule T2, ceiling Sugg…Suggestive: genetically determined age at menopause is not associated with coronary heart disease (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6). The cohort synthesis (Muka 2016) stands. Lowered from Moderate by the binding rule once the genetic evidence was recorded. |
Outcome match, Outcome measured: The estimate measures: Overall CHD (fatal and non-fatal). measured_outcome
Grade: Suggestive: genetically determined age at menopause is not associated with coronary heart disease (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6). The cohort synthesis (Muka 2016) stands. Lowered from Moderate by the binding rule once the genetic evidence was recorded. Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr null (status was supportive) with its sources recorded (dam2022_menopause_chd_mr, wang2026_menopause_cvd_mr_review) (card G11, blocker 4): Genetically determined age at menopause is not associated with coronary heart disease (Dam 2022; a 2026 meta-analysis of 17 Mendelian randomisation studies, OR 0.97, 0.87 to 1.07). Grade Moderate to Suggestive (blocker 4, binding rule T2): Suggestive: genetically determined age at menopause is not associated with coronary heart disease (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6). The cohort synthesis (Muka 2016) stands. Lowered from Moderate by the binding rule once the genetic evidence was recorded. grade_basisT2C3
Grade basis: Suggestive: genetically determined age at menopause is not associated with coronary heart disease (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6). The cohort synthesis (Muka 2016) stands. Lowered from Moderate by the binding rule once the genetic evidence was recorded. grade_basisT2C3
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source menopause_muka, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr null (status was supportive) with its sources recorded (dam2022_menopause_chd_mr, wang2026_menopause_cvd_mr_review) (card G11, blocker 4): Genetically determined age at menopause is not associated with coronary heart disease (Dam 2022; a 2026 meta-analysis of 17 Mendelian randomisation studies, OR 0.97, 0.87 to 1.07). Grade Moderate to Suggestive (blocker 4, binding rule T2): Suggestive: genetically determined age at menopause is not associated with coronary heart disease (rule T2, ceiling Suggestive; C3 gives Suggestive by default, card G6). The cohort synthesis (Muka 2016) stands. Lowered from Moderate by the binding rule once the genetic evidence was recorded. corrections.json _whyT2C3
Polycystic ovary syndrome → Fatty liver disease (MASLD)
pcos|masld
| Field | Before | After |
| Reviews counted | 3 | 2 |
| Effective reviews (N_eff) | 2 | 1.5 |
| Score (ESS) | 18.7 | 15.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source pcos_nafld_wu Estimate design cohort synthesis Outcome match exact Outcome measured Non-alcoholic fatty liver disease (the former name of MASLD) |
Outcome match, Outcome measured: The estimate measures: Non-alcoholic fatty liver disease (the former name of MASLD). measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: pcos_nafld_wu (weight 1.0), pcos_nafld_zhang (weight 0.5). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
High body-mass index → Fracture in adults
high_bmi|fracture
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 6.7 | 4.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source bmi_fracture_ma Estimate design pooled IPD Outcome match narrower Outcome measured Hip fracture only Grade basis Suggestive: one pooled analysis of about 60,000 people (hip fracture, BMI 30 against 25) with an interval that only just…Suggestive: one pooled analysis of about 60,000 people (hip fracture, BMI 30 against 25) with an interval that only just excludes 1 (z about 2, rule T9b); the protective effect largely disappears after adjustment for bone density (review note). No genetic study of BMI and fracture is cited. Lowered from Moderate once the unsupported genetic status was removed (blocker 4). |
Outcome match, Outcome measured: The estimate measures: Hip fracture only. measured_outcome
Grade: Suggestive: one pooled analysis of about 60,000 people (hip fracture, BMI 30 against 25) with an interval that only just excludes 1 (z about 2, rule T9b); the protective effect largely disappears after adjustment for bone density (review note). No genetic study of BMI and fracture is cited. Lowered from Moderate once the unsupported genetic status was removed (blocker 4). Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr none (status was supportive) with its sources recorded (none) (card G11, blocker 4): No Mendelian randomisation study of BMI and fracture is cited; the largest fracture GWAS could not test BMI because its analyses were adjusted for weight. Grade Moderate to Suggestive (blocker 4, rule T9b): Suggestive: one pooled analysis of about 60,000 people (hip fracture, BMI 30 against 25) with an interval that only just excludes 1 (z about 2, rule T9b); the protective effect largely disappears after adjustment for bone density (review note). No genetic study of BMI and fracture is cited. Lowered from Moderate once the unsupported genetic status was removed (blocker 4). grade_basisT9b
Grade basis: Suggestive: one pooled analysis of about 60,000 people (hip fracture, BMI 30 against 25) with an interval that only just excludes 1 (z about 2, rule T9b); the protective effect largely disappears after adjustment for bone density (review note). No genetic study of BMI and fracture is cited. Lowered from Moderate once the unsupported genetic status was removed (blocker 4). grade_basisT9b
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match narrower, measured outcome recorded (cards O1 and O5). estimate_source bmi_fracture_ma, estimate_design pooled IPD, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr none (status was supportive) with its sources recorded (none) (card G11, blocker 4): No Mendelian randomisation study of BMI and fracture is cited; the largest fracture GWAS could not test BMI because its analyses were adjusted for weight. Grade Moderate to Suggestive (blocker 4, rule T9b): Suggestive: one pooled analysis of about 60,000 people (hip fracture, BMI 30 against 25) with an interval that only just excludes 1 (z about 2, rule T9b); the protective effect largely disappears after adjustment for bone density (review note). No genetic study of BMI and fracture is cited. Lowered from Moderate once the unsupported genetic status was removed (blocker 4). corrections.json _whyT9b
Occupational noise → Coronary heart disease
occ_noise|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source noise_whoilo Estimate design cohort synthesis Outcome match exact Outcome measured Incident ischaemic heart disease Grade basis Kept at Weak by the verified dry run: The WHO/ILO review itself rates the evidence low quality from two studies and is '…Kept at Weak by the verified dry run: The WHO/ILO review itself rates the evidence low quality from two studies and is 'very uncertain'; the adjudicator exemption hides the small-review rule. Adjudicating bodies noise_whoilo: WHO/ILO 2021 review: low quality of evidence, two cohort studies External grades GRADE (WHO/ILO review) low (noise_whoilo) |
Outcome match, Outcome measured: The estimate measures: Incident ischaemic heart disease. measured_outcome
Grade basis: Kept at Weak by the verified dry run: The WHO/ILO review itself rates the evidence low quality from two studies and is 'very uncertain'; the adjudicator exemption hides the small-review rule. grade_basis
Also changed in: 1.4 (9 Oct 2026)
Tooth loss → Coronary heart disease
tooth_loss|chd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.38 |
| Score (ESS) | 4.5 | 5.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source perio_gao Estimate design cohort synthesis Outcome match exact Outcome measured Coronary heart disease |
Outcome match, Outcome measured: The estimate measures: Coronary heart disease. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: toothloss_cheng (weight 1.0), perio_gao (weight 0.38). reviews_counted
Chronic psychological stress → Coronary heart disease
chronic_stress|chd
| Field | Before | After |
| Reviews counted | 5 | 1 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 11.0 | 5.5 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source stress_chd_richardson Estimate design cohort synthesis Outcome match exact Outcome measured Incident coronary heart disease Grade basis Suggestive: most cohorts did not account for depression and anxiety (caveat). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: Incident coronary heart disease. measured_outcome
Grade basis: Suggestive: most cohorts did not account for depression and anxiety (caveat). Kept by the verifier. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: stress_chd_richardson (weight 1.0). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Adverse childhood experiences → Type 2 diabetes
aces|t2d
| Field | Before | After |
| Reviews counted | 3 | 1 |
| Effective reviews (N_eff) | 2 | 1.0 |
| Score (ESS) | 9.9 | 6.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source aces_t2d Estimate design cohort synthesis Outcome match exact Outcome measured Type 2 diabetes (3 of 7 studies cross-sectional) Grade basis Suggestive: adversity was recalled in adulthood in three of the seven studies (review note). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: Type 2 diabetes (3 of 7 studies cross-sectional). measured_outcome
Grade basis: Suggestive: adversity was recalled in adulthood in three of the seven studies (review note). Kept by the verifier. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: aces_t2d (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Low educational attainment → Depression
low_education|depression
| Field | Before | After |
| Grade | Suggestive | Moderate |
| Reviews counted | 4 | 2 |
| Effective reviews (N_eff) | 3 | 1.58 |
| Score (ESS) | 15.6 | 16.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources wan2023_education_mdd_mr shi2026_education_mental_mr viinikainen2018_educat…Trial none; Genetic (MR) supportive (sources wan2023_education_mdd_mr shi2026_education_mental_mr viinikainen2018_education_depression_mr); dose-response yes |
| Sources | chang_education_depression_2010 lorant_ses_depression | chang_education_depression_2010 lorant_ses_depression wan2023_education_mdd_mr shi2026_education_mental_mr viinikainen2018_education_depression_mr |
| New fields | not recorded before | Measure RR Estimate source chang_education_depression_2010 Estimate design cohort synthesis Outcome match exact Outcome measured Depression arising in later life (12 prospective studies) Grade basis T3: MR evidence is mixed. Supportive: Wan 2023 (each SD of schooling lowers MDD risk by 30.7%) and Shi 2026 (OR 0.97 per…T3: MR evidence is mixed. Supportive: Wan 2023 (each SD of schooling lowers MDD risk by 30.7%) and Shi 2026 (OR 0.97 per year of education, 0.94-1.00). Null: Viinikainen 2018 (Young Finns, N=1,733, depressive symptoms). T4: two syntheses (Chang-Quan 2010, 12 prospective studies; Lorant 2003). Moderate is arguable; the MR is not unanimous. Disease name follows card O2. Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. Studies 12 |
Outcome match, Outcome measured: The estimate measures: Depression arising in later life (12 prospective studies). measured_outcome
Grade: T3: MR evidence is mixed. Supportive: Wan 2023 (each SD of schooling lowers MDD risk by 30.7%) and Shi 2026 (OR 0.97 per year of education, 0.94-1.00). Null: Viinikainen 2018 (Young Finns, N=1,733, depressive symptoms). T4: two syntheses (Chang-Quan 2010, 12 prospective studies; Lorant 2003). Moderate is arguable; the MR is not unanimous. Disease name follows card O2. Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)): Sources added (card G11): wan2023_education_mdd_mr, shi2026_education_mental_mr, viinikainen2018_education_depression_mr; the displayed estimate is unchanged. estimate_source chang_education_depression_2010, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.mr supportive recorded with its sources (card G11, research pass): Two two-sample Mendelian randomisation studies support an effect of education. The Young Finns study (1,733 people, depressive symptoms) is null, and a within-sibship analysis was too imprecise for depression. n_studies from the displayed review (card G12, research pass; PubMed 20565049). Grade Suggestive to Moderate (card G12, not settled; the verifier's best estimate applies). Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (wan2023_education_mdd_mr, shi2026_education_mental_mr, viinikainen2018_education_depression_mr) (card G11, blocker 2, blocker 4): Two large two-sample Mendelian randomisation studies support an effect of education (Wan 2023; Shi 2026). The Young Finns study (1,733 people, depressive symptoms) is null and is noted. grade_override removed (minor d): the grade equals the table grade; the unsettled status is recorded in grade_basis instead. grade_basis no longer names a within-sibship Mendelian randomisation study, which was not cited (blocker 9). hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). grade_basisT3T4
Grade basis: T3: MR evidence is mixed. Supportive: Wan 2023 (each SD of schooling lowers MDD risk by 30.7%) and Shi 2026 (OR 0.97 per year of education, 0.94-1.00). Null: Viinikainen 2018 (Young Finns, N=1,733, depressive symptoms). T4: two syntheses (Chang-Quan 2010, 12 prospective studies; Lorant 2003). Moderate is arguable; the MR is not unanimous. Disease name follows card O2. Not settled by the curation pass of card G12, so the verifier's best estimate (Moderate) applies. grade_basisT3T4
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: lorant_ses_depression (weight 1.0), chang_education_depression_2010 (weight 0.58). reviews_counted
Studies, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)): Sources added (card G11): wan2023_education_mdd_mr, shi2026_education_mental_mr, viinikainen2018_education_depression_mr; the displayed estimate is unchanged. estimate_source chang_education_depression_2010, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.mr supportive recorded with its sources (card G11, research pass): Two two-sample Mendelian randomisation studies support an effect of education. The Young Finns study (1,733 people, depressive symptoms) is null, and a within-sibship analysis was too imprecise for depression. n_studies from the displayed review (card G12, research pass; PubMed 20565049). Grade Suggestive to Moderate (card G12, not settled; the verifier's best estimate applies). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (wan2023_education_mdd_mr, shi2026_education_mental_mr, viinikainen2018_education_depression_mr) (card G11, blocker 2, blocker 4): Two large two-sample Mendelian randomisation studies support an effect of education (Wan 2023; Shi 2026). The Young Finns study (1,733 people, depressive symptoms) is null and is noted. grade_override removed (minor d): the grade equals the table grade; the unsettled status is recorded in grade_basis instead. grade_basis no longer names a within-sibship Mendelian randomisation study, which was not cited (blocker 9). hand value(s) ess removed (minor e): the build computes them from the counting rule (card K1). corrections.json _why
Also changed in: 1.4 (19 Sep 2026)
Prediabetes → Chronic kidney disease
prediabetes|ckd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source prediabetes_ckd_ma Estimate design cohort synthesis Outcome match exact Outcome measured Incident chronic kidney disease |
The estimate measures: Incident chronic kidney disease. measured_outcome
Metabolic syndrome → Type 2 diabetes
metabolic_syndrome|t2d
| Field | Before | After |
| Reviews counted | 3 | 2 |
| Effective reviews (N_eff) | 2 | 1.0 |
| Score (ESS) | 34.5 | 21.5 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source mets_t2d_ford Estimate design cohort synthesis Outcome match exact Outcome measured Incident diabetes, type not stated Grade override Moderate. T9a proposes Weak because the quote names four cohorts for another definition; the displayed estimate for the…Moderate. T9a proposes Weak because the quote names four cohorts for another definition; the displayed estimate for the 2005 IDF definition pools nine cohorts. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. |
Outcome match, Outcome measured: The estimate measures: Incident diabetes, type not stated. measured_outcome
Grade override: Curator override to Moderate: T9a proposes Weak because the quote names four cohorts for another definition; the displayed estimate for the 2005 IDF definition pools nine cohorts. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT9a
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: t2d_umbrella (weight 1.0), mets_t2d_ford (weight 0.0). reviews_counted
High blood uric acid → Coronary heart disease
high_urate|chd
| Field | Before | After |
| Trial and genetic evidence | Trial contradicts; Genetic (MR) supportive; dose-response yes | Trial contradicts (sources urate_mr); Genetic (MR) supportive (sources urate_mr); dose-response yes |
| New fields | not recorded before | Measure OR Estimate source urate_mr Estimate design MR Outcome match exact Outcome measured Coronary heart disease (Mendelian randomisation) Conflict Side A: Mendelian randomisation links genetically higher urate with more coronary heart disease (1.19, 1.10 to 1.30 per…Side A: Mendelian randomisation links genetically higher urate with more coronary heart disease (1.19, 1.10 to 1.30 per standard deviation). Side B: Trials that lowered urate with medication found no significant reduction in major cardiovascular events (0.67, 0.44 to 1.03). Sources: urate_mr |
The estimate measures: Coronary heart disease (Mendelian randomisation). measured_outcome
Also changed in: 1.4 (21 Oct 2026)1.4 (9 Oct 2026)
High triglycerides → Type 2 diabetes
high_tg|t2d
| Field | Before | After |
| Reviews counted | 4 | 1 |
| Effective reviews (N_eff) | 3 | 1.0 |
| Score (ESS) | 8.6 | 4.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) contradicts; dose-response yes | Trial none; Genetic (MR) contradicts (sources tg_t2d_mr_desilva); dose-response yes |
| New fields | not recorded before | Measure HR Estimate source htg_t2d_ma Estimate design cohort synthesis Outcome match exact Outcome measured Incident type 2 diabetes Conflict Side A: Cohorts link fasting triglycerides above 1.7 mmol/L with more diabetes (1.73, 1.31 to 2.29). Side B: Mendelian r…Side A: Cohorts link fasting triglycerides above 1.7 mmol/L with more diabetes (1.73, 1.31 to 2.29). Side B: Mendelian randomisation finds that genetically raised triglycerides do not increase diabetes risk. Sources: htg_t2d_ma tg_t2d_mr_desilva |
Outcome match, Outcome measured: The estimate measures: Incident type 2 diabetes. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: htg_t2d_ma (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Occupational silica dust → Chronic kidney disease
silica|ckd
| Field | Before | After |
| Reviews counted | 3 | 1 |
| Effective reviews (N_eff) | 2 | 1.0 |
| Score (ESS) | 7.1 | 4.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure SMR Estimate source silica_renal_ma Estimate design cohort synthesis Outcome match narrower Outcome measured Death from kidney disease only (standardised mortality ratio) Grade basis Kept at Weak by the verified dry run: Kidney-disease death SMR, no clear dose-response, authors cite diagnostic and methodological problems. |
Outcome match, Outcome measured: The estimate measures: Death from kidney disease only (standardised mortality ratio). measured_outcome
Grade basis: Kept at Weak by the verified dry run: Kidney-disease death SMR, no clear dose-response, authors cite diagnostic and methodological problems. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: silica_renal_ma (weight 1.0). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
Pesticide exposure → Type 2 diabetes
pesticides|t2d
| Field | Before | After |
| Effective reviews (N_eff) | 2 | 1.55 |
| Score (ESS) | 14.2 | 12.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source pest_t2d_evangelou Estimate design cohort synthesis Outcome match exact Outcome measured Type 2 diabetes Grade basis Suggestive: the body burden of organochlorines tracks body fat, a route for reverse causation (review note). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: Type 2 diabetes. measured_outcome
Grade basis: Suggestive: the body burden of organochlorines tracks body fat, a route for reverse causation (review note). Kept by the verifier. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: t2d_umbrella (weight 1.0), pest_t2d_evangelou (weight 0.0), pest_t2d_2024 (weight 0.55). reviews_counted
Low cardiorespiratory fitness → Type 2 diabetes
low_fitness|t2d
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | crf_t2d_tarp pa_t2d_aune | crf_t2d_tarp |
| New fields | not recorded before | Measure RR Estimate source crf_t2d_tarp Estimate design cohort synthesis Outcome match exact Outcome measured Incident type 2 diabetes Grade basis Moderate: adjusted for adiposity, with a large cohort base. Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: Incident type 2 diabetes. measured_outcome
Grade basis: Moderate: adjusted for adiposity, with a large cohort base. Kept by the verifier. grade_basis
Reviews counted: Counted from the cited syntheses under the review-counting rule: crf_t2d_tarp (weight 1.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source crf_t2d_tarp, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). grade_basis records why the grade stands (card G3) 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source pa_t2d_aune removed from the link's sources (issue 2, card K7 A topic check, PROPOSAL section 5.1): it is a meta-analysis of physical activity, another exposure, so it does not replicate this pair and must not count in the replication term. corrections.json _why
Also changed in: 1.4 (19 Sep 2026)
Low muscle strength → Dementia (all-cause)
low_grip|dementia
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.17 |
| Score (ESS) | 3.7 | 4.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source grip_cognition_meta_2022 Estimate design cohort synthesis Outcome match exact Outcome measured Dementia External grades GRADE low to very low (grip_dementia_meta_2021) |
Outcome match, Outcome measured: The estimate measures: Dementia. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: grip_dementia_meta_2021 (weight 1.0), grip_cognition_meta_2022 (weight 0.17). reviews_counted
Epstein-Barr virus infection → Multiple sclerosis
ebv|multiple_sclerosis
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source ms_umbrella_belbasis Estimate design mixed Outcome match exact Outcome measured Multiple sclerosis Grade basis Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure…Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure and outcome, and no adjudicating body that rated this pair; T4 rests on one observational synthesis with no second line of evidence (1 independent synthesis group; lines: obs). |
Outcome match, Outcome measured: The estimate measures: Multiple sclerosis. measured_outcome
Grade basis: Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure and outcome, and no adjudicating body that rated this pair; T4 rests on one observational synthesis with no second line of evidence (1 independent synthesis group; lines: obs). grade_basisT3T4
Also changed in: 1.4 (9 Oct 2026)
Current cigarette smoking → Multiple sclerosis
smoking|multiple_sclerosis
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.58 |
| Score (ESS) | 3.7 | 5.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) null; dose-response yes | Trial none; Genetic (MR) null (sources smoking_ms_mr_mitchell smoking_ms_mr_vandebergh); dose-response yes |
| New fields | not recorded before | Measure OR Estimate source ms_umbrella_belbasis Estimate design mixed Outcome match exact Outcome measured Multiple sclerosis Adjudicating bodies bprf_smoking: 3 stars External grades Burden of Proof 3 stars (bprf_smoking) Conflict Side A: Observational studies consistently link smoking with more multiple sclerosis (1.52, 1.39 to 1.66), and Burden of…Side A: Observational studies consistently link smoking with more multiple sclerosis (1.52, 1.39 to 1.66), and Burden of Proof rates the evidence at three stars. Side B: Two Mendelian randomisation studies found no clear causal effect (lifetime smoking 1.10, 0.87 to 1.40). Sources: ms_umbrella_belbasis bprf_smoking smoking_ms_mr_mitchell smoking_ms_mr_vandebergh |
Outcome match, Outcome measured: The estimate measures: Multiple sclerosis. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: ms_umbrella_belbasis (weight 1.0), bprf_smoking (weight 0.58). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Childhood obesity → Multiple sclerosis
childhood_obesity|multiple_sclerosis
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 15.8 | 10.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources harroud2021_childhood_bmi_ms_mr); dose-response yes |
| Sources | ms_childhood_bmi_ma ms_umbrella_belbasis | ms_childhood_bmi_ma harroud2021_childhood_bmi_ms_mr |
| New fields | not recorded before | Measure RR Estimate source ms_childhood_bmi_ma Estimate design mixed Outcome match exact Outcome measured Multiple sclerosis Grade basis Count: five studies, of which three are case-control and two are cohort; the estimate pools both designs (T5b: mostly ca…Count: five studies, of which three are case-control and two are cohort; the estimate pools both designs (T5b: mostly case-control). Amended T9 skips a supportive MR: Harroud 2021 supports (OR 1.26 per SD of childhood BMI, 1.07-1.50) but the effect is carried by adult obesity (direct childhood effect OR 1.03, 0.70-1.53). So the MR lifts T9 but does not clearly show a childhood effect. Girls only. Suggestive. Grade override Suggestive. Not settled by the curation pass of card G12, so the verifier's best estimate (Suggestive) applies. Five stu…Suggestive. Not settled by the curation pass of card G12, so the verifier's best estimate (Suggestive) applies. Five studies, three of them case-control. Mendelian randomisation supports an effect of childhood BMI that disappears after adjusting for adult BMI. The amended table would allow Moderate; the owner decides. Studies 5 |
Outcome match, Outcome measured: The estimate measures: Multiple sclerosis. measured_outcome
Grade: Curator override to Suggestive: Not settled by the curation pass of card G12, so the verifier's best estimate (Suggestive) applies. Five studies, three of them case-control. Mendelian randomisation supports an effect of childhood BMI that disappears after adjusting for adult BMI. The amended table would allow Moderate; the owner decides. Count: five studies, of which three are case-control and two are cohort; the estimate pools both designs (T5b: mostly case-control). Amended T9 skips a supportive MR: Harroud 2021 supports (OR 1.26 per SD of childhood BMI, 1.07-1.50) but the effect is carried by adult obesity (direct childhood effect OR 1.03, 0.70-1.53). So the MR lifts T9 but does not clearly show a childhood effect. Girls only. Suggestive. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G11): harroud2021_childhood_bmi_ms_mr; the displayed estimate is unchanged. estimate_source ms_childhood_bmi_ma, estimate_design mixed, measure RR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation.mr supportive recorded with its sources (card G11, research pass): Genetically predicted childhood BMI raises the odds of multiple sclerosis (OR 1.26 per standard deviation, 1.07 to 1.50), but the direct childhood effect disappears after adjusting for adult BMI (OR 1.03, 0.70 to 1.53). n_studies from the displayed review (card G12, research pass; PubMed 27723651). Grade Moderate to Suggestive (card G12, not settled; the verifier's best estimate applies). grade_override and grade_basisT5bT9
Grade basis, Grade override: Curator override to Suggestive: Not settled by the curation pass of card G12, so the verifier's best estimate (Suggestive) applies. Five studies, three of them case-control. Mendelian randomisation supports an effect of childhood BMI that disappears after adjusting for adult BMI. The amended table would allow Moderate; the owner decides. Count: five studies, of which three are case-control and two are cohort; the estimate pools both designs (T5b: mostly case-control). Amended T9 skips a supportive MR: Harroud 2021 supports (OR 1.26 per SD of childhood BMI, 1.07-1.50) but the effect is carried by adult obesity (direct childhood effect OR 1.03, 0.70-1.53). So the MR lifts T9 but does not clearly show a childhood effect. Girls only. Suggestive. grade_override and grade_basisT5bT9
Studies, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G11): harroud2021_childhood_bmi_ms_mr; the displayed estimate is unchanged. estimate_source ms_childhood_bmi_ma, estimate_design mixed, measure RR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation.mr supportive recorded with its sources (card G11, research pass): Genetically predicted childhood BMI raises the odds of multiple sclerosis (OR 1.26 per standard deviation, 1.07 to 1.50), but the direct childhood effect disappears after adjusting for adult BMI (OR 1.03, 0.70 to 1.53). n_studies from the displayed review (card G12, research pass; PubMed 27723651). Grade Moderate to Suggestive (card G12, not settled; the verifier's best estimate applies). 23 Oct 2026 fix round 3 (verifier of the data step, third check, blockers 1 to 3 and minor items 4, 6, 7): Source ms_umbrella_belbasis removed from the link's sources (minor item 7, card K7 A topic check): its abstract (PubMed 25662901) lists vaccinations, comorbid diseases, surgeries, traumatic events, environmental agents and biomarkers and no anthropometric factor, and its search closed on 22 November 2014, before the first meta-analysis of childhood or adolescent excess weight and multiple sclerosis (2016, the displayed estimate); the full text is paywalled, so no obesity row could be confirmed. n_reviews 2 to 1, N_eff 1.17 to 1.00, score 12.2 to 10.9. The owner may restore it if the full text shows an obesity row. corrections.json _why
High body-mass index → Multiple sclerosis
high_bmi|multiple_sclerosis
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources mokry2016_bmi_ms_mr); dose-response yes |
| Sources | ms_bmi_ma2024 | ms_bmi_ma2024 mokry2016_bmi_ms_mr |
| New fields | not recorded before | Measure RR Estimate source ms_bmi_ma2024 Estimate design cohort synthesis Outcome match exact Outcome measured Multiple sclerosis |
Outcome match, Outcome measured: The estimate measures: Multiple sclerosis. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source ms_bmi_ma2024, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (mokry2016_bmi_ms_mr) (card G11, blocker 4): Genetically increased BMI raises multiple sclerosis (Mokry 2016). corrections.json _why
Short sleep → High blood pressure
short_sleep|hypertension
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 5.8 | 4.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source shortsleep_itani Estimate design cohort synthesis Outcome match exact Outcome measured Incident hypertension (prospective cohorts) Grade basis Suggestive: One observational review; self-reported sleep. Rules T7, T8c (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Incident hypertension (prospective cohorts). measured_outcome
Grade: Suggestive: One observational review; self-reported sleep. Rules T7, T8c (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source shortsleep_itani, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): One observational review; self-reported sleep. grade_basisT7T8c
Grade basis: Suggestive: One observational review; self-reported sleep. Rules T7, T8c (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7T8c
Short sleep → Obesity
short_sleep|obesity
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 10.0 | 6.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source shortsleep_itani Estimate design cohort synthesis Outcome match exact Outcome measured Incident obesity (prospective cohorts) Grade basis Suggestive: The relation runs both ways. Rules T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Incident obesity (prospective cohorts). measured_outcome
Grade: Suggestive: The relation runs both ways. Rules T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source shortsleep_itani, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): The relation runs both ways. grade_basisT7T8a
Grade basis: Suggestive: The relation runs both ways. Rules T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7T8a
Food insecurity → High blood pressure
food_insecurity|hypertension
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source foodinsec_umbrella Estimate design mixed Outcome match exact Outcome measured Hypertension at one time point (mostly cross-sectional studies) |
The estimate measures: Hypertension at one time point (mostly cross-sectional studies). measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Food insecurity → Obesity
food_insecurity|obesity
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 1 | 2 |
| Score (ESS) | 10.6 | 7.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| Sources | foodinsec_umbrella | foodinsec_umbrella moradi2019_foodinsecurity_weight |
| New fields | not recorded before | Measure OR Estimate source foodinsec_umbrella Estimate design mixed Outcome match exact Outcome measured Obesity (odds ratio from an umbrella review; design not stated) Grade basis The umbrella review reports OR 1.42 (1.24-1.63) for obesity. The pooled adult meta-analysis found (Moradi 2019, 31 studi…The umbrella review reports OR 1.42 (1.24-1.63) for obesity. The pooled adult meta-analysis found (Moradi 2019, 31 studies) gives a smaller OR 1.15 (1.06-1.23) and warns of high heterogeneity. The design mix of the umbrella row was not read. Food insecurity and obesity are likely to be mostly cross-sectional, and obesity can cause food insecurity through costs. Verifier estimate stands. Not settled by the curation pass of card G12, so the verifier's best estimate (Suggestive) applies. The design mix behind the umbrella review's obesity estimate was not read; an adult meta-analysis gives a smaller 1.15 (1.06 to 1.23). |
Outcome match, Outcome measured: The estimate measures: Obesity (odds ratio from an umbrella review; design not stated). measured_outcome
Grade: The umbrella review reports OR 1.42 (1.24-1.63) for obesity. The pooled adult meta-analysis found (Moradi 2019, 31 studies) gives a smaller OR 1.15 (1.06-1.23) and warns of high heterogeneity. The design mix of the umbrella row was not read. Food insecurity and obesity are likely to be mostly cross-sectional, and obesity can cause food insecurity through costs. Verifier estimate stands. Not settled by the curation pass of card G12, so the verifier's best estimate (Suggestive) applies. The design mix behind the umbrella review's obesity estimate was not read; an adult meta-analysis gives a smaller 1.15 (1.06 to 1.23). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): moradi2019_foodinsecurity_weight; the displayed estimate is unchanged. estimate_source foodinsec_umbrella, estimate_design mixed, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). Grade Moderate to Suggestive (card G12, not settled; the verifier's best estimate applies). Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): grade_override removed (minor d): the grade equals the table grade, so the unsettled status of card G12 is recorded in grade_basis instead. grade_basis
Grade basis: The umbrella review reports OR 1.42 (1.24-1.63) for obesity. The pooled adult meta-analysis found (Moradi 2019, 31 studies) gives a smaller OR 1.15 (1.06-1.23) and warns of high heterogeneity. The design mix of the umbrella row was not read. Food insecurity and obesity are likely to be mostly cross-sectional, and obesity can cause food insecurity through costs. Verifier estimate stands. Not settled by the curation pass of card G12, so the verifier's best estimate (Suggestive) applies. The design mix behind the umbrella review's obesity estimate was not read; an adult meta-analysis gives a smaller 1.15 (1.06 to 1.23). grade_basis
Reviews counted: Counted from the cited syntheses under the review-counting rule: foodinsec_umbrella (weight 1.0), moradi2019_foodinsecurity_weight (weight 0.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): moradi2019_foodinsecurity_weight; the displayed estimate is unchanged. estimate_source foodinsec_umbrella, estimate_design mixed, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). Grade Moderate to Suggestive (card G12, not settled; the verifier's best estimate applies). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Food insecurity → Type 2 diabetes
food_insecurity|t2d
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 11.4 | 7.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source foodinsec_umbrella Estimate design mixed Outcome match exact Outcome measured Diabetes, type not stated (odds ratio) Grade basis Suggestive: Umbrella-review odds ratio; direction unsettled. Rules T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Diabetes, type not stated (odds ratio). measured_outcome
Grade: Suggestive: Umbrella-review odds ratio; direction unsettled. Rules T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source foodinsec_umbrella, estimate_design mixed, measure OR, by rule E1 (read by hand) (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Umbrella-review odds ratio; direction unsettled. grade_basisT7T8a
Grade basis: Suggestive: Umbrella-review odds ratio; direction unsettled. Rules T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7T8a
Also changed in: 1.4 (9 Oct 2026)
Food insecurity → Depression
food_insecurity|depression
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 17.0 | 11.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source foodinsec_umbrella Estimate design mixed Outcome match exact Outcome measured Depression in adults, by diagnosis or symptom scales Grade basis Suggestive: Mostly cross-sectional; reverse causation recorded. Rules T5b, T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Depression in adults, by diagnosis or symptom scales. measured_outcome
Grade: Suggestive: Mostly cross-sectional; reverse causation recorded. Rules T5b, T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)). estimate_source foodinsec_umbrella, estimate_design mixed, measure OR, by rule E1 (read by hand) (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Mostly cross-sectional; reverse causation recorded. grade_basisT5bT7T8a
Grade basis: Suggestive: Mostly cross-sectional; reverse causation recorded. Rules T5b, T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT5bT7T8a
Also changed in: 1.4 (9 Oct 2026)
Food insecurity → Anxiety disorders
food_insecurity|anxiety_disorders
| Field | Before | After |
| Score (ESS) | 8.8 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source foodinsec_umbrella Estimate design mixed Outcome match broader Outcome measured Anxiety, symptoms or disorder not stated (odds ratio) Related outcome true |
The estimate measures: Anxiety, symptoms or disorder not stated (odds ratio). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Low physical activity → High blood pressure
low_pa|hypertension
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources cornelissen2013_exercise_bp_ma); Genetic (MR) none; dose-response yes |
| Sources | pa_htn_liu | pa_htn_liu cornelissen2013_exercise_bp_ma |
| New fields | not recorded before | Measure RR Estimate source pa_htn_liu Estimate design cohort synthesis Outcome match exact Outcome measured Incident hypertension |
Outcome match, Outcome measured: The estimate measures: Incident hypertension. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source pa_htn_liu, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct supportive with its sources recorded (cornelissen2013_exercise_bp_ma) (card G11, blocker 4): Exercise training lowers blood pressure, the quantity that defines hypertension (93 trials, Cornelissen 2013). corrections.json _why
DASH eating pattern → High blood pressure
dash_diet|hypertension
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources appel1997_dash_trial saneei2014_dash_bp_ma); Genetic (MR) none; dose-response yes |
| Sources | dash_htn_ma | dash_htn_ma appel1997_dash_trial saneei2014_dash_bp_ma |
| New fields | not recorded before | Measure HR Estimate source dash_htn_ma Estimate design cohort synthesis Outcome match exact Outcome measured Incident hypertension |
Outcome match, Outcome measured: The estimate measures: Incident hypertension. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source dash_htn_ma, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct supportive with its sources recorded (appel1997_dash_trial, saneei2014_dash_bp_ma) (card G11, blocker 4): The DASH trial and a meta-analysis of 17 trials measured blood pressure, the quantity that defines hypertension (systolic 5.5 and 6.7 mmHg lower). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
DASH eating pattern → Type 2 diabetes
dash_diet|t2d
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source dash_t2d_ma Estimate design cohort synthesis Outcome match exact Outcome measured Diabetes mellitus, type not stated Grade override Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. N…Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. |
Outcome match, Outcome measured: The estimate measures: Diabetes mellitus, type not stated. measured_outcome
Grade override: Curator override to Moderate: T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT8c
Repeated antibiotic courses → Obesity
antibiotics_exposure|obesity
| Field | Before | After |
| Score (ESS) | 8.6 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source abx_obesity_dr Estimate design cohort synthesis Outcome match broader Outcome measured Childhood overweight or obesity Related outcome true Grade basis Moderate: a dose-response across prescriptions; confounding by infection is noted. Kept by the verifier. |
Outcome match, Outcome measured, Related outcome: The estimate measures: Childhood overweight or obesity. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: Moderate: a dose-response across prescriptions; confounding by infection is noted. Kept by the verifier. grade_basis
Also changed in: 1.4 (9 Oct 2026)
Having been breastfed → Obesity
breastfed_infant|obesity
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 6.7 | 4.6 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial null (sources probit_kramer2009 probit_martin2013); Genetic (MR) none; dose-response yes |
| Sources | bf_obesity_ma | bf_obesity_ma probit_kramer2009 probit_martin2013 |
| New fields | not recorded before | Measure OR Estimate source bf_obesity_ma Estimate design cohort synthesis Outcome match exact Outcome measured Obesity at ages two to six (prospective cohorts) Grade basis Suggestive: PROBIT found no lasting effect; the trial field now records it as null (card G11). Rules T2, T8d, T9b (ceili…Suggestive: PROBIT found no lasting effect; the trial field now records it as null (card G11). Rules T2, T8d, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Obesity at ages two to six (prospective cohorts). measured_outcome
Grade: Suggestive: PROBIT found no lasting effect; the trial field now records it as null (card G11). Rules T2, T8d, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G11): probit_kramer2009, probit_martin2013; the displayed estimate is unchanged. estimate_source bf_obesity_ma, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). triangulation.rct null recorded with its sources (card G11, research pass): PROBIT promoted longer and exclusive breastfeeding and found no lasting effect on overweight or obesity at 6.5 and 11.5 years. The link contrasts ever with never breastfed, and its outcome is obesity at ages 2 to 6. Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): PROBIT found no lasting effect; rct field to be corrected to null. grade_basisT2T8dT9b
Grade basis: Suggestive: PROBIT found no lasting effect; the trial field now records it as null (card G11). Rules T2, T8d, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT2T8dT9b
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G11): probit_kramer2009, probit_martin2013; the displayed estimate is unchanged. estimate_source bf_obesity_ma, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). triangulation.rct null recorded with its sources (card G11, research pass): PROBIT promoted longer and exclusive breastfeeding and found no lasting effect on overweight or obesity at 6.5 and 11.5 years. The link contrasts ever with never breastfed, and its outcome is obesity at ages 2 to 6. Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): PROBIT found no lasting effect; rct field to be corrected to null. corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Ultra-processed food → Obesity
upf|obesity
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 1 | 2 |
| Score (ESS) | 12.2 | 8.4 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources hall2019_upf_trial); Genetic (MR) none; dose-response yes |
| Sources | upf_umbrella_bmj upf_evalue | upf_umbrella_bmj upf_evalue hall2019_upf_trial |
| New fields | not recorded before | Measure OR Estimate source upf_umbrella_bmj Estimate design mixed Outcome match exact Outcome measured Obesity prevalence (cross-sectional odds ratio) Grade basis Suggestive: Graded low quality; prevalence odds ratio. Verified on 21 October 2026 (card G3). External grades GRADE low (upf_umbrella_bmj) |
Outcome match, Outcome measured: The estimate measures: Obesity prevalence (cross-sectional odds ratio). measured_outcome
Grade: Suggestive: Graded low quality; prevalence odds ratio. Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source upf_umbrella_bmj, estimate_design mixed, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). external_grades transcribed from the caveat, the review note or the quote (rule T11): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Graded low quality; prevalence odds ratio. grade_basisT11
Grade basis: Suggestive: Graded low quality; prevalence odds ratio. Verified on 21 October 2026 (card G3). grade_basis
Reviews counted: Counted from the cited syntheses under the review-counting rule: upf_umbrella_bmj (weight 1.0), upf_evalue (weight 0.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source upf_umbrella_bmj, estimate_design mixed, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). external_grades transcribed from the caveat, the review note or the quote (rule T11): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Graded low quality; prevalence odds ratio. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct supportive with its sources recorded (hall2019_upf_trial) (card G11, blocker 4): A two-week inpatient crossover trial: an ultra-processed diet raised energy intake by 508 kcal a day and weight by 0.9 kg in weight-stable adults (Hall 2019). corrections.json _whyT11
Also changed in: 1.4 (9 Oct 2026)
Ultra-processed food → Anxiety disorders
upf|anxiety_disorders
| Field | Before | After |
| Score (ESS) | 7.8 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source upf_umbrella_bmj Estimate design cross-sectional Outcome match proxy Outcome measured Anxiety symptom outcomes measured at one time point Related outcome true Grade override Suggestive. T5a proposes Weak: the anxiety analyses pooled prevalence data measured at one point in time. The link sits…Suggestive. T5a proposes Weak: the anxiety analyses pooled prevalence data measured at one point in time. The link sits in the related-outcome layer. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. |
Outcome match, Outcome measured, Related outcome: The estimate measures: Anxiety symptom outcomes measured at one time point. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade override: Curator override to Suggestive: T5a proposes Weak: the anxiety analyses pooled prevalence data measured at one point in time. The link sits in the related-outcome layer. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT5a
Also changed in: 1.4 (9 Oct 2026)
Cannabis use → Schizophrenia
cannabis|schizophrenia
| Field | Before | After |
| Score (ESS) | 20.9 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources vaucher2018_cannabis_schizophrenia_mr); dose-response yes |
| Sources | cannabis_psychosis_dr | cannabis_psychosis_dr vaucher2018_cannabis_schizophrenia_mr |
| New fields | not recorded before | Measure OR Estimate source cannabis_psychosis_dr Estimate design cohort synthesis Outcome match broader Outcome measured Schizophrenia and other psychosis-related outcomes Related outcome true |
Outcome match, Outcome measured, Related outcome: The estimate measures: Schizophrenia and other psychosis-related outcomes. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source cannabis_psychosis_dr, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (vaucher2018_cannabis_schizophrenia_mr) (card G11, blocker 4): Genetically predicted cannabis use raises schizophrenia (OR 1.37, Vaucher 2018). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Recreational screen time → Obesity
screen_time|obesity
| Field | Before | After |
| Grade | Suggestive | Weak |
| Score (ESS) | 5.5 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source screen_obesity_ma Estimate design cohort synthesis Outcome match broader Outcome measured Overweight or obesity in adolescents Related outcome true Grade basis Weak: Adolescents; mostly cross-sectional. Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured, Related outcome: The estimate measures: Overweight or obesity in adolescents. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Weak: Adolescents; mostly cross-sectional. Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source screen_obesity_ma, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): Adolescents; mostly cross-sectional. grade_basis
Grade basis: Weak: Adolescents; mostly cross-sectional. Verified on 21 October 2026 (card G3). grade_basis
Also changed in: 1.4 (9 Oct 2026)
High body-mass index → Psoriasis
high_bmi|psoriasis
| Field | Before | After |
| Grade | Convincing (now Strong) | Moderate |
| Reviews counted | 1 | 0 |
| Score (ESS) | 2.1 | 1.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources bmi_psoriasis_mr); dose-response yes |
| New fields | not recorded before | Measure OR Estimate source bmi_psoriasis_mr Estimate design MR Outcome match exact Outcome measured Psoriasis (Mendelian randomisation) Grade basis Moderate: One MR study with nothing beside it. Rule T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: Psoriasis (Mendelian randomisation). measured_outcome
Grade: Moderate: One MR study with nothing beside it. Rule T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source bmi_psoriasis_mr, estimate_design MR, measure OR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11): Grade Strong to Moderate (card G3, PROPOSAL section 3.1): One MR study with nothing beside it. grade_basisT4
Grade basis: Moderate: One MR study with nothing beside it. Rule T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). grade_basisT4
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Also changed in: 1.4 (9 Oct 2026)
High body-mass index → Back pain
high_bmi|low_back_pain
| Field | Before | After |
| Grade | Convincing (now Strong) | Moderate |
| Effective reviews (N_eff) | 1 | 1.64 |
| Score (ESS) | 15.0 | 17.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources backpain_mr_ma); dose-response yes |
| Sources | obesity_lbp_shiri backpain_mr_ma | obesity_lbp_shiri backpain_mr_ma zhang2018_obesity_lbp |
| New fields | not recorded before | Measure OR Estimate source obesity_lbp_shiri Estimate design cohort synthesis Outcome match exact Outcome measured Low back pain for 1 day or more in the past 12 months Grade basis T3 met: MR is supportive (genetically predicted BMI, OR 1.18, 1.08-1.30, pooled over MR studies). T4 met: cohort synthes…T3 met: MR is supportive (genetically predicted BMI, OR 1.18, 1.08-1.30, pooled over MR studies). T4 met: cohort syntheses (Shiri 2010 OR 1.53; Zhang 2018, 10 cohorts, obesity OR 1.36) plus MR. Strong also needs a judgement that reversal is implausible. Back pain can limit activity and raise weight, the MR effect is modest, and no completed trial of weight loss with a back-pain outcome was found. Moderate. |
Outcome match, Outcome measured: The estimate measures: Low back pain for 1 day or more in the past 12 months. measured_outcome
Grade: T3 met: MR is supportive (genetically predicted BMI, OR 1.18, 1.08-1.30, pooled over MR studies). T4 met: cohort syntheses (Shiri 2010 OR 1.53; Zhang 2018, 10 cohorts, obesity OR 1.36) plus MR. Strong also needs a judgement that reversal is implausible. Back pain can limit activity and raise weight, the MR effect is modest, and no completed trial of weight loss with a back-pain outcome was found. Moderate. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)): Sources added (card G12): zhang2018_obesity_lbp; the displayed estimate is unchanged. estimate_source obesity_lbp_shiri, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). Grade Strong to Moderate (card G12, settled by the research pass). grade_basisT3T4
Grade basis: T3 met: MR is supportive (genetically predicted BMI, OR 1.18, 1.08-1.30, pooled over MR studies). T4 met: cohort syntheses (Shiri 2010 OR 1.53; Zhang 2018, 10 cohorts, obesity OR 1.36) plus MR. Strong also needs a judgement that reversal is implausible. Back pain can limit activity and raise weight, the MR effect is modest, and no completed trial of weight loss with a back-pain outcome was found. Moderate. grade_basisT3T4
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: obesity_lbp_shiri (weight 1.0), zhang2018_obesity_lbp (weight 0.64). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)): Sources added (card G12): zhang2018_obesity_lbp; the displayed estimate is unchanged. estimate_source obesity_lbp_shiri, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). Grade Strong to Moderate (card G12, settled by the research pass). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Current cigarette smoking → Back pain
smoking|low_back_pain
| Field | Before | After |
| Grade | Convincing (now Strong) | Moderate |
| Score (ESS) | 10.8 | 8.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response no | Trial none; Genetic (MR) supportive (sources backpain_mr_ma); dose-response no |
| New fields | not recorded before | Measure OR Estimate source backpain_mr_ma Estimate design MR Outcome match exact Outcome measured Back pain of any duration (Mendelian randomisation) Grade basis Moderate: One MR meta-analysis; no observational synthesis recorded. Rule T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Back pain of any duration (Mendelian randomisation). measured_outcome
Grade: Moderate: One MR meta-analysis; no observational synthesis recorded. Rule T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)). estimate_source backpain_mr_ma, estimate_design MR, measure OR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11): Grade Strong to Moderate (card G3, PROPOSAL section 3.1): One MR meta-analysis; no observational synthesis recorded. grade_basisT4
Grade basis: Moderate: One MR meta-analysis; no observational synthesis recorded. Rule T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). grade_basisT4
Also changed in: 1.4 (21 Oct 2026)1.4 (9 Oct 2026)
Insomnia → Back pain
insomnia|low_back_pain
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 10.0 | 6.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response no | Trial none; Genetic (MR) supportive (sources backpain_mr_ma); dose-response no |
| New fields | not recorded before | Measure OR Estimate source backpain_mr_ma Estimate design MR Outcome match exact Outcome measured Back pain of any duration (Mendelian randomisation) Grade basis Suggestive: MR meta-analysis, z 2.8; pain and poor sleep feed each other. Rule T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Back pain of any duration (Mendelian randomisation). measured_outcome
Grade: Suggestive: MR meta-analysis, z 2.8; pain and poor sleep feed each other. Rule T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (card O2 (disease renamed to what its studies measure)). estimate_source backpain_mr_ma, estimate_design MR, measure OR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): MR meta-analysis, z 2.8; pain and poor sleep feed each other. grade_basisT9b
Grade basis: Suggestive: MR meta-analysis, z 2.8; pain and poor sleep feed each other. Rule T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT9b
Also changed in: 1.4 (21 Oct 2026)1.4 (9 Oct 2026)
Sedentary behaviour → Back pain
sedentary|low_back_pain
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response no | Trial none; Genetic (MR) supportive (sources backpain_mr_ma); dose-response no |
| New fields | not recorded before | Measure OR Estimate source backpain_mr_ma Estimate design MR Outcome match exact Outcome measured Back pain of any duration (Mendelian randomisation) |
The estimate measures: Back pain of any duration (Mendelian randomisation). measured_outcome
Also changed in: 1.4 (21 Oct 2026)1.4 (9 Oct 2026)
Heavy alcohol use → Back pain
alcohol_heavy|low_back_pain
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response no | Trial none; Genetic (MR) supportive (sources backpain_mr_ma); dose-response no |
| New fields | not recorded before | Measure OR Estimate source backpain_mr_ma Estimate design MR Outcome match exact Outcome measured Back pain of any duration (Mendelian randomisation) |
The estimate measures: Back pain of any duration (Mendelian randomisation). measured_outcome
Also changed in: 1.4 (21 Oct 2026)1.4 (9 Oct 2026)
Long-term NSAID use → Peptic ulcer
nsaids|peptic_ulcer
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.67 |
| Score (ESS) | 25.0 | empty |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources nsaids_cnt2013); Genetic (MR) none; dose-response yes |
| Sources | nsaid_sos hp_nsaid_huang | nsaid_sos hp_nsaid_huang nsaids_cnt2013 |
| New fields | not recorded before | Measure RR Estimate source nsaid_sos Estimate design cohort synthesis Outcome match proxy Outcome measured Upper gastrointestinal complications (bleeding or perforation) Related outcome true Grade basis Kept at Strong by the verified dry run: Trials and pharmacology establish NSAID ulcer complications; relabel the outcome as ulcer complications. |
Outcome match, Outcome measured, Related outcome: The estimate measures: Upper gastrointestinal complications (bleeding or perforation). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: Kept at Strong by the verified dry run: Trials and pharmacology establish NSAID ulcer complications; relabel the outcome as ulcer complications. grade_basis
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: hp_nsaid_huang (weight 1.0), nsaid_sos (weight 0.67). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match proxy, measured outcome recorded (cards O1 and O5). estimate_source nsaid_sos, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11): Grade stays Strong (card G3: kept by the verifier). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct supportive with its sources recorded (nsaids_cnt2013) (card G11, blocker 4): Individual-participant meta-analyses of randomised trials: upper gastrointestinal complications were raised by coxibs (1.81), diclofenac (1.89), ibuprofen (3.97) and naproxen (4.22) against placebo. corrections.json _why
H. pylori eradication therapy → Peptic ulcer
hp_eradication|peptic_ulcer
| Field | Before | After |
| Score (ESS) | 22.0 | empty |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response no | Trial supportive (sources hp_cochrane_ulcer); Genetic (MR) none; dose-response no |
| Caveat | Cochrane graded this trial evidence very low quality despite the size of the effect. The outcome is the return of a duod…Cochrane graded this trial evidence very low quality despite the size of the effect. The outcome is the return of a duodenal ulcer in people who have already had one; eradication also prevented gastric ulcer recurrence (0.31, 0.22 to 0.45). This is the effect of treatment; carrying H. pylori raises ulcer risk, roughly doubling it among people taking NSAIDs (odds ratio 2.12, 1.68 to 2.67). | Cochrane graded this trial evidence very low quality despite the size of the effect. The outcome is the return of a duod…Cochrane graded this trial evidence very low quality despite the size of the effect. The outcome is the return of a duodenal ulcer in people who have already had one; eradication also prevented gastric ulcer recurrence (0.31, 0.22 to 0.45). This is the effect of treatment in people who carry the infection and have already had an ulcer. |
| Sources | hp_cochrane_ulcer hp_nsaid_huang | hp_cochrane_ulcer |
| New fields | not recorded before | Measure RR Estimate source hp_cochrane_ulcer Estimate design trial synthesis Outcome match progression Outcome measured Duodenal ulcer recurrence in people who already had an ulcer Related outcome true External grades GRADE very low (hp_cochrane_ulcer) |
Outcome match, Outcome measured, Related outcome: The estimate measures: Duodenal ulcer recurrence in people who already had an ulcer. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Caveat, Sources: 21 Oct 2026 grading reform v2.0: outcome_match progression, measured outcome recorded (card O4). estimate_source hp_cochrane_ulcer, estimate_design trial synthesis, measure RR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). external_grades transcribed from the caveat, the review note or the quote (rule T11) 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source hp_nsaid_huang removed from the link's sources (issue 2, card K7 A topic check, PROPOSAL section 5.1): it is a meta-analysis of H. pylori infection and NSAID use as causes of ulcer, another exposure, so it does not replicate this pair and must not count in the replication term. caveat: the odds ratio from the removed source is dropped; the sentence keeps the point in words (issue 2). caveat_zh: the same figure dropped. 23 Oct 2026 fix round 3 (verifier of the data step, third check, blockers 1 to 3 and minor items 4, 6, 7): caveat: the last sentence is cut to what the cited Cochrane review supports (its trials enrolled H. pylori-positive people with peptic ulcer); the statement about NSAID users came from a source that is no longer cited (minor item 6). caveat_zh: the same sentence. corrections.json _whyT11
Also changed in: 1.4 (19 Sep 2026)1.3 (9 Sep 2026)
Smokeless tobacco → Gum disease (periodontitis)
smokeless_tobacco|periodontitis_disease
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.38 |
| Score (ESS) | 19.3 | 16.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| Sources | slt_perio_ma | slt_perio_ma mehta2021_slt_periodontitis |
| New fields | not recorded before | Measure OR Estimate source slt_perio_ma Estimate design mixed Outcome match exact Outcome measured Prevalence of periodontitis in smokeless tobacco users Grade basis T5a/T5b: the pooled odds ratio comes from studies of periodontitis prevalence in users against non-users. A second synth…T5a/T5b: the pooled odds ratio comes from studies of periodontitis prevalence in users against non-users. A second synthesis (Mehta 2021, Asia) states that 33 of 36 eligible studies were cross-sectional and calls for longitudinal studies. No prospective study was found. Region split in the 2024 review: high-income countries OR 1.69 (1.20-2.37), lower-middle and low-income countries OR 3.91 (2.66-5.77). Suggestive. Studies 19 |
Outcome match, Outcome measured: The estimate measures: Prevalence of periodontitis in smokeless tobacco users. measured_outcome
Grade: T5a/T5b: the pooled odds ratio comes from studies of periodontitis prevalence in users against non-users. A second synthesis (Mehta 2021, Asia) states that 33 of 36 eligible studies were cross-sectional and calls for longitudinal studies. No prospective study was found. Region split in the 2024 review: high-income countries OR 1.69 (1.20-2.37), lower-middle and low-income countries OR 3.91 (2.66-5.77). Suggestive. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): mehta2021_slt_periodontitis; the displayed estimate is unchanged. estimate_source slt_perio_ma, estimate_design mixed, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). n_studies from the displayed review (card G12, research pass; PubMed 38757716). Grade Moderate to Suggestive (card G12, settled by the research pass). grade_basisT5aT5b
Grade basis: T5a/T5b: the pooled odds ratio comes from studies of periodontitis prevalence in users against non-users. A second synthesis (Mehta 2021, Asia) states that 33 of 36 eligible studies were cross-sectional and calls for longitudinal studies. No prospective study was found. Region split in the 2024 review: high-income countries OR 1.69 (1.20-2.37), lower-middle and low-income countries OR 3.91 (2.66-5.77). Suggestive. grade_basisT5aT5b
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: mehta2021_slt_periodontitis (weight 1.0), slt_perio_ma (weight 0.38). reviews_counted
Studies, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): mehta2021_slt_periodontitis; the displayed estimate is unchanged. estimate_source slt_perio_ma, estimate_design mixed, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). n_studies from the displayed review (card G12, research pass; PubMed 38757716). Grade Moderate to Suggestive (card G12, settled by the research pass). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Current cigarette smoking → Venous thromboembolism
smoking|vte
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.38 |
| Score (ESS) | 7.2 | 9.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source smoke_vte_ma Estimate design cohort synthesis Outcome match exact Outcome measured Incident venous thromboembolism |
Outcome match, Outcome measured: The estimate measures: Incident venous thromboembolism. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoke_vte_ma (weight 1.0), cvrf_vte_ipd (weight 0.38). reviews_counted
Former smoking → Venous thromboembolism
former_smoking|vte
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source smoke_vte_ma Estimate design cohort synthesis Outcome match exact Outcome measured Incident venous thromboembolism |
The estimate measures: Incident venous thromboembolism. measured_outcome
Low dietary fibre → Diverticular disease
low_fibre|diverticular_disease
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source fibre_divertic_aune Estimate design cohort synthesis Outcome match exact Outcome measured Diverticular disease (prospective cohorts) Grade override Moderate. T8c (healthy-user check, amended) proposes Suggestive; an umbrella review rates the pair Class I (convincing),…Moderate. T8c (healthy-user check, amended) proposes Suggestive; an umbrella review rates the pair Class I (convincing), and no trial has tested fibre for prevention. T3 and T4 cap at Moderate, the v1.4 grade. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. External grades umbrella review class Class I (convincing) (fibre_umbrella_2025) |
Outcome match, Outcome measured: The estimate measures: Diverticular disease (prospective cohorts). measured_outcome
Grade override: Curator override to Moderate: T8c (healthy-user check, amended) proposes Suggestive; an umbrella review rates the pair Class I (convincing), and no trial has tested fibre for prevention. T3 and T4 cap at Moderate, the v1.4 grade. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT8cT3T4
High body-mass index → Gallstones
high_bmi|gallstones
| Field | Before | After |
| Score (ESS) | 16.3 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources yuan2022_gallstone_mr); dose-response yes |
| Sources | bmi_gallbladder_aune | bmi_gallbladder_aune yuan2022_gallstone_mr |
| New fields | not recorded before | Measure RR Estimate source bmi_gallbladder_aune Estimate design cohort synthesis Outcome match broader Outcome measured Gallbladder disease (gallstones, cholecystitis and related) Related outcome true Grade basis Kept at Strong by the verified dry run: Gallbladder disease is mostly gallstone disease and MR is supportive; set outcome_match broader. |
Outcome match, Outcome measured, Related outcome: The estimate measures: Gallbladder disease (gallstones, cholecystitis and related). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: Kept at Strong by the verified dry run: Gallbladder disease is mostly gallstone disease and MR is supportive; set outcome_match broader. grade_basis
Sources: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source bmi_gallbladder_aune, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11): Grade stays Strong (card G3: kept by the verifier). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (yuan2022_gallstone_mr) (card G11, blocker 4): Genetically predicted BMI raises gallstone disease (OR 1.63 per SD, UK Biobank and FinnGen). corrections.json _why
Abdominal obesity → Gallstones
central_adiposity|gallstones
| Field | Before | After |
| Score (ESS) | 11.1 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source bmi_gallbladder_aune Estimate design cohort synthesis Outcome match broader Outcome measured Gallbladder disease Related outcome true |
The estimate measures: Gallbladder disease. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
High body-mass index → Migraine
high_bmi|migraine
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.5 |
| Score (ESS) | 8.1 | 10.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source bmi_migraine_ma Estimate design cohort synthesis Outcome match exact Outcome measured Migraine |
Outcome match, Outcome measured: The estimate measures: Migraine. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: bmi_migraine_ma (weight 1.0), bmi_headache_dr (weight 0.5). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Type 2 diabetes (as a risk factor) → Glaucoma
t2d_exposure|glaucoma
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 10.3 | 7.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source dm_poag_ma Estimate design cohort synthesis Outcome match narrower Outcome measured Primary open-angle glaucoma only Grade basis Suggestive: Detection bias; no dose-response. Rule T7 (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Primary open-angle glaucoma only. measured_outcome
Grade: Suggestive: Detection bias; no dose-response. Rule T7 (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match narrower, measured outcome recorded (cards O1 and O5). estimate_source dm_poag_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Detection bias; no dose-response. grade_basisT7
Grade basis: Suggestive: Detection bias; no dose-response. Rule T7 (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7
Also changed in: 1.4 (9 Oct 2026)
Long working hours → Coronary heart disease
long_hours|chd
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.5 |
| Score (ESS) | 4.7 | 6.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | longhours_cvd | longhours_cvd li2020_longhours_ihd kivimaki2020_longhours_critique |
| New fields | not recorded before | Measure RR Estimate source longhours_cvd Estimate design pooled IPD Outcome match exact Outcome measured Incident coronary heart disease Grade basis T3 met: the WHO/ILO review judged working 55 hours or more a week as "sufficient evidence of harmfulness" for incident I…T3 met: the WHO/ILO review judged working 55 hours or more a week as "sufficient evidence of harmfulness" for incident IHD (RR 1.13, 1.02-1.26, 22 studies, I-squared 5%, moderate quality). T4 met by two syntheses (Kivimaki 2015 and WHO/ILO 2020). A published critique (Kivimaki 2020, cited) reports 1.08 (0.93-1.25) in low-risk-of-bias cohorts and no excess in high-status jobs, so the lower bound is fragile. Moderate with that dispute named. Adjudicating bodies li2020_longhours_ihd: WHO/ILO 2020 review: sufficient evidence of harmfulness for ischaemic heart disease |
Outcome match, Outcome measured: The estimate measures: Incident coronary heart disease. measured_outcome
Grade basis: T3 met: the WHO/ILO review judged working 55 hours or more a week as "sufficient evidence of harmfulness" for incident IHD (RR 1.13, 1.02-1.26, 22 studies, I-squared 5%, moderate quality). T4 met by two syntheses (Kivimaki 2015 and WHO/ILO 2020). A published critique (Kivimaki 2020, cited) reports 1.08 (0.93-1.25) in low-risk-of-bias cohorts and no excess in high-status jobs, so the lower bound is fragile. Moderate with that dispute named. grade_basisT3T4
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: longhours_cvd (weight 1.0), li2020_longhours_ihd (weight 0.5). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): li2020_longhours_ihd; the displayed estimate is unchanged. estimate_source longhours_cvd, estimate_design pooled IPD, measure RR, by rule E1 (cards G8, K5, P2). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). Grade stays Moderate (card G12, settled by the research pass); grade_basis records the rules. 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Kivimaki 2020 (Environment International, PubMed 33051042) added to the sources; its figures in the grade_basis were checked against the abstract: 1.08 (0.93 to 1.25) in the studies with a lower risk of bias and no excess in high socioeconomic status occupations (issue 5). corrections.json _whyT3T4
Long working hours → Ischaemic stroke
long_hours|stroke_isch
| Field | Before | After |
| Score (ESS) | 9.2 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source longhours_cvd Estimate design pooled IPD Outcome match broader Outcome measured Incident stroke of any type Related outcome true |
The estimate measures: Incident stroke of any type. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Bisphenol A → Type 2 diabetes
bisphenol_a|t2d
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source bpa_t2d_ma Estimate design cohort synthesis Outcome match exact Outcome measured Type 2 diabetes (12 of 16 studies cross-sectional) Conflict Side A: A meta-analysis of sixteen studies finds a clear positive association (1.28, 1.14 to 1.44). Side B: A systematic…Side A: A meta-analysis of sixteen studies finds a clear positive association (1.28, 1.14 to 1.44). Side B: A systematic review of the same field finds the results inconsistent across studies, and single urine measurements misclassify exposure. Sources: bpa_t2d_ma bpa_critical_review |
Outcome match, Outcome measured: The estimate measures: Type 2 diabetes (12 of 16 studies cross-sectional). measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: bpa_t2d_ma (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Damp and mould at home → Asthma (adult)
damp_mould|asthma
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.38 |
| Score (ESS) | 11.4 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| Sources | damp_asthma_ma | damp_asthma_ma who2009_dampness |
| New fields | not recorded before | Measure RR Estimate source damp_asthma_ma Estimate design cohort synthesis Outcome match broader Outcome measured New asthma at all ages (11 cohort and 5 incident case-control studies) Related outcome true Grade basis T3 met: the WHO 2009 dampness guideline lists asthma development among outcomes with sufficient evidence of an associati…T3 met: the WHO 2009 dampness guideline lists asthma development among outcomes with sufficient evidence of an association (adjudicating body for this pair). T4 met: WHO plus the 2012 meta-analysis (16 studies, 11 cohort). T7: no dose-response over exposure levels was examined, but the effect differs by exposure type (mould odour 1.73, visible mould 1.29, dampness 1.33, water damage 1.12 not significant), and the authors point to mould-related agents as the likely mechanism. Moderate. Studies 16 Adjudicating bodies who2009_dampness: WHO 2009 guideline: enough evidence of an association with developing asthma; a causal relation was not concluded |
Outcome match, Outcome measured, Related outcome: The estimate measures: New asthma at all ages (11 cohort and 5 incident case-control studies). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: T3 met: the WHO 2009 dampness guideline lists asthma development among outcomes with sufficient evidence of an association (adjudicating body for this pair). T4 met: WHO plus the 2012 meta-analysis (16 studies, 11 cohort). T7: no dose-response over exposure levels was examined, but the effect differs by exposure type (mould odour 1.73, visible mould 1.29, dampness 1.33, water damage 1.12 not significant), and the authors point to mould-related agents as the likely mechanism. Moderate. grade_basisT3T4T7
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: who2009_dampness (weight 1.0), damp_asthma_ma (weight 0.38). reviews_counted
Studies, Sources: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5): Sources added (card G12): who2009_dampness; the displayed estimate is unchanged. estimate_source damp_asthma_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). adjudication recorded for each cited body that rules on causality, with pair_match (rules T3, T4, card G5). n_studies from the displayed review (card G12, research pass; PubMed 23144822). Grade stays Moderate (card G12, settled by the research pass); grade_basis records the rules. corrections.json _whyT3T4
Also changed in: 1.4 (9 Oct 2026)
Cleaning products and disinfectants → Asthma (adult)
cleaning_agents|asthma
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 9.5 | 6.5 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source cleaning_asthma_ma Estimate design cohort synthesis Outcome match exact Outcome measured Asthma in hospital workers (asthma-like symptoms reported separately) Grade basis Suggestive: One review of hospital workers, z 2.7. Rules T7, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Asthma in hospital workers (asthma-like symptoms reported separately). measured_outcome
Grade: Suggestive: One review of hospital workers, z 2.7. Rules T7, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source cleaning_asthma_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): One review of hospital workers, z 2.7. grade_basisT7T9b
Grade basis: Suggestive: One review of hospital workers, z 2.7. Rules T7, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7T9b
Antidepressant (SSRI) use → Fracture in adults
ssri|fracture
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 17.9 | 12.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source ssri_fracture_ma Estimate design cohort synthesis Outcome match narrower Outcome measured Hip fracture only Grade basis Suggestive: Depression itself causes falls and bone loss. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Hip fracture only. measured_outcome
Grade: Suggestive: Depression itself causes falls and bone loss. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match narrower, measured outcome recorded (cards O1 and O5). estimate_source ssri_fracture_ma, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Depression itself causes falls and bone loss. grade_basisT8a
Grade basis: Suggestive: Depression itself causes falls and bone loss. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT8a
Also changed in: 1.4 (9 Oct 2026)
Influenza vaccination → Coronary heart disease
flu_vaccination|chd
| Field | Before | After |
| Grade | Convincing (now Strong) | Moderate |
| Score (ESS) | 13.0 | empty |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response no | Trial supportive (sources flu_vacc_cvd_rct); Genetic (MR) none; dose-response no |
| Mediation note | Influenza infection itself is associated with cardiovascular events (odds ratio 1.76, 1.02-3.03), which is the effect th…Influenza infection itself is associated with cardiovascular events (odds ratio 1.76, 1.02-3.03), which is the effect the vaccine is thought to prevent. | The cited trial synthesis describes seasonal influenza as a recognised trigger of acute cardiovascular events, so the va…The cited trial synthesis describes seasonal influenza as a recognised trigger of acute cardiovascular events, so the vaccine is thought to act by preventing infection. |
| Sources | flu_vacc_cvd_rct flu_infection_cvd | flu_vacc_cvd_rct |
| New fields | not recorded before | Measure OR Estimate source flu_vacc_cvd_rct Estimate design trial synthesis Outcome match composite_other Outcome measured Composite of all-cause death, heart attack and stent thrombosis in adults with established cardiovascular disease Related outcome true Grade basis Moderate: One trial synthesis in people with CVD; the composite includes all-cause death. Rule T4 (ceiling Moderate). Ve…Moderate: One trial synthesis in people with CVD; the composite includes all-cause death. Rule T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). Studies 8 |
Outcome match, Outcome measured, Related outcome: The estimate measures: Composite of all-cause death, heart attack and stent thrombosis in adults with established cardiovascular disease. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Moderate: One trial synthesis in people with CVD; the composite includes all-cause death. Rule T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match composite_other, measured outcome recorded (cards O1 and O5). estimate_source flu_vacc_cvd_rct, estimate_design trial synthesis, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11): Grade Strong to Moderate (card G3, PROPOSAL section 3.1): One trial synthesis in people with CVD; the composite includes all-cause death. grade_basisT4
Grade basis: Moderate: One trial synthesis in people with CVD; the composite includes all-cause death. Rule T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). grade_basisT4
Studies, Sources: 21 Oct 2026 grading reform v2.0: outcome_match composite_other, measured outcome recorded (cards O1 and O5). estimate_source flu_vacc_cvd_rct, estimate_design trial synthesis, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11): Grade Strong to Moderate (card G3, PROPOSAL section 3.1): One trial synthesis in people with CVD; the composite includes all-cause death. 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source flu_infection_cvd removed from the link's sources (issue 2, card K7 A topic check, PROPOSAL section 5.1): it is a meta-analysis of influenza infection, another exposure, so it does not replicate this pair and must not count in the replication term. mediation: the figure from the removed source is dropped; the mechanism statement stays (issue 2). mediation_zh: the same figure dropped. n_studies 8 recorded from the abstract (PubMed 42042785: eight randomised trials met the inclusion criteria); with five or more trials pooled, rule T9 does not apply (PROPOSAL 2.3, amended T9). 23 Oct 2026 fix round 3 (verifier of the data step, third check, blockers 1 to 3 and minor items 4, 6, 7): mediation: the sentence now attributes the mechanism to the cited trial synthesis, whose abstract (PubMed 42042785) calls seasonal influenza a recognised trigger of acute cardiovascular events; the source behind the earlier general statement is no longer cited (minor item 6). mediation_zh: the same sentence. corrections.json _whyT9
Mediation note: 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source flu_infection_cvd removed from the link's sources (issue 2, card K7 A topic check, PROPOSAL section 5.1): it is a meta-analysis of influenza infection, another exposure, so it does not replicate this pair and must not count in the replication term. mediation: the figure from the removed source is dropped; the mechanism statement stays (issue 2). mediation_zh: the same figure dropped. n_studies 8 recorded from the abstract (PubMed 42042785: eight randomised trials met the inclusion criteria); with five or more trials pooled, rule T9 does not apply (PROPOSAL 2.3, amended T9). 23 Oct 2026 fix round 3 (verifier of the data step, third check, blockers 1 to 3 and minor items 4, 6, 7): mediation: the sentence now attributes the mechanism to the cited trial synthesis, whose abstract (PubMed 42042785) calls seasonal influenza a recognised trigger of acute cardiovascular events; the source behind the earlier general statement is no longer cited (minor item 6). mediation_zh: the same sentence. corrections.json _whyT9
Also changed in: 1.4 (21 Oct 2026)1.4 (9 Oct 2026)
E-cigarette use → COPD
ecigs|copd
| Field | Before | After |
| Reviews counted | 1 | 0 |
| Score (ESS) | 3.7 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| Sources | ecig_switch_review | ecig_switch_review bhatta2020_ecig_respiratory xie2020_ecig_incident_resp |
| New fields | not recorded before | Measure OR Estimate source ecig_switch_review Estimate design cross-sectional Outcome match proxy Outcome measured Wheezing, self-reported, in adults who switched from smoking (one cross-sectional study) Related outcome true Rests on primary studies true Conflict Side A: Adults who switched from cigarettes to e-cigarettes report less wheezing than people who kept smoking (0.66, 0.5…Side A: Adults who switched from cigarettes to e-cigarettes report less wheezing than people who kept smoking (0.66, 0.50 to 0.87, one cross-sectional study). Side B: In a prospective cohort, current e-cigarette users developed COPD more often than people who never used them (incidence rate ratio 1.57, 1.15 to 2.13). Sources: ecig_switch_review bhatta2020_ecig_respiratory xie2020_ecig_incident_resp |
Outcome match, Outcome measured, Related outcome: The estimate measures: Wheezing, self-reported, in adults who switched from smoking (one cross-sectional study). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match proxy, measured outcome recorded (card G12 source check: the displayed 0.66 is wheezing from one cross-sectional analysis of the PATH study, so the estimate stands in for COPD without diagnosing it): Sources added (card G12 source check): bhatta2020_ecig_respiratory, xie2020_ecig_incident_resp; the displayed estimate is unchanged. estimate_source ecig_switch_review, estimate_design cross-sectional, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). conflict records both sides and their sources from the caveat and review note (rule C2, card G1). 23 Oct 2026 fix round 3 (verifier of the data step, third check, blockers 1 to 3 and minor items 4, 6, 7): ecig_switch_review is retyped to review (blocker 3): it pools nothing, so the link rests on primary studies (n_reviews 1 to 0, primary_only true); its displayed 0.66 is one cross-sectional PATH analysis reported in that review, as the card G12 source check found. The link stays in the related layer with no score. corrections.json _whyC2
Also changed in: 1.4 (9 Oct 2026)
High lipoprotein(a) → Aortic valve stenosis
high_lpa|aortic_stenosis
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Score (ESS) | 17.7 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources lpa_gene_cavs); dose-response yes |
| New fields | not recorded before | Measure RR Estimate source lpa_cavd_ma Estimate design cohort synthesis Outcome match broader Outcome measured Calcific aortic valve disease (all stages) at lipoprotein(a) of 50 mg/dL or more Related outcome true |
Outcome match, Outcome measured, Related outcome: The estimate measures: Calcific aortic valve disease (all stages) at lipoprotein(a) of 50 mg/dL or more. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: lpa_cavd_ma (weight 1.0). reviews_counted
Refined grains and white rice → Type 2 diabetes
refined_grains|t2d
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.64 |
| Score (ESS) | 0.7 | 1.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source grains_t2d_aune Estimate design cohort synthesis Outcome match exact Outcome measured Incident type 2 diabetes per 3 servings a day of refined grains Conflict Side A: Refined grains as a whole show no association with diabetes (0.95, 0.88 to 1.04 per 3 servings a day). Side B: W…Side A: Refined grains as a whole show no association with diabetes (0.95, 0.88 to 1.04 per 3 servings a day). Side B: White rice, one refined grain, carries a 6% higher risk for every extra 150 g a day in a later meta-analysis of 1.5 million people. Sources: grains_t2d_aune whiterice_ma |
Outcome match, Outcome measured: The estimate measures: Incident type 2 diabetes per 3 servings a day of refined grains. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: grains_t2d_aune (weight 1.0), whiterice_ma (weight 0.64). reviews_counted
Also changed in: 1.3 (9 Sep 2026)
Plant-based eating pattern → Type 2 diabetes
plant_based_diet|t2d
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source pdi_t2d_pooled Estimate design pooled IPD Outcome match exact Outcome measured Incident type 2 diabetes per 10% rise in a healthful plant-based diet index Grade override Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. N…Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. |
Outcome match, Outcome measured: The estimate measures: Incident type 2 diabetes per 10% rise in a healthful plant-based diet index. measured_outcome
Grade override: Curator override to Moderate: T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT8c
Low potassium intake → Ischaemic stroke
low_potassium|stroke_isch
| Field | Before | After |
| Score (ESS) | 7.7 | empty |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources sscar; a different exposure); Genetic (MR) none; dose-response yes |
| Sources | potassium_stroke_ma | potassium_stroke_ma sscar |
| New fields | not recorded before | Measure RR Estimate source potassium_stroke_ma Estimate design cohort synthesis Outcome match broader Outcome measured Stroke of any type Related outcome true |
Outcome match, Outcome measured, Related outcome: The estimate measures: Stroke of any type. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source potassium_stroke_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_exposure false (cards G6, G11): The caveat cites trials of potassium-enriched salt substitutes, which also lower sodium: No trial is cited on the link. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct supportive with its sources recorded (sscar), same_exposure false (card G11, blocker 4): The salt-substitute trial (SSaSS) raised potassium and lowered sodium together, so it is another exposure contrast. corrections.json _why
Low physical activity → Sarcopenia
low_pa|sarcopenia
| Field | Before | After |
| Grade | Convincing (now Strong) | Moderate |
| Score (ESS) | 17.4 | 13.9 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response no | Trial supportive (sources peterson2011_resistance_lbm_ma; a different outcome); Genetic (MR) none; dose-response no |
| Sources | sarcopenia_factors_ma | sarcopenia_factors_ma peterson2011_resistance_lbm_ma |
| New fields | not recorded before | Measure OR Estimate source sarcopenia_factors_ma Estimate design mixed Outcome match exact Outcome measured Prevalent sarcopenia (odds ratio) in community-dwelling older adults, mostly cross-sectional Grade basis Moderate: Mostly cross-sectional review; the trials test training on muscle. Rules T3, T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). Grade override Moderate. Approved change from Strong to Moderate (card G3). The table proposes Suggestive (T5b: mostly cross-sectional…Moderate. Approved change from Strong to Moderate (card G3). The table proposes Suggestive (T5b: mostly cross-sectional studies) because the resistance-training trials measure muscle mass and strength and so give no outside support on the same outcome. The verifier weighed this and chose Moderate. |
Outcome match, Outcome measured: The estimate measures: Prevalent sarcopenia (odds ratio) in community-dwelling older adults, mostly cross-sectional. measured_outcome
Grade: Curator override to Moderate: Approved change from Strong to Moderate (card G3). The table proposes Suggestive (T5b: mostly cross-sectional studies) because the resistance-training trials measure muscle mass and strength and so give no outside support on the same outcome. The verifier weighed this and chose Moderate. Moderate: Mostly cross-sectional review; the trials test training on muscle. Rules T3, T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source sarcopenia_factors_ma, estimate_design mixed, measure OR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_outcome false (cards G6, G11): Resistance-training trials measured muscle mass and strength, which stand in for sarcopenia: Grade Strong to Moderate (card G3, PROPOSAL section 3.1): Mostly cross-sectional review; the trials test training on muscle. grade_override keeps Moderate: Approved change from Strong to Moderate (card G3). The table proposes Suggestive (T5b: mostly cross-sectional studies) because the resistance-training trials measure muscle mass and strength and so give no outside support on the same outcome. The verifier weighed this and chose Moderate. grade_override and grade_basisT3T4T5b
Grade basis, Grade override: Curator override to Moderate: Approved change from Strong to Moderate (card G3). The table proposes Suggestive (T5b: mostly cross-sectional studies) because the resistance-training trials measure muscle mass and strength and so give no outside support on the same outcome. The verifier weighed this and chose Moderate. Moderate: Mostly cross-sectional review; the trials test training on muscle. Rules T3, T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). grade_override and grade_basisT3T4T5b
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source sarcopenia_factors_ma, estimate_design mixed, measure OR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_outcome false (cards G6, G11): Resistance-training trials measured muscle mass and strength, which stand in for sarcopenia: Grade Strong to Moderate (card G3, PROPOSAL section 3.1): Mostly cross-sectional review; the trials test training on muscle. grade_override keeps Moderate: Approved change from Strong to Moderate (card G3). The table proposes Suggestive (T5b: mostly cross-sectional studies) because the resistance-training trials measure muscle mass and strength and so give no outside support on the same outcome. The verifier weighed this and chose Moderate. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.rct supportive with its sources recorded (peterson2011_resistance_lbm_ma), same_outcome false (card G11, blocker 4): Resistance-training trials increase lean body mass in older adults (49 studies, Peterson 2011), a measure that stands in for sarcopenia. corrections.json _whyT5b
Also changed in: 1.4 (9 Oct 2026)
Current cigarette smoking → Sarcopenia
smoking|sarcopenia
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 6.6 | 4.5 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source sarcopenia_factors_ma Estimate design mixed Outcome match exact Outcome measured Prevalent sarcopenia (odds ratio) in community-dwelling older adults, mostly cross-sectional Grade basis Suggestive: Mostly cross-sectional review. Rules T5b, T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Prevalent sarcopenia (odds ratio) in community-dwelling older adults, mostly cross-sectional. measured_outcome
Grade: Suggestive: Mostly cross-sectional review. Rules T5b, T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source sarcopenia_factors_ma, estimate_design mixed, measure OR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Mostly cross-sectional review. grade_basisT5bT7T8a
Grade basis: Suggestive: Mostly cross-sectional review. Rules T5b, T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT5bT7T8a
Also changed in: 1.4 (9 Oct 2026)
Low nut and seed intake → Obesity
low_nuts|obesity
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 3.0 | empty |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial null (sources nuts_weight_ma); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source nuts_weight_ma Estimate design cohort synthesis Outcome match broader Outcome measured New cases of overweight or obesity Related outcome true Grade basis Suggestive: 86 trials found no effect on weight; the trial field now records it as null (card G11). Rules T2, T8c, T9b (…Suggestive: 86 trials found no effect on weight; the trial field now records it as null (card G11). Rules T2, T8c, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). External grades GRADE moderate (nuts_weight_ma) |
Outcome match, Outcome measured, Related outcome: The estimate measures: New cases of overweight or obesity. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Suggestive: 86 trials found no effect on weight; the trial field now records it as null (card G11). Rules T2, T8c, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source nuts_weight_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct null recorded with its sources (card G11, research pass): Eighty-six trials of nut intake found no effect on body weight: The link outcome is new overweight or obesity in cohorts; the trial outcome is body weight change, which is closely related. external_grades transcribed from the caveat, the review note or the quote (rule T11). Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): 86 trials found no effect on weight; rct field to be corrected to null. grade_basisT2T8cT9bT11
Grade basis: Suggestive: 86 trials found no effect on weight; the trial field now records it as null (card G11). Rules T2, T8c, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT2T8cT9b
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source nuts_weight_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct null recorded with its sources (card G11, research pass): Eighty-six trials of nut intake found no effect on body weight: The link outcome is new overweight or obesity in cohorts; the trial outcome is body weight change, which is closely related. external_grades transcribed from the caveat, the review note or the quote (rule T11). Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): 86 trials found no effect on weight; rct field to be corrected to null. corrections.json _whyT11
Also changed in: 1.4 (9 Oct 2026)
High body-mass index → Obstructive sleep apnoea
high_bmi|osa_outcome
| Field | Before | After |
| Grade | Convincing (now Strong) | Moderate |
| Reviews counted | 2 | 1 |
| Score (ESS) | 21.3 | 17.1 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) supportive; dose-response yes | Trial supportive (sources glp1_osa_rct; a different outcome); Genetic (MR) supportive (sources mr_bmi_osa); dose-response yes |
| Sources | mr_bmi_osa glp1_osa_rct | mr_bmi_osa glp1_osa_rct esmaeili2025_obesity_osa_ipd |
| New fields | not recorded before | Measure OR Estimate source mr_bmi_osa Estimate design MR Outcome match exact Outcome measured Obstructive sleep apnoea (odds ratio per SD of genetically predicted BMI, Mendelian randomisation) Grade basis Moderate: the displayed estimate is one Mendelian randomisation analysis of BMI on sleep apnoea, and the genetic evidenc…Moderate: the displayed estimate is one Mendelian randomisation analysis of BMI on sleep apnoea, and the genetic evidence meets rule T3. The other synthesis cited (Esmaeili 2025) pools the prevalence of sleep apnoea at a sleep study in four community cohorts and compares the odds of sleep apnoea across weight groups, so it is cross-sectional and gives no second line under rule T4 (one MR line; the Strong definition excludes cross-sectional data). GLP-1 trials lower the apnoea-hypopnoea index in people who already have sleep apnoea (another outcome, noted). No synthesis of prospective studies of BMI and new sleep apnoea was found. Lowered from Strong on 23 Oct 2026 (second check); the owner may restore Strong if a prospective synthesis is cited. |
Outcome match, Outcome measured: The estimate measures: Obstructive sleep apnoea (odds ratio per SD of genetically predicted BMI, Mendelian randomisation). measured_outcome
Grade: Moderate: the displayed estimate is one Mendelian randomisation analysis of BMI on sleep apnoea, and the genetic evidence meets rule T3. The other synthesis cited (Esmaeili 2025) pools the prevalence of sleep apnoea at a sleep study in four community cohorts and compares the odds of sleep apnoea across weight groups, so it is cross-sectional and gives no second line under rule T4 (one MR line; the Strong definition excludes cross-sectional data). GLP-1 trials lower the apnoea-hypopnoea index in people who already have sleep apnoea (another outcome, noted). No synthesis of prospective studies of BMI and new sleep apnoea was found. Lowered from Strong on 23 Oct 2026 (second check); the owner may restore Strong if a prospective synthesis is cited. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source mr_bmi_osa, estimate_design MR, measure OR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_outcome false (cards G6, G11): The GLP-1 trials measured the apnoea-hypopnoea index in people who already have sleep apnoea. grade_override keeps Strong: The GLP-1 trials measured the apnoea-hypopnoea index in people who already have sleep apnoea, so they are recorded with same_outcome false: The link then rests on one Mendelian randomisation analysis and rule T4 (Moderate) fails as written. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Source added (blocker 2, card K6): an individual-participant meta-analysis of four community cohorts (12,860 adults; odds of sleep apnoea 4.84, 3.09 to 6.00, for obesity against BMI under 25), the observational line beside the genetic estimate. grade_override removed (blocker 2): the pooled cohort analysis gives the second line that T4 asks for beside the genetic estimate. Grade stays Strong (blocker 2); grade_basis rewritten: Strong: Mendelian randomisation of BMI on sleep apnoea (the displayed estimate) and a pooled analysis of four community cohorts agree (T3, T4); GLP-1 trials lower the apnoea-hypopnoea index in people who already have sleep apnoea (another outcome, noted). Verified at Strong on 21 October 2026. Curator record: 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Grade Strong to Moderate (issue 4): Moderate: the displayed estimate is one Mendelian randomisation analysis of BMI on sleep apnoea, and the genetic evidence meets rule T3. The other synthesis cited (Esmaeili 2025) pools the prevalence of sleep apnoea at a sleep study in four community cohorts and compares the odds of sleep apnoea across weight groups, so it is cross-sectional and gives no second line under rule T4 (one MR line; the Strong definition excludes cross-sectional data). GLP-1 trials lower the apnoea-hypopnoea index in people who already have sleep apnoea (another outcome, noted). No synthesis of prospective studies of BMI and new sleep apnoea was found. Lowered from Strong on 23 Oct 2026 (second check); the owner may restore Strong if a prospective synthesis is cited. grade_basisT3T4
Grade basis: Moderate: the displayed estimate is one Mendelian randomisation analysis of BMI on sleep apnoea, and the genetic evidence meets rule T3. The other synthesis cited (Esmaeili 2025) pools the prevalence of sleep apnoea at a sleep study in four community cohorts and compares the odds of sleep apnoea across weight groups, so it is cross-sectional and gives no second line under rule T4 (one MR line; the Strong definition excludes cross-sectional data). GLP-1 trials lower the apnoea-hypopnoea index in people who already have sleep apnoea (another outcome, noted). No synthesis of prospective studies of BMI and new sleep apnoea was found. Lowered from Strong on 23 Oct 2026 (second check); the owner may restore Strong if a prospective synthesis is cited. grade_basisT3T4
Reviews counted: Counted from the cited syntheses under the review-counting rule: esmaeili2025_obesity_osa_ipd (weight 1.0). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source mr_bmi_osa, estimate_design MR, measure OR, by rule E1 (cards G8, K5, P2). triangulation.rct supportive, same_outcome false (cards G6, G11): The GLP-1 trials measured the apnoea-hypopnoea index in people who already have sleep apnoea. grade_override keeps Strong: The GLP-1 trials measured the apnoea-hypopnoea index in people who already have sleep apnoea, so they are recorded with same_outcome false: The link then rests on one Mendelian randomisation analysis and rule T4 (Moderate) fails as written. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Source added (blocker 2, card K6): an individual-participant meta-analysis of four community cohorts (12,860 adults; odds of sleep apnoea 4.84, 3.09 to 6.00, for obesity against BMI under 25), the observational line beside the genetic estimate. grade_override removed (blocker 2): the pooled cohort analysis gives the second line that T4 asks for beside the genetic estimate. Grade stays Strong (blocker 2); grade_basis rewritten: Strong: Mendelian randomisation of BMI on sleep apnoea (the displayed estimate) and a pooled analysis of four community cohorts agree (T3, T4); GLP-1 trials lower the apnoea-hypopnoea index in people who already have sleep apnoea (another outcome, noted). Verified at Strong on 21 October 2026. 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Grade Strong to Moderate (issue 4): Moderate: the displayed estimate is one Mendelian randomisation analysis of BMI on sleep apnoea, and the genetic evidence meets rule T3. The other synthesis cited (Esmaeili 2025) pools the prevalence of sleep apnoea at a sleep study in four community cohorts and compares the odds of sleep apnoea across weight groups, so it is cross-sectional and gives no second line under rule T4 (one MR line; the Strong definition excludes cross-sectional data). GLP-1 trials lower the apnoea-hypopnoea index in people who already have sleep apnoea (another outcome, noted). No synthesis of prospective studies of BMI and new sleep apnoea was found. Lowered from Strong on 23 Oct 2026 (second check); the owner may restore Strong if a prospective synthesis is cited. corrections.json _whyT4T3
Also changed in: 1.4 (9 Oct 2026)
Heavy alcohol use → Obstructive sleep apnoea
alcohol_heavy|osa_outcome
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source osa_alcohol_ma Estimate design cohort synthesis Outcome match exact Outcome measured Obstructive sleep apnoea (odds ratio) in alcohol users compared with non-users External grades GRADE low to very low (osa_alcohol_ma) |
Outcome match, Outcome measured: The estimate measures: Obstructive sleep apnoea (odds ratio) in alcohol users compared with non-users. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: osa_alcohol_ma (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Blood pressure treatment → Diabetic retinopathy
antihypertensives|diabetic_retinopathy
| Field | Before | After |
| Grade | Convincing (now Strong) | Moderate |
| Score (ESS) | 8.8 | 7.0 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response no | Trial supportive (sources cochrane_bp_dr_2023); Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source cochrane_bp_dr_2023 Estimate design trial synthesis Outcome match exact Outcome measured Five-year incidence of diabetic retinopathy Grade basis Moderate: One Cochrane synthesis, moderate certainty. Rules T4, T11 (ceiling Moderate). Verified on 21 October 2026 (card G3). External grades GRADE moderate (cochrane_bp_dr_2023) |
Outcome match, Outcome measured: The estimate measures: Five-year incidence of diabetic retinopathy. measured_outcome
Grade: Moderate: One Cochrane synthesis, moderate certainty. Rules T4, T11 (ceiling Moderate). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source cochrane_bp_dr_2023, estimate_design trial synthesis, measure RR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). external_grades transcribed from the caveat, the review note or the quote (rule T11): Grade Strong to Moderate (card G3, PROPOSAL section 3.1): One Cochrane synthesis, moderate certainty. grade_basisT4T11
Grade basis: Moderate: One Cochrane synthesis, moderate certainty. Rules T4, T11 (ceiling Moderate). Verified on 21 October 2026 (card G3). grade_basisT4T11
Also changed in: 1.3 (18 Sep 2026)
Tight blood sugar control → Diabetic retinopathy
glucose_control|diabetic_retinopathy
| Field | Before | After |
| Score (ESS) | 6.0 | empty |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response no | Trial supportive (sources glucose_intensive_kunutsor); Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure HR Estimate source glucose_intensive_kunutsor Estimate design trial synthesis Outcome match progression Outcome measured Retinopathy, new or worsening as each trial defined it, in people with type 2 diabetes Related outcome true External grades GRADE moderate at best (glucose_intensive_kunutsor) |
The estimate measures: Retinopathy, new or worsening as each trial defined it, in people with type 2 diabetes. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Tight blood sugar control → Chronic kidney disease
glucose_control|ckd
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 10.4 | empty |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response no | Trial supportive (sources glucose_intensive_kunutsor advance2008 perkovic2013_advance_kidney; a different outcome); Gene…Trial supportive (sources glucose_intensive_kunutsor advance2008 perkovic2013_advance_kidney; a different outcome); Genetic (MR) none; dose-response no |
| Sources | glucose_intensive_kunutsor | glucose_intensive_kunutsor advance2008 perkovic2013_advance_kidney |
| New fields | not recorded before | Measure HR Estimate source glucose_intensive_kunutsor Estimate design trial synthesis Outcome match progression Outcome measured Nephropathy, new or worsening as each trial defined it, in people with type 2 diabetes Related outcome true Grade basis T4 (ceiling Moderate): one trial synthesis, no second trial synthesis or adjudicator. Curator override to Suggestive. Ne…T4 (ceiling Moderate): one trial synthesis, no second trial synthesis or adjudicator. Curator override to Suggestive. Nephropathy is as each trial defined it. The largest trial (ADVANCE) defined it as new or worsening nephropathy, so onset and progression are mixed. The harder endpoint (doubling of creatinine) did not fall significantly in the pooled data. Some pooled trials also intensified blood pressure and lipid care. |
Outcome match, Outcome measured, Related outcome: The estimate measures: Nephropathy, new or worsening as each trial defined it, in people with type 2 diabetes. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: T4 (ceiling Moderate): one trial synthesis, no second trial synthesis or adjudicator. Curator override to Suggestive. Nephropathy is as each trial defined it. The largest trial (ADVANCE) defined it as new or worsening nephropathy, so onset and progression are mixed. The harder endpoint (doubling of creatinine) did not fall significantly in the pooled data. Some pooled trials also intensified blood pressure and lipid care. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match progression, measured outcome recorded (card G12 source check: the largest trial (ADVANCE) counted new or worsening nephropathy, so people who already had kidney disease contribute (card O4)): Sources added (card G11): advance2008, perkovic2013_advance_kidney; the displayed estimate is unchanged. estimate_source glucose_intensive_kunutsor, estimate_design trial synthesis, measure HR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation.rct supportive recorded with its sources (card G11, research pass): Nephropathy was counted as each trial defined it. ADVANCE, the largest trial, counted new or worsening nephropathy, so people who already had kidney disease contribute. Grade Moderate to Suggestive (card G12, settled by the research pass). grade_basisT4
Grade basis: T4 (ceiling Moderate): one trial synthesis, no second trial synthesis or adjudicator. Curator override to Suggestive. Nephropathy is as each trial defined it. The largest trial (ADVANCE) defined it as new or worsening nephropathy, so onset and progression are mixed. The harder endpoint (doubling of creatinine) did not fall significantly in the pooled data. Some pooled trials also intensified blood pressure and lipid care. grade_basisT4
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match progression, measured outcome recorded (card G12 source check: the largest trial (ADVANCE) counted new or worsening nephropathy, so people who already had kidney disease contribute (card O4)): Sources added (card G11): advance2008, perkovic2013_advance_kidney; the displayed estimate is unchanged. estimate_source glucose_intensive_kunutsor, estimate_design trial synthesis, measure HR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation.rct supportive recorded with its sources (card G11, research pass): Nephropathy was counted as each trial defined it. ADVANCE, the largest trial, counted new or worsening nephropathy, so people who already had kidney disease contribute. Grade Moderate to Suggestive (card G12, settled by the research pass). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Current cigarette smoking → Diabetic retinopathy
smoking|diabetic_retinopathy
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source smoke_dr_cai Estimate design mixed Outcome match exact Outcome measured Diabetic retinopathy (risk ratio) in smokers with type 2 diabetes, mostly cross-sectional Conflict Side A: In type 2 diabetes, smokers had less retinopathy (0.92, 0.86 to 0.98). Side B: In type 1 diabetes, smokers had m…Side A: In type 2 diabetes, smokers had less retinopathy (0.92, 0.86 to 0.98). Side B: In type 1 diabetes, smokers had more retinopathy (1.23, 1.14 to 1.33) and more proliferative retinopathy (1.48, 1.20 to 1.81). Sources: smoke_dr_cai |
The estimate measures: Diabetic retinopathy (risk ratio) in smokers with type 2 diabetes, mostly cross-sectional. measured_outcome
High blood pressure → Erectile dysfunction
high_sbp|erectile_dysfunction
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source htn_ed_ma Estimate design cross-sectional Outcome match exact Outcome measured Prevalent erectile dysfunction (odds ratio), 18 cross-sectional studies |
The estimate measures: Prevalent erectile dysfunction (odds ratio), 18 cross-sectional studies. measured_outcome
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Cannabis use → Erectile dysfunction
cannabis|erectile_dysfunction
| Field | Before | After |
| Grade | Suggestive | Weak |
| Score (ESS) | 14.3 | 7.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source cannabis_ed Estimate design case-control Outcome match exact Outcome measured Erectile dysfunction (odds ratio) in regular cannabis users compared with non-users, five case-control studies Grade basis Weak: Five case-control studies; prediction interval includes 1. Rule T10 (ceiling Weak). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Erectile dysfunction (odds ratio) in regular cannabis users compared with non-users, five case-control studies. measured_outcome
Grade: Weak: Five case-control studies; prediction interval includes 1. Rule T10 (ceiling Weak). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source cannabis_ed, estimate_design case-control, measure OR, by rule E1 (read by hand) (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): Five case-control studies; prediction interval includes 1. grade_basisT10
Grade basis: Weak: Five case-control studies; prediction interval includes 1. Rule T10 (ceiling Weak). Verified on 21 October 2026 (card G3). grade_basisT10
Also changed in: 1.4 (9 Oct 2026)
Job insecurity and unemployment → Coronary heart disease
job_insecurity|chd
| Field | Before | After |
| Grade | Suggestive | Weak |
| Score (ESS) | 4.3 | 2.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source ipd_jobinsec_chd Estimate design pooled IPD Outcome match exact Outcome measured Incident coronary heart disease Grade basis Weak: the full text gives the fully adjusted estimate as 1.19 (1.00 to 1.42, P = 0.055), so the interval includes 1 befo…Weak: the full text gives the fully adjusted estimate as 1.19 (1.00 to 1.42, P = 0.055), so the interval includes 1 before rounding (lower bound about 0.996) and rule T1 applies. Much of the association reflects social position. Verified on 21 October 2026 (card G3). ci_low_exact 0.996 |
Outcome match, Outcome measured: The estimate measures: Incident coronary heart disease. measured_outcome
Grade: Weak: the full text gives the fully adjusted estimate as 1.19 (1.00 to 1.42, P = 0.055), so the interval includes 1 before rounding (lower bound about 0.996) and rule T1 applies. Much of the association reflects social position. Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source ipd_jobinsec_chd, estimate_design pooled IPD, measure RR, by rule E1 (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): Adjusted interval touches 1; largely explained by social position (confirm the unrounded bound). Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Grade stays Weak (blocker 7); grade_basis rewritten: Weak: the full text gives the fully adjusted estimate as 1.19 (1.00 to 1.42, P = 0.055), so the interval includes 1 before rounding (lower bound about 0.996) and rule T1 applies. Much of the association reflects social position. Verified on 21 October 2026 (card G3). ci_low_exact 0.996 recorded, derived from P = 0.055 in the full text (BMJ 2013, PMC3738256) (blocker 7). grade_basisT1
Grade basis: Weak: the full text gives the fully adjusted estimate as 1.19 (1.00 to 1.42, P = 0.055), so the interval includes 1 before rounding (lower bound about 0.996) and rule T1 applies. Much of the association reflects social position. Verified on 21 October 2026 (card G3). grade_basisT1
ci_low_exact: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source ipd_jobinsec_chd, estimate_design pooled IPD, measure RR, by rule E1 (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): Adjusted interval touches 1; largely explained by social position (confirm the unrounded bound). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Grade stays Weak (blocker 7); grade_basis rewritten: Weak: the full text gives the fully adjusted estimate as 1.19 (1.00 to 1.42, P = 0.055), so the interval includes 1 before rounding (lower bound about 0.996) and rule T1 applies. Much of the association reflects social position. Verified on 21 October 2026 (card G3). ci_low_exact 0.996 recorded, derived from P = 0.055 in the full text (BMJ 2013, PMC3738256) (blocker 7). corrections.json _whyT1
Also changed in: 1.3 (18 Sep 2026)1.3 (9 Sep 2026)
Workplace dusts, gases and fumes → COPD
vgdf|copd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source jem_copd_ma Estimate design cohort synthesis Outcome match exact Outcome measured COPD (odds ratio) after occupational exposure assigned by a job-exposure matrix |
The estimate measures: COPD (odds ratio) after occupational exposure assigned by a job-exposure matrix. measured_outcome
Also changed in: 1.4 (9 Oct 2026)1.3 (18 Sep 2026)
Binge drinking → Coronary heart disease
binge_drinking|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source roerecke_ihd Estimate design cohort synthesis Outcome match exact Outcome measured Ischaemic heart disease risk in drinkers with heavy drinking occasions |
The estimate measures: Ischaemic heart disease risk in drinkers with heavy drinking occasions. measured_outcome
Also changed in: 1.4 (19 Sep 2026)1.3 (18 Sep 2026)1.3 (9 Sep 2026)
Skipping breakfast → Type 2 diabetes
skipping_breakfast|t2d
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 2 | 1 |
| Score (ESS) | 9.2 | 6.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source breakfast_t2d Estimate design cohort synthesis Outcome match exact Outcome measured Incident type 2 diabetes Grade basis T8a: on the watch list with no mitigation. BMI-adjusted estimate: 1.22 (1.12-1.34), four studies, against 1.33 (1.22-1.4…T8a: on the watch list with no mitigation. BMI-adjusted estimate: 1.22 (1.12-1.34), four studies, against 1.33 (1.22-1.46) with six unadjusted. Eleven breakfast trials tested weight and lipids and none tested diabetes: skipping breakfast lowered weight and raised LDL cholesterol, so they do not support a mechanism. Suggestive. Grade override Suggestive. Settled at Suggestive by the curation pass (card G12): T8a, with no handling of reverse causation. The table…Suggestive. Settled at Suggestive by the curation pass (card G12): T8a, with no handling of reverse causation. The table proposes Weak (T9a) because the quote names four studies for the BMI-adjusted figure; the displayed estimate pools six. Studies 6 |
Outcome match, Outcome measured: The estimate measures: Incident type 2 diabetes. measured_outcome
Grade: Curator override to Suggestive: Settled at Suggestive by the curation pass (card G12): T8a, with no handling of reverse causation. The table proposes Weak (T9a) because the quote names four studies for the BMI-adjusted figure; the displayed estimate pools six. T8a: on the watch list with no mitigation. BMI-adjusted estimate: 1.22 (1.12-1.34), four studies, against 1.33 (1.22-1.46) with six unadjusted. Eleven breakfast trials tested weight and lipids and none tested diabetes: skipping breakfast lowered weight and raised LDL cholesterol, so they do not support a mechanism. Suggestive. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source breakfast_t2d, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). n_studies from the displayed review (card G12, research pass; PubMed 30418612): Grade Moderate to Suggestive (card G12, settled by the research pass). grade_override keeps Suggestive: Settled at Suggestive by the curation pass (card G12): T8a, with no handling of reverse causation. The table proposes Weak (T9a) because the quote names four studies for the BMI-adjusted figure; the displayed estimate pools six. grade_override and grade_basisT8aT9a
Grade basis, Grade override: Curator override to Suggestive: Settled at Suggestive by the curation pass (card G12): T8a, with no handling of reverse causation. The table proposes Weak (T9a) because the quote names four studies for the BMI-adjusted figure; the displayed estimate pools six. T8a: on the watch list with no mitigation. BMI-adjusted estimate: 1.22 (1.12-1.34), four studies, against 1.33 (1.22-1.46) with six unadjusted. Eleven breakfast trials tested weight and lipids and none tested diabetes: skipping breakfast lowered weight and raised LDL cholesterol, so they do not support a mechanism. Suggestive. grade_override and grade_basisT8aT9a
Reviews counted: Counted from the cited syntheses under the review-counting rule: breakfast_t2d (weight 1.0). reviews_counted
Studies: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source breakfast_t2d, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). n_studies from the displayed review (card G12, research pass; PubMed 30418612): Grade Moderate to Suggestive (card G12, settled by the research pass). grade_override keeps Suggestive: Settled at Suggestive by the curation pass (card G12): T8a, with no handling of reverse causation. The table proposes Weak (T9a) because the quote names four studies for the BMI-adjusted figure; the displayed estimate pools six. corrections.json _whyT8aT9a
Cold weather and cold spells → Coronary heart disease
cold_spells|chd
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 4.1 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure rate ratio Estimate source coldspells_ryti Estimate design cohort synthesis Outcome match broader Outcome measured Cardiovascular deaths during cold spells Related outcome true Grade basis Suggestive: Deaths during cold spells, an acute trigger. Rule T7 (ceiling Suggestive). Verified on 21 October 2026 (card G3). Grade override Suggestive. Approved change from Moderate to Suggestive (card G3). The table proposes Weak (T9a) because the quote names…Suggestive. Approved change from Moderate to Suggestive (card G3). The table proposes Weak (T9a) because the quote names five studies for all-cause deaths; the cardiovascular estimate pools 12 estimates. The link sits in the related-outcome layer. |
Outcome match, Outcome measured, Related outcome: The estimate measures: Cardiovascular deaths during cold spells. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Curator override to Suggestive: Approved change from Moderate to Suggestive (card G3). The table proposes Weak (T9a) because the quote names five studies for all-cause deaths; the cardiovascular estimate pools 12 estimates. The link sits in the related-outcome layer. Suggestive: Deaths during cold spells, an acute trigger. Rule T7 (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source coldspells_ryti, estimate_design cohort synthesis, measure rate ratio, by rule E1 (read by hand) (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Deaths during cold spells, an acute trigger. grade_override keeps Suggestive: Approved change from Moderate to Suggestive (card G3). The table proposes Weak (T9a) because the quote names five studies for all-cause deaths; the cardiovascular estimate pools 12 estimates. The link sits in the related-outcome layer. grade_override and grade_basisT7T9a
Grade basis, Grade override: Curator override to Suggestive: Approved change from Moderate to Suggestive (card G3). The table proposes Weak (T9a) because the quote names five studies for all-cause deaths; the cardiovascular estimate pools 12 estimates. The link sits in the related-outcome layer. Suggestive: Deaths during cold spells, an acute trigger. Rule T7 (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_override and grade_basisT7T9a
Cold weather and cold spells → COPD
cold_spells|copd
| Field | Before | After |
| Reviews counted | 1 | 2 |
| Effective reviews (N_eff) | 1 | 1.17 |
| Score (ESS) | 6.5 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source extreme_temp_copd_tran Estimate design cohort synthesis Outcome match proxy Outcome measured COPD hospital visits or deaths during extreme cold, mainly flare-ups in people who already have COPD Related outcome true Adjudicating bodies gbd2021rf: rates this pair in GBD 2021 (star rating not recorded on the link) |
Outcome match, Outcome measured, Related outcome: The estimate measures: COPD hospital visits or deaths during extreme cold, mainly flare-ups in people who already have COPD. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: gbd2021rf (weight 1.0), extreme_temp_copd_tran (weight 0.17). reviews_counted
Also changed in: 1.4 (19 Sep 2026)1.3 (18 Sep 2026)1.3 (9 Sep 2026)
Living with several long-term conditions → Dementia (all-cause)
multimorbidity|dementia
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 9.3 | 6.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure HR Estimate source multimorb_dementia Estimate design cohort synthesis Outcome match exact Outcome measured Incident all-cause dementia (hazard ratio) Grade basis Suggestive: Early dementia brings other diagnoses to light. Rules T7, T8a, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Incident all-cause dementia (hazard ratio). measured_outcome
Grade: Suggestive: Early dementia brings other diagnoses to light. Rules T7, T8a, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source multimorb_dementia, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Early dementia brings other diagnoses to light. grade_basisT7T8aT9b
Grade basis: Suggestive: Early dementia brings other diagnoses to light. Rules T7, T8a, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7T8aT9b
Also changed in: 1.4 (9 Oct 2026)
Added sugar in food → Type 2 diabetes
added_sugar|t2d
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.67 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source sugar_t2d_dr Estimate design cohort synthesis Outcome match exact Outcome measured Incident type 2 diabetes per 20 g a day of added sugar External grades GRADE low (sugar_t2d_dr) |
Outcome match, Outcome measured: The estimate measures: Incident type 2 diabetes per 20 g a day of added sugar. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: asb_t2d_imamura (weight 1.0), sugar_t2d_dr (weight 0.67). reviews_counted
Also changed in: 1.3 (9 Sep 2026)
Egg consumption → Heart failure
eggs|heart_failure
| Field | Before | After |
| Grade | Suggestive | Weak |
| Score (ESS) | 3.6 | 2.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source eggs_cvd_dr Estimate design cohort synthesis Outcome match exact Outcome measured Heart failure risk per egg a day Grade basis Weak: Four studies; the review rates the evidence low. Rule T9a (ceiling Weak). Verified on 21 October 2026 (card G3). External grades review authors' rating low strength of evidence (eggs_cvd_dr) |
Outcome match, Outcome measured: The estimate measures: Heart failure risk per egg a day. measured_outcome
Grade: Weak: Four studies; the review rates the evidence low. Rule T9a (ceiling Weak). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source eggs_cvd_dr, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). external_grades transcribed from the caveat, the review note or the quote (rule T11): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): Four studies; the review rates the evidence low. grade_basisT9aT11
Grade basis: Weak: Four studies; the review rates the evidence low. Rule T9a (ceiling Weak). Verified on 21 October 2026 (card G3). grade_basisT9a
Egg consumption → Coronary heart disease
eggs|chd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.17 |
| Score (ESS) | 0.5 | 0.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source eggs_cvd_dr Estimate design cohort synthesis Outcome match exact Outcome measured Coronary heart disease incidence or mortality Conflict Side A: A dose-response analysis found slightly lower coronary risk at two eggs a week (0.96, 0.91 to 1.00), and an umbr…Side A: A dose-response analysis found slightly lower coronary risk at two eggs a week (0.96, 0.91 to 1.00), and an umbrella review found largely no association. Side B: Other pooled analyses report higher coronary risk in people with diabetes and in some Asian cohorts. Sources: eggs_cvd_dr eggs_umbrella |
Outcome match, Outcome measured: The estimate measures: Coronary heart disease incidence or mortality. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: eggs_umbrella (weight 1.0), eggs_cvd_dr (weight 0.17). reviews_counted
Also changed in: 1.3 (9 Sep 2026)
Non-sugar sweeteners → Type 2 diabetes
nonsugar_sweeteners|t2d
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.29 |
| Score (ESS) | 1.0 | 1.2 |
| Trial and genetic evidence | Trial conflicting; Genetic (MR) none; dose-response yes | Trial conflicting (sources nns_azad; a different outcome); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source asb_t2d_imamura Estimate design cohort synthesis Outcome match exact Outcome measured Incident type 2 diabetes per daily serving of artificially sweetened drinks Conflict Side A: Cohorts link artificially sweetened drinks with more diabetes (1.08, 1.02 to 1.15 per daily serving, after adjus…Side A: Cohorts link artificially sweetened drinks with more diabetes (1.08, 1.02 to 1.15 per daily serving, after adjustment for body fatness). Side B: Randomised trials pooled in CMAJ found no effect of non-nutritive sweeteners on body-mass index (mean difference -0.37 kg/m2, -1.10 to 0.36). Sources: asb_t2d_imamura nns_azad |
Outcome match, Outcome measured: The estimate measures: Incident type 2 diabetes per daily serving of artificially sweetened drinks. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: asb_t2d_imamura (weight 1.0), nns_azad (weight 0.29). reviews_counted
Trial and genetic evidence: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source asb_t2d_imamura, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation.rct conflicting, same_outcome false (cards G6, G11): The trials pooled in CMAJ measured body-mass index; none counted new diabetes. conflict records both sides and their sources from the caveat and review note (rule C2, card G1) corrections.json _whyC2
Also changed in: 1.4 (21 Oct 2026)1.4 (19 Sep 2026)
Mother smoked in pregnancy → Obesity
maternal_smoking_preg|obesity
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| Sources | matsmoke_obesity adhd_umbrella | matsmoke_obesity |
| New fields | not recorded before | Measure OR Estimate source matsmoke_obesity Estimate design cohort synthesis Outcome match exact Outcome measured Obesity in children aged 2 to 18 (unadjusted odds ratio) |
Outcome match, Outcome measured: The estimate measures: Obesity in children aged 2 to 18 (unadjusted odds ratio). measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: matsmoke_obesity (weight 1.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source matsmoke_obesity, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2) 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source adhd_umbrella removed from the link's sources (issue 2, card K7 A topic check, PROPOSAL section 5.1): it is an umbrella review of risk factors for ADHD, another outcome, so it does not replicate this pair and must not count in the replication term. corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Mother smoked in pregnancy → Eczema (atopic dermatitis)
maternal_smoking_preg|atopic_dermatitis
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.62 |
| Score (ESS) | 0.7 | 0.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source matsmoke_ad Estimate design cohort synthesis Outcome match exact Outcome measured Atopic dermatitis in offspring (odds ratio) |
Outcome match, Outcome measured: The estimate measures: Atopic dermatitis in offspring (odds ratio). measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoke_ad_kantor (weight 1.0), matsmoke_ad (weight 0.62). reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.3 (9 Sep 2026)
Secondhand smoke → Eczema (atopic dermatitis)
shs|atopic_dermatitis
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Effective reviews (N_eff) | 1 | 1.62 |
| Score (ESS) | 11.9 | 11.5 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source matsmoke_ad Estimate design cohort synthesis Outcome match exact Outcome measured Atopic dermatitis in offspring (odds ratio) Grade basis Suggestive: Only passive maternal smoking is associated, a sign of reporting bias. Rule T7 (ceiling Suggestive). Verifie…Suggestive: Only passive maternal smoking is associated, a sign of reporting bias. Rule T7 (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Atopic dermatitis in offspring (odds ratio). measured_outcome
Grade: Suggestive: Only passive maternal smoking is associated, a sign of reporting bias. Rule T7 (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source matsmoke_ad, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Only passive maternal smoking is associated, a sign of reporting bias. grade_basisT7
Grade basis: Suggestive: Only passive maternal smoking is associated, a sign of reporting bias. Rule T7 (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoke_ad_kantor (weight 1.0), matsmoke_ad (weight 0.62). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Current cigarette smoking → Eczema (atopic dermatitis)
smoking|atopic_dermatitis
| Field | Before | After |
| Grade | Suggestive | Weak |
| Score (ESS) | 10.3 | 5.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source smoke_ad_kantor Estimate design cohort synthesis Outcome match exact Outcome measured Prevalent atopic dermatitis (odds ratio of active smoking), all cross-sectional Grade basis Weak: Every study cross-sectional. Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Prevalent atopic dermatitis (odds ratio of active smoking), all cross-sectional. measured_outcome
Grade: Weak: Every study cross-sectional. Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source smoke_ad_kantor, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): Every study cross-sectional. grade_basis
Grade basis: Weak: Every study cross-sectional. Verified on 21 October 2026 (card G3). grade_basis
Also changed in: 1.4 (9 Oct 2026)
Repeated antibiotic courses → Eczema (atopic dermatitis)
antibiotics_exposure|atopic_dermatitis
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source prenatal_ad_ma Estimate design cohort synthesis Outcome match exact Outcome measured Early-onset atopic dermatitis in offspring after antibiotics in pregnancy |
The estimate measures: Early-onset atopic dermatitis in offspring after antibiotics in pregnancy. measured_outcome
High blood pressure → Venous thromboembolism
high_sbp|vte
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure HR Estimate source cvrf_vte_ipd Estimate design pooled IPD Outcome match exact Outcome measured Incident venous thromboembolism (hazard ratio) at systolic pressure 160 vs 110 mmHg Conflict Side A: In nine pooled cohorts, higher systolic pressure went with less venous thromboembolism (0.79, 0.68 to 0.92 at 16…Side A: In nine pooled cohorts, higher systolic pressure went with less venous thromboembolism (0.79, 0.68 to 0.92 at 160 against 110 mmHg). Side B: Hypertension as a category showed no association in the same analysis (0.98, 0.89 to 1.07), and the authors could not explain the inverse trend. Sources: cvrf_vte_ipd |
The estimate measures: Incident venous thromboembolism (hazard ratio) at systolic pressure 160 vs 110 mmHg. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Type 2 diabetes (as a risk factor) → Venous thromboembolism
t2d_exposure|vte
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure HR Estimate source cvrf_vte_ipd Estimate design pooled IPD Outcome match exact Outcome measured Incident venous thromboembolism (hazard ratio) |
The estimate measures: Incident venous thromboembolism (hazard ratio). measured_outcome
Also changed in: 1.4 (9 Oct 2026)1.3 (9 Sep 2026)
Fine particulate air pollution → High blood pressure
pm25|hypertension
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source pm_cardiometabolic Estimate design cohort synthesis Outcome match exact Outcome measured Hypertension (relative risk per 10 micrograms per cubic metre) |
The estimate measures: Hypertension (relative risk per 10 micrograms per cubic metre). measured_outcome
Road traffic noise → High blood pressure
traffic_noise|hypertension
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source noise_htn_dzhambov Estimate design cohort synthesis Outcome match exact Outcome measured Hypertension (relative risk per 10 decibels), seven cohort and two case-control studies External grades GRADE low (noise_htn_dzhambov) |
The estimate measures: Hypertension (relative risk per 10 decibels), seven cohort and two case-control studies. measured_outcome
Also changed in: 1.3 (18 Sep 2026)1.3 (9 Sep 2026)
Heavy alcohol use → High blood pressure
alcohol_heavy|hypertension
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive (sources alcohol_bp_rct); Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source alcohol_htn_ma Estimate design cohort synthesis Outcome match exact Outcome measured Incident hypertension per 10 g a day of alcohol in cohort studies |
Outcome match, Outcome measured: The estimate measures: Incident hypertension per 10 g a day of alcohol in cohort studies. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: alcohol_htn_ma (weight 1.0). reviews_counted
Long-term opioid painkillers → Fracture in adults
opioids|fracture
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Effective reviews (N_eff) | 1 | 1.44 |
| Score (ESS) | 12.1 | 10.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source opioid_hip_fracture Estimate design cohort synthesis Outcome match narrower Outcome measured Hip fracture Grade basis Suggestive: Confounding by indication. Rules T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Hip fracture. measured_outcome
Grade: Suggestive: Confounding by indication. Rules T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match narrower, measured outcome recorded (cards O1 and O5). estimate_source opioid_hip_fracture, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Confounding by indication. grade_basisT7T8a
Grade basis: Suggestive: Confounding by indication. Rules T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7T8a
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: opioid_hip_fracture (weight 1.0), opioid_falls_ma (weight 0.44). reviews_counted
Long-term oral steroids → Fracture in adults
oral_corticosteroids|fracture
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source gc_fracture_devries Estimate design case-control Outcome match narrower Outcome measured Hip or femur fracture (odds ratio) Grade override Moderate. Accepted by the verifier: a nested case-control study adjusted for disease severity, a pooled analysis of seve…Moderate. Accepted by the verifier: a nested case-control study adjusted for disease severity, a pooled analysis of seven cohorts and a strong mechanism. T5b proposes Suggestive because the displayed estimate is case-control. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. |
Outcome match, Outcome measured: The estimate measures: Hip or femur fracture (odds ratio). measured_outcome
Grade override: Curator override to Moderate: Accepted by the verifier: a nested case-control study adjusted for disease severity, a pooled analysis of seven cohorts and a strong mechanism. T5b proposes Suggestive because the displayed estimate is case-control. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT5b
Reviews counted: Counted from the cited syntheses under the review-counting rule: gc_fracture_kanis (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Irregular sleep timing → Coronary heart disease
irregular_sleep|chd
| Field | Before | After |
| Grade | Suggestive | Weak |
| Reviews counted | 2 | 0 |
| Score (ESS) | 11.3 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source sleep_irregularity_mesa Estimate design single cohort Outcome match broader Outcome measured Any cardiovascular event Related outcome true Grade basis Weak: One cohort, 111 events. Rule T5c (ceiling Weak). Verified on 21 October 2026 (card G3). Rests on primary studies true |
Outcome match, Outcome measured, Related outcome: The estimate measures: Any cardiovascular event. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Weak: One cohort, 111 events. Rule T5c (ceiling Weak). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source sleep_irregularity_mesa, estimate_design single cohort, measure HR, by rule E1 (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): One cohort, 111 events. grade_basisT5c
Grade basis: Weak: One cohort, 111 events. Rule T5c (ceiling Weak). Verified on 21 October 2026 (card G3). grade_basisT5c
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Car-dependent neighbourhood → Type 2 diabetes
low_walkability|t2d
| Field | Before | After |
| Grade | Suggestive | Weak |
| Reviews counted | 2 | 1 |
| Score (ESS) | 5.5 | 3.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source walkability_t2d Estimate design mixed Outcome match exact Outcome measured Type 2 diabetes risk or prevalence (odds ratio), mostly cross-sectional Grade basis Weak: I-squared 92%; mostly cross-sectional; self-selection. Rule T10 (ceiling Weak). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Type 2 diabetes risk or prevalence (odds ratio), mostly cross-sectional. measured_outcome
Grade: Weak: I-squared 92%; mostly cross-sectional; self-selection. Rule T10 (ceiling Weak). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source walkability_t2d, estimate_design mixed, measure OR, by rule E1 (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): I-squared 92%; mostly cross-sectional; self-selection. grade_basisT10
Grade basis: Weak: I-squared 92%; mostly cross-sectional; self-selection. Rule T10 (ceiling Weak). Verified on 21 October 2026 (card G3). grade_basisT10
Reviews counted: Counted from the cited syntheses under the review-counting rule: walkability_t2d (weight 1.0). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Having been born preterm → Chronic kidney disease
preterm_birth|ckd
| Field | Before | After |
| Reviews counted | 1 | 0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source preterm_ckd_crump Estimate design single cohort Outcome match exact Outcome measured Incident chronic kidney disease (hazard ratio) in a national birth cohort Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: Incident chronic kidney disease (hazard ratio) in a national birth cohort. measured_outcome
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Having been born preterm → Type 2 diabetes
preterm_birth|t2d
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source preterm_t2d_li Estimate design cohort synthesis Outcome match exact Outcome measured Type 2 diabetes (odds ratio) Grade basis Kept at Suggestive by the verified dry run: Five studies with I2 0 plus a national cohort with sibling analysis agree; t…Kept at Suggestive by the verified dry run: Five studies with I2 0 plus a national cohort with sibling analysis agree; this is not sparse in the Weak sense. |
Outcome match, Outcome measured: The estimate measures: Type 2 diabetes (odds ratio). measured_outcome
Grade basis: Kept at Suggestive by the verified dry run: Five studies with I2 0 plus a national cohort with sibling analysis agree; this is not sparse in the Weak sense. grade_basis
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Phthalate plasticisers → Eczema (atopic dermatitis)
phthalates|atopic_dermatitis
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.17 |
| Score (ESS) | 2.4 | 2.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source phthalate_allergy_ma Estimate design cohort synthesis Outcome match exact Outcome measured Childhood eczema after prenatal phthalate exposure (relative risk) |
Outcome match, Outcome measured: The estimate measures: Childhood eczema after prenatal phthalate exposure (relative risk). measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: plastics_umbrella (weight 1.0), phthalate_allergy_ma (weight 0.17). reviews_counted
Phthalate plasticisers → Asthma (adult)
phthalates|asthma
| Field | Before | After |
| Grade | Suggestive | Weak |
| Effective reviews (N_eff) | 1 | 1.17 |
| Score (ESS) | 2.6 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source phthalate_allergy_ma Estimate design cohort synthesis Outcome match proxy Outcome measured Childhood wheeze Related outcome true Grade basis Weak: the pooled risk ratio for childhood wheeze is 1.10 with a lower bound printed as 1.00. Only the abstract is open (…Weak: the pooled risk ratio for childhood wheeze is 1.10 with a lower bound printed as 1.00. Only the abstract is open (PubMed Central holds no full text yet), so the unrounded bound could not be confirmed and the approved change (card G3) stands at the table's medium confidence (T1). The outcome is childhood wheeze (related-outcome layer). For the owner: confirm the bound from the full text. |
Outcome match, Outcome measured, Related outcome: The estimate measures: Childhood wheeze. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Weak: the pooled risk ratio for childhood wheeze is 1.10 with a lower bound printed as 1.00. Only the abstract is open (PubMed Central holds no full text yet), so the unrounded bound could not be confirmed and the approved change (card G3) stands at the table's medium confidence (T1). The outcome is childhood wheeze (related-outcome layer). For the owner: confirm the bound from the full text. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match proxy, measured outcome recorded (cards O1 and O5). estimate_source phthalate_allergy_ma, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): Lower bound 1.00; the outcome is childhood wheeze (confirm the unrounded bound). Curator record: 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Grade stays Weak (blocker 7); grade_basis rewritten: Weak: the pooled risk ratio for childhood wheeze is 1.10 with a lower bound printed as 1.00. Only the abstract is open (PubMed Central holds no full text yet), so the unrounded bound could not be confirmed and the approved change (card G3) stands at the table's medium confidence (T1). The outcome is childhood wheeze (related-outcome layer). For the owner: confirm the bound from the full text. grade_basisT1
Grade basis: Weak: the pooled risk ratio for childhood wheeze is 1.10 with a lower bound printed as 1.00. Only the abstract is open (PubMed Central holds no full text yet), so the unrounded bound could not be confirmed and the approved change (card G3) stands at the table's medium confidence (T1). The outcome is childhood wheeze (related-outcome layer). For the owner: confirm the bound from the full text. grade_basisT1
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: plastics_umbrella (weight 1.0), phthalate_allergy_ma (weight 0.17). reviews_counted
Also changed in: 1.3 (18 Sep 2026)1.3 (9 Sep 2026)
PFAS 'forever chemicals' → High blood pressure
pfas|hypertension
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| Caveat | Fourteen studies of 71,663 people, most of them cross-sectional, so blood levels and blood pressure were often measured…Fourteen studies of 71,663 people, most of them cross-sectional, so blood levels and blood pressure were often measured at the same moment. A separate review of 129 studies found consistent associations with diabetes in pregnancy but inconsistent or null associations with type 2 diabetes. | Fourteen studies of 71,663 people, most of them cross-sectional, so blood levels and blood pressure were often measured at the same moment. |
| Sources | pfas_hypertension pfas_diabetes_markers | pfas_hypertension |
| New fields | not recorded before | Measure OR Estimate source pfas_hypertension Estimate design mixed Outcome match exact Outcome measured Hypertension (odds ratio), 14 studies, mostly cross-sectional |
Outcome match, Outcome measured: The estimate measures: Hypertension (odds ratio), 14 studies, mostly cross-sectional. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: pfas_hypertension (weight 1.0). reviews_counted
Caveat: 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source pfas_diabetes_markers removed from the link's sources (issue 2, card K7 A topic check, PROPOSAL section 5.1): it is a meta-analysis of glycaemic markers and diabetes, another outcome, so it does not replicate this pair and must not count in the replication term. caveat: the sentence about diabetes, which came from the removed source and concerns another outcome, is dropped (issue 2). caveat_zh: the same sentence dropped. corrections.json _why
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source pfas_hypertension, estimate_design mixed, measure OR, by rule E1 (cards G8, K5, P2) 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source pfas_diabetes_markers removed from the link's sources (issue 2, card K7 A topic check, PROPOSAL section 5.1): it is a meta-analysis of glycaemic markers and diabetes, another outcome, so it does not replicate this pair and must not count in the replication term. caveat: the sentence about diabetes, which came from the removed source and concerns another outcome, is dropped (issue 2). caveat_zh: the same sentence dropped. corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Ultra-processed food → Asthma (adult)
upf|asthma
| Field | Before | After |
| Score (ESS) | 7.1 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source upf_umbrella_bmj Estimate design cohort synthesis Outcome match proxy Outcome measured Wheezing Related outcome true External grades GRADE low (upf_umbrella_bmj) |
The estimate measures: Wheezing. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
High body-mass index → Venous thromboembolism
high_bmi|vte
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.44 |
| Score (ESS) | 12.9 | 16.8 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) supportive (sources larsson2020_bmi_cvd_mr lindstrom2017_bmi_vte_mr); dose-response yes |
| Sources | bmi_vte_dr cvrf_vte_ipd | bmi_vte_dr cvrf_vte_ipd larsson2020_bmi_cvd_mr lindstrom2017_bmi_vte_mr |
| New fields | not recorded before | Measure HR Estimate source bmi_vte_dr Estimate design cohort synthesis Outcome match exact Outcome measured Incident venous thromboembolism (hazard ratio) in obese vs normal-weight people Grade basis Kept at Moderate by the verified dry run: I2 95% reflects spread in size while the direction is the same everywhere: the…Kept at Moderate by the verified dry run: I2 95% reflects spread in size while the direction is the same everywhere: the gradient rises steadily, the pulmonary embolism estimate is consistent with no heterogeneity, and MR evidence (unrecorded) supports. I2 alone should not set Weak. |
Outcome match, Outcome measured: The estimate measures: Incident venous thromboembolism (hazard ratio) in obese vs normal-weight people. measured_outcome
Grade basis: Kept at Moderate by the verified dry run: I2 95% reflects spread in size while the direction is the same everywhere: the gradient rises steadily, the pulmonary embolism estimate is consistent with no heterogeneity, and MR evidence (unrecorded) supports. I2 alone should not set Weak. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: cvrf_vte_ipd (weight 1.0), bmi_vte_dr (weight 0.44). reviews_counted
Trial and genetic evidence, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G11): larsson2020_bmi_cvd_mr, lindstrom2017_bmi_vte_mr; the displayed estimate is unchanged. estimate_source bmi_vte_dr, estimate_design cohort synthesis, measure HR, by rule E1 (cards G8, K5, P2). triangulation.mr supportive recorded with its sources (card G11, research pass): Two independent Mendelian randomisation analyses support an effect: the INVENT consortium (7,507 cases; OR 1.59 per standard deviation of BMI) and UK Biobank (deep vein thrombosis and pulmonary embolism). Grade stays Moderate (card G3: kept by the verifier). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Coffee consumption → Gallstones
coffee|gallstones
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source coffee_gallstone Estimate design cohort synthesis Outcome match exact Outcome measured Gallstone disease (relative risk) in prospective studies Grade basis Moderate: prospective studies with a gradient; only the reverse-causation watch list points lower. Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: Gallstone disease (relative risk) in prospective studies. measured_outcome
Grade basis: Moderate: prospective studies with a gradient; only the reverse-causation watch list points lower. Kept by the verifier. grade_basis
Current cigarette smoking → Diverticular disease
smoking|diverticular_disease
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 2 | 3 |
| Effective reviews (N_eff) | 1 | 1.78 |
| Score (ESS) | 9.7 | 10.0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | smoke_diverticular lifestyle_diverticulitis | smoke_diverticular lifestyle_diverticulitis wijarnpreecha2018_smoking_diverticulosis chitneni2026_smoking_diverticulosis |
| New fields | not recorded before | Measure RR Estimate source smoke_diverticular Estimate design cohort synthesis Outcome match exact Outcome measured Incident diverticular disease Grade basis Displayed review: five prospective studies, four for current smokers, I-squared 84%; T9a would give Weak. Current > form…Displayed review: five prospective studies, four for current smokers, I-squared 84%; T9a would give Weak. Current > former > never gradient and a dose-dependent trend argue for Suggestive. Two later syntheses exist but do not add independent support: Wijarnpreecha 2018 re-pools three prospective cohorts (diverticulosis, RR 1.46, 1.13-1.89) and Chitneni 2026 (62 studies, OR 1.36) mixes designs. Suggestive. Studies 4 I-squared 84 |
Outcome match, Outcome measured: The estimate measures: Incident diverticular disease. measured_outcome
Grade: Displayed review: five prospective studies, four for current smokers, I-squared 84%; T9a would give Weak. Current > former > never gradient and a dose-dependent trend argue for Suggestive. Two later syntheses exist but do not add independent support: Wijarnpreecha 2018 re-pools three prospective cohorts (diverticulosis, RR 1.46, 1.13-1.89) and Chitneni 2026 (62 studies, OR 1.36) mixes designs. Suggestive. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): wijarnpreecha2018_smoking_diverticulosis, chitneni2026_smoking_diverticulosis; the displayed estimate is unchanged. estimate_source smoke_diverticular, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). n_studies and i2 from the displayed review (card G12, research pass; PubMed 28556447). Grade Moderate to Suggestive (card G12, settled by the research pass). grade_basisT9a
Grade basis: Displayed review: five prospective studies, four for current smokers, I-squared 84%; T9a would give Weak. Current > former > never gradient and a dose-dependent trend argue for Suggestive. Two later syntheses exist but do not add independent support: Wijarnpreecha 2018 re-pools three prospective cohorts (diverticulosis, RR 1.46, 1.13-1.89) and Chitneni 2026 (62 studies, OR 1.36) mixes designs. Suggestive. grade_basisT9a
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoke_diverticular (weight 1.0), wijarnpreecha2018_smoking_diverticulosis (weight 0.17), chitneni2026_smoking_diverticulosis (weight 0.62). reviews_counted
Studies, I-squared, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): wijarnpreecha2018_smoking_diverticulosis, chitneni2026_smoking_diverticulosis; the displayed estimate is unchanged. estimate_source smoke_diverticular, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). n_studies and i2 from the displayed review (card G12, research pass; PubMed 28556447). Grade Moderate to Suggestive (card G12, settled by the research pass). corrections.json _why
Current cigarette smoking → Gum disease (periodontitis)
smoking|periodontitis_disease
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.17 |
| Score (ESS) | 14.8 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source smoke_perio_leite Estimate design cohort synthesis Outcome match broader Outcome measured Incidence or progression of periodontitis Related outcome true Grade basis Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure…Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure and outcome, and no adjudicating body that rated this pair. |
Outcome match, Outcome measured, Related outcome: The estimate measures: Incidence or progression of periodontitis. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade basis: Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure and outcome, and no adjudicating body that rated this pair. grade_basisT3
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoke_perio_leite (weight 1.0), quit_perio_leite (weight 0.17). reviews_counted
Former smoking → Gum disease (periodontitis)
former_smoking|periodontitis_disease
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.17 |
| Score (ESS) | 0.5 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source quit_perio_leite Estimate design cohort synthesis Outcome match broader Outcome measured Incidence or progression of periodontitis Related outcome true |
Outcome match, Outcome measured, Related outcome: The estimate measures: Incidence or progression of periodontitis. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoke_perio_leite (weight 1.0), quit_perio_leite (weight 0.17). reviews_counted
Also changed in: 1.3 (9 Sep 2026)
Adverse childhood experiences → Schizophrenia
aces|schizophrenia
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Effective reviews (N_eff) | 1 | 1.62 |
| Score (ESS) | 12.0 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source parental_sep_psychosis Estimate design cohort synthesis Outcome match broader Outcome measured Psychosis (any psychotic disorder) Related outcome true Grade basis Suggestive: Parental separation only; psychosis; recall after illness. Rule T7 (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured, Related outcome: The estimate measures: Psychosis (any psychotic disorder). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Suggestive: Parental separation only; psychosis; recall after illness. Rule T7 (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source parental_sep_psychosis, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Parental separation only; psychosis; recall after illness. grade_basisT7
Grade basis: Suggestive: Parental separation only; psychosis; recall after illness. Rule T7 (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: aces_schizophrenia_ma (weight 1.0), parental_sep_psychosis (weight 0.62). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Low cardiorespiratory fitness → Anxiety disorders
low_fitness|anxiety_disorders
| Field | Before | After |
| Score (ESS) | 4.2 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source crf_mental_kandola Estimate design cohort synthesis Outcome match broader Outcome measured Depression or anxiety disorder pooled together (common mental disorders) Related outcome true |
The estimate measures: Depression or anxiety disorder pooled together (common mental disorders). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Type 2 diabetes (as a risk factor) → Gum disease (periodontitis)
t2d_exposure|periodontitis_disease
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.62 |
| Score (ESS) | 14.9 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source perio_diabetes_nascimento Estimate design cohort synthesis Outcome match broader Outcome measured Incidence or progression of periodontitis Related outcome true Grade override Moderate. Kept by the verifier: diabetes is a recognised grade modifier of periodontitis with a gradient by blood sugar…Moderate. Kept by the verifier: diabetes is a recognised grade modifier of periodontitis with a gradient by blood sugar control. T7 and T8a propose Suggestive because the gradient and the mechanism are not recorded as fields. |
Outcome match, Outcome measured, Related outcome: The estimate measures: Incidence or progression of periodontitis. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade override: Curator override to Moderate: Kept by the verifier: diabetes is a recognised grade modifier of periodontitis with a gradient by blood sugar control. T7 and T8a propose Suggestive because the gradient and the mechanism are not recorded as fields. grade_overrideT7T8a
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: perio_diabetes_nascimento (weight 1.0), oral_diabetes_lancet (weight 0.62). reviews_counted
Also changed in: 1.3 (18 Sep 2026)
Current cigarette smoking → Erectile dysfunction
smoking|erectile_dysfunction
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | smoke_ed_cao diabetes_ed_kouidrat | smoke_ed_cao |
| New fields | not recorded before | Measure OR Estimate source smoke_ed_cao Estimate design cohort synthesis Outcome match exact Outcome measured Erectile dysfunction (odds ratio) in prospective cohort studies Grade override Moderate. Rule T9a proposes Weak: the displayed estimate pools four prospective cohorts (Cao 2013), five or fewer studie…Moderate. Rule T9a proposes Weak: the displayed estimate pools four prospective cohorts (Cao 2013), five or fewer studies. The four cohorts agree, the interval is well clear of 1 (1.51, 1.34 to 1.71) and no publication bias was found. New disagreement for the owner (card G3 A), raised once the off-topic diabetes synthesis stopped counting as a second group: kept at the verified grade until the owner decides. Studies 4 |
Outcome match, Outcome measured: The estimate measures: Erectile dysfunction (odds ratio) in prospective cohort studies. measured_outcome
Grade override: Curator override to Moderate: Rule T9a proposes Weak: the displayed estimate pools four prospective cohorts (Cao 2013), five or fewer studies. The four cohorts agree, the interval is well clear of 1 (1.51, 1.34 to 1.71) and no publication bias was found. New disagreement for the owner (card G3 A), raised once the off-topic diabetes synthesis stopped counting as a second group: kept at the verified grade until the owner decides. grade_overrideT9a
Reviews counted: Counted from the cited syntheses under the review-counting rule: smoke_ed_cao (weight 1.0). reviews_counted
Studies, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source smoke_ed_cao, estimate_design cohort synthesis, measure OR, by rule E1 (read by hand) (cards G8, K5, P2) 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source diabetes_ed_kouidrat removed from the link's sources (issue 2, card K7 A topic check, PROPOSAL section 5.1): it is a meta-analysis of erectile dysfunction in people with diabetes, another exposure, so it does not replicate this pair and must not count in the replication term. n_studies 4 recorded from the abstract (PubMed 23573257: the displayed odds ratio pools the four prospective cohort studies). grade_override keeps Moderate (issue 2): Rule T9a proposes Weak: the displayed estimate pools four prospective cohorts (Cao 2013), five or fewer studies. The four cohorts agree, the interval is well clear of 1 (1.51, 1.34 to 1.71) and no publication bias was found. New disagreement for the owner (card G3 A), raised once the off-topic diabetes synthesis stopped counting as a second group: kept at the verified grade until the owner decides. corrections.json _whyT9a
Former smoking → Erectile dysfunction
former_smoking|erectile_dysfunction
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source smoke_ed_cao Estimate design cohort synthesis Outcome match exact Outcome measured Erectile dysfunction (odds ratio) in prospective cohort studies |
The estimate measures: Erectile dysfunction (odds ratio) in prospective cohort studies. measured_outcome
Type 2 diabetes (as a risk factor) → Erectile dysfunction
t2d_exposure|erectile_dysfunction
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source diabetes_ed_kouidrat Estimate design cross-sectional Outcome match exact Outcome measured Prevalence of erectile dysfunction (odds ratio) in men with and without diabetes |
The estimate measures: Prevalence of erectile dysfunction (odds ratio) in men with and without diabetes. measured_outcome
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
DASH eating pattern → Coronary heart disease
dash_diet|chd
| Field | Before | After |
| Effective reviews (N_eff) | 1 | 1.55 |
| Score (ESS) | 7.0 | 9.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source dash_cad_yang Estimate design cohort synthesis Outcome match exact Outcome measured Coronary artery disease risk in seven prospective cohorts Grade basis Moderate: seven cohorts, with blood pressure trials behind the route; residual confounding is acknowledged. Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: Coronary artery disease risk in seven prospective cohorts. measured_outcome
Grade basis: Moderate: seven cohorts, with blood pressure trials behind the route; residual confounding is acknowledged. Kept by the verifier. grade_basis
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: dash_cvd_meta (weight 1.0), dash_cad_yang (weight 0.55). reviews_counted
Also changed in: 1.4 (19 Sep 2026)
DASH eating pattern → Dementia (all-cause)
dash_diet|dementia
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure HR Estimate source wang_diet_dementia_2026 Estimate design cohort synthesis Outcome match exact Outcome measured Incident all-cause dementia (hazard ratio) |
The estimate measures: Incident all-cause dementia (hazard ratio). measured_outcome
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Plant-based eating pattern → Coronary heart disease
plant_based_diet|chd
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | pdi_cvd_gan pdi_t2d_pooled | pdi_cvd_gan |
| New fields | not recorded before | Measure RR Estimate source pdi_cvd_gan Estimate design cohort synthesis Outcome match exact Outcome measured Coronary heart disease risk Grade override Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. N…Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. |
Outcome match, Outcome measured: The estimate measures: Coronary heart disease risk. measured_outcome
Grade override: Curator override to Moderate: T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT8c
Reviews counted: Counted from the cited syntheses under the review-counting rule: pdi_cvd_gan (weight 1.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source pdi_cvd_gan, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). grade_override keeps Moderate: T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone: New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source pdi_t2d_pooled removed from the link's sources (issue 2, card K7 A topic check, PROPOSAL section 5.1): it is a pooled analysis of plant-based diet scores and type 2 diabetes, another outcome, so it does not replicate this pair and must not count in the replication term. corrections.json _whyT8c
Plant-based eating pattern → Ischaemic stroke
plant_based_diet|stroke_isch
| Field | Before | After |
| Score (ESS) | 2.0 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source pdi_cvd_gan Estimate design cohort synthesis Outcome match broader Outcome measured Stroke of any type Related outcome true |
The estimate measures: Stroke of any type. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Also changed in: 1.3 (18 Sep 2026)1.3 (9 Sep 2026)
Long working hours → Type 2 diabetes
long_hours|t2d
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| Sources | longhours_outcomewide longhours_cvd | longhours_outcomewide |
| New fields | not recorded before | Measure HR Estimate source longhours_outcomewide Estimate design pooled IPD Outcome match exact Outcome measured Diabetes of any type (hospital or drug-reimbursement records) |
Outcome match, Outcome measured: The estimate measures: Diabetes of any type (hospital or drug-reimbursement records). measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: longhours_outcomewide (weight 1.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source longhours_outcomewide, estimate_design pooled IPD, measure HR, by rule E1 (cards G8, K5, P2) 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): Source longhours_cvd removed from the link's sources (issue 2, card K7 A topic check, PROPOSAL section 5.1): it is a synthesis of coronary heart disease and stroke, other outcomes, so it does not replicate this pair and must not count in the replication term. corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
E-cigarette use → Asthma (adult)
ecigs|asthma
| Field | Before | After |
| Reviews counted | 2 | 1 |
| Score (ESS) | 3.0 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source ecig_asthma_ma Estimate design cross-sectional Outcome match broader Outcome measured Asthma at any age, in surveys of mostly adolescents and young adults (all cross-sectional) Related outcome true Conflict Side A: Cross-sectional studies find more asthma in current e-cigarette users (1.36, 1.21 to 1.52). Side B: Reviews of s…Side A: Cross-sectional studies find more asthma in current e-cigarette users (1.36, 1.21 to 1.52). Side B: Reviews of smokers who switch to e-cigarettes report better respiratory measures. Sources: ecig_asthma_ma ecig_switch_review |
Outcome match, Outcome measured, Related outcome: The estimate measures: Asthma at any age, in surveys of mostly adolescents and young adults (all cross-sectional). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Reviews counted: Counted from the cited syntheses under the review-counting rule: ecig_asthma_ma (weight 1.0). reviews_counted
Antidepressant (SSRI) use → Peptic ulcer
ssri|peptic_ulcer
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Effective reviews (N_eff) | 1 | 1.62 |
| Score (ESS) | 14.1 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source ssri_nsaid_gib Estimate design cohort synthesis Outcome match proxy Outcome measured Upper gastrointestinal bleeding in NSAID users taking an SSRI Related outcome true Grade basis Suggestive: The estimate is GI bleeding in NSAID users. Rules T7, T8c (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured, Related outcome: The estimate measures: Upper gastrointestinal bleeding in NSAID users taking an SSRI. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Suggestive: The estimate is GI bleeding in NSAID users. Rules T7, T8c (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match proxy, measured outcome recorded (cards O1 and O5). estimate_source ssri_nsaid_gib, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): The estimate is GI bleeding in NSAID users. grade_basisT7T8c
Grade basis: Suggestive: The estimate is GI bleeding in NSAID users. Rules T7, T8c (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7T8c
Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: ssri_nsaid_oka (weight 1.0), ssri_nsaid_gib (weight 0.62). reviews_counted
Also changed in: 1.4 (9 Oct 2026)
High body-mass index → High blood pressure
high_bmi|hypertension
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources larsson2020_bmi_cvd_mr); dose-response yes |
| Sources | adiposity_cvd_umbrella | adiposity_cvd_umbrella larsson2020_bmi_cvd_mr |
| New fields | not recorded before | Measure RR Estimate source adiposity_cvd_umbrella Estimate design cohort synthesis Outcome match exact Outcome measured Hypertension (relative risk per 5 kg/m2) External grades GRADE high (adiposity_cvd_umbrella) |
Outcome match, Outcome measured: The estimate measures: Hypertension (relative risk per 5 kg/m2). measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source adiposity_cvd_umbrella, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). external_grades transcribed from the caveat, the review note or the quote (rule T11) 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): triangulation.mr supportive with its sources recorded (larsson2020_bmi_cvd_mr) (card G11, blocker 4): Genetically predicted BMI raises arterial hypertension in UK Biobank (Larsson 2020). corrections.json _whyT11
Coffee consumption → Coronary heart disease
coffee|chd
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 4.2 | 2.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source coffee_umbrella_poole Estimate design cohort synthesis Outcome match exact Outcome measured Incident coronary heart disease Grade basis Suggestive: Best point of a curved relation; authors ask for trials. Rules T8a, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Incident coronary heart disease. measured_outcome
Grade: Suggestive: Best point of a curved relation; authors ask for trials. Rules T8a, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source coffee_umbrella_poole, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Best point of a curved relation; authors ask for trials. grade_basisT8aT9b
Grade basis: Suggestive: Best point of a curved relation; authors ask for trials. Rules T8a, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT8aT9b
Also changed in: 1.4 (21 Oct 2026)
Tight blood sugar control → Coronary heart disease
glucose_control|chd
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response no | Trial supportive (sources glucose_intensive_kunutsor); Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure HR Estimate source glucose_intensive_kunutsor Estimate design trial synthesis Outcome match narrower Outcome measured Non-fatal myocardial infarction |
The estimate measures: Non-fatal myocardial infarction. measured_outcome
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Tight blood sugar control → Peripheral artery disease
glucose_control|pad
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response no | Trial supportive (sources glucose_intensive_kunutsor); Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure HR Estimate source glucose_intensive_kunutsor Estimate design trial synthesis Outcome match exact Outcome measured Peripheral vascular disease events in type 2 diabetes (hazard ratio) |
The estimate measures: Peripheral vascular disease events in type 2 diabetes (hazard ratio). measured_outcome
Also changed in: 1.4 (9 Oct 2026)1.4 (19 Sep 2026)
Racism and discrimination → Type 2 diabetes
racism_discrimination|t2d
| Field | Before | After |
| Grade | Suggestive | Weak |
| Reviews counted | 1 | 0 |
| Score (ESS) | 6.1 | 3.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure HR Estimate source racism_t2d_bwhs Estimate design single cohort Outcome match exact Outcome measured Incident type 2 diabetes in Black women Grade basis Weak: One cohort; half the effect runs through BMI. Rule T5c (ceiling Weak). Verified on 21 October 2026 (card G3). Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: Incident type 2 diabetes in Black women. measured_outcome
Grade: Weak: One cohort; half the effect runs through BMI. Rule T5c (ceiling Weak). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source racism_t2d_bwhs, estimate_design single cohort, measure HR, by rule E1 (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): One cohort; half the effect runs through BMI. grade_basisT5c
Grade basis: Weak: One cohort; half the effect runs through BMI. Rule T5c (ceiling Weak). Verified on 21 October 2026 (card G3). grade_basisT5c
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Also changed in: 1.4 (9 Oct 2026)
Racism and discrimination → Obesity
racism_discrimination|obesity
| Field | Before | After |
| Grade | Suggestive | Weak |
| Reviews counted | 1 | 0 |
| Score (ESS) | 9.3 | 5.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure rate ratio Estimate source racism_obesity_bwhs Estimate design single cohort Outcome match exact Outcome measured Incident obesity in Black women (incidence rate ratio) Grade basis Weak: One cohort; self-reported exposure. Rule T5c (ceiling Weak). Verified on 21 October 2026 (card G3). Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: Incident obesity in Black women (incidence rate ratio). measured_outcome
Grade: Weak: One cohort; self-reported exposure. Rule T5c (ceiling Weak). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source racism_obesity_bwhs, estimate_design single cohort, measure rate ratio, by rule E1 (read by hand) (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): One cohort; self-reported exposure. grade_basisT5c
Grade basis: Weak: One cohort; self-reported exposure. Rule T5c (ceiling Weak). Verified on 21 October 2026 (card G3). grade_basisT5c
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Racism and discrimination → Schizophrenia
racism_discrimination|schizophrenia
| Field | Before | After |
| Score (ESS) | 9.8 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source ped_psychosis_meta Estimate design mixed Outcome match proxy Outcome measured Psychotic symptoms and experiences in surveys of ethnic minority groups Related outcome true |
The estimate measures: Psychotic symptoms and experiences in surveys of ethnic minority groups. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Intensive unpaid caregiving → Coronary heart disease
caregiving_burden|chd
| Field | Before | After |
| Reviews counted | 1 | 0 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source caregiving_chd_nhs Estimate design single cohort Outcome match exact Outcome measured Incident coronary heart disease Rests on primary studies true Conflict Side A: The Nurses' Health Study found more coronary heart disease in women giving nine or more hours a week of care to…Side A: The Nurses' Health Study found more coronary heart disease in women giving nine or more hours a week of care to an ill spouse (1.82, 1.08 to 3.05). Side B: Whitehall II found no excess risk in caregivers as a whole (1.18, 0.96 to 1.45), and a raised risk only in caregivers who already reported poor health. Sources: caregiving_chd_nhs caregiving_chd_whitehall |
Outcome match, Outcome measured: The estimate measures: Incident coronary heart disease. measured_outcome
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Skipping breakfast → Obesity
skipping_breakfast|obesity
| Field | Before | After |
| Score (ESS) | 3.4 | empty |
| Trial and genetic evidence | Trial conflicting; Genetic (MR) none; dose-response no | Trial conflicting (sources breakfast_rct_meta); Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source breakfast_obesity_meta Estimate design cohort synthesis Outcome match broader Outcome measured Overweight or obesity (relative risk) in cohort studies Related outcome true Conflict Side A: Across 45 observational studies, people who skip breakfast carry more weight (1.44, 1.25 to 1.66). Side B: Seven…Side A: Across 45 observational studies, people who skip breakfast carry more weight (1.44, 1.25 to 1.66). Side B: Seven randomised trials found that skipping breakfast for about nine weeks gave slightly lower body weight (-0.54 kg, -1.05 to -0.03). Sources: breakfast_obesity_meta breakfast_rct_meta |
The estimate measures: Overweight or obesity (relative risk) in cohort studies. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Job insecurity and unemployment → Depression
job_insecurity|depression
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 8.5 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source jobinsec_depression_meta Estimate design cohort synthesis Outcome match proxy Outcome measured Depressive symptoms on a questionnaire Related outcome true Grade basis Suggestive: Symptom scores; effect largest in unadjusted models. Rules T7, T8c, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured, Related outcome: The estimate measures: Depressive symptoms on a questionnaire. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Suggestive: Symptom scores; effect largest in unadjusted models. Rules T7, T8c, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match proxy, measured outcome recorded (cards O1 and O5). estimate_source jobinsec_depression_meta, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Symptom scores; effect largest in unadjusted models. grade_basisT7T8cT9b
Grade basis: Suggestive: Symptom scores; effect largest in unadjusted models. Rules T7, T8c, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7T8cT9b
Also changed in: 1.4 (9 Oct 2026)
Added sugar in food → Fatty liver disease (MASLD)
added_sugar|masld
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source addedfructose_nafld_meta Estimate design mixed Outcome match exact Outcome measured Prevalence of fatty liver (odds ratio), mostly cross-sectional |
The estimate measures: Prevalence of fatty liver (odds ratio), mostly cross-sectional. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
High body-mass index → Erectile dysfunction
high_bmi|erectile_dysfunction
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 11.1 | 7.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source bmi_ed_meta Estimate design mixed Outcome match exact Outcome measured Presence of erectile dysfunction (odds ratio), mostly cross-sectional surveys Grade basis Suggestive: Mostly cross-sectional surveys, I-squared 72%. Rules T5b, T8d (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Presence of erectile dysfunction (odds ratio), mostly cross-sectional surveys. measured_outcome
Grade: Suggestive: Mostly cross-sectional surveys, I-squared 72%. Rules T5b, T8d (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source bmi_ed_meta, estimate_design mixed, measure OR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Mostly cross-sectional surveys, I-squared 72%. grade_basisT5bT8d
Grade basis: Suggestive: Mostly cross-sectional surveys, I-squared 72%. Rules T5b, T8d (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT5bT8d
Also changed in: 1.4 (9 Oct 2026)
Current cigarette smoking → Psoriasis
smoking|psoriasis
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 1 | 4 |
| Effective reviews (N_eff) | 1 | 2.09 |
| Score (ESS) | 14.3 | 16.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | smoking_psoriasis_meta | smoking_psoriasis_meta chen2026_smoking_psoriasis ye2026_smoking_psoriasis zhou2020_smoking_psoriasis |
| New fields | not recorded before | Measure OR Estimate source smoking_psoriasis_meta Estimate design cohort synthesis Outcome match exact Outcome measured Prevalent psoriasis (odds ratio) in 25 prevalence studies Grade basis T5a: the displayed OR comes from 25 prevalence studies. Prospective support agrees: three incidence studies with a possi…T5a: the displayed OR comes from 25 prevalence studies. Prospective support agrees: three incidence studies with a possible dose effect (Armstrong 2014), and newer syntheses with dose-response (Chen 2026: 30 observational studies, 1.67, 1.46-1.90; Ye 2026: current smokers OR 1.89; Zhou 2020: 1.63). T5a then gives Suggestive (amended), so Weak does not apply. Suggestive. |
Outcome match, Outcome measured: The estimate measures: Prevalent psoriasis (odds ratio) in 25 prevalence studies. measured_outcome
Grade: T5a: the displayed OR comes from 25 prevalence studies. Prospective support agrees: three incidence studies with a possible dose effect (Armstrong 2014), and newer syntheses with dose-response (Chen 2026: 30 observational studies, 1.67, 1.46-1.90; Ye 2026: current smokers OR 1.89; Zhou 2020: 1.63). T5a then gives Suggestive (amended), so Weak does not apply. Suggestive. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): chen2026_smoking_psoriasis, ye2026_smoking_psoriasis, zhou2020_smoking_psoriasis; the displayed estimate is unchanged. estimate_source smoking_psoriasis_meta, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). Grade Moderate to Suggestive (card G12, settled by the research pass). grade_basisT5a
Grade basis: T5a: the displayed OR comes from 25 prevalence studies. Prospective support agrees: three incidence studies with a possible dose effect (Armstrong 2014), and newer syntheses with dose-response (Chen 2026: 30 observational studies, 1.67, 1.46-1.90; Ye 2026: current smokers OR 1.89; Zhou 2020: 1.63). T5a then gives Suggestive (amended), so Weak does not apply. Suggestive. grade_basisT5a
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: smoking_psoriasis_meta (weight 1.0), zhou2020_smoking_psoriasis (weight 0.55), chen2026_smoking_psoriasis (weight 0.55), ye2026_smoking_psoriasis (weight 0.0). reviews_counted
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): chen2026_smoking_psoriasis, ye2026_smoking_psoriasis, zhou2020_smoking_psoriasis; the displayed estimate is unchanged. estimate_source smoking_psoriasis_meta, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2). Grade Moderate to Suggestive (card G12, settled by the research pass). corrections.json _why
Also changed in: 1.4 (9 Oct 2026)
Former smoking → Psoriasis
former_smoking|psoriasis
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source smoking_psoriasis_meta Estimate design cohort synthesis Outcome match exact Outcome measured Prevalent psoriasis (odds ratio) in prevalence studies |
The estimate measures: Prevalent psoriasis (odds ratio) in prevalence studies. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Long working hours → Depression
long_hours|depression
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 5.0 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source longhours_depression_ipd Estimate design pooled IPD Outcome match proxy Outcome measured Onset of depressive symptoms on a questionnaire Related outcome true Grade basis Suggestive: Symptom scores; strong regional heterogeneity. Rules T7, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured, Related outcome: The estimate measures: Onset of depressive symptoms on a questionnaire. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Suggestive: Symptom scores; strong regional heterogeneity. Rules T7, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match proxy, measured outcome recorded (cards O1 and O5). estimate_source longhours_depression_ipd, estimate_design pooled IPD, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Symptom scores; strong regional heterogeneity. grade_basisT7T9b
Grade basis: Suggestive: Symptom scores; strong regional heterogeneity. Rules T7, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7T9b
Egg consumption → Type 2 diabetes
eggs|t2d
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure HR Estimate source eggs_t2d_meta Estimate design cohort synthesis Outcome match exact Outcome measured Incident type 2 diabetes per 3 eggs a week in US cohorts Conflict Side A: Five US cohorts show higher diabetes risk with each extra three eggs a week (1.18, 1.13 to 1.24). Side B: Seven…Side A: Five US cohorts show higher diabetes risk with each extra three eggs a week (1.18, 1.13 to 1.24). Side B: Seven cohorts outside the US show no association (0.97, 0.90 to 1.05). Sources: eggs_t2d_meta |
The estimate measures: Incident type 2 diabetes per 3 eggs a week in US cohorts. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Insomnia → High blood pressure
insomnia|hypertension
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 6.8 | 4.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source insomnia_htn_meta Estimate design cohort synthesis Outcome match exact Outcome measured Incident hypertension in prospective cohorts Grade basis Suggestive: Self-reported insomnia; seen in Europe only. Rules T7, T8c (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Incident hypertension in prospective cohorts. measured_outcome
Grade: Suggestive: Self-reported insomnia; seen in Europe only. Rules T7, T8c (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source insomnia_htn_meta, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Self-reported insomnia; seen in Europe only. grade_basisT7T8c
Grade basis: Suggestive: Self-reported insomnia; seen in Europe only. Rules T7, T8c (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7T8c
E-cigarette use → Coronary heart disease
ecigs|chd
| Field | Before | After |
| Grade | Suggestive | Weak |
| Score (ESS) | 6.3 | 3.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure OR Estimate source ecig_mi_meta Estimate design cohort synthesis Outcome match narrower Outcome measured History of myocardial infarction in cross-sectional surveys Grade basis Weak: Four cross-sectional surveys; confounded by smoking. Rule T9a (ceiling Weak). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: History of myocardial infarction in cross-sectional surveys. measured_outcome
Grade: Weak: Four cross-sectional surveys; confounded by smoking. Rule T9a (ceiling Weak). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match narrower, measured outcome recorded (cards O1 and O5). estimate_source ecig_mi_meta, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): Four cross-sectional surveys; confounded by smoking. grade_basisT9a
Grade basis: Weak: Four cross-sectional surveys; confounded by smoking. Rule T9a (ceiling Weak). Verified on 21 October 2026 (card G3). grade_basisT9a
Also changed in: 1.4 (9 Oct 2026)
Menopausal hormone therapy → Venous thromboembolism
mht|vte
| Field | Before | After |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response no | Trial supportive (sources whi_cushman2004_vte); Genetic (MR) none; dose-response no |
| Sources | mht_vte_meta | mht_vte_meta whi_cushman2004_vte |
| New fields | not recorded before | Measure OR Estimate source mht_vte_meta Estimate design mixed Outcome match exact Outcome measured Venous thromboembolism (odds ratio) in oral hormone therapy users External grades review authors' rating low to moderate (mht_vte_meta) |
Outcome match, Outcome measured: The estimate measures: Venous thromboembolism (odds ratio) in oral hormone therapy users. measured_outcome
Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source mht_vte_meta, estimate_design mixed, measure OR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). external_grades transcribed from the caveat, the review note or the quote (rule T11) 23 Oct 2026 fix round 2 (verifier of the data step, second check, issues 1 to 7): triangulation.rct supportive with its sources recorded (whi_cushman2004_vte) (issue 7, card G11): The WHI oestrogen plus progestin trial found venous thrombosis doubled against placebo (hazard ratio 2.06, 1.57 to 2.70; Cushman 2004). The displayed estimate is the mixed meta-analysis of trials, cohorts and case-control studies. corrections.json _whyT11
Also changed in: 1.4 (9 Oct 2026)
Combined oral contraceptives → Venous thromboembolism
ocp|vte
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source ocp_vte_cochrane Estimate design cohort synthesis Outcome match exact Outcome measured Venous thrombosis (relative risk) in current pill users Grade basis Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure…Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure and outcome, and no adjudicating body that rated this pair; T4 rests on one observational synthesis with no second line of evidence (1 independent synthesis group; lines: obs). |
Outcome match, Outcome measured: The estimate measures: Venous thrombosis (relative risk) in current pill users. measured_outcome
Grade basis: Lowered from Strong to Moderate by the decision table (binding rule): T3 no supportive trial or MR on the same exposure and outcome, and no adjudicating body that rated this pair; T4 rests on one observational synthesis with no second line of evidence (1 independent synthesis group; lines: obs). grade_basisT3T4
Current cigarette smoking → Glaucoma
smoking|glaucoma
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source smoking_poag_meta Estimate design cohort synthesis Outcome match narrower Outcome measured Primary open-angle glaucoma |
The estimate measures: Primary open-angle glaucoma. measured_outcome
Also changed in: 1.3 (9 Sep 2026)
Vitamin D deficiency → Multiple sclerosis
vitd_deficiency|multiple_sclerosis
| Field | Before | After |
| Grade | Convincing (now Strong) | Moderate |
| Reviews counted | 1 | 0 |
| Score (ESS) | 19.7 | 15.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response no | Trial none; Genetic (MR) supportive (sources vitd_ms_mr); dose-response no |
| New fields | not recorded before | Measure OR Estimate source vitd_ms_mr Estimate design MR Outcome match exact Outcome measured Multiple sclerosis (odds ratio per SD of genetically predicted vitamin D, Mendelian randomisation) Grade basis Moderate: One MR study; no prevention trial; pleiotropy noted. Rule T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: Multiple sclerosis (odds ratio per SD of genetically predicted vitamin D, Mendelian randomisation). measured_outcome
Grade: Moderate: One MR study; no prevention trial; pleiotropy noted. Rule T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source vitd_ms_mr, estimate_design MR, measure OR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11): Grade Strong to Moderate (card G3, PROPOSAL section 3.1): One MR study; no prevention trial; pleiotropy noted. grade_basisT4
Grade basis: Moderate: One MR study; no prevention trial; pleiotropy noted. Rule T4 (ceiling Moderate). Verified on 21 October 2026 (card G3). grade_basisT4
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Also changed in: 1.4 (9 Oct 2026)
High body-mass index → Diverticular disease
high_bmi|diverticular_disease
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source bmi_pa_divert_meta Estimate design cohort synthesis Outcome match exact Outcome measured Incident diverticular disease per 5 kg/m2 |
The estimate measures: Incident diverticular disease per 5 kg/m2. measured_outcome
Low physical activity → Diverticular disease
low_pa|diverticular_disease
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source bmi_pa_divert_meta Estimate design cohort synthesis Outcome match exact Outcome measured Incident diverticular disease (inverted from high vs low activity) Grade basis Kept at Suggestive by the verified dry run: Five prospective cohorts with I2 54%; the five-study rule treats five large cohorts as sparse. |
Outcome match, Outcome measured: The estimate measures: Incident diverticular disease (inverted from high vs low activity). measured_outcome
Grade basis: Kept at Suggestive by the verified dry run: Five prospective cohorts with I2 54%; the five-study rule treats five large cohorts as sparse. grade_basis
Obstructive sleep apnoea → High blood pressure
osa|hypertension
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source osa_htn_meta Estimate design cohort synthesis Outcome match exact Outcome measured Essential hypertension (odds ratio), mostly prospective cohorts Grade basis Moderate: risk rises with severity, and CPAP lowers blood pressure in trials (not yet recorded as a field). Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: Essential hypertension (odds ratio), mostly prospective cohorts. measured_outcome
Grade basis: Moderate: risk rises with severity, and CPAP lowers blood pressure in trials (not yet recorded as a field). Kept by the verifier. grade_basis
Also changed in: 1.4 (9 Oct 2026)
High body-mass index → Aortic valve stenosis
high_bmi|aortic_stenosis
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 1 | 0 |
| Score (ESS) | 3.5 | 2.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources avs_mr_ukb); dose-response yes |
| New fields | not recorded before | Measure HR Estimate source avs_mr_ukb Estimate design MR Outcome match exact Outcome measured Aortic valve stenosis (hazard ratio per SD of genetically predicted BMI, Mendelian randomisation) Grade basis Suggestive: One MR analysis in UK Biobank, z 2.8, no replication. Rule T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: Aortic valve stenosis (hazard ratio per SD of genetically predicted BMI, Mendelian randomisation). measured_outcome
Grade: Suggestive: One MR analysis in UK Biobank, z 2.8, no replication. Rule T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source avs_mr_ukb, estimate_design MR, measure HR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): One MR analysis in UK Biobank, z 2.8, no replication. grade_basisT9b
Grade basis: Suggestive: One MR analysis in UK Biobank, z 2.8, no replication. Rule T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT9b
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Also changed in: 1.4 (9 Oct 2026)
High LDL cholesterol → Aortic valve stenosis
high_ldl|aortic_stenosis
| Field | Before | After |
| Reviews counted | 1 | 0 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) supportive (sources avs_mr_ukb); dose-response yes |
| New fields | not recorded before | Measure HR Estimate source avs_mr_ukb Estimate design MR Outcome match exact Outcome measured Aortic valve stenosis (hazard ratio per SD of genetically predicted LDL cholesterol, Mendelian randomisation) Rests on primary studies true |
Outcome match, Outcome measured: The estimate measures: Aortic valve stenosis (hazard ratio per SD of genetically predicted LDL cholesterol, Mendelian randomisation). measured_outcome
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Also changed in: 1.4 (9 Oct 2026)
High triglycerides → Aortic valve stenosis
high_tg|aortic_stenosis
| Field | Before | After |
| Reviews counted | 1 | 0 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response no | Trial none; Genetic (MR) supportive (sources avs_mr_ukb); dose-response no |
| New fields | not recorded before | Measure HR Estimate source avs_mr_ukb Estimate design MR Outcome match exact Outcome measured Aortic valve stenosis (hazard ratio per SD of genetically predicted triglycerides, Mendelian randomisation) Grade basis Suggestive: the Results section of the source (Figure 4) gives the genetic estimate as 1.08 (1.01 to 1.16), so the bound…Suggestive: the Results section of the source (Figure 4) gives the genetic estimate as 1.08 (1.01 to 1.16), so the bound excludes 1 and rule T1 does not apply; the abstract rounds it to 1.00. One MR analysis with no second line (T4, ceiling Moderate) and z about 2 (T9b). Triglycerides travel with weight and LDL (caveat). The approved change to Weak (card G3) was conditional on the unrounded bound and is withdrawn. Rests on primary studies true ci_low_exact 1.01 |
Outcome match, Outcome measured: The estimate measures: Aortic valve stenosis (hazard ratio per SD of genetically predicted triglycerides, Mendelian randomisation). measured_outcome
Grade basis: Suggestive: the Results section of the source (Figure 4) gives the genetic estimate as 1.08 (1.01 to 1.16), so the bound excludes 1 and rule T1 does not apply; the abstract rounds it to 1.00. One MR analysis with no second line (T4, ceiling Moderate) and z about 2 (T9b). Triglycerides travel with weight and LDL (caveat). The approved change to Weak (card G3) was conditional on the unrounded bound and is withdrawn. grade_basisT1T4T9b
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
ci_low_exact: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source avs_mr_ukb, estimate_design MR, measure HR, by rule E1 (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): MR interval touches 1; not separated from LDL and weight (confirm the unrounded bound). 23 Oct 2026 fix round (verifier of the data step, blockers 1 to 10): Grade Weak to Suggestive (blocker 7): Suggestive: the Results section of the source (Figure 4) gives the genetic estimate as 1.08 (1.01 to 1.16), so the bound excludes 1 and rule T1 does not apply; the abstract rounds it to 1.00. One MR analysis with no second line (T4, ceiling Moderate) and z about 2 (T9b). Triglycerides travel with weight and LDL (caveat). The approved change to Weak (card G3) was conditional on the unrounded bound and is withdrawn. ci_low_exact 1.01 recorded from the Results section of the source (Nutrients 2022, PMC9182826) (blocker 7). corrections.json _whyT1T4T9b
Also changed in: 1.4 (9 Oct 2026)1.3 (18 Sep 2026)1.3 (9 Sep 2026)
Insomnia → Aortic valve stenosis
insomnia|aortic_stenosis
| Field | Before | After |
| Grade | Suggestive | Weak |
| Reviews counted | 1 | 0 |
| Score (ESS) | 6.2 | 3.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response no | Trial none; Genetic (MR) supportive (sources avs_mr_ukb); dose-response no |
| New fields | not recorded before | Measure HR Estimate source avs_mr_ukb Estimate design MR Outcome match exact Outcome measured Aortic valve stenosis (hazard ratio per category of genetically predicted insomnia, Mendelian randomisation) Grade basis T5d/T5c: one genetic analysis in one cohort. A PubMed title search for a second study of insomnia or sleep and aortic va…T5d/T5c: one genetic analysis in one cohort. A PubMed title search for a second study of insomnia or sleep and aortic valve stenosis found only sleep apnoea and procedure studies. Nothing replicates the MR. Weak. Rests on primary studies true Studies 1 |
Outcome match, Outcome measured: The estimate measures: Aortic valve stenosis (hazard ratio per category of genetically predicted insomnia, Mendelian randomisation). measured_outcome
Grade: T5d/T5c: one genetic analysis in one cohort. A PubMed title search for a second study of insomnia or sleep and aortic valve stenosis found only sleep apnoea and procedure studies. Nothing replicates the MR. Weak. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source avs_mr_ukb, estimate_design MR, measure HR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). n_studies from the displayed review (card G12, research pass; PubMed 35684074): Grade Suggestive to Weak (card G12, settled by the research pass). grade_basisT5dT5c
Grade basis: T5d/T5c: one genetic analysis in one cohort. A PubMed title search for a second study of insomnia or sleep and aortic valve stenosis found only sleep apnoea and procedure studies. Nothing replicates the MR. Weak. grade_basisT5dT5c
Reviews counted, Rests on primary studies: No synthesis is cited, so N_eff is set to 1 and the link is flagged as resting on primary studies. reviews_counted
Studies: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source avs_mr_ukb, estimate_design MR, measure HR, by rule E1 (read by hand) (cards G8, K5, P2). triangulation recorded as objects with their sources, same exposure and same outcome (card G11). n_studies from the displayed review (card G12, research pass; PubMed 35684074): Grade Suggestive to Weak (card G12, settled by the research pass). corrections.json _why
Repeated antibiotic courses → Inflammatory bowel disease
antibiotics_exposure|ibd
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 13.3 | 9.1 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source abx_ibd_meta Estimate design cohort synthesis Outcome match exact Outcome measured Inflammatory bowel disease (odds ratio), mostly case-control studies Grade basis Suggestive: 18 of 23 studies case-control; prescribing for early symptoms. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Inflammatory bowel disease (odds ratio), mostly case-control studies. measured_outcome
Grade: Suggestive: 18 of 23 studies case-control; prescribing for early symptoms. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source abx_ibd_meta, estimate_design cohort synthesis, measure OR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): 18 of 23 studies case-control; prescribing for early symptoms. grade_basisT8a
Grade basis: Suggestive: 18 of 23 studies case-control; prescribing for early symptoms. Rule T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT8a
Also changed in: 1.4 (9 Oct 2026)
Refined grains and white rice → Coronary heart disease
refined_grains|chd
| Field | Before | After |
| Score (ESS) | 1.2 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure HR Estimate source refined_grain_cvd_meta Estimate design cohort synthesis Outcome match broader Outcome measured Cardiovascular disease (hazard ratio) Related outcome true |
The estimate measures: Cardiovascular disease (hazard ratio). The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Also changed in: 1.4 (9 Oct 2026)1.3 (18 Sep 2026)1.3 (9 Sep 2026)
Non-sugar sweeteners → Coronary heart disease
nonsugar_sweeteners|chd
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 6 | 1 |
| Effective reviews (N_eff) | 5 | 1.0 |
| Score (ESS) | 5.7 | 1.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source nssb_umbrella Estimate design cohort synthesis Outcome match exact Outcome measured Coronary heart disease per 250 mL a day of non-sugar-sweetened drinks Grade basis Suggestive: Reverse causation through the reason for switching. Rules T8a, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). External grades GRADE high (nssb_umbrella) |
Outcome match, Outcome measured: The estimate measures: Coronary heart disease per 250 mL a day of non-sugar-sweetened drinks. measured_outcome
Grade: Suggestive: Reverse causation through the reason for switching. Rules T8a, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source nssb_umbrella, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). external_grades transcribed from the caveat, the review note or the quote (rule T11): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Reverse causation through the reason for switching. grade_basisT8aT9bT11
Grade basis: Suggestive: Reverse causation through the reason for switching. Rules T8a, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT8aT9b
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: nssb_umbrella (weight 1.0). reviews_counted
Non-sugar sweeteners → High blood pressure
nonsugar_sweeteners|hypertension
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 6 | 1 |
| Effective reviews (N_eff) | 5 | 1.0 |
| Score (ESS) | 11.7 | 3.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure RR Estimate source nssb_umbrella Estimate design cohort synthesis Outcome match exact Outcome measured Hypertension (high vs low intake) in prospective cohorts Grade basis Suggestive: Reverse causation through the reason for switching. Rules T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). External grades GRADE moderate (nssb_umbrella) |
Outcome match, Outcome measured: The estimate measures: Hypertension (high vs low intake) in prospective cohorts. measured_outcome
Grade: Suggestive: Reverse causation through the reason for switching. Rules T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source nssb_umbrella, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). external_grades transcribed from the caveat, the review note or the quote (rule T11): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): Reverse causation through the reason for switching. grade_basisT7T8aT11
Grade basis: Suggestive: Reverse causation through the reason for switching. Rules T7, T8a (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7T8a
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: nssb_umbrella (weight 1.0). reviews_counted
Recreational screen time → Type 2 diabetes
screen_time|t2d
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Reviews counted | 1 | 3 |
| Effective reviews (N_eff) | 1 | 1.75 |
| Score (ESS) | 6.6 | 6.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Sources | tv_t2d_cvd_meta | tv_t2d_cvd_meta sed_t2d_patterson sed_t2d_bailey |
| New fields | not recorded before | Measure RR Estimate source tv_t2d_cvd_meta Estimate design cohort synthesis Outcome match exact Outcome measured Incident type 2 diabetes per 2 hours of television a day Grade basis Four cohorts in the displayed review (6,428 cases). Two later syntheses agree: Patterson 2018 (34 studies across all its…Four cohorts in the displayed review (6,428 cases). Two later syntheses agree: Patterson 2018 (34 studies across all its outcomes; TV viewing RR 1.09, 1.07-1.12 per hour, adjusted for physical activity) and Guo 2020 (8% per hour). So T9 no longer applies. Screen time is on the watch list and the caveat names diet and income as unhandled, so T8a keeps the ceiling at Suggestive. Studies 4 |
Outcome match, Outcome measured: The estimate measures: Incident type 2 diabetes per 2 hours of television a day. measured_outcome
Grade: Four cohorts in the displayed review (6,428 cases). Two later syntheses agree: Patterson 2018 (34 studies across all its outcomes; TV viewing RR 1.09, 1.07-1.12 per hour, adjusted for physical activity) and Guo 2020 (8% per hour). So T9 no longer applies. Screen time is on the watch list and the caveat names diet and income as unhandled, so T8a keeps the ceiling at Suggestive. Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): sed_t2d_patterson, sed_t2d_bailey; the displayed estimate is unchanged. estimate_source tv_t2d_cvd_meta, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). n_studies from the displayed review (card G12, research pass; PubMed 21673296). Grade Moderate to Suggestive (card G12, settled by the research pass). grade_basisT9T8a
Grade basis: Four cohorts in the displayed review (6,428 cases). Two later syntheses agree: Patterson 2018 (34 studies across all its outcomes; TV viewing RR 1.09, 1.07-1.12 per hour, adjusted for physical activity) and Guo 2020 (8% per hour). So T9 no longer applies. Screen time is on the watch list and the caveat names diet and income as unhandled, so T8a keeps the ceiling at Suggestive. grade_basisT9T8a
Reviews counted, Effective reviews (N_eff): Counted from the cited syntheses under the review-counting rule: tv_t2d_cvd_meta (weight 1.0), sed_t2d_patterson (weight 0.58), sed_t2d_bailey (weight 0.17). reviews_counted
Studies, Sources: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5): Sources added (card G12): sed_t2d_patterson, sed_t2d_bailey; the displayed estimate is unchanged. estimate_source tv_t2d_cvd_meta, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2). n_studies from the displayed review (card G12, research pass; PubMed 21673296). Grade Moderate to Suggestive (card G12, settled by the research pass). corrections.json _why
Recreational screen time → Coronary heart disease
screen_time|chd
| Field | Before | After |
| Grade | Suggestive | Weak |
| Score (ESS) | 3.6 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source tv_t2d_cvd_meta Estimate design cohort synthesis Outcome match broader Outcome measured Fatal or non-fatal cardiovascular disease Related outcome true Grade basis Weak: Four cohorts; CVD outcome. Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured, Related outcome: The estimate measures: Fatal or non-fatal cardiovascular disease. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade: Weak: Four cohorts; CVD outcome. Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match broader, measured outcome recorded (cards O1 and O5). estimate_source tv_t2d_cvd_meta, estimate_design cohort synthesis, measure RR, by rule E1 (cards G8, K5, P2): Grade Suggestive to Weak (card G3, PROPOSAL section 3.1): Four cohorts; CVD outcome. grade_basis
Grade basis: Weak: Four cohorts; CVD outcome. Verified on 21 October 2026 (card G3). grade_basis
Long working hours → Atrial fibrillation
long_hours|afib
| Field | Before | After |
| Grade | Probable (now Moderate) | Suggestive |
| Score (ESS) | 10.6 | 7.3 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response no | Trial none; Genetic (MR) none; dose-response no |
| New fields | not recorded before | Measure HR Estimate source longhours_af_ipd Estimate design pooled IPD Outcome match exact Outcome measured Incident atrial fibrillation (hazard ratio) Grade basis Suggestive: One IPD analysis, 1,061 cases, no replication. Rules T7, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). |
Outcome match, Outcome measured: The estimate measures: Incident atrial fibrillation (hazard ratio). measured_outcome
Grade: Suggestive: One IPD analysis, 1,061 cases, no replication. Rules T7, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). Curator record: 21 Oct 2026 grading reform v2.0: outcome_match exact, measured outcome recorded (cards O1 and O5). estimate_source longhours_af_ipd, estimate_design pooled IPD, measure HR, by rule E1 (cards G8, K5, P2): Grade Moderate to Suggestive (card G3, PROPOSAL section 3.1): One IPD analysis, 1,061 cases, no replication. grade_basisT7T9b
Grade basis: Suggestive: One IPD analysis, 1,061 cases, no replication. Rules T7, T9b (ceiling Suggestive). Verified on 21 October 2026 (card G3). grade_basisT7T9b
Also changed in: 1.4 (9 Oct 2026)
DASH eating pattern → Heart failure
dash_diet|heart_failure
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source dash_cvd_meta Estimate design cohort synthesis Outcome match exact Outcome measured Heart failure risk Grade basis Moderate: six cohorts; the route through blood pressure is backed by trials. Kept by the verifier. |
Outcome match, Outcome measured: The estimate measures: Heart failure risk. measured_outcome
Grade basis: Moderate: six cohorts; the route through blood pressure is backed by trials. Kept by the verifier. grade_basis
DASH eating pattern → Ischaemic stroke
dash_diet|stroke_isch
| Field | Before | After |
| Score (ESS) | 7.3 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure RR Estimate source dash_cvd_meta Estimate design cohort synthesis Outcome match broader Outcome measured Stroke of any type Related outcome true Grade override Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. T…Moderate. T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. The link sits in the related-outcome layer. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. |
Outcome match, Outcome measured, Related outcome: The estimate measures: Stroke of any type. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Grade override: Curator override to Moderate: T8c (healthy-user check, amended) proposes Suggestive: a beneficial diet judged on observational data alone. The link sits in the related-outcome layer. New disagreement for the owner (card G3 A): kept at the verified grade until the owner decides. grade_overrideT8c
Depression (as a risk factor) → Back pain
depression_exposure|low_back_pain
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source depression_lbp_meta Estimate design cohort synthesis Outcome match exact Outcome measured New episodes of low back pain of any duration |
The estimate measures: New episodes of low back pain of any duration. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Repeated antibiotic courses → Psoriasis
antibiotics_exposure|psoriasis
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source abx_children_meta Estimate design cohort synthesis Outcome match exact Outcome measured Psoriasis (odds ratio) after antibiotic exposure in childhood |
The estimate measures: Psoriasis (odds ratio) after antibiotic exposure in childhood. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Night shift work → Obesity
night_shift|obesity
| Field | Before | After |
| Score (ESS) | 7.2 | empty |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| New fields | not recorded before | Measure OR Estimate source shiftwork_obesity_meta Estimate design cohort synthesis Outcome match broader Outcome measured Obesity or overweight (odds ratio), cohort and cross-sectional studies pooled Related outcome true |
The estimate measures: Obesity or overweight (odds ratio), cohort and cross-sectional studies pooled. The link sits in the related-outcome layer, outside the counts and the score. measured_outcome
Also changed in: 1.4 (9 Oct 2026)
Version 1.49 Oct 2026
release eaa7e6d · 431 links · 196 changed · 3 removed
Both explorers: October 2026 review
Risk factor renamed: Low fruit intake to Low fruit and vegetable intake.
Risk factor renamed: Occupational solvents to Trichloroethylene in drinking water.
Risk factor renamed: Long-term proton pump inhibitors to Proton pump inhibitors (acid-suppressing tablets).
Risk factor renamed: Long-term benzodiazepines to Benzodiazepines and similar sedatives.
Rows by field: Comparison 195, Trial and genetic evidence 2, Provenance 1.
Current cigarette smoking → Coronary heart disease
smoking|chd
| Field | Before | After |
| Comparison | current vs never smokers aged 60 and over, acute coronary events | current vs never smokers aged 60 and over, acute coronary events (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Former smoking → Coronary heart disease
former_smoking|chd
| Field | Before | After |
| Comparison | former vs never smokers aged 60 and older, acute coronary events | former vs never smokers aged 60 and older, acute coronary events (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
High LDL cholesterol → Coronary heart disease
high_ldl|chd
| Field | Before | After |
| Comparison | per 1 SD (33 mg/dL, about 0.85 mmol/L) higher directly measured LDL cholesterol | per 1 standard deviation (33 mg/dL, about 0.85 mmol/L, a typical spread between people) higher directly measured LDL cholesterol (hazard ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High lipoprotein(a) → Coronary heart disease
high_lpa|chd
| Field | Before | After |
| Comparison | per 3.5-fold (1 SD) higher usual lipoprotein(a), adjusted for lipids and conventional risk factors | per 3.5-fold (1 standard deviation, a typical spread between people) higher usual lipoprotein(a), adjusted for lipids and conventional risk factors |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High triglycerides → Coronary heart disease
high_tg|chd
| Field | Before | After |
| Comparison | per 1 SD (0.52 log-e) higher triglyceride, adjusted for HDL-C and non-HDL-C | per 1 standard deviation (a typical spread between people) higher triglyceride, adjusted for HDL-C and non-HDL-C (hazard ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.3 (9 Sep 2026)
Type 2 diabetes (as a risk factor) → Coronary heart disease
t2d_exposure|chd
| Field | Before | After |
| Comparison | diabetes vs no diabetes, people without vascular disease at baseline | diabetes vs no diabetes, people without vascular disease at baseline (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Prediabetes → Coronary heart disease
prediabetes|chd
| Field | Before | After |
| Comparison | fasting glucose 6.10-6.99 vs 3.90-5.59 mmol/L | fasting glucose 6.10-6.99 vs 3.90-5.59 mmol/L (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High body-mass index → Coronary heart disease
high_bmi|chd
| Field | Before | After |
| Comparison | per 1 SD (4.56 kg/m²) higher BMI, in people with BMI of 20 kg/m² or more | per 1 standard deviation (4.56 kg/m², a typical spread between people) higher BMI, in people with BMI of 20 kg/m² or more |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Abdominal obesity → Coronary heart disease
central_adiposity|chd
| Field | Before | After |
| Comparison | per 1 SD (0.083) higher waist-to-hip ratio, cardiovascular disease | per 1 standard deviation (0.083, a typical spread between people) higher waist-to-hip ratio, cardiovascular disease (hazard ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Sedentary behaviour → Coronary heart disease
sedentary|chd
| Field | Before | After |
| Comparison | about 12.5 h/day vs about 2.5 h/day sedentary time, incident CVD | about 12.5 h/day vs about 2.5 h/day sedentary time, new cases of cardiovascular disease (hazard ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High salt intake → Coronary heart disease
high_sodium|chd
| Field | Before | After |
| Comparison | per 1000 mg/day higher 24-hour urinary sodium excretion, cardiovascular events | per 1000 mg/day higher 24-hour urinary sodium excretion, cardiovascular events (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Low nut and seed intake → Coronary heart disease
low_nuts|chd
| Field | Before | After |
| Comparison | per 4 fewer weekly 28.4 g servings of nuts, fatal IHD | per 4 fewer weekly 28.4 g servings of nuts, fatal ischaemic heart disease |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Low legume intake → Coronary heart disease
low_legumes|chd
| Field | Before | After |
| Comparison | per 4 fewer weekly 100 g servings of legumes, total IHD | per 4 fewer weekly 100 g servings of legumes, total ischaemic heart disease |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (21 Oct 2026)
Heavy alcohol use → Coronary heart disease
alcohol_heavy|chd
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) supportive; dose-response yes | Trial none; Genetic (MR) conflicting; dose-response yes |
7 Oct 2026 review: the caveat says the genetic studies point in different directions, so the badge cannot say they support the link. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Road traffic noise → Coronary heart disease
traffic_noise|chd
| Field | Before | After |
| Comparison | per 10 dB (Lden) higher road traffic noise, incident IHD | per 10 dB (day-evening-night average) higher road traffic noise, new cases of ischaemic heart disease |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Job strain → Coronary heart disease
job_strain|chd
| Field | Before | After |
| Comparison | high strain vs low strain job | high strain vs low strain job (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Social isolation and loneliness → Coronary heart disease
isolation|chd
| Field | Before | After |
| Comparison | poor social relationships vs not, incident CHD | poor social relationships vs not, new cases of coronary heart disease |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Menopausal hormone therapy → Coronary heart disease
mht|chd
| Field | Before | After |
| Comparison | conjugated equine oestrogens plus medroxyprogesterone vs placebo, women aged 50–79, trial intervention phase (median 5.6 years) | conjugated equine oestrogens plus medroxyprogesterone vs placebo, women aged 50–79, trial intervention phase (median 5.6 years), hazard ratio |
| Trial and genetic evidence | Trial null; Genetic (MR) none; dose-response yes | Trial null; Genetic (MR) none; dose-response no |
Comparison: 7 Oct 2026 review: the quoted estimate is a hazard ratio. 7 Oct 2026 review: a single trial arm against placebo cannot show a dose-response. corrections.json _why
Trial and genetic evidence: 7 Oct 2026 review: a single trial arm against placebo cannot show a dose-response. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Gum disease → Coronary heart disease
periodontitis|chd
| Field | Before | After |
| Comparison | periodontitis vs no periodontitis, incident CHD | periodontitis vs no periodontitis, new cases of coronary heart disease |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Vitamin D deficiency → Coronary heart disease
vitd_deficiency|chd
| Field | Before | After |
| Comparison | lowest vs highest circulating 25(OH)D category | lowest vs highest category of blood vitamin D |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Low muscle strength → Coronary heart disease
low_grip|chd
| Field | Before | After |
| Comparison | per 5 kg lower grip strength | per 5 kg lower grip strength (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Ischaemic stroke
smoking|stroke_isch
| Field | Before | After |
| Comparison | current vs never smokers, new ischaemic stroke | current vs never smokers, new ischaemic stroke (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Current cigarette smoking → Haemorrhagic stroke
smoking|stroke_haem
| Field | Before | After |
| Comparison | current vs never smokers, new haemorrhagic stroke | current vs never smokers, new haemorrhagic stroke (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Type 2 diabetes (as a risk factor) → Ischaemic stroke
t2d_exposure|stroke_isch
| Field | Before | After |
| Comparison | diabetes vs no diabetes, ischaemic stroke | diabetes vs no diabetes, ischaemic stroke (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High body-mass index → Ischaemic stroke
high_bmi|stroke_isch
| Field | Before | After |
| Comparison | per 1 SD (4.56 kg/m²) higher BMI, cardiovascular disease | per 1 standard deviation (4.56 kg/m², a typical spread between people) higher BMI, cardiovascular disease (hazard ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High LDL cholesterol → Ischaemic stroke
high_ldl|stroke_isch
| Field | Before | After |
| Comparison | per 1 SD (43 mg/dL) higher non-HDL cholesterol, ischaemic stroke | per 1 standard deviation (43 mg/dL, a typical spread between people) higher non-HDL cholesterol, ischaemic stroke (hazard ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High salt intake → Ischaemic stroke
high_sodium|stroke_isch
| Field | Before | After |
| Comparison | per 1000 mg/day higher 24-hour urinary sodium excretion, cardiovascular events | per 1000 mg/day higher 24-hour urinary sodium excretion, cardiovascular events (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Low physical activity → Ischaemic stroke
low_pa|stroke_isch
| Field | Before | After |
| Comparison | no regular physical activity vs regular physical activity, all stroke | no regular physical activity vs regular physical activity, all stroke (case-control odds ratio; the interval shown is a 99% interval) |
7 Oct 2026 review: the INTERSTROKE estimate is a case-control odds ratio and its interval is 99%, not 95%. Re-sourcing to a cohort estimate waits for the owner (decision D5). corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Chronic kidney disease (as a risk factor) → Ischaemic stroke
ckd_exposure|stroke_isch
| Field | Before | After |
| Comparison | eGFR <60 vs ≥60 mL/min/1.73m² | kidney filtering rate (eGFR) below 60 vs 60 or more mL/min/1.73m² |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Depression (as a risk factor) → Ischaemic stroke
depression_exposure|stroke_isch
| Field | Before | After |
| Comparison | depression vs no depression, ischaemic stroke | depression vs no depression, ischaemic stroke (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Low socioeconomic position → Ischaemic stroke
low_sep|stroke_isch
| Field | Before | After |
| Comparison | lowest vs highest socioeconomic status, all strokes | lowest vs highest socioeconomic status, all strokes (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)1.3 (9 Sep 2026)
Menopausal hormone therapy → Ischaemic stroke
mht|stroke_isch
| Field | Before | After |
| Comparison | hormone therapy vs placebo or control in randomised trials | hormone therapy vs placebo or control in randomised trials (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Heavy alcohol use → Heart failure
alcohol_heavy|heart_failure
| Field | Before | After |
| Comparison | heavy drinking (>=46 g/day men, >=23 g/day women) vs light drinking | heavy drinking (>=46 g/day men, >=23 g/day women) vs light drinking (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Obstructive sleep apnoea → Heart failure
osa|heart_failure
| Field | Before | After |
| Comparison | per 10-unit higher apnoea-hypopnoea index, men | per 10-unit higher apnoea-hypopnoea index, men (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Heavy alcohol use → Atrial fibrillation
alcohol_heavy|afib
| Field | Before | After |
| Comparison | high alcohol intake vs low or none | high alcohol intake vs low or none (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Type 2 diabetes (as a risk factor) → Peripheral artery disease
t2d_exposure|pad
| Field | Before | After |
| Comparison | diabetes vs no diabetes (high-income settings) | diabetes vs no diabetes (high-income settings; odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High blood pressure → Peripheral artery disease
high_sbp|pad
| Field | Before | After |
| Comparison | per 20 mmHg higher genetically predicted systolic blood pressure (Mendelian randomisation) | per 20 mmHg higher genetically predicted systolic blood pressure (Mendelian randomisation; odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Chronic kidney disease (as a risk factor) → Peripheral artery disease
ckd_exposure|pad
| Field | Before | After |
| Comparison | eGFR 45 vs 95 mL/min/1.73m² | eGFR 45 vs 95 mL/min/1.73m² (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Low physical activity → Type 2 diabetes
low_pa|t2d
| Field | Before | After |
| Comparison | lowest vs highest total physical activity (inverse of the published high-vs-low estimate) | lowest vs highest total physical activity |
The proposed value is the exact inverse of Aune 2015's high-versus-low total physical activity estimate (1/0.65 = 1.54; 1/0.71 = 1.41; 1/0.59 = 1.69); the leisure-time-only estimate inverts to 1.35 (1.27-1.43), so the filed 1.45 sits between the two and matches neither. The cited DPP is a randomised lifestyle trial combining diet, exercise and weight loss and cannot support an observational inactive-versus-active contrast. The number shown is the inverse of the published high-vs-low estimate. review_note
Also changed in: 2.0 (23 Oct 2026)
Processed meat → Type 2 diabetes
processed_meat|t2d
| Field | Before | After |
| Comparison | per 50 g/day higher processed meat intake | per 50 g/day higher processed meat intake (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Unprocessed red meat → Type 2 diabetes
red_meat|t2d
| Field | Before | After |
| Comparison | per 100 g/day higher unprocessed red meat intake | per 100 g/day higher unprocessed red meat intake (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Low whole grain intake → Type 2 diabetes
low_wholegrain|t2d
| Field | Before | After |
| Comparison | per 30 g/day lower whole grain intake (inverse of the published per-30 g/day estimate) | per 30 g/day lower whole grain intake (hazard ratio) |
The filed quantile figure is not traceable to any meta-analysis I found. The published high-quality evidence is dose-response, not categorical: 0.87 (0.82-0.93) per 30 g/day, which inverts to the proposed 1.15 (1.08-1.22). For scale, Aune 2013's dose-response gives 0.68 (0.58-0.81) per 3 servings/day, whose inverse is 1.47, so a lowest-versus-highest contrast could plausibly be anywhere between about 1.15 and 1.47 depending on the intake range assumed, which is why the per-unit form should be published instead. The number shown is the inverse of the published per-30 g/day estimate. review_note
Also changed in: 2.0 (23 Oct 2026)
Night shift work → Type 2 diabetes
night_shift|t2d
| Field | Before | After |
| Comparison | night shift work vs daytime work | night shift work vs daytime work (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Fine particulate air pollution → Type 2 diabetes
pm25|t2d
| Field | Before | After |
| Comparison | per 10 µg/m³ higher annual PM2.5 | per 10 µg/m³ higher annual PM2.5 (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Statin treatment → Type 2 diabetes
statins|t2d
| Field | Before | After |
| Comparison | statin therapy vs control, incident diabetes | statin vs placebo or no statin, new cases of diabetes (odds ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Low birth weight → Type 2 diabetes
low_birthweight|t2d
| Field | Before | After |
| Comparison | per 1 kg lower birth weight | per 1 kg lower birth weight (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Childhood obesity → Type 2 diabetes
childhood_obesity|t2d
| Field | Before | After |
| Comparison | high vs normal childhood BMI | high vs normal childhood BMI (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Vitamin D deficiency → Type 2 diabetes
vitd_deficiency|t2d
| Field | Before | After |
| Comparison | lowest vs highest quartile of 25(OH)D (inverse of the published highest-vs-lowest estimate) | lowest vs highest quarter of blood vitamin D |
The filed 1.25 is the exact inverse of the per-1-SD observational estimate in Zheng 2020 ('each 1-standard deviation (SD) higher level of 25(OH)D was associated with a 20% lower risk of T2D (relative risk [RR]: 0.80; 95% CI 0.77, 0.84)'), carried on a lowest-versus-highest quantile label, a per-unit figure wearing a quantile contrast. The quartile contrast is much stronger at 1.69. Both are observational only: the same paper's Mendelian randomisation finds no causal effect (OR 0.96, 95% CI 0.89-1.03 per SD), matching the null supplementation trials, so Contested is the right grade whichever number is published. The number shown is the inverse of the published highest-vs-lowest estimate. review_note
Also changed in: 2.0 (23 Oct 2026)
Abdominal obesity → Fatty liver disease (MASLD)
central_adiposity|masld
| Field | Before | After |
| Comparison | per 1 SD higher waist circumference (Mendelian randomisation) | per 1 standard deviation (a typical spread between people) higher waist circumference (Mendelian randomisation; odds ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Type 2 diabetes (as a risk factor) → Fatty liver disease (MASLD)
t2d_exposure|masld
| Field | Before | After |
| Comparison | genetically predicted liability to type 2 diabetes, per unit higher log-odds (Mendelian randomisation) | genetically predicted liability to type 2 diabetes, per unit higher log-odds (Mendelian randomisation; odds ratio) |
| Provenance | editorial | sourced |
Comparison: 7 Oct 2026 review: the quoted estimate is an odds ratio. 7 Oct 2026 review: the link cites a named source (nafld_mr), so its provenance is sourced. corrections.json _why
Provenance: 7 Oct 2026 review: the link cites a named source (nafld_mr), so its provenance is sourced. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)1.3 (9 Sep 2026)
Sugar-sweetened drinks → Fatty liver disease (MASLD)
ssb|masld
| Field | Before | After |
| Comparison | highest vs lowest consumption | highest vs lowest consumption (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Coffee consumption → Fatty liver disease (MASLD)
coffee|masld
| Field | Before | After |
| Comparison | highest vs lowest coffee consumption, incident fatty liver | highest vs lowest coffee consumption, new cases of fatty liver |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.3 (9 Sep 2026)
Type 2 diabetes (as a risk factor) → Liver cirrhosis
t2d_exposure|cirrhosis
| Field | Before | After |
| Comparison | type 2 diabetes vs no diabetes, severe liver disease (cirrhosis, its complications or death from liver disease) | type 2 diabetes vs no diabetes, severe liver disease (cirrhosis, its complications or death from liver disease), hazard ratio |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
High blood pressure → Chronic kidney disease
high_sbp|ckd
| Field | Before | After |
| Comparison | SBP >=140 mmHg vs <120 mmHg, incident CKD or ESRD (women) | SBP >=140 mmHg vs <120 mmHg, new cases of CKD or kidney failure (women) |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High body-mass index → Chronic kidney disease
high_bmi|ckd
| Field | Before | After |
| Comparison | per 1 kg/m² higher BMI, incident eGFR <60 | per 1 kg/m² higher BMI, new cases of kidney filtering rate (eGFR) below 60 |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Long-term NSAID use → Chronic kidney disease
nsaids|ckd
| Field | Before | After |
| Comparison | chronic NSAID use vs none, incident CKD in people without CKD at baseline | chronic NSAID use vs none, new cases of CKD in people without CKD at baseline (hazard ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Fine particulate air pollution → Chronic kidney disease
pm25|ckd
| Field | Before | After |
| Comparison | per 10 µg/m³ higher PM2.5 | per 10 µg/m³ higher PM2.5 (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Lead exposure → Chronic kidney disease
lead|ckd
| Field | Before | After |
| Comparison | higher vs lower lead exposure, reduced eGFR | higher vs lower lead exposure, reduced eGFR (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Cadmium exposure → Chronic kidney disease
cadmium|ckd
| Field | Before | After |
| Comparison | high vs low cadmium exposure, proteinuria | high vs low cadmium exposure, proteinuria (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Extreme heat → Chronic kidney disease
heat|ckd
| Field | Before | After |
| Comparison | heat-exposed agricultural work vs not, in CKDnt-endemic regions | heat-exposed agricultural work vs not, in CKDnt-endemic regions (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Pre-eclampsia → Chronic kidney disease
preeclampsia|ckd
| Field | Before | After |
| Comparison | history of pre-eclampsia vs none | history of pre-eclampsia vs none (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Low birth weight → Chronic kidney disease
low_birthweight|ckd
| Field | Before | After |
| Comparison | <2.5 kg vs normal birth weight | <2.5 kg vs normal birth weight (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Secondhand smoke → COPD
shs|copd
| Field | Before | After |
| Comparison | secondhand smoke exposed vs not exposed | secondhand smoke exposed vs not exposed (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Fine particulate air pollution → COPD
pm25|copd
| Field | Before | After |
| Comparison | per 10 µg/m³ higher annual PM2.5 | per 10 µg/m³ higher annual PM2.5 (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.3 (9 Sep 2026)
Occupational silica dust → COPD
silica|copd
| Field | Before | After |
| Comparison | men occupationally exposed to respirable crystalline silica vs unexposed | men occupationally exposed to respirable crystalline silica vs unexposed (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Low birth weight → COPD
low_birthweight|copd
| Field | Before | After |
| Comparison | <2.5 kg vs normal birth weight | <2.5 kg vs normal birth weight (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High body-mass index → Asthma (adult)
high_bmi|asthma
| Field | Before | After |
| Comparison | obese (BMI >=30) vs normal weight (BMI <25) | obese (BMI >=30) vs normal weight (BMI <25), odds ratio |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Asthma (adult)
smoking|asthma
| Field | Before | After |
| Comparison | current smoker vs never smoker | current smoker vs never smoker (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (21 Oct 2026)1.3 (9 Sep 2026)
Short sleep → Dementia (all-cause)
short_sleep|dementia
| Field | Before | After |
| Comparison | short vs normal sleep duration, as each cohort defined them | short vs normal sleep duration, as each cohort defined them (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)1.3 (9 Sep 2026)
Obstructive sleep apnoea → Dementia (all-cause)
osa|dementia
| Field | Before | After |
| Comparison | diagnosed sleep-disordered breathing / OSA vs none | diagnosed sleep-disordered breathing / OSA vs none (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Anticholinergic medicines → Dementia (all-cause)
anticholinergics|dementia
| Field | Before | After |
| Comparison | >1095 total standardised daily doses vs no anticholinergic prescriptions | >1095 total standardised daily doses vs no anticholinergic prescriptions (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Tooth loss → Dementia (all-cause)
tooth_loss|dementia
| Field | Before | After |
| Comparison | suboptimal dentition (<20 teeth) vs optimal dentition (>=20 teeth) | suboptimal dentition (<20 teeth) vs optimal dentition (>=20 teeth), hazard ratio |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Mediterranean dietary pattern → Dementia (all-cause)
mediterranean|dementia
| Field | Before | After |
| Comparison | highest vs lowest tertile of MIND diet score | highest vs lowest tertile of MIND diet score (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High blood pressure → Alzheimer's disease
high_sbp|alzheimers
| Field | Before | After |
| Comparison | midlife systolic hypertension (above 140 mmHg) vs lower systolic pressure | midlife systolic hypertension (above 140 mmHg) vs lower systolic pressure (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Type 2 diabetes (as a risk factor) → Alzheimer's disease
t2d_exposure|alzheimers
| Field | Before | After |
| Comparison | diabetes vs no diabetes, incident Alzheimer's disease | diabetes vs no diabetes, new cases of Alzheimer's disease |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Low educational attainment → Alzheimer's disease
low_education|alzheimers
| Field | Before | After |
| Comparison | low vs higher education (dichotomous), incident Alzheimer's disease | low vs higher education (dichotomous), new cases of Alzheimer's disease (odds ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Trichloroethylene in drinking water → Parkinson's disease
occ_solvents|parkinsons
| Field | Before | After |
| Comparison | residence at a TCE-contaminated base vs an uncontaminated base (Camp Lejeune cohort) | residence at a TCE-contaminated base vs an uncontaminated base (Camp Lejeune cohort; odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Adverse childhood experiences → Major depression
aces|depression
| Field | Before | After |
| Comparison | any prospectively measured childhood maltreatment vs none | any prospectively measured childhood maltreatment vs none (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.3 (18 Sep 2026)
Social isolation and loneliness → Major depression
isolation|depression
| Field | Before | After |
| Comparison | often lonely vs not often lonely | often lonely vs not often lonely (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Low socioeconomic position → Major depression
low_sep|depression
| Field | Before | After |
| Comparison | poorer vs better neighbourhood socioeconomic conditions (longitudinal studies, high-income countries) | poorer vs better neighbourhood socioeconomic conditions (longitudinal studies, high-income countries; odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)1.3 (9 Sep 2026)
Insomnia → Major depression
insomnia|depression
| Field | Before | After |
| Comparison | insomnia at baseline vs no sleep difficulties | insomnia at baseline vs no sleep difficulties (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Major depression
smoking|depression
| Field | Before | After |
| Comparison | current smoking vs not currently smoking, incident major depression | current smoking vs not currently smoking, new cases of major depression |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Access to green space → Major depression
green_space|depression
| Field | Before | After |
| Comparison | per 0.1 unit higher NDVI | per 0.1 unit higher NDVI (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Vitamin D deficiency → Major depression
vitd_deficiency|depression
| Field | Before | After |
| Comparison | per 10 ng/mL LOWER serum 25(OH)D | per 10 ng/mL lower blood vitamin D (odds ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Vitamin D deficiency → Osteoporotic fracture
vitd_deficiency|fracture
| Field | Before | After |
| Comparison | lowest vs highest 25(OH)D | lowest vs highest blood vitamin D |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.3 (9 Sep 2026)
Early menopause → Osteoporotic fracture
early_menopause|fracture
| Field | Before | After |
| Comparison | menopause before 45 vs after 45 | menopause before 45 vs after 45 (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Proton pump inhibitors (acid-suppressing tablets) → Osteoporotic fracture
ppi|fracture
| Field | Before | After |
| Comparison | any PPI use vs non-use | any PPI use vs non-use (odds ratio) |
Oct 2026 review, phase 2c (critic B3): the source quote gives the duration subgroups as odds ratios from the same meta-analysis, so the pooled 1.28 is labelled as an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High body-mass index → Knee osteoarthritis
high_bmi|oa_knee
| Field | Before | After |
| Comparison | obese vs normal weight | obese vs normal weight (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Heavy physical work → Knee osteoarthritis
heavy_work|oa_knee
| Field | Before | After |
| Comparison | physically demanding occupation vs sedentary occupation | physically demanding occupation vs sedentary occupation (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Low muscle strength → Knee osteoarthritis
low_grip|oa_knee
| Field | Before | After |
| Comparison | knee extensor muscle weakness vs not, incident radiographic knee OA (women) | knee extensor muscle weakness vs not, new cases of knee osteoarthritis seen on X-ray (women; odds ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Gum disease → Rheumatoid arthritis
periodontitis|ra
| Field | Before | After |
| Comparison | periodontitis vs no periodontitis | periodontitis vs no periodontitis (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Occupational silica dust → Rheumatoid arthritis
silica|ra
| Field | Before | After |
| Comparison | occupationally exposed to free crystalline silica vs not | occupationally exposed to free crystalline silica vs not (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High blood uric acid → Gout
high_urate|gout
| Field | Before | After |
| Comparison | per 1 SD higher genetically predicted serum urate | per 1 standard deviation (a typical spread between people) higher genetically predicted serum urate (odds ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Heavy alcohol use → Gout
alcohol_heavy|gout
| Field | Before | After |
| Comparison | drinkers vs non-drinkers | drinkers vs non-drinkers (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Sugar-sweetened drinks → Gout
ssb|gout
| Field | Before | After |
| Comparison | highest vs lowest sugar-sweetened beverage intake, incident gout | highest vs lowest sugar-sweetened beverage intake, new cases of gout |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Unprocessed red meat → Gout
red_meat|gout
| Field | Before | After |
| Comparison | highest vs lowest red meat intake | highest vs lowest red meat intake (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Chronic kidney disease (as a risk factor) → Gout
ckd_exposure|gout
| Field | Before | After |
| Comparison | chronic kidney disease vs none, women | chronic kidney disease vs none, women (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Age-related macular degeneration
smoking|amd
| Field | Before | After |
| Comparison | smoker vs non-smoker | smoker vs non-smoker (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Cataract
smoking|cataract
| Field | Before | After |
| Comparison | ever smoker vs never smoker, cohort studies | ever smoker vs never smoker, cohort studies (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Type 2 diabetes (as a risk factor) → Cataract
t2d_exposure|cataract
| Field | Before | After |
| Comparison | type 2 diabetes vs no diabetes, any cataract (mostly cross-sectional studies) | type 2 diabetes vs no diabetes, any cataract (mostly cross-sectional studies; odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Type 2 diabetes (as a risk factor) → Age-related hearing loss
t2d_exposure|hearing_loss
| Field | Before | After |
| Comparison | diabetes vs no diabetes, prevalent hearing impairment | diabetes vs no diabetes, prevalent hearing impairment (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Long sleep → Dementia (all-cause)
long_sleep|dementia
| Field | Before | After |
| Comparison | long sleep duration vs normal (7-8 h/night) | long sleep duration vs normal (7-8 h/night), hazard ratio |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Nitrogen dioxide → COPD
no2|copd
| Field | Before | After |
| Comparison | per 10 µg/m³ higher NO2 | per 10 µg/m³ higher NO2 (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.3 (9 Sep 2026)
Arsenic in drinking water → Type 2 diabetes
arsenic|t2d
| Field | Before | After |
| Comparison | high vs low drinking-water arsenic | high vs low drinking-water arsenic (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Mediterranean dietary pattern → Major depression
mediterranean|depression
| Field | Before | After |
| Comparison | high vs low Mediterranean diet adherence, prospective cohorts only | high vs low Mediterranean diet adherence, prospective cohorts only (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.3 (9 Sep 2026)
HIV infection → COPD
hiv|copd
| Field | Before | After |
| Comparison | HIV positive vs HIV negative | HIV positive vs HIV negative (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Gum disease → Type 2 diabetes
periodontitis|t2d
| Field | Before | After |
| Comparison | periodontitis vs no periodontitis at baseline | periodontitis vs no periodontitis at baseline (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Proton pump inhibitors (acid-suppressing tablets) → Chronic kidney disease
ppi|ckd
| Field | Before | After |
| Comparison | PPI use vs non-use | PPI use vs non-use (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Blood pressure treatment → Dementia (all-cause)
antihypertensives|dementia
| Field | Before | After |
| Comparison | any antihypertensive use vs none, among people with hypertensive-level blood pressure | any antihypertensive use vs none, among people with hypertensive-level blood pressure (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Statin treatment → Peripheral artery disease
statins|pad
| Field | Before | After |
| Comparison | statin use vs none in people who already have PAD, major adverse limb events (amputation, graft occlusion or revascularisation) | statin use vs none in people who already have PAD, major adverse limb events (amputation, graft occlusion or revascularisation), hazard ratio |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Polycystic ovary syndrome → Fatty liver disease (MASLD)
pcos|masld
| Field | Before | After |
| Comparison | PCOS vs no PCOS | PCOS vs no PCOS (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Occupational noise → Coronary heart disease
occ_noise|chd
| Field | Before | After |
| Comparison | occupational noise >=85 dBA vs <85 dBA, incident IHD | occupational noise >=85 dBA vs <85 dBA, new cases of ischaemic heart disease |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Adverse childhood experiences → Type 2 diabetes
aces|t2d
| Field | Before | After |
| Comparison | any adverse childhood experience vs none | any adverse childhood experience vs none (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High blood uric acid → Coronary heart disease
high_urate|chd
| Field | Before | After |
| Comparison | per 1 SD higher genetically predicted serum urate | per 1 standard deviation (a typical spread between people) higher genetically predicted serum urate (odds ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (21 Oct 2026)
High triglycerides → Type 2 diabetes
high_tg|t2d
| Field | Before | After |
| Comparison | fasting triglycerides above 1.7 mmol/L vs below | fasting triglycerides above 1.7 mmol/L vs below (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Epstein-Barr virus infection → Multiple sclerosis
ebv|multiple_sclerosis
| Field | Before | After |
| Comparison | antibodies to Epstein-Barr nuclear antigen present vs absent | antibodies to Epstein-Barr nuclear antigen present vs absent (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Multiple sclerosis
smoking|multiple_sclerosis
| Field | Before | After |
| Comparison | smokers vs non-smokers (ever or current smoking, as each study reported it) | smokers vs non-smokers (ever or current smoking, as each study reported it; odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Food insecurity → High blood pressure
food_insecurity|hypertension
| Field | Before | After |
| Comparison | food insecure vs food secure adults | food insecure vs food secure adults (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Food insecurity → Obesity
food_insecurity|obesity
| Field | Before | After |
| Comparison | food insecure vs food secure adults | food insecure vs food secure adults (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Food insecurity → Type 2 diabetes
food_insecurity|t2d
| Field | Before | After |
| Comparison | food insecure vs food secure adults | food insecure vs food secure adults (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Food insecurity → Major depression
food_insecurity|depression
| Field | Before | After |
| Comparison | food insecure vs food secure adults | food insecure vs food secure adults (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Food insecurity → Anxiety disorders
food_insecurity|anxiety_disorders
| Field | Before | After |
| Comparison | food insecure vs food secure adults | food insecure vs food secure adults (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
DASH eating pattern → High blood pressure
dash_diet|hypertension
| Field | Before | After |
| Comparison | highest vs lowest DASH adherence score | highest vs lowest DASH adherence score (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Repeated antibiotic courses → Obesity
antibiotics_exposure|obesity
| Field | Before | After |
| Comparison | four or more antibiotic prescriptions in early life vs none, outcome childhood overweight or obesity | four or more antibiotic prescriptions in early life vs none, outcome childhood overweight or obesity (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Having been breastfed → Obesity
breastfed_infant|obesity
| Field | Before | After |
| Comparison | ever breastfed vs never breastfed, outcome obesity at ages two to six | ever breastfed vs never breastfed, outcome obesity at ages two to six (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Ultra-processed food → Obesity
upf|obesity
| Field | Before | After |
| Comparison | highest vs lowest ultra-processed food exposure | highest vs lowest ultra-processed food exposure (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio (plan C07; added at verification, the scan had missed it). corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Ultra-processed food → Anxiety disorders
upf|anxiety_disorders
| Field | Before | After |
| Comparison | highest vs lowest ultra-processed food exposure | highest vs lowest ultra-processed food exposure (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Cannabis use → Schizophrenia
cannabis|schizophrenia
| Field | Before | After |
| Comparison | heaviest cannabis users vs non-users | heaviest cannabis users vs non-users (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Recreational screen time → Obesity
screen_time|obesity
| Field | Before | After |
| Comparison | highest vs lowest category of screen time in adolescents | highest vs lowest category of screen time in adolescents (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High body-mass index → Psoriasis
high_bmi|psoriasis
| Field | Before | After |
| Comparison | per 1 kg/m² higher genetically predicted BMI | per 1 kg/m² higher genetically predicted BMI (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High body-mass index → Chronic low back pain
high_bmi|low_back_pain
| Field | Before | After |
| Comparison | obese vs non-overweight, incident low back pain in cohort studies | obese vs non-overweight, new cases of low back pain in cohort studies (odds ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Chronic low back pain
smoking|low_back_pain
| Field | Before | After |
| Comparison | per unit higher genetically predicted smoking | per unit higher genetically predicted smoking (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (21 Oct 2026)
Insomnia → Chronic low back pain
insomnia|low_back_pain
| Field | Before | After |
| Comparison | genetically predicted insomnia | genetically predicted insomnia (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (21 Oct 2026)
Sedentary behaviour → Chronic low back pain
sedentary|low_back_pain
| Field | Before | After |
| Comparison | genetically predicted leisure sedentary behaviour | genetically predicted leisure sedentary behaviour (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (21 Oct 2026)
Heavy alcohol use → Chronic low back pain
alcohol_heavy|low_back_pain
| Field | Before | After |
| Comparison | per unit higher genetically predicted alcohol consumption | per unit higher genetically predicted alcohol consumption (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (21 Oct 2026)
Smokeless tobacco → Gum disease (periodontitis)
smokeless_tobacco|periodontitis_disease
| Field | Before | After |
| Comparison | smokeless tobacco users vs non-users | smokeless tobacco users vs non-users (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High body-mass index → Migraine
high_bmi|migraine
| Field | Before | After |
| Comparison | obese vs normal weight | obese vs normal weight (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Type 2 diabetes (as a risk factor) → Glaucoma
t2d_exposure|glaucoma
| Field | Before | After |
| Comparison | diabetes vs no diabetes, incident primary open-angle glaucoma | diabetes vs no diabetes, new cases of primary open-angle glaucoma |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Bisphenol A → Type 2 diabetes
bisphenol_a|t2d
| Field | Before | After |
| Comparison | higher vs lower bisphenol A concentration in urine or blood | higher vs lower bisphenol A concentration in urine or blood (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Damp and mould at home → Asthma (adult)
damp_mould|asthma
| Field | Before | After |
| Comparison | any dampness or mould in the home vs none, incident asthma | any dampness or mould in the home vs none, new cases of asthma |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Antidepressant (SSRI) use → Osteoporotic fracture
ssri|fracture
| Field | Before | After |
| Comparison | users of newer antidepressants vs non-users, outcome hip fracture | users of newer antidepressants vs non-users, outcome hip fracture (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Influenza vaccination → Coronary heart disease
flu_vaccination|chd
| Field | Before | After |
| Comparison | influenza vaccine vs placebo or usual care in adults with established cardiovascular disease; composite of death, heart attack and stent thrombosis | influenza vaccine vs placebo or usual care in adults with established cardiovascular disease; composite of death, heart…influenza vaccine vs placebo or usual care in adults with established cardiovascular disease; composite of death, heart attack and stent thrombosis (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (21 Oct 2026)
E-cigarette use → COPD
ecigs|copd
| Field | Before | After |
| Comparison | former smokers who switched to e-cigarettes vs people still smoking, outcome respiratory disease including COPD | former smokers who switched to e-cigarettes vs people still smoking, outcome respiratory disease including COPD (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Low physical activity → Sarcopenia
low_pa|sarcopenia
| Field | Before | After |
| Comparison | physically inactive vs active older adults living in the community | physically inactive vs active older adults living in the community (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Sarcopenia
smoking|sarcopenia
| Field | Before | After |
| Comparison | smokers vs non-smokers among community-dwelling older adults | smokers vs non-smokers among community-dwelling older adults (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Low nut and seed intake → Obesity
low_nuts|obesity
| Field | Before | After |
| Comparison | lower vs higher nut intake, incident overweight or obesity | lower vs higher nut intake, new cases of overweight or obesity |
7 Oct 2026 review: contrast reworded in plain language. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High body-mass index → Obstructive sleep apnoea
high_bmi|osa_outcome
| Field | Before | After |
| Comparison | per 1 standard deviation higher genetically predicted body-mass index | per 1 standard deviation higher genetically predicted body-mass index (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Heavy alcohol use → Obstructive sleep apnoea
alcohol_heavy|osa_outcome
| Field | Before | After |
| Comparison | people who drink alcohol vs people who do not | people who drink alcohol vs people who do not (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Tight blood sugar control → Diabetic retinopathy
glucose_control|diabetic_retinopathy
| Field | Before | After |
| Comparison | intensive vs standard glucose lowering in type 2 diabetes, retinopathy as each trial defined it | intensive vs standard glucose lowering in type 2 diabetes, retinopathy as each trial defined it (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Tight blood sugar control → Chronic kidney disease
glucose_control|ckd
| Field | Before | After |
| Comparison | intensive vs standard glucose lowering in type 2 diabetes, nephropathy as each trial defined it | intensive vs standard glucose lowering in type 2 diabetes, nephropathy as each trial defined it (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
High blood pressure → Erectile dysfunction
high_sbp|erectile_dysfunction
| Field | Before | After |
| Comparison | people with high blood pressure vs people without, adjusted for obesity, lipids, alcohol, activity, smoking and education (cross-sectional studies) | people with high blood pressure vs people without, adjusted for obesity, lipids, alcohol, activity, smoking and educatio…people with high blood pressure vs people without, adjusted for obesity, lipids, alcohol, activity, smoking and education (cross-sectional studies; odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Cannabis use → Erectile dysfunction
cannabis|erectile_dysfunction
| Field | Before | After |
| Comparison | regular cannabis users vs non-users | regular cannabis users vs non-users (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Workplace dusts, gases and fumes → COPD
vgdf|copd
| Field | Before | After |
| Comparison | occupational exposure to airborne pollutants assigned by a job-exposure matrix vs unexposed work | occupational exposure to airborne pollutants assigned by a job-exposure matrix vs unexposed work (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.3 (18 Sep 2026)
Living with several long-term conditions → Dementia (all-cause)
multimorbidity|dementia
| Field | Before | After |
| Comparison | two or more chronic conditions at baseline vs fewer | two or more chronic conditions at baseline vs fewer (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Mother smoked in pregnancy → Obesity
maternal_smoking_preg|obesity
| Field | Before | After |
| Comparison | children of mothers who smoked throughout pregnancy vs children of non-smokers | children of mothers who smoked throughout pregnancy vs children of non-smokers (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Mother smoked in pregnancy → Eczema (atopic dermatitis)
maternal_smoking_preg|atopic_dermatitis
| Field | Before | After |
| Comparison | mother smoked actively during pregnancy vs did not | mother smoked actively during pregnancy vs did not (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.3 (9 Sep 2026)
Secondhand smoke → Eczema (atopic dermatitis)
shs|atopic_dermatitis
| Field | Before | After |
| Comparison | second-hand smoke exposure during pregnancy vs none | second-hand smoke exposure during pregnancy vs none (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Eczema (atopic dermatitis)
smoking|atopic_dermatitis
| Field | Before | After |
| Comparison | active smokers vs non-smokers | active smokers vs non-smokers (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High blood pressure → Venous thromboembolism
high_sbp|vte
| Field | Before | After |
| Comparison | systolic blood pressure of 160 mmHg vs 110 mmHg | systolic blood pressure of 160 mmHg vs 110 mmHg (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Type 2 diabetes (as a risk factor) → Venous thromboembolism
t2d_exposure|vte
| Field | Before | After |
| Comparison | people with diabetes vs without | people with diabetes vs without (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.3 (9 Sep 2026)
Long-term oral steroids → Osteoporotic fracture
oral_corticosteroids|fracture
| Field | Before | After |
| Comparison | current oral steroid use vs none, adjusted for the severity of the underlying disease | current oral steroid use vs none, adjusted for the severity of the underlying disease (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Irregular sleep timing → Coronary heart disease
irregular_sleep|chd
| Field | Before | After |
| Comparison | night-to-night variation in sleep length of more than 2 hours vs 1 hour or less | night-to-night variation in sleep length of more than 2 hours vs 1 hour or less (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Car-dependent neighbourhood → Type 2 diabetes
low_walkability|t2d
| Field | Before | After |
| Comparison | living in a car-dependent neighbourhood vs a highly walkable one | living in a car-dependent neighbourhood vs a highly walkable one (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Having been born preterm → Chronic kidney disease
preterm_birth|ckd
| Field | Before | After |
| Comparison | born before 37 weeks vs at full term (one national cohort) | born before 37 weeks vs at full term (one national cohort; hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Having been born preterm → Type 2 diabetes
preterm_birth|t2d
| Field | Before | After |
| Comparison | born preterm (before 37 weeks) vs at term | born preterm (before 37 weeks) vs at term (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
PFAS 'forever chemicals' → High blood pressure
pfas|hypertension
| Field | Before | After |
| Comparison | higher vs lower blood levels of perfluoroalkyl chemicals | higher vs lower blood levels of PFAS (odds ratio) |
7 Oct 2026 review: contrast reworded in plain language; the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High body-mass index → Venous thromboembolism
high_bmi|vte
| Field | Before | After |
| Comparison | obese vs normal body-mass index | obese vs normal body-mass index (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Adverse childhood experiences → Schizophrenia
aces|schizophrenia
| Field | Before | After |
| Comparison | parents separated during childhood vs not | parents separated during childhood vs not (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Low cardiorespiratory fitness → Anxiety disorders
low_fitness|anxiety_disorders
| Field | Before | After |
| Comparison | lowest vs highest third of cardiorespiratory fitness; outcome is depression or anxiety disorder, pooled together | lowest vs highest third of cardiorespiratory fitness; outcome is depression or anxiety disorder, pooled together (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Type 2 diabetes (as a risk factor) → Erectile dysfunction
t2d_exposure|erectile_dysfunction
| Field | Before | After |
| Comparison | men with diabetes vs healthy controls, prevalence of erectile dysfunction | men with diabetes vs healthy controls, prevalence of erectile dysfunction (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
DASH eating pattern → Dementia (all-cause)
dash_diet|dementia
| Field | Before | After |
| Comparison | highest vs lowest adherence to the DASH diet, older adults | highest vs lowest adherence to the DASH diet, older adults (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Long working hours → Type 2 diabetes
long_hours|t2d
| Field | Before | After |
| Comparison | working 55 hours or more a week vs 35 to 40 hours | working 55 hours or more a week vs 35 to 40 hours (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Antidepressant (SSRI) use → Peptic ulcer
ssri|peptic_ulcer
| Field | Before | After |
| Comparison | taking an SSRI alongside an anti-inflammatory painkiller vs the painkiller alone | taking an SSRI alongside an anti-inflammatory painkiller vs the painkiller alone (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Tight blood sugar control → Coronary heart disease
glucose_control|chd
| Field | Before | After |
| Comparison | intensive vs standard glucose lowering in type 2 diabetes, outcome non-fatal heart attack | intensive vs standard glucose lowering in type 2 diabetes, outcome non-fatal heart attack (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Tight blood sugar control → Peripheral artery disease
glucose_control|pad
| Field | Before | After |
| Comparison | intensive vs standard glucose lowering in type 2 diabetes, outcome peripheral vascular disease | intensive vs standard glucose lowering in type 2 diabetes, outcome peripheral vascular disease (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.4 (19 Sep 2026)
Racism and discrimination → Type 2 diabetes
racism_discrimination|t2d
| Field | Before | After |
| Comparison | highest quarter of everyday racism vs lowest quarter | highest quarter of everyday racism vs lowest quarter (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Racism and discrimination → Schizophrenia
racism_discrimination|schizophrenia
| Field | Before | After |
| Comparison | perceived ethnic discrimination reported vs not reported, outcome psychotic symptoms | perceived ethnic discrimination reported vs not reported, outcome psychotic symptoms (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Job insecurity and unemployment → Major depression
job_insecurity|depression
| Field | Before | After |
| Comparison | perceived job insecurity vs secure employment | perceived job insecurity vs secure employment (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Added sugar in food → Fatty liver disease (MASLD)
added_sugar|masld
| Field | Before | After |
| Comparison | regular consumption of foods with added fructose (biscuits, cakes, sweets, sugary drinks) vs low consumption | regular consumption of foods with added fructose (biscuits, cakes, sweets, sugary drinks) vs low consumption (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High body-mass index → Erectile dysfunction
high_bmi|erectile_dysfunction
| Field | Before | After |
| Comparison | obesity (BMI 30 or above) vs normal weight, adjusted for confounders | obesity (BMI 30 or above) vs normal weight, adjusted for confounders (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Psoriasis
smoking|psoriasis
| Field | Before | After |
| Comparison | current smoker vs never smoker | current smoker vs never smoker (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Former smoking → Psoriasis
former_smoking|psoriasis
| Field | Before | After |
| Comparison | former smoker vs never smoker | former smoker vs never smoker (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Egg consumption → Type 2 diabetes
eggs|t2d
| Field | Before | After |
| Comparison | each extra 3 eggs a week, United States cohorts | each extra 3 eggs a week, United States cohorts (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
E-cigarette use → Coronary heart disease
ecigs|chd
| Field | Before | After |
| Comparison | e-cigarette use vs no e-cigarette use, outcome myocardial infarction | e-cigarette use vs no e-cigarette use, outcome myocardial infarction (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Menopausal hormone therapy → Venous thromboembolism
mht|vte
| Field | Before | After |
| Comparison | oral menopausal hormone therapy vs no hormone therapy | oral menopausal hormone therapy vs no hormone therapy (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Vitamin D deficiency → Multiple sclerosis
vitd_deficiency|multiple_sclerosis
| Field | Before | After |
| Comparison | each 1 standard deviation lower genetically predicted blood vitamin D level | each 1 standard deviation lower genetically predicted blood vitamin D level (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Obstructive sleep apnoea → High blood pressure
osa|hypertension
| Field | Before | After |
| Comparison | high apnoea-hypopnoea index vs low apnoea-hypopnoea index | high apnoea-hypopnoea index vs low apnoea-hypopnoea index (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High body-mass index → Aortic valve stenosis
high_bmi|aortic_stenosis
| Field | Before | After |
| Comparison | each 1 standard deviation higher genetically predicted body-mass index | each 1 standard deviation higher genetically predicted body-mass index (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High LDL cholesterol → Aortic valve stenosis
high_ldl|aortic_stenosis
| Field | Before | After |
| Comparison | each 1 standard deviation higher genetically predicted LDL cholesterol | each 1 standard deviation higher genetically predicted LDL cholesterol (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
High triglycerides → Aortic valve stenosis
high_tg|aortic_stenosis
| Field | Before | After |
| Comparison | each 1 standard deviation higher genetically predicted triglycerides | each 1 standard deviation higher genetically predicted triglycerides (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.3 (18 Sep 2026)1.3 (9 Sep 2026)
Repeated antibiotic courses → Inflammatory bowel disease
antibiotics_exposure|ibd
| Field | Before | After |
| Comparison | any antibiotic exposure vs none | any antibiotic exposure vs none (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Refined grains and white rice → Coronary heart disease
refined_grains|chd
| Field | Before | After |
| Comparison | high vs low refined grain intake, outcome cardiovascular disease | high vs low refined grain intake, outcome cardiovascular disease (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)1.3 (18 Sep 2026)1.3 (9 Sep 2026)
Long working hours → Atrial fibrillation
long_hours|afib
| Field | Before | After |
| Comparison | 55 or more working hours a week vs 35 to 40 hours | 55 or more working hours a week vs 35 to 40 hours (hazard ratio) |
7 Oct 2026 review: the quoted estimate is a hazard ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Depression (as a risk factor) → Chronic low back pain
depression_exposure|low_back_pain
| Field | Before | After |
| Comparison | depressive symptoms present vs absent, in people free of back pain at the start | depressive symptoms present vs absent, in people free of back pain at the start (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Repeated antibiotic courses → Psoriasis
antibiotics_exposure|psoriasis
| Field | Before | After |
| Comparison | antibiotic exposure in childhood vs none | antibiotic exposure in childhood vs none (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Night shift work → Obesity
night_shift|obesity
| Field | Before | After |
| Comparison | night shift work vs day work | night shift work vs day work (odds ratio) |
7 Oct 2026 review: the quoted estimate is an odds ratio. corrections.json _why
Also changed in: 2.0 (23 Oct 2026)
Trichloroethylene in drinking water → COPD
occ_solvents|copd
Link removed (rr 1.43 grade Probable).
7 Oct 2026 review: duplicates vgdf|copd. The estimate is for vapours, gases, dusts and fumes in general, so it says nothing about solvents. corrections.json remove_links
Short sleep → Major depression
short_sleep|depression
Link removed (rr 1.82 grade Suggestive).
7 Oct 2026 review: the source measures sleep difficulties, which insomnia|depression already covers. It does not measure short sleep. corrections.json remove_links
Also changed in: 1.3 (18 Sep 2026)
Chronic psychological stress → Major depression
chronic_stress|depression
Link removed (rr 1.27 grade Limited).
7 Oct 2026 review: same estimate, quote and source as job_strain|depression, so the one result was counted twice. corrections.json remove_links
Version 1.419 Sep 2026
release 9a5a568 · 434 links · 92 changed · 8 removed
Chronic explorer v1.4: re-check of 100 flagged links (audit batch 4)
Risk factors removed: Diesel engine exhaust, Hepatitis B virus, Hepatitis C virus.
Grade moves: 11 Convincing to Probable; 8 Probable to Suggestive; 7 Probable to Limited; 4 Suggestive to Limited; 3 Probable to Contested; 1 Convincing to Limited; 1 Suggestive to Probable.
Rows by field: Caveat 75, Score (ESS) 74, Quoted sentence 73, Comparison 70, Interval, upper 67, Estimate 65, Sources 65, Interval, lower 64, Review status 64, Grade 35, Trial and genetic evidence 14, Comparison type 10, Reviews counted 1, Effective reviews (N_eff) 1.
Current cigarette smoking → Coronary heart disease
smoking|chd
| Field | Before | After |
| Estimate | 2.5 | 1.98 |
| Interval, lower | 2.2 | 1.75 |
| Interval, upper | 2.9 | 2.25 |
| Comparison | current smoker vs never smoker | current vs never smokers aged 60 and over, acute coronary events |
| Score (ESS) | 55.2 | 48.1 |
| Caveat | empty | The pooled cohorts cover people aged 60 and over. In the same analysis the hazard ratio was 2.02 at ages 60 to 69 and 1.…The pooled cohorts cover people aged 60 and over. In the same analysis the hazard ratio was 2.02 at ages 60 to 69 and 1.88 at 70 and over, and 2.26 in women against 1.80 in men. The Burden of Proof analysis gives 2.12 (1.14 to 4.10) for ischaemic heart disease at 10 cigarettes a day. |
| Quoted sentence | Random effects meta-analysis of the association of smoking status with cardiovascular mortality yielded a summary hazard…Random effects meta-analysis of the association of smoking status with cardiovascular mortality yielded a summary hazard ratio of 2.07 (95% CI 1.82 to 2.36) for current smokers and 1.37 (1.25 to 1.49) for former smokers compared with never smokers. | Hazard ratios for acute coronary events were 1.98 (1.75 to 2.25) for current smokers and 1.18 (1.06 to 1.32) for former smokers. |
| Sources | bprf_smoking interheart smoking_chances gbd2021rf | smoking_chances bprf_smoking smoking_mr_levin smoking_cvd_mr_larsson interheart |
| Review status | confirmed | adjust |
Re-checked on 18 Sep 2026. The filed 2.5 (2.2–2.9) appears in none of the cited sources, and the old quote gave a cardiovascular-mortality figure. The estimate now comes from the CHANCES individual-participant meta-analysis of cohorts aged 60 and over: 1.98 (1.75–2.25) for acute coronary events. Genetic studies support causality, so the grade stays Convincing. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Former smoking → Coronary heart disease
former_smoking|chd
| Field | Before | After |
| Estimate | 1.37 | 1.18 |
| Interval, lower | 1.25 | 1.06 |
| Interval, upper | 1.49 | 1.32 |
| Comparison | former smoker vs never smoker, cardiovascular mortality | former vs never smokers aged 60 and older, acute coronary events |
| Grade | Convincing | Probable |
| Score (ESS) | 12.3 | 6.1 |
| Caveat | Risk falls steadily after quitting and approaches that of never-smokers after roughly 10-15 years. | Estimated in people aged 60 and older. Risk falls with time since quitting: in the same study, each further 10 years sin…Estimated in people aged 60 and older. Risk falls with time since quitting: in the same study, each further 10 years since stopping multiplied the risk of acute coronary events by 0.83 (0.78 to 0.89). |
| Quoted sentence | Random effects meta-analysis of the association of smoking status with cardiovascular mortality yielded a summary hazard…Random effects meta-analysis of the association of smoking status with cardiovascular mortality yielded a summary hazard ratio of 2.07 (95% CI 1.82 to 2.36) for current smokers and 1.37 (1.25 to 1.49) for former smokers compared with never smokers. | Hazard ratios for acute coronary events were 1.98 (1.75 to 2.25) for current smokers and 1.18 (1.06 to 1.32) for former smokers. |
| Sources | smoking_chances bprf_smoking gbd2021rf | smoking_chances |
Re-checked on 18 Sep 2026. The link carried the paper's cardiovascular-mortality figure, 1.37 (1.25–1.49); the coronary outcome in the same paper is 1.18 (1.06–1.32). The grade falls to Probable because the cited syntheses that adjudicate causality model current smoking only. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
High blood pressure → Coronary heart disease
high_sbp|chd
| Field | Before | After |
| Estimate | 1.9 | 2.1 |
| Interval, lower | 1.8 | 1.66 |
| Interval, upper | 2.0 | 2.62 |
| Comparison | per 20 mmHg higher usual systolic BP | per 20 mmHg higher usual systolic blood pressure, at ages 55–64 when measured |
| Score (ESS) | 46.6 | 50.1 |
| Caveat | empty | Estimate for people aged 55–64 when blood pressure was measured; the relative effect is larger at younger ages and small…Estimate for people aged 55–64 when blood pressure was measured; the relative effect is larger at younger ages and smaller in old age. Measured another way, the Burden of Proof analysis puts coronary risk at a systolic pressure of 140 mmHg at 2.38 times (2.17 to 2.62) that at 100 mmHg, and rates the evidence at five stars. |
| Quoted sentence | At ages 40-69 years, each difference of 20 mm Hg usual SBP (or, approximately equivalently, 10 mm Hg usual DBP) is assoc…At ages 40-69 years, each difference of 20 mm Hg usual SBP (or, approximately equivalently, 10 mm Hg usual DBP) is associated with more than a twofold difference in the stroke death rate, and with twofold differences in the death rates from IHD and from other vascular causes. | 55−64 | PSC | 1.37(1.35−1.39) | APCSC | 1.54(1.45−1.63) | Pooled | 1.45(1.29−1.62) |
| Sources | psc_bp bpltt gbd2021rf | metab_rf_singh psc_bp bop_sbp_ihd bpltt |
| Review status | confirmed | adjust |
Re-checked on 18 Sep 2026. The filed 1.9 (1.8–2.0) could not be found in any accessible source. A pooled analysis of the Prospective Studies Collaboration and the Asia Pacific Cohort Studies Collaboration gives 1.45 (1.29–1.62) per 10 mmHg at ages 55–64 (Figure 1A). It is shown per 20 mmHg, like the other blood-pressure links, by squaring under the log-linear model: 2.10 (1.66–2.62). review_note
Also changed in: 2.0 (23 Oct 2026)
Type 2 diabetes (as a risk factor) → Coronary heart disease
t2d_exposure|chd
| Field | Before | After |
| Comparison | diabetes vs no diabetes | diabetes vs no diabetes, people without vascular disease at baseline |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) supportive; dose-response yes |
| Sources | erfc_diabetes | erfc_diabetes t2d_chd_mr_ahmad |
Re-checked on 18 Sep 2026: the estimate matches the Emerging Risk Factors Collaboration analysis of 102 prospective studies. A Mendelian randomisation study supporting a causal effect is added. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
High body-mass index → Coronary heart disease
high_bmi|chd
| Field | Before | After |
| Estimate | 1.23 | 1.29 |
| Interval, lower | 1.17 | 1.22 |
| Interval, upper | 1.29 | 1.37 |
| Comparison | per 1 SD (4.56 kg/m²) higher BMI, cardiovascular disease | per 1 SD (4.56 kg/m²) higher BMI, in people with BMI of 20 kg/m² or more |
| Score (ESS) | 9.0 | 10.6 |
| Caveat | empty | Adjusted for age, sex and smoking. Adding blood pressure, diabetes and cholesterol to the model lowers the hazard ratio…Adjusted for age, sex and smoking. Adding blood pressure, diabetes and cholesterol to the model lowers the hazard ratio to 1.11 (1.05 to 1.17), because much of the effect of excess weight on the heart runs through those three factors, which appear as separate links. |
| Quoted sentence | In people with BMI of 20 kg/m(2) or higher, HRs for cardiovascular disease were 1.23 (95% CI 1.17-1.29) with BMI, 1.27 (…In people with BMI of 20 kg/m(2) or higher, HRs for cardiovascular disease were 1.23 (95% CI 1.17-1.29) with BMI, 1.27 (1.20-1.33) with waist circumference, and 1.25 (1.19-1.31) with waist-to-hip ratio, after adjustment for age, sex, and smoking status. | Coronary heart disease (39 studies, 143 710 participants, 5259 cases) | BMI | 1·29 (1·22–1·37) | 65% (52–75) | 1·11 (1·05–1·17) | 45% (20–62) |
Re-checked on 18 Sep 2026. The link carried the ERFC row for all cardiovascular disease, 1.23 (1.17–1.29). The coronary heart disease row of the same table (Table 1) is 1.29 (1.22–1.37) per 4.56 kg/m² higher BMI, adjusted for age, sex and smoking. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Low vegetable intake → Coronary heart disease
low_veg|chd
| Field | Before | After |
| Grade | Probable | Suggestive |
| Score (ESS) | 8.6 | 5.9 |
| Caveat | The Burden of Proof analysis found the vegetable-IHD relationship weaker than earlier reviews suggested once study bias was modelled. | The Burden of Proof analysis found the vegetable-IHD relationship weaker than earlier reviews suggested once study bias…The Burden of Proof analysis found the vegetable-IHD relationship weaker than earlier reviews suggested once study bias was modelled, and found evidence of publication bias. No randomised trials exist. |
| Quoted sentence | Increasing from no vegetable consumption to the theoretical minimum risk exposure level (306-372 g daily) was associated…Increasing from no vegetable consumption to the theoretical minimum risk exposure level (306-372 g daily) was associated with a 23.2% decline (95% uncertainty interval, including between-study heterogeneity: 16.4-29.4) in ischemic stroke risk; a 22.9% (13.6-31.3) decline in IHD risk; a 15.9% (1.7-28.1) decline in hemorrhagic stroke risk. | Increasing from no vegetable consumption to the theoretical minimum risk exposure level (306–372 g daily) was associated…Increasing from no vegetable consumption to the theoretical minimum risk exposure level (306–372 g daily) was associated with a 23.2% decline (95% uncertainty interval, including between-study heterogeneity: 16.4–29.4) in ischemic stroke risk; a 22.9% (13.6–31.3) decline in IHD risk; a 15.9% (1.7–28.1) decline in hemorrhagic stroke risk; a 28.5% (−0.02–51.4) decline in esophageal cancer risk; and a 26.1% (−3.6–48.3) decline in type 2 diabetes risk. |
Re-checked on 18 Sep 2026. The estimate is the inverse of the Burden of Proof finding that moving from no vegetables to 306–372 g a day goes with 22.9% (13.6–31.3) lower ischaemic heart disease risk: 1/0.771 = 1.30. The analysis rates the pair at two stars, so the grade moves from Probable to Suggestive. review_note
Also changed in: 2.0 (23 Oct 2026)
Low dietary fibre → Coronary heart disease
low_fibre|chd
| Field | Before | After |
| Estimate | 1.15 | 1.32 |
| Interval, lower | 1.08 | 1.2 |
| Interval, upper | 1.23 | 1.45 |
| Comparison | lowest vs highest intake | lowest vs highest total dietary fibre intake |
| Score (ESS) | 10.4 | 17.8 |
| Caveat | empty | The published comparison runs the other way: people eating the most fibre had 0.76 (0.69 to 0.83) times the coronary ris…The published comparison runs the other way: people eating the most fibre had 0.76 (0.69 to 0.83) times the coronary risk of those eating the least. The review recommends at least 25–29 g of fibre a day. |
| Quoted sentence | Observational data suggest a 15-30% decrease in all-cause and cardiovascular related mortality, and incidence of coronar…Observational data suggest a 15-30% decrease in all-cause and cardiovascular related mortality, and incidence of coronary heart disease, stroke incidence and mortality, type 2 diabetes, and colorectal cancer when comparing the highest dietary fibre consumers with the lowest consumers. | Coronary heart disease incidence | 9 | 7155 | 2·7 million person-years | RR 0·76 (0·69–0·83) | Moderate |
| Sources | fibre_reynolds wholegrain_aune | fibre_reynolds |
| Review status | confirmed | adjust |
Re-checked on 18 Sep 2026. The filed 1.15 (1.08–1.23) is not in the cited review, and whole-grain intake is a different exposure. The estimate is now the inverse of the review's coronary heart disease incidence figure, 0.76 (0.69–0.83) from nine cohorts (Reynolds et al. 2019, Table 1): 1/0.76 = 1.32, 1/0.83 = 1.20, 1/0.69 = 1.45. review_note
Also changed in: 2.0 (23 Oct 2026)
Low seafood omega-3 intake → Coronary heart disease
low_omega3|chd
| Field | Before | After |
| Estimate | 1.11 | 1.1 |
| Comparison | lowest vs highest seafood omega-3 intake | lowest vs highest fish consumption |
| Score (ESS) | 5.6 | 5.2 |
| Caveat | Most randomised trials of omega-3 supplements have been null. REDUCE-IT found benefit with high-dose icosapent ethyl, bu…Most randomised trials of omega-3 supplements have been null. REDUCE-IT found benefit with high-dose icosapent ethyl, but the mineral-oil comparator remains disputed. | The pooled studies measured fish consumption, the main dietary source of seafood omega-3. Randomised trials of omega-3 s…The pooled studies measured fish consumption, the main dietary source of seafood omega-3. Randomised trials of omega-3 supplements show little or no coronary benefit overall; REDUCE-IT found benefit with high-dose icosapent ethyl, but its mineral-oil comparator remains disputed. |
| Quoted sentence | Among them, 22 studies investigated the association between fish consumption and CHD incidence (28,261 cases and 918,783…Among them, 22 studies investigated the association between fish consumption and CHD incidence (28,261 cases and 918,783 participants), and the summary estimate showed that higher fish consumption was significantly associated with a lower CHD incidence [RR: 0.91, 95% CI: (0.84, 0.97)]. | By comparing the highest and lowest fish consumption categories, the combined RR for the CHD incidence was found to be 0…By comparing the highest and lowest fish consumption categories, the combined RR for the CHD incidence was found to be 0.91 (0.84, 0.97) (p = 0.008), with a moderate level of heterogeneity (I2 = 47.4%). |
| Sources | fish_chd_jiang gbd2021rf | fish_chd_jiang omega3_chd_alexander |
| Review status | new_citation | adjust |
Re-checked on 18 Sep 2026. The estimate is the inverse of the pooled highest-versus-lowest fish consumption figure, 0.91 (0.84–0.97), from 22 cohorts (Jiang et al. 2020): 1/0.91 = 1.10, 1/0.97 = 1.03, 1/0.84 = 1.19. The source measured fish consumption, so the contrast now says so. review_note
Also changed in: 2.0 (23 Oct 2026)
Heavy alcohol use → Coronary heart disease
alcohol_heavy|chd
| Field | Before | After |
| Estimate | 1.25 | 1.04 |
| Interval, lower | 1.14 | 0.83 |
| Interval, upper | 1.37 | 1.31 |
| Comparison | heavy or binge drinking vs light drinking | chronic heavy drinking (60 g or more of alcohol a day on average) vs lifetime abstainers, men |
| Grade | Probable | Contested |
| Score (ESS) | 16.8 | 1.2 |
| Caveat | empty | The interval includes no effect: in these observational studies, men who drank heavily had about the same coronary risk…The interval includes no effect: in these observational studies, men who drank heavily had about the same coronary risk as men who never drank. Genetic studies point in different directions: one found that people genetically inclined to drink less had fewer coronary events, and another found no link with heart attack. Heavy drinking does raise blood pressure and stroke risk, which are separate links. |
| Quoted sentence | For myocardial infarction, however, genotype-predicted mean alcohol intake was not significantly associated with risk (R…For myocardial infarction, however, genotype-predicted mean alcohol intake was not significantly associated with risk (RR per 280 g per week 0.96, 95% CI 0.78-1.18, p=0.69). | In population studies among men, the pooled risk for IHD incidence (fatal+non-fatal events) among chronic heavy drinkers…In population studies among men, the pooled risk for IHD incidence (fatal+non-fatal events) among chronic heavy drinkers (on average ≥60 g pure alcohol/day) in comparison to lifetime abstainers (n=11 studies) was relative risk (RR)=1.04 (95% CI 0.83 to 1.31, I(2)=54%). |
| Sources | ckb_alcohol mr_alcohol_holmes gbd2021rf | alc_heavy_ihd_roerecke mr_alcohol_holmes ckb_alcohol |
| Review status | suspect | adjust |
Re-checked on 18 Sep 2026. The filed 1.25 (1.14–1.37) for heavy or binge drinking versus light drinking appears in none of the cited sources, and no eligible source gives that contrast for coronary disease. The estimate now comes from a meta-analysis of chronic heavy drinking and ischaemic heart disease (Roerecke and Rehm 2014). It is graded Contested because the genetic studies disagree with each other and with the observational result. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Fine particulate air pollution → Coronary heart disease
pm25|chd
| Field | Before | After |
| Estimate | 1.11 | 1.23 |
| Interval, lower | 1.07 | 1.15 |
| Interval, upper | 1.15 | 1.31 |
| Comparison | per 10 µg/m³ higher annual PM2.5 | per 10 µg/m³ higher long-term PM2.5, death from ischaemic heart disease |
| Score (ESS) | 12.0 | 21.1 |
| Caveat | empty | The pooled estimate is for death from ischaemic heart disease. For first heart attacks the same review found a smaller i…The pooled estimate is for death from ischaemic heart disease. For first heart attacks the same review found a smaller increase that did not reach significance (1.08, 0.99 to 1.18 per 10 µg/m³), and the European ESCAPE cohorts found 1.13 (0.98 to 1.30) per 5 µg/m³. |
| Quoted sentence | empty | The combined estimate of the RR of IHD mortality among studies was 1.23 (95% CI, 1.15–1.31) per 10‐µg/m3 increase in lon…The combined estimate of the RR of IHD mortality among studies was 1.23 (95% CI, 1.15–1.31) per 10‐µg/m3 increase in long‐term PM2.5. There was substantial heterogeneity among studies (I2=94.4%). |
| Sources | who_air escape gbd2021rf | pm25_ihd_alexeeff who_air escape_coronary gbd2021rf |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026. The filed 1.11 (1.07–1.15) has no located source. A meta-analysis gives 1.23 (1.15–1.31) per 10 µg/m³ for ischaemic heart disease deaths across 23 studies (Alexeeff et al. 2021). The grade stays Convincing: WHO rates the evidence on PM2.5 and circulatory deaths as high certainty. review_note
Also changed in: 2.0 (23 Oct 2026)
Household air pollution → Coronary heart disease
hap|chd
| Field | Before | After |
| Estimate | 1.21 | 1.08 |
| Interval, lower | 1.1 | 1.03 |
| Interval, upper | 1.34 | 1.13 |
| Comparison | highest vs lowest solid fuel use, composite cardiovascular events | household use of polluting fuels (coal, wood, charcoal, crop waste, dung or kerosene) for cooking or heating vs no such use, longitudinal studies |
| Grade | Probable | Suggestive |
| Score (ESS) | 6.8 | 2.2 |
| Caveat | empty | Exposure is simply whether a household cooks or heats with polluting fuels, and such households are poorer in ways the s…Exposure is simply whether a household cooks or heats with polluting fuels, and such households are poorer in ways the studies could only partly adjust for. Pooling studies of all designs gives a similar 1.10 (1.09 to 1.11). |
| Quoted sentence | The risk of CVEs was increased 21% with the highest versus the lowest solid fuel use (highest/lowest, RR = 1.21, 95% CI: 1.10-1.34). | Ischemic heart disease | 8 | 22.6% | 1.08 (1.03–1.13) |
| Sources | solidfuel_cve_huang gbd2021rf | hap_health_lee2020 solidfuel_cve_huang |
Re-checked on 18 Sep 2026. The link carried a composite cardiovascular-events estimate, 1.21 (1.10–1.34), that pools case-control and cross-sectional studies. A 2020 meta-analysis gives the ischaemic heart disease estimate from longitudinal studies, 1.08 (1.03–1.13) (appendix, Figure S32), graded Suggestive. review_note
Also changed in: 2.0 (23 Oct 2026)
Job strain → Coronary heart disease
job_strain|chd
| Field | Before | After |
| Caveat | empty | This estimate is adjusted for age and sex. With socioeconomic status also taken into account it is 1.17 (1.05 to 1.31).…This estimate is adjusted for age and sex. With socioeconomic status also taken into account it is 1.17 (1.05 to 1.31). Leaving out heart events in the first 3 years of follow-up gave 1.31 (1.15 to 1.48), which makes reverse causation an unlikely explanation. |
Re-checked on 18 Sep 2026: the estimate, interval and contrast match the IPD-Work individual-participant analysis of 13 European cohorts (197,473 people). review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Adverse childhood experiences → Coronary heart disease
aces|chd
| Field | Before | After |
| Estimate | 1.25 | 1.36 |
| Interval, upper | 1.38 | 1.63 |
| Comparison | 4+ adverse childhood experiences vs none | most vs fewest childhood adversities (recalled in adulthood); combined cardiovascular outcomes: high blood pressure, cor…most vs fewest childhood adversities (recalled in adulthood); combined cardiovascular outcomes: high blood pressure, coronary heart disease, heart attack and stroke |
| Grade | Suggestive | Limited |
| Reviews counted | 4 | 1 |
| Effective reviews (N_eff) | 3 | 1 |
| Score (ESS) | 10.4 | 3.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) null; dose-response yes |
| Caveat | Rests largely on retrospective recall of childhood, which is subject to recall bias. | Adults recalled their childhood adversity at the start of follow-up, and the pooled outcome combines high blood pressure…Adults recalled their childhood adversity at the start of follow-up, and the pooled outcome combines high blood pressure, coronary heart disease, heart attack and stroke. A genetic (Mendelian randomisation) study found no causal effect of childhood maltreatment on coronary artery disease. |
| Quoted sentence | Associations were weak or modest for physical inactivity, overweight or obesity, and diabetes (ORs of less than two); mo…Associations were weak or modest for physical inactivity, overweight or obesity, and diabetes (ORs of less than two); moderate for smoking, heavy alcohol use, poor self-rated health, cancer, heart disease, and respiratory disease (ORs of two to three), strong for sexual risk taking, mental ill health, and problematic alcohol use (ORs of more than three to six), and strongest for problematic drug use and interpersonal and self-directed violence (ORs of more than seven). | CVD clinical outcomes (k=12) | 1.36* | 1.13 – 1.63 | 41.11* | |
| Sources | aces_hughes | aces_cvd_jakubowski maltreatment_mr_warrier |
| Review status | suspect | adjust |
Re-checked on 18 Sep 2026. The filed 1.25 (1.13–1.38) is not in the cited review, which pools mostly cross-sectional surveys that the framework excludes. No eligible meta-analysis gives a coronary-specific estimate. The only prospective pooled estimate covers combined cardiovascular outcomes (Table 2 of Jakubowski et al. 2018), so the link is relabelled and graded Limited. review_note
Also changed in: 2.0 (23 Oct 2026)
Chronic kidney disease (as a risk factor) → Coronary heart disease
ckd_exposure|chd
| Field | Before | After |
| Estimate | 1.65 | 1.4 |
| Interval, lower | 1.48 | 1.3 |
| Interval, upper | 1.84 | 1.5 |
| Comparison | eGFR <60 vs ≥60 mL/min/1.73m² | eGFR 45–59 vs 90–104 mL/min/1.73 m², both without albuminuria (urine albumin-to-creatinine ratio under 10 mg/g) |
| Comparison type | binary | category |
| Grade | Convincing | Probable |
| Score (ESS) | 36.3 | 22.6 |
| Caveat | empty | Compares moderately reduced kidney function (eGFR 45–59) with normal function in people without albuminuria, adjusted fo…Compares moderately reduced kidney function (eGFR 45–59) with normal function in people without albuminuria, adjusted for the usual cardiovascular risk factors. Risk is higher when albuminuria is also present: 1.7 (1.6 to 1.8) at a urine albumin-to-creatinine ratio of 10–29 mg/g. |
| Quoted sentence | empty | Coronary heart disease | 1 [Reference] | 1.4 (1.3-1.5) | 1.7 (1.6-1.8) | 1.6 (1.4-1.8) | 1 [Reference] | 1.6 (1.3-2.0) | 2.0 (1.7-2.3) | |
| Sources | gbd_ckd | ckdpc_jama gbd_ckd |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026. The filed 1.65 (1.48–1.84) had no quote, and the cited GBD kidney paper reports no relative risks. The estimate now comes from the CKD Prognosis Consortium's individual-participant analysis (JAMA 2023, Table 2). The grade moves to Probable: the evidence is observational, with no trial or genetic support recorded. review_note
Also changed in: 2.0 (23 Oct 2026)
Menopausal hormone therapy → Coronary heart disease
mht|chd
| Field | Before | After |
| Estimate | 1.29 | 1.18 |
| Interval, lower | 1.02 | 0.95 |
| Interval, upper | 1.63 | 1.45 |
| Comparison | conjugated equine oestrogens plus medroxyprogesterone vs placebo, women aged 50-79 | conjugated equine oestrogens plus medroxyprogesterone vs placebo, women aged 50–79, trial intervention phase (median 5.6 years) |
| Grade | Convincing | Limited |
| Score (ESS) | 10.6 | 2.3 |
| Trial and genetic evidence | Trial contradicts; Genetic (MR) none; dose-response yes | Trial null; Genetic (MR) none; dose-response yes |
| Caveat | A textbook reversal. Observational studies suggested ~50% protection; the WHI randomised trial found early harm. Timing…A textbook reversal. Observational studies suggested ~50% protection; the WHI randomised trial found early harm. Timing matters: initiation near menopause appears less harmful than initiation years later. | Observational studies once suggested about 50% protection, and randomised trials showed no benefit. In the WHI combined-…Observational studies once suggested about 50% protection, and randomised trials showed no benefit. In the WHI combined-therapy trial coronary risk was raised in the first year (HR 1.80) and faded later; oestrogen alone showed no increase (HR 0.94); and across 25 randomised trials there is no overall effect (1.00, 0.90 to 1.11). A Cochrane review found lower coronary risk when therapy began within 10 years of menopause. |
| Quoted sentence | Estimated hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: CHD, 1.29 (1.02-1.63) with 286 c…Estimated hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: CHD, 1.29 (1.02-1.63) with 286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41 (1.07-1.85) with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases. | During the intervention phase for CEE+MPA, the hazard ratio (HR) for CHD was 1.18 (95% confidence interval [CI] 0.95–1.4…During the intervention phase for CEE+MPA, the hazard ratio (HR) for CHD was 1.18 (95% confidence interval [CI] 0.95–1.45) and overall risks outweighed benefits, with increases in invasive breast cancer, stroke, pulmonary embolism, and the global index. |
| Sources | whi | whi_manson2013 hrt_vascular_sare2008 whi |
Re-checked on 18 Sep 2026. The filed 1.29 (1.02–1.63) is the 2002 WHI estimate with unadjusted intervals. The WHI long-term report gives 1.18 (0.95–1.45) for the intervention phase, and a meta-analysis of 25 trials finds no overall effect. The interval includes no effect, so the grade moves from Convincing to Limited; WHI 2002 stays as supporting evidence. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Vitamin D deficiency → Coronary heart disease
vitd_deficiency|chd
| Field | Before | After |
| Estimate | 1.2 | 1.38 |
| Interval, lower | 1.1 | 1.21 |
| Interval, upper | 1.31 | 1.57 |
| Comparison | lowest vs highest 25(OH)D | lowest vs highest circulating 25(OH)D category |
| Score (ESS) | 4.5 | 6.9 |
| Quoted sentence | The Mendelian randomization odds ratio (OR) for CAD was 0.99 (95% confidence interval, 0.84-1.17; P=0.93; I(2)=0) per SD…The Mendelian randomization odds ratio (OR) for CAD was 0.99 (95% confidence interval, 0.84-1.17; P=0.93; I(2)=0) per SD decrease in log-transformed 25OHD levels. | In a comparison of the lowest with the highest 25(OH)-vitamin D categories, the pooled relative risk was 1.52 (95% confi…In a comparison of the lowest with the highest 25(OH)-vitamin D categories, the pooled relative risk was 1.52 (95% confidence interval, 1.30-1.77) for total CVD, 1.42 (95% confidence interval, 1.19-1.71) for CVD mortality, 1.38 (95% confidence interval, 1.21-1.57) for coronary heart disease, and 1.64 (95% confidence interval, 1.27-2.10) for stroke. |
| Sources | vitd_mr vital d_health | vitd_cvd_wang2012 vitd_mr vital d_health |
| Review status | suspect | adjust |
Re-checked on 18 Sep 2026. The filed 1.20 (1.10–1.31) was in neither cited source. A meta-analysis of prospective studies gives 1.38 (1.21–1.57) for coronary heart disease (Wang et al. 2012). Mendelian randomisation (0.99, 0.84–1.17) and the VITAL trial contradict it, so the grade stays Contested. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
High blood pressure → Ischaemic stroke
high_sbp|stroke_isch
| Field | Before | After |
| Estimate | 2.2 | 2.66 |
| Interval, lower | 2.05 | 2.46 |
| Interval, upper | 2.36 | 2.86 |
| Comparison | per 20 mmHg higher usual systolic BP | per 20 mmHg higher usual systolic blood pressure, at ages 55–64 when measured |
| Score (ESS) | 51.6 | 56.8 |
| Caveat | Blood pressure is the single largest modifiable contributor to stroke worldwide. | Estimate for people aged 55–64 when blood pressure was measured; the relative effect is larger at younger ages and small…Estimate for people aged 55–64 when blood pressure was measured; the relative effect is larger at younger ages and smaller in old age. Blood pressure is the single largest modifiable contributor to stroke worldwide. |
| Quoted sentence | At ages 40-69 years, each difference of 20 mm Hg usual SBP (or, approximately equivalently, 10 mm Hg usual DBP) is assoc…At ages 40-69 years, each difference of 20 mm Hg usual SBP (or, approximately equivalently, 10 mm Hg usual DBP) is associated with more than a twofold difference in the stroke death rate, and with twofold differences in the death rates from IHD and from other vascular causes. | At the baseline age of 55-64 years, the RR for 10 mmHg higher SBP was largest for HHD (2.16; 95% CI 2.09-2.24), followed…At the baseline age of 55-64 years, the RR for 10 mmHg higher SBP was largest for HHD (2.16; 95% CI 2.09-2.24), followed by effects on both stroke subtypes (1.66; 1.39-1.98 for hemorrhagic stroke and 1.63; 1.57-1.69 for ischemic stroke). |
| Sources | psc_bp bpltt interstroke | metab_rf_singh psc_bp bpltt bp_stroke_mr_georgakis interstroke |
| Review status | confirmed | adjust |
Re-checked on 18 Sep 2026. The filed 2.2 (2.05–2.36) could not be found in any accessible source. A pooled analysis of the Prospective Studies Collaboration and the Asia Pacific Cohort Studies Collaboration gives 1.63 (1.57–1.69) per 10 mmHg at ages 55–64, shown per 20 mmHg by squaring: 2.66 (2.46–2.86). review_note
Also changed in: 2.0 (23 Oct 2026)
High blood pressure → Haemorrhagic stroke
high_sbp|stroke_haem
| Field | Before | After |
| Estimate | 2.6 | 2.76 |
| Interval, lower | 2.35 | 1.93 |
| Interval, upper | 2.88 | 3.92 |
| Comparison | per 20 mmHg higher usual systolic BP | per 20 mmHg higher usual systolic blood pressure, at ages 55–64 when measured |
| Score (ESS) | 55.1 | 56.5 |
| Caveat | empty | Estimate for people aged 55–64 when blood pressure was measured; the relative effect is larger at younger ages. The two…Estimate for people aged 55–64 when blood pressure was measured; the relative effect is larger at younger ages. The two consortia differ (1.52 per 10 mmHg in the mainly Western cohorts, 1.82 in the Asia-Pacific cohorts), hence the wide interval. Per unit of blood pressure the pooled estimates for haemorrhagic and ischaemic stroke are about the same. |
| Quoted sentence | Hypertension was more associated with intracerebral haemorrhage than with ischaemic stroke, whereas current smoking, dia…Hypertension was more associated with intracerebral haemorrhage than with ischaemic stroke, whereas current smoking, diabetes, apolipoproteins, and cardiac causes were more associated with ischaemic stroke (p<0.0001). | At the baseline age of 55-64 years, the RR for 10 mmHg higher SBP was largest for HHD (2.16; 95% CI 2.09-2.24), followed…At the baseline age of 55-64 years, the RR for 10 mmHg higher SBP was largest for HHD (2.16; 95% CI 2.09-2.24), followed by effects on both stroke subtypes (1.66; 1.39-1.98 for hemorrhagic stroke and 1.63; 1.57-1.69 for ischemic stroke). |
| Sources | psc_bp interstroke | metab_rf_singh psc_bp bp_stroke_mr_georgakis interstroke |
| Review status | confirmed | adjust |
Re-checked on 18 Sep 2026. The filed 2.6 (2.35–2.88) could not be found in any accessible source. A pooled analysis of the Prospective Studies Collaboration and the Asia Pacific Cohort Studies Collaboration gives 1.66 (1.39–1.98) per 10 mmHg at ages 55–64, shown per 20 mmHg by squaring: 2.76 (1.93–3.92). review_note
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Ischaemic stroke
smoking|stroke_isch
| Field | Before | After |
| Estimate | 1.92 | 2.09 |
| Interval, lower | 1.75 | 1.74 |
| Interval, upper | 2.1 | 2.5 |
| Comparison | current smoker vs never smoker | current vs never smokers, new ischaemic stroke |
| Score (ESS) | 46.1 | 49.0 |
| Caveat | empty | Risk falls after quitting: in the same meta-analysis the odds of ischaemic stroke three years after stopping were 0.59 (…Risk falls after quitting: in the same meta-analysis the odds of ischaemic stroke three years after stopping were 0.59 (0.48 to 0.73) times those at the time of quitting. |
| Quoted sentence | Hypertension was more associated with intracerebral haemorrhage than with ischaemic stroke, whereas current smoking, dia…Hypertension was more associated with intracerebral haemorrhage than with ischaemic stroke, whereas current smoking, diabetes, apolipoproteins, and cardiac causes were more associated with ischaemic stroke (p<0.0001). | Compared with never smoker, the pooled OR of IS incidence for ever smokers, former smokers and current smokers was 1.55…Compared with never smoker, the pooled OR of IS incidence for ever smokers, former smokers and current smokers was 1.55 (1.26–1.91, P < 0.0001), 1.05 (1.00–1.11, P = 0.03), and 2.09 (1.74–2.50, P < 0.00001; Supplementary Figure 2); … |
| Sources | interstroke bprf_smoking smoking_chances gbd2021rf | smoking_stroke_luo bprf_smoking smoking_chances lifestyle_stroke_mr_harshfield smoking_cvd_mr_larsson interstroke |
| Review status | confirmed | adjust |
Re-checked on 18 Sep 2026. The filed 1.92 (1.75–2.10) was not found in any cited source. A dose-response meta-analysis of prospective cohorts gives 2.09 (1.74–2.50) for current smokers and new ischaemic stroke (Luo et al. 2022). Genetic studies support causality. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Current cigarette smoking → Haemorrhagic stroke
smoking|stroke_haem
| Field | Before | After |
| Estimate | 1.35 | 2.58 |
| Interval, lower | 1.2 | 2.23 |
| Interval, upper | 1.52 | 2.97 |
| Comparison | current smoker vs never smoker | current vs never smokers, new haemorrhagic stroke |
| Score (ESS) | 20.9 | 40.0 |
| Caveat | The association is clearer for subarachnoid haemorrhage than for intracerebral haemorrhage. | The excess is much larger for subarachnoid haemorrhage (3.39) than for intracerebral haemorrhage (1.61). Genetic studies are inconclusive for both. |
| Quoted sentence | Hypertension was more associated with intracerebral haemorrhage than with ischaemic stroke, whereas current smoking, dia…Hypertension was more associated with intracerebral haemorrhage than with ischaemic stroke, whereas current smoking, diabetes, apolipoproteins, and cardiac causes were more associated with ischaemic stroke (p<0.0001). | … the pooled OR of HS incidence for ever smokers, former smokers and current smokers was 1.49 (1.06–2.11, P = 0.02), 1.0…… the pooled OR of HS incidence for ever smokers, former smokers and current smokers was 1.49 (1.06–2.11, P = 0.02), 1.01 (0.86–1.18, P = 0.90) and 2.58 (2.23–2.97, P < 0.00001; Supplementary Figure 3); … |
| Sources | interstroke bprf_smoking | smoking_stroke_luo bprf_smoking smoking_cvd_mr_larsson lifestyle_stroke_mr_harshfield interstroke |
| Review status | confirmed | adjust |
Re-checked on 18 Sep 2026. The filed 1.35 (1.20–1.52) was not found in any cited source. The same meta-analysis of prospective cohorts gives 2.58 (2.23–2.97) for current smokers and haemorrhagic stroke (Luo et al. 2022). review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Fine particulate air pollution → Ischaemic stroke
pm25|stroke_isch
| Field | Before | After |
| Estimate | 1.19 | 1.18 |
| Interval, lower | 0.88 | 1.14 |
| Interval, upper | 1.62 | 1.22 |
| Comparison | per 5 µg/m³ higher annual PM2.5, incident stroke | per 10 µg/m³ higher long-term PM2.5, new ischaemic stroke |
| Grade | Suggestive | Probable |
| Score (ESS) | 4.3 | 6.1 |
| Caveat | The confidence interval includes no effect. | Only five cohorts report ischaemic stroke separately. The European ESCAPE analysis of all strokes was imprecise (1.19, 0…Only five cohorts report ischaemic stroke separately. The European ESCAPE analysis of all strokes was imprecise (1.19, 0.88 to 1.62 per 5 µg/m³) but stronger in people aged 60 or over and in never-smokers. |
| Quoted sentence | A 5-microg/m3 increase in annual PM2.5 exposure was associated with 19% increased risk of incident stroke [hazard ratio…A 5-microg/m3 increase in annual PM2.5 exposure was associated with 19% increased risk of incident stroke [hazard ratio (HR) = 1.19, 95% CI: 0.88, 1.62]. | The RR of an incident ischemic stroke in the random effects meta‐analysis was 1.18 (95% CI, 1.14–1.22), with low heterog…The RR of an incident ischemic stroke in the random effects meta‐analysis was 1.18 (95% CI, 1.14–1.22), with low heterogeneity among studies (I2=11.8%). |
| Sources | escape_stroke escape who_air gbd2021rf | pm25_ihd_alexeeff escape_stroke who_air gbd2021rf |
Re-checked on 18 Sep 2026. The filed 1.19 (0.88–1.62) per 5 µg/m³ was for all strokes in the ESCAPE cohorts. A meta-analysis gives 1.18 (1.14–1.22) per 10 µg/m³ for new ischaemic stroke, with low heterogeneity (Alexeeff et al. 2021), so the grade moves to Probable. review_note
Also changed in: 2.0 (23 Oct 2026)1.3 (9 Sep 2026)
Low vegetable intake → Ischaemic stroke
low_veg|stroke_isch
| Field | Before | After |
| Quoted sentence | Increasing from no vegetable consumption to the theoretical minimum risk exposure level (306-372 g daily) was associated…Increasing from no vegetable consumption to the theoretical minimum risk exposure level (306-372 g daily) was associated with a 23.2% decline (95% uncertainty interval, including between-study heterogeneity: 16.4-29.4) in ischemic stroke risk; a 22.9% (13.6-31.3) decline in IHD risk; a 15.9% (1.7-28.1) decline in hemorrhagic stroke risk. | Increasing from no vegetable consumption to the theoretical minimum risk exposure level (306–372 g daily) was associated…Increasing from no vegetable consumption to the theoretical minimum risk exposure level (306–372 g daily) was associated with a 23.2% decline (95% uncertainty interval, including between-study heterogeneity: 16.4–29.4) in ischemic stroke risk; a 22.9% (13.6–31.3) decline in IHD risk; a 15.9% (1.7–28.1) decline in hemorrhagic stroke risk; a 28.5% (−0.02–51.4) decline in esophageal cancer risk; and a 26.1% (−3.6–48.3) decline in type 2 diabetes risk. |
| Review status | adjust | confirmed |
Re-checked on 18 Sep 2026: the estimate is the inverse of the Burden of Proof finding of 23.2% (16.4–29.4) lower ischaemic stroke risk from no vegetables to 306–372 g a day (1/0.768 = 1.30), rated three stars. review_note
Also changed in: 2.0 (23 Oct 2026)
Low socioeconomic position → Ischaemic stroke
low_sep|stroke_isch
| Field | Before | After |
| Estimate | 1.3 | 1.67 |
| Interval, lower | 0.99 | 1.46 |
| Interval, upper | 1.72 | 1.91 |
| Comparison | low vs high income, total stroke | lowest vs highest socioeconomic status, all strokes |
| Score (ESS) | 5.9 | 9.2 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) supportive; dose-response yes |
| Caveat | The confidence interval includes no effect. | The pooled outcome is stroke of any type; no pooled estimate separates ischaemic stroke. Adjusting for classic vascular…The pooled outcome is stroke of any type; no pooled estimate separates ischaemic stroke. Adjusting for classic vascular risk factors lowered the estimate to 1.31 (1.16 to 1.48), so those factors explain part of the excess. Genetic studies of education, one part of socioeconomic position, point to a causal effect on ischaemic stroke (1.30, 1.16 to 1.45 per 3.6 fewer years of education). |
| Quoted sentence | Effects of low and medium income versus high on these corresponding cardiovascular diseases were 1.49 (1.16-1.91) and 1.…Effects of low and medium income versus high on these corresponding cardiovascular diseases were 1.49 (1.16-1.91) and 1.27 (1.10-1.47) for coronary artery diseases, 1.17 (0.96-1.44) and 1.05 (0.98-1.13) for cardiovascular events, 1.30 (0.99-1.72) and 1.24 (1.00-1.53) for strokes, and 1.76 (1.45-2.14) and 1.34 (1.17-1.54) for cardiovascular deaths. | Those with a lower SES were more likely to have a stroke (HR 1.67; 95% CI 1.46-1.91). Additional risk was reduced, but n…Those with a lower SES were more likely to have a stroke (HR 1.67; 95% CI 1.46-1.91). Additional risk was reduced, but not eliminated, when classic vascular risk factors were adjusted for (HR 1.31; 95% CI 1.16-1.48). |
| Sources | sep_khaing sep_backholer | sep_stroke_kerr sep_khaing sep_educ_mr_gill |
Re-checked on 18 Sep 2026. The filed 1.30 (0.99–1.72) was for low income and all strokes, and its interval includes no effect. No pooled estimate for socioeconomic position and ischaemic stroke alone was found, so the link now shows a meta-analysis of lowest versus highest socioeconomic status and stroke incidence (Kerr et al. 2011), labelled as all strokes. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)1.3 (9 Sep 2026)
Menopausal hormone therapy → Ischaemic stroke
mht|stroke_isch
| Field | Before | After |
| Estimate | 1.41 | 1.29 |
| Interval, lower | 1.07 | 1.06 |
| Interval, upper | 1.85 | 1.56 |
| Comparison | conjugated equine oestrogens plus medroxyprogesterone vs placebo, total stroke | hormone therapy vs placebo or control in randomised trials |
| Score (ESS) | 13.0 | 10.6 |
| Caveat | empty | Trial evidence comes mainly from oral conjugated equine oestrogens, largely from the WHI trials in women aged 50–79. The…Trial evidence comes mainly from oral conjugated equine oestrogens, largely from the WHI trials in women aged 50–79. The excess is ischaemic; haemorrhagic stroke was not increased. In the Cochrane review, women starting within 10 years of menopause showed no clear stroke increase, while those starting later did. |
| Quoted sentence | Estimated hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: CHD, 1.29 (1.02-1.63) with 286 c…Estimated hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: CHD, 1.29 (1.02-1.63) with 286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41 (1.07-1.85) with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases. | Hormone replacement therapy was associated with significant increases in total stroke (odds ratio 1.29 (95% confidence i…Hormone replacement therapy was associated with significant increases in total stroke (odds ratio 1.29 (95% confidence interval 1.13 to 1.47), n = 28), non-fatal stroke (1.23 (1.06 to 1.44), n = 21), stroke leading to death or disability (1.56 (1.11 to 2.20), n = 14), ischaemic stroke (1.29 (1.06 to 1.56), n = 16), and a trend to more fatal stroke (1.28 (0.87 to 1.88), n = 22). |
| Sources | whi | hrt_stroke_bath2005 hrt_cvd_cochrane2015 whi_stroke2003 whi |
Re-checked on 18 Sep 2026. The filed 1.41 (1.07–1.85) was the 2002 WHI estimate for all strokes. A meta-analysis of randomised trials gives 1.29 (1.06–1.56) for ischaemic stroke across 16 trials, with no heterogeneity, and the WHI trial of oestrogen plus progestin found 1.44 (1.09–1.90) for ischaemic stroke. The grade stays Convincing on this randomised evidence. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Type 2 diabetes (as a risk factor) → Heart failure
t2d_exposure|heart_failure
| Field | Before | After |
| Estimate | 1.85 | 2.06 |
| Interval, lower | 1.68 | 1.73 |
| Interval, upper | 2.04 | 2.46 |
| Comparison | diabetes vs no diabetes | diabetes vs no diabetes, population-based prospective studies |
| Grade | Convincing | Probable |
| Score (ESS) | 43.2 | 37.5 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) supportive; dose-response yes |
| Caveat | SGLT2 inhibitor trials reduce heart failure hospitalisation in diabetes, supporting a causal pathway. | Results vary widely between studies. The excess is larger in women (type 2 diabetes: 1.95 in women, 1.74 in men). A Mend…Results vary widely between studies. The excess is larger in women (type 2 diabetes: 1.95 in women, 1.74 in men). A Mendelian randomisation study supports a causal role, with some sign of pleiotropy. SGLT2 inhibitors cut heart-failure admissions in people with diabetes; those trials test a drug and say little about whether diabetes itself causes heart failure. |
| Quoted sentence | Corresponding pooled RRs for heart failure associated with type 2 diabetes were 1.95 (1.70, 2.22) in women and 1.74 (1.5…Corresponding pooled RRs for heart failure associated with type 2 diabetes were 1.95 (1.70, 2.22) in women and 1.74 (1.55, 1.95) in men, with a pooled RRR of 1.09 (1.05, 1.13). | Among the population-based prospective studies, the summary RR for individuals with diabetes vs. no diabetes was 2.06 (9…Among the population-based prospective studies, the summary RR for individuals with diabetes vs. no diabetes was 2.06 (95% CIs: 1.73-2.46, I2 = 99.8%, n = 30 studies, 401495 cases, 21416780 participants). |
| Sources | ohkuma_dm_hf dm_hf_cvd | dm_hf_aune2018 ohkuma_dm_hf dm_hf_cvd t2d_hf_mr_mordi |
| Review status | new_citation | adjust |
Re-checked on 18 Sep 2026. The filed 1.85 (1.68–2.04) is published nowhere. A meta-analysis of 30 population-based prospective studies gives 2.06 (1.73–2.46) (Aune et al. 2018). The grade moves to Probable because heterogeneity is extreme and the trial tag rested on drug trials. review_note
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Heart failure
smoking|heart_failure
| Field | Before | After |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) supportive; dose-response yes |
| Caveat | empty | Results vary between studies (I² 81%). Risk falls with time since quitting and after about 30 years approaches that of never smokers. |
| Sources | smk_hf_aune bprf_smoking | smk_hf_aune smoking_cvd_mr_larsson |
| Review status | adjust | confirmed |
Re-checked on 18 Sep 2026: the estimate matches the meta-analysis of prospective studies (Aune et al. 2019). The Burden of Proof smoking study has no heart-failure outcome and is no longer cited; a Mendelian randomisation study supporting a causal effect is added. review_note
Also changed in: 2.0 (23 Oct 2026)
Chronic kidney disease (as a risk factor) → Heart failure
ckd_exposure|heart_failure
| Field | Before | After |
| Estimate | 1.8 | 1.6 |
| Interval, lower | 1.6 | 1.5 |
| Interval, upper | 2.02 | 1.7 |
| Comparison | eGFR <60 vs ≥60 mL/min/1.73m² | eGFR 45–59 vs 90–104 mL/min/1.73 m², both without albuminuria (urine albumin-to-creatinine ratio under 10 mg/g) |
| Comparison type | binary | category |
| Grade | Convincing | Probable |
| Score (ESS) | 35.6 | 25.1 |
| Caveat | empty | Compares moderately reduced kidney function (eGFR 45–59) with normal function in people without albuminuria. Heart and k…Compares moderately reduced kidney function (eGFR 45–59) with normal function in people without albuminuria. Heart and kidney disease share causes such as high blood pressure and diabetes, and each can worsen the other, so part of this association may not be causal. |
| Quoted sentence | empty | Heart failure | 1 [Reference] | 1.6 (1.5-1.7) | 1.8 (1.7-2.0) | 1.9 (1.8-2.1) | 1 [Reference] | 1.5 (1.1-2.1) | 2.2 (1.8-2.8) | |
| Sources | gbd_ckd | ckdpc_jama |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026. The filed 1.80 (1.60–2.02) had no quote and rested on a GBD paper that reports no relative risks and does not model heart failure. The estimate now comes from the CKD Prognosis Consortium's individual-participant analysis (JAMA 2023, Table 2), graded Probable. review_note
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Peripheral artery disease
smoking|pad
| Field | Before | After |
| Estimate | 2.8 | 3.8 |
| Interval, lower | 2.4 | 2.1 |
| Interval, upper | 3.27 | 7.14 |
| Comparison | current smoker vs never smoker | current smoking of 10 cigarettes a day vs non-smokers |
| Comparison type | binary | category |
| Score (ESS) | 54.9 | 60.4 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) supportive; dose-response yes |
| Caveat | Smoking is the dominant risk factor for peripheral artery disease, with a stronger relative effect than for coronary disease. | Risk rises steeply with dose: 2.52 at 5, 3.80 at 10 and 5.69 at 20 cigarettes a day, at a reference age of 60–64. The Bu…Risk rises steeply with dose: 2.52 at 5, 3.80 at 10 and 5.69 at 20 cigarettes a day, at a reference age of 60–64. The Burden of Proof analysis rates this pair at five stars, and genetic studies agree. Smoking is the dominant risk factor for peripheral artery disease, with a stronger relative effect than for coronary disease. |
| Quoted sentence | Smoking was an important risk factor in both HIC and LMIC, with meta-OR for current smoking of 2·72 (95% CI 2·39-3·09) i…Smoking was an important risk factor in both HIC and LMIC, with meta-OR for current smoking of 2·72 (95% CI 2·39-3·09) in HIC and 1·42 (1·25-1·62) in LMIC | Peripheral artery disease (ref. age: 60–64 years) | Cigarettes per day | 2.52 (1.67, 3.90) | 3.80 (2.10, 7.14) | 5.69 (2…Peripheral artery disease (ref. age: 60–64 years) | Cigarettes per day | 2.52 (1.67, 3.90) | 3.80 (2.10, 7.14) | 5.69 (2.62, 12.94) | 7.82 (3.13, 20.68) | 31.25 | 7.16 (2.98, 18.16) | 0.86 | 2.37 | 136.53 | 5 | 0 | 6 |
| Sources | pad_fowkes bprf_smoking pad_global2019 | bprf_smoking smoking_mr_levin smoking_cvd_mr_larsson pad_fowkes |
| Review status | confirmed | adjust |
Re-checked on 18 Sep 2026. The filed 2.80 (2.40–3.27) was not found in any source, and the pooled PAD estimates that exist come mostly from prevalence surveys, which the framework excludes. The Burden of Proof smoking study gives 3.80 (2.10–7.14) at 10 cigarettes a day against non-smokers (Table 2) and rates the evidence five stars. review_note
Also changed in: 2.0 (23 Oct 2026)
High blood pressure → Peripheral artery disease
high_sbp|pad
| Field | Before | After |
| Estimate | 1.63 | 1.44 |
| Interval, lower | 1.59 | 1.35 |
| Interval, upper | 1.66 | 1.56 |
| Comparison | per 20 mmHg higher usual systolic blood pressure | per 20 mmHg higher genetically predicted systolic blood pressure (Mendelian randomisation) |
| Grade | Convincing | Probable |
| Score (ESS) | 16.3 | 10.9 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial contradicts; Genetic (MR) supportive; dose-response yes |
| Caveat | empty | Genetic estimate: people whose genes raise systolic pressure by 10 mmHg had 20% higher odds of PAD, shown here per 20 mm…Genetic estimate: people whose genes raise systolic pressure by 10 mmHg had 20% higher odds of PAD, shown here per 20 mmHg. In a UK cohort of 4.2 million adults, 20 mmHg higher usual systolic pressure went with 63% higher risk. A meta-analysis of trials found more PAD events with intensive blood pressure lowering in people at high cardiometabolic risk, so the effect of treatment on PAD is uncertain. |
| Quoted sentence | A 20 mm Hg higher than usual systolic blood pressure was associated with a 63% higher risk of peripheral arterial diseas…A 20 mm Hg higher than usual systolic blood pressure was associated with a 63% higher risk of peripheral arterial disease (hazard ratio 1.63, 95% confidence interval 1.59 to 1.66). | In inverse-variance weighted analyses, each genetically-proxied 10mmHg increase in SBP, DBP, MAP, and PP significantly i…In inverse-variance weighted analyses, each genetically-proxied 10mmHg increase in SBP, DBP, MAP, and PP significantly increased the risk of PAD (SBP OR 1.20 [1.16–1.25] per 10mmHg increase, p = 1 × 10−24; DBP OR 1.27 [1.18–1.35], p = 4 × 10−11; MAP OR 1.26 [1.19–1.33], p = 6 × 10−16; PP OR 1.31 [1.24–1.39], p = 9 × 10−23) (Figure 1, Supplemental Table 3). |
| Sources | bp_pad_emdin bpltt | bp_pad_mr_levin bp_pad_emdin bp_pad_rct_2025 |
Re-checked on 18 Sep 2026. The filed 1.63 (1.59–1.66) comes from a single cohort, which the framework admits only as supporting evidence, and the cited trial collaboration did not study peripheral artery disease. The eligible estimate is Mendelian randomisation: 1.20 (1.16–1.25) per 10 mmHg, shown per 20 mmHg by squaring, 1.44 (1.35–1.56). The grade moves to Probable because trials of intensive blood pressure lowering found more PAD. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
High blood pressure → Abdominal aortic aneurysm
high_sbp|aaa
| Field | Before | After |
| Caveat | empty | Diastolic pressure is more strongly linked to aneurysm than systolic pressure in this review: 1.28 (1.12 to 1.46) per 10…Diastolic pressure is more strongly linked to aneurysm than systolic pressure in this review: 1.28 (1.12 to 1.46) per 10 mmHg higher diastolic pressure. |
| Quoted sentence | In addition, there was a 14% (95% CI: 6-23%, I2 = 30.5%, n = 6) and a 28% (95% CI: 12-46%, I2 = 80.1%, n = 6) increase i…In addition, there was a 14% (95% CI: 6-23%, I2 = 30.5%, n = 6) and a 28% (95% CI: 12-46%, I2 = 80.1%, n = 6) increase in the RR of AAA for every 20 mmHg and 10 mmHg increase in systolic blood pressure (SBP) and diastolic blood pressure (DBP), respectively. | The risk for AAA increased by 14% for every 20 mmHg increase in SBP (summary RR = 1.14, 95% CI: 1.06–1.23, I2 = 30.5%, p…The risk for AAA increased by 14% for every 20 mmHg increase in SBP (summary RR = 1.14, 95% CI: 1.06–1.23, I2 = 30.5%, pheterogeneity = 0.21) (Fig. 3a). |
| Review status | adjust | confirmed |
Re-checked on 18 Sep 2026: the estimate, interval and contrast match the meta-analysis of six cohort studies (Kobeissi et al. 2019), and the quote now states the relative risk. review_note
Also changed in: 2.0 (23 Oct 2026)
Unprocessed red meat → Type 2 diabetes
red_meat|t2d
| Field | Before | After |
| Grade | Probable | Suggestive |
| Score (ESS) | 3.8 | 2.6 |
| Caveat | empty | Results varied between cohorts (I² 61%). The Burden of Proof analysis, which allows for differences between studies, fou…Results varied between cohorts (I² 61%). The Burden of Proof analysis, which allows for differences between studies, found only weak evidence: 1.23 (0.96 to 1.52) at 100 g a day compared with none. |
| Quoted sentence | Quality of evidence was also high for the association for increased incidence of type 2 diabetes with higher intake of r…Quality of evidence was also high for the association for increased incidence of type 2 diabetes with higher intake of red meat (for an increment of 100 g/day, 1.17 (1.08 to 1.26)), processed meat (for an increment of 50 g/day, 1.37 (1.22 to 1.54)). | Greater consumption of each of the three types of meat was associated with increased incidence of type 2 diabetes, with…Greater consumption of each of the three types of meat was associated with increased incidence of type 2 diabetes, with HRs of 1·10 (95% CI 1·06-1·15) per 100 g/day of unprocessed red meat (I2=61%), 1·15 (1·11-1·20) per 50 g/day of processed meat (I2=59%), and 1·08 (1·02-1·14) per 100 g/day of poultry (I2=68%). |
Re-checked on 18 Sep 2026: the estimate matches the InterConnect analysis of 31 cohorts, and the quote now carries it. The cited Burden of Proof study rates unprocessed red meat and type 2 diabetes at two stars, so the grade moves from Probable to Suggestive. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Gestational diabetes → Type 2 diabetes
gdm|t2d
| Field | Before | After |
| Estimate | 9.5 | 9.51 |
| Interval, lower | 7.1 | 7.14 |
| Interval, upper | 12.7 | 12.67 |
| Review status | new_citation | adjust |
Re-checked on 18 Sep 2026: the estimate now shows the published values exactly, 9.51 (7.14–12.67), from 20 cohort studies with at least 12 months of follow-up after birth (Vounzoulaki et al. 2020). review_note
Also changed in: 2.0 (23 Oct 2026)
Type 2 diabetes (as a risk factor) → Fatty liver disease (MASLD)
t2d_exposure|masld
| Field | Before | After |
| Estimate | 2.4 | 1.21 |
| Interval, lower | 2.1 | 1.15 |
| Interval, upper | 2.74 | 1.27 |
| Comparison | diabetes vs no diabetes | genetically predicted liability to type 2 diabetes, per unit higher log-odds (Mendelian randomisation) |
| Comparison type | binary | per-unit |
| Score (ESS) | 38.6 | 14.9 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) supportive; dose-response yes |
| Caveat | empty | This estimate comes from genetic variants that raise the risk of diabetes, so it measures genetic liability and cannot b…This estimate comes from genetic variants that raise the risk of diabetes, so it measures genetic liability and cannot be read as the risk for a person with diabetes compared with one without. It rests on one genetic analysis; no pooled cohort estimate comparing people with and without diabetes was found. The association held after allowing for genetically predicted body-mass index. |
| Quoted sentence | empty | There were associations with NAFLD for lifetime smoking index (odds ratio (OR) 1.59, 95% confidence interval (CI) 1.31-1…There were associations with NAFLD for lifetime smoking index (odds ratio (OR) 1.59, 95% confidence interval (CI) 1.31-1.93 per SD-increase), body mass index (BMI, OR 1.33, 95% CI 1.23-1.43 per SD-increase), waist circumference (OR 1.82; 95% CI 1.48-2.24 per SD-increase), type 2 diabetes (OR 1.21, 95% CI 1.15-1.27 per unit increase in log-transformed odds), systolic blood pressure (OR 1.17; 95% CI 1.07-1.26 per 10 mmHg increase), high-density lipoprotein cholesterol (OR 0.84, 95% CI 0.77-0.90 per SD-increase), and triglycerides (OR 1.23, 95% CI 1.15-1.33 per SD-increase). |
| Sources | empty | nafld_mr |
| Review status | suspect | adjust |
Re-checked on 18 Sep 2026. The filed 2.4 (2.1–2.74) had no source. No pooled cohort estimate for diabetes and new fatty liver disease was found; the only eligible estimate is a Mendelian randomisation result already in the dataset (Yuan et al. 2022), shown with its own contrast and graded Probable. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)1.3 (9 Sep 2026)
Heavy alcohol use → Liver cirrhosis
alcohol_heavy|cirrhosis
| Field | Before | After |
| Estimate | 8.0 | 10.7 |
| Interval, lower | 6.2 | 2.95 |
| Interval, upper | 10.3 | 38.78 |
| Comparison | heavy drinking vs light or none | 7 or more drinks a day vs long-term abstainers (cohort studies, mostly deaths from cirrhosis) |
| Score (ESS) | 71.3 | 73.5 |
| Caveat | One of the clearest dose-response relationships in chronic disease epidemiology. | One of the clearest dose-response relationships in chronic disease epidemiology. The cohorts disagreed widely on the siz…One of the clearest dose-response relationships in chronic disease epidemiology. The cohorts disagreed widely on the size of the risk, so the interval is very wide. Risk rose much more steeply in women (24.58, 14.77 to 40.90 at 7 or more drinks a day) than in men (6.93, 1.07 to 44.99). One drink was counted as about 12 g of alcohol. |
| Quoted sentence | Drinking >=5 drinks per day was associated with a substantially increased risk in both women (relative risk [RR] = 12.44…Drinking >=5 drinks per day was associated with a substantially increased risk in both women (relative risk [RR] = 12.44, 95% confidence interval [CI]: 6.65-23.27 for 5-6 drinks, and RR = 24.58, 95% CI: 14.77-40.90 for >=7 drinks) and men (RR = 3.80, 95% CI: 0.85-17.02, and RR = 6.93, 95% CI: 1.07-44.99, respectively). | Alcohol consumption beyond occasional drinking, which showed a similar risk compared to long-term abstainers, was associ…Alcohol consumption beyond occasional drinking, which showed a similar risk compared to long-term abstainers, was associated with increasing risk for liver cirrhosis ( Figure 2 ) with a pooled RR of 10.70 (95% CI: 2.95–38.78) for consumption of 7 drinks or more per day. |
| Review status | confirmed | adjust |
Re-checked on 18 Sep 2026. The filed 8.0 (6.2–10.3) for heavy versus light or no drinking appears in neither cited source. The meta-analysis gives 10.70 (2.95–38.78) for 7 or more drinks a day against long-term abstainers, men and women combined (Roerecke et al. 2019). review_note
Also changed in: 2.0 (23 Oct 2026)
Type 2 diabetes (as a risk factor) → Liver cirrhosis
t2d_exposure|cirrhosis
| Field | Before | After |
| Estimate | 2.2 | 2.25 |
| Interval, lower | 1.9 | 1.83 |
| Interval, upper | 2.55 | 2.76 |
| Comparison | diabetes vs no diabetes | type 2 diabetes vs no diabetes, severe liver disease (cirrhosis, its complications or death from liver disease) |
| Score (ESS) | 33.1 | 33.5 |
| Caveat | empty | The outcome combines cirrhosis, its complications and deaths from liver disease, and results varied widely between the 1…The outcome combines cirrhosis, its complications and deaths from liver disease, and results varied widely between the 12 cohorts. Undiagnosed liver disease can itself disturb blood sugar, so some of the association may run in the other direction. |
| Review status | new_citation | adjust |
Re-checked on 18 Sep 2026. The filed 2.2 (1.9–2.55) appears in neither cited source. A meta-analysis of 12 population cohorts (22.8 million people) gives 2.25 (1.83–2.76) for severe liver disease events (Jarvis et al. 2020). review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Type 2 diabetes (as a risk factor) → Chronic kidney disease
t2d_exposure|ckd
| Field | Before | After |
| Estimate | 2.6 | 2.84 |
| Interval, lower | 2.25 | 1.73 |
| Interval, upper | 3.0 | 4.68 |
| Comparison | diabetes vs no diabetes | diabetes vs no diabetes, men |
| Score (ESS) | 55.1 | 57.1 |
| Caveat | Glucose-lowering and SGLT2 inhibitor trials slow progression, confirming causality. | The source reports women and men separately and found no clear difference between them; the lower, men's figure is shown…The source reports women and men separately and found no clear difference between them; the lower, men's figure is shown (women 3.34, 2.27 to 4.93). Glucose-lowering and SGLT2 inhibitor trials slow kidney disease in people with diabetes, which supports causality. |
| Quoted sentence | empty | The pooled adjusted risk ratio of chronic kidney disease associated with diabetes mellitus was 3.34 (95 % CI 2.27, 4.93)…The pooled adjusted risk ratio of chronic kidney disease associated with diabetes mellitus was 3.34 (95 % CI 2.27, 4.93) in women and 2.84 (95 % CI 1.73, 4.68) in men. |
| Sources | gbd_ckd | t2d_ckd_shen glucose_intensive_kunutsor |
| Review status | confirmed | adjust |
Re-checked on 18 Sep 2026. The filed 2.6 (2.25–3.0) is not in the cited GBD paper, which reports no diabetes-to-CKD relative risk. A meta-analysis of cohorts with more than 5 million people gives 2.84 (1.73–4.68) in men and 3.34 (2.27–4.93) in women (Shen et al. 2017). review_note
Also changed in: 2.0 (23 Oct 2026)
Low birth weight → Chronic kidney disease
low_birthweight|ckd
| Field | Before | After |
| Estimate | 1.7 | 1.73 |
| Interval, lower | 1.45 | 1.44 |
| Interval, upper | 1.99 | 2.08 |
| Grade | Probable | Suggestive |
| Score (ESS) | 21.9 | 15.4 |
| Caveat | Consistent with reduced nephron endowment at birth. | Consistent with reduced nephron endowment at birth. Sixteen of the 31 studies found no significant association. The esti…Consistent with reduced nephron endowment at birth. Sixteen of the 31 studies found no significant association. The estimate is similar whether kidney disease was measured as albuminuria (1.81, 1.19 to 2.77), low filtration (1.79, 1.31 to 2.45) or kidney failure (1.58, 1.33 to 1.88). |
| Review status | new_citation | adjust |
Re-checked on 18 Sep 2026. The filed 1.70 (1.45–1.99) is not in the cited meta-analysis, which gives 1.73 (1.44–2.08) from 18 studies (White et al. 2009). Half the studies were null and maternal and socioeconomic confounding was not well addressed, so the grade moves to Suggestive. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Household air pollution → COPD
hap|copd
| Field | Before | After |
| Estimate | 2.3 | 1.21 |
| Interval, lower | 1.95 | 1.12 |
| Interval, upper | 2.71 | 1.31 |
| Comparison | solid fuel use vs clean fuel | household use of polluting fuels (coal, wood, charcoal, crop waste, dung or kerosene) for cooking or heating vs no such use, longitudinal studies |
| Score (ESS) | 50.1 | 19.8 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) none; dose-response yes |
| Caveat | The dominant cause among women in low-income settings who cook on biomass stoves. | This figure pools the 15 longitudinal study estimates in a 2020 meta-analysis (its appendix, Figure S32). Pooling all de…This figure pools the 15 longitudinal study estimates in a 2020 meta-analysis (its appendix, Figure S32). Pooling all designs, most of them cross-sectional or case-control, gives a larger figure (1.70 in the same meta-analysis), and those designs are more open to confounding by poverty and smoking. A 2018 review found no trials of cleaner stoves that measured COPD. The grade rests on GBD 2021, which rates fine-particle pollution and COPD at four stars. |
| Quoted sentence | The pooled analysis showed that exposure to indoor air pollution due to solid biomass fuels increased risk of COPD by 2.…The pooled analysis showed that exposure to indoor air pollution due to solid biomass fuels increased risk of COPD by 2.65 (95% confidence interval [CI] 2.13-3.31; n = 73,122) and chronic bronchitis by 2.89 (95% CI 2.18-3.82) times more compared to non-biomass fuels. | COPD | 15 | 85% | 1.21 (1.12−1.31) |
| Sources | gbd2021rf biomass_copd_ma | hap_health_lee2020 gbd2021rf |
| Review status | confirmed | adjust |
Re-checked on 18 Sep 2026. The filed 2.30 (1.95–2.71) is in no cited source, and the cited meta-analysis (2.65) pooled only case-control, retrospective and cross-sectional studies, which the framework excludes. The estimate now comes from the longitudinal studies in a 2020 meta-analysis. No trial of cleaner stoves has measured COPD, so the trial tag is removed. review_note
Also changed in: 2.0 (23 Oct 2026)
Fine particulate air pollution → Asthma (adult)
pm25|asthma
| Field | Before | After |
| Estimate | 1.15 | 1.07 |
| Interval, lower | 1.08 | 1.01 |
| Interval, upper | 1.23 | 1.13 |
| Comparison | per 10 µg/m³ higher annual PM2.5 | per 5 µg/m³ higher long-term PM2.5, adult-onset asthma |
| Grade | Probable | Suggestive |
| Score (ESS) | 11.6 | 4.2 |
| Caveat | empty | The nine contributing studies disagreed strongly with one another (I² = 88%), and the authors advise caution, so the pooled figure is uncertain. |
| Quoted sentence | Pooled random effects RRs for incident adult asthma per 5 μg/m3 increase in PM2.5 were 1.07 (95% CI 1.01 to 1.13) and pe…Pooled random effects RRs for incident adult asthma per 5 μg/m3 increase in PM2.5 were 1.07 (95% CI 1.01 to 1.13) and per 10 μg/m3 in NO2 were 1.11 (1.03 to 1.20). | Pooled random effects RRs for incident adult asthma per 5 μg/m3 increase in PM2·5 were 1·07 (95% CI 1·01 to 1·13) and pe…Pooled random effects RRs for incident adult asthma per 5 μg/m3 increase in PM2·5 were 1·07 (95% CI 1·01 to 1·13) and per 10 μg/m3 in NO2 were 1·11 (1·03 to 1·20). |
| Sources | who_air airpoll_adult_asthma_ma | airpoll_adult_asthma_ma |
| Review status | confirmed | adjust |
Re-checked on 18 Sep 2026. The filed 1.15 (1.08–1.23) per 10 µg/m³ rescaled the point estimate but narrowed the interval. The source's own contrast, per 5 µg/m³, is now shown: 1.07 (1.01–1.13). The grade moves to Suggestive: one meta-analysis with very high heterogeneity. review_note
Also changed in: 2.0 (23 Oct 2026)
Nitrogen dioxide → Asthma (adult)
no2|asthma
| Field | Before | After |
| Estimate | 1.12 | 1.11 |
| Interval, lower | 1.06 | 1.03 |
| Interval, upper | 1.19 | 1.2 |
| Comparison | per 10 µg/m³ higher NO2 | per 10 µg/m³ higher long-term NO2, adult-onset asthma |
| Score (ESS) | 9.7 | 9.1 |
| Caveat | Strongly correlated with other traffic pollutants, so attributing the effect to NO2 specifically is difficult. | Strongly correlated with other traffic pollutants, so attributing the effect to NO2 specifically is difficult. The nine…Strongly correlated with other traffic pollutants, so attributing the effect to NO2 specifically is difficult. The nine contributing studies disagreed strongly with one another (I² = 88%). A 2024 review of concentration-response functions for WHO rated this pair reliable, from an independent estimate of 1.10 (1.01 to 1.21). |
| Quoted sentence | Pooled random effects RRs for incident adult asthma per 5 μg/m3 increase in PM2.5 were 1.07 (95% CI 1.01 to 1.13) and pe…Pooled random effects RRs for incident adult asthma per 5 μg/m3 increase in PM2.5 were 1.07 (95% CI 1.01 to 1.13) and per 10 μg/m3 in NO2 were 1.11 (1.03 to 1.20). | Pooled random effects RRs for incident adult asthma per 5 μg/m3 increase in PM2·5 were 1·07 (95% CI 1·01 to 1·13) and pe…Pooled random effects RRs for incident adult asthma per 5 μg/m3 increase in PM2·5 were 1·07 (95% CI 1·01 to 1·13) and per 10 μg/m3 in NO2 were 1·11 (1·03 to 1·20). |
| Sources | who_air airpoll_adult_asthma_ma | airpoll_adult_asthma_ma airpoll_crf_forastiere |
| Review status | confirmed | adjust |
Re-checked on 18 Sep 2026. The filed 1.12 (1.06–1.19) matched no source. The meta-analysis cited for this link gives 1.11 (1.03–1.20) per 10 µg/m³, and the WHO air quality guideline, which gives no adult asthma estimate, is no longer cited. review_note
Also changed in: 2.0 (23 Oct 2026)
Secondhand smoke → Asthma (adult)
shs|asthma
| Field | Before | After |
| Estimate | 1.3 | 1.21 |
| Interval, lower | 1.18 | 1.16 |
| Interval, upper | 1.43 | 1.26 |
| Comparison | exposed vs not exposed | exposed vs not exposed to secondhand smoke |
| Score (ESS) | 7.1 | 5.6 |
| Caveat | Evidence is strongest for childhood-onset asthma. The cited Burden of Proof study places the secondhand-smoke and asthma…Evidence is strongest for childhood-onset asthma. The cited Burden of Proof study places the secondhand-smoke and asthma association in its weakest evidence tier (one star). | The Burden of Proof study rates this pair at one star, its weakest tier. It pools 125 studies of all ages, 96 of them wi…The Burden of Proof study rates this pair at one star, its weakest tier. It pools 125 studies of all ages, 96 of them with data on children aged 16 or under, and gives no adult-only estimate. Allowing for differences between studies, the interval widens to 0.88 to 1.66, which includes no effect. |
| Quoted sentence | The evidence supporting the harmful associations between SHS and otitis media, asthma, lower respiratory infections, bre…The evidence supporting the harmful associations between SHS and otitis media, asthma, lower respiratory infections, breast cancer and chronic obstructive pulmonary disease was weaker (one star). | Asthma | 1.21 (1.16–1.26) | 1.21 (0.88–1.66) | 0.93 | −0.04 | No | 125 | Self-reported outcome; children population | N |
Re-checked on 18 Sep 2026. The filed 1.30 (1.18–1.43) appears nowhere in the cited Burden of Proof study. Its main estimate for asthma is 1.21 (1.16–1.26) (Table 2), rated one star. review_note
Also changed in: 2.0 (23 Oct 2026)1.3 (9 Sep 2026)
Hearing loss (as a risk factor) → Dementia (all-cause)
hearing_loss_exposure|dementia
| Field | Before | After |
| Estimate | 1.9 | 1.37 |
| Interval, lower | 1.4 | 1.0 |
| Interval, upper | 2.7 | 1.87 |
| Comparison | midlife hearing loss (>=25 dB) vs normal hearing | hearing loss measured by pure-tone audiometry vs normal hearing, cohorts followed for more than 5 years |
| Grade | Probable | Suggestive |
| Score (ESS) | 15.1 | 6.8 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial null; Genetic (MR) none; dose-response yes |
| Caveat | The ACHIEVE trial found hearing aids slowed cognitive decline in a higher-risk subgroup but not in the whole trial popul…The ACHIEVE trial found hearing aids slowed cognitive decline in a higher-risk subgroup but not in the whole trial population. The Lancet Commission treats hearing loss as the largest single modifiable contributor in midlife. | The Commission's 2024 meta-analysis, restricted to cohorts that measured hearing by pure-tone audiometry, found a smalle…The Commission's 2024 meta-analysis, restricted to cohorts that measured hearing by pure-tone audiometry, found a smaller and less certain association than its 2020 figure. In the ACHIEVE trial, hearing intervention had no overall effect on cognition at three years; a pre-specified higher-risk subgroup did benefit. The Commission still ranks hearing loss among the largest modifiable contributors to dementia. |
| Quoted sentence | Hearing loss | 1·9 (1·4–2·7) | 31·7% | 45·6% | 22·2% | 8·2% | We conducted an updated meta-analysis of the relative risk for dementia associated with hearing loss (in main paper). Th…We conducted an updated meta-analysis of the relative risk for dementia associated with hearing loss (in main paper). The updated relative risk is 1.37 (95% CI 1.00-1.87) and mean age of included participants is 59 means this risk factor is now considered more relevant in midlife. |
| Sources | lancet_dementia2020 lancet_dementia | lancet_dementia |
Re-checked on 18 Sep 2026. Updated from the 2020 Lancet Commission figure, 1.9 (1.4–2.7), to the 2024 Commission's meta-analysis, 1.37 (1.00–1.87). The grade moves from Probable to Suggestive: the interval reaches no effect, heterogeneity is high (I² 80%), and the ACHIEVE trial had no overall effect on its primary outcome. review_note
Also changed in: 2.0 (23 Oct 2026)
Low educational attainment → Dementia (all-cause)
low_education|dementia
| Field | Before | After |
| Estimate | 1.6 | 1.59 |
| Interval, lower | 1.3 | 1.35 |
| Interval, upper | 2.0 | 1.86 |
| Comparison | less education vs more education | low vs high educational attainment |
| Score (ESS) | 12.7 | 12.6 |
| Caveat | empty | The 2024 Commission reuses a 2006 meta-analysis and describes this interval as coming from its 13 prospective cohort stu…The 2024 Commission reuses a 2006 meta-analysis and describes this interval as coming from its 13 prospective cohort studies. The paper's abstract reports 1.59 (1.26 to 2.01) across all 19 cohort and case-control studies. |
| Quoted sentence | Less education | 1·6 (1·3–2·0) | 40·0% | 61·2% | 19·4% | 7·1% | We found no new meta-analyses providing an estimate of relative risk for less education so we have used the previous est…We found no new meta-analyses providing an estimate of relative risk for less education so we have used the previous estimate of RR 1.59 (95% CI 1.35 to 1.86) from a meta-analysis of 13 prospective cohort studies. |
| Sources | lancet_dementia2020 lancet_dementia | lancet_dementia education_dementia_caamano |
Re-checked on 18 Sep 2026. Updated from the 2020 Lancet Commission figure, 1.6 (1.3–2.0), to the 2024 figure, 1.59 (1.35–1.86). review_note
Also changed in: 2.0 (23 Oct 2026)
High blood pressure → Dementia (all-cause)
high_sbp|dementia
| Field | Before | After |
| Estimate | 1.6 | 1.2 |
| Interval, lower | 1.2 | 1.06 |
| Interval, upper | 2.2 | 1.35 |
| Score (ESS) | 12.7 | 6.6 |
| Quoted sentence | Hypertension | 1·6 (1·2–2·2) | 8·9% | 68·3% | 5·1% | 1·9% | One paper meta-analysed 9 studies to give a RR of dementia associated with midlife hypertension of 1.20 (1.06-1.35). We…One paper meta-analysed 9 studies to give a RR of dementia associated with midlife hypertension of 1.20 (1.06-1.35). We used this estimate for our PAF calculations. |
| Sources | lancet_dementia2020 lancet_dementia sprint_mind | lancet_dementia ou_bp_cognition_2020 sprint_mind |
Re-checked on 18 Sep 2026. Updated from the 2020 Lancet Commission figure, 1.6 (1.2–2.2), to the 2024 figure from a meta-analysis of nine studies, 1.20 (1.06–1.35). review_note
Also changed in: 2.0 (23 Oct 2026)1.3 (18 Sep 2026)
Current cigarette smoking → Dementia (all-cause)
smoking|dementia
| Field | Before | After |
| Estimate | 1.6 | 1.3 |
| Interval, lower | 1.2 | 1.18 |
| Interval, upper | 2.2 | 1.45 |
| Score (ESS) | 12.7 | 8.6 |
| Quoted sentence | Smoking | 1·6 (1·2–2·2) | 27·4% | 62·3% | 14·1% | 5·2% | Compared with never smokers, current smokers showed an increased risk of all-cause dementia (risk ratio (RR) 1.30, 95% c…Compared with never smokers, current smokers showed an increased risk of all-cause dementia (risk ratio (RR) 1.30, 95% confidence interval (CI) 1.18-1.45), AD (RR 1.40, 95% CI 1.13-1.73) and VaD (RR 1.38, 95% CI 1.15-1.66). |
| Sources | lancet_dementia2020 lancet_dementia | lancet_dementia zhong_smoking_dementia_2015 |
Re-checked on 18 Sep 2026. Updated from the 2020 Lancet Commission figure, 1.6 (1.2–2.2), to the 2024 figure from a meta-analysis of 37 prospective cohort studies (Zhong et al. 2015). review_note
Also changed in: 2.0 (23 Oct 2026)
Type 2 diabetes (as a risk factor) → Dementia (all-cause)
t2d_exposure|dementia
| Field | Before | After |
| Estimate | 1.5 | 1.73 |
| Interval, lower | 1.3 | 1.65 |
| Interval, upper | 1.8 | 1.82 |
| Score (ESS) | 11.6 | 13.9 |
| Quoted sentence | Diabetes | 1·5 (1·3–1·8) | 6·4% | 71·4% | 3·1% | 1·1% | The most up to date meta-analysis on risk for dementia showed a pooled RR of developing dementia in 20 studies of 1.73 (1.65–1.82) I2 = 71.2%. |
| Sources | lancet_dementia2020 lancet_dementia | lancet_dementia dm_dementia_gudala |
Re-checked on 18 Sep 2026. Updated from the 2020 Lancet Commission figure, 1.5 (1.3–1.8), to the 2024 figure from a meta-analysis of 20 studies (Gudala et al. 2013). review_note
Also changed in: 2.0 (23 Oct 2026)
High body-mass index → Dementia (all-cause)
high_bmi|dementia
| Field | Before | After |
| Estimate | 1.6 | 1.31 |
| Interval, lower | 1.3 | 1.02 |
| Interval, upper | 1.9 | 1.68 |
| Score (ESS) | 20.4 | 14.2 |
| Quoted sentence | Obesity (body-mass index ≥30) | 1·6 (1·3–1·9) | 3·4% | 58·5% | 2·0% | 0·7% | A large and new systematic review and meta-analysis examining the relationship between obesity and dementia included 11…A large and new systematic review and meta-analysis examining the relationship between obesity and dementia included 11 studies and 64,265 participants and found that midlife obesity was associated with subsequent all cause dementia (RR 1.31, 1.02-1.68). |
| Sources | lancet_dementia2020 lancet_dementia | lancet_dementia |
Re-checked on 18 Sep 2026. Updated from the 2020 Lancet Commission figure, 1.6 (1.3–1.9), to the 2024 figure from a meta-analysis of 11 studies of midlife obesity. review_note
Also changed in: 2.0 (23 Oct 2026)
Low physical activity → Dementia (all-cause)
low_pa|dementia
| Field | Before | After |
| Estimate | 1.4 | 1.25 |
| Interval, lower | 1.2 | 1.19 |
| Interval, upper | 1.7 | 1.29 |
| Comparison | physically inactive vs active | lowest vs higher physical activity |
| Comparison type | binary | quantile |
| Score (ESS) | 7.1 | 5.3 |
| Caveat | Exercise trials have not convincingly prevented dementia. Reverse causation is a serious concern because the prodromal phase lasts a decade or more. | The figure inverts the pooled comparison of higher with the lowest activity, 0.80 (0.77 to 0.84). In the source meta-ana…The figure inverts the pooled comparison of higher with the lowest activity, 0.80 (0.77 to 0.84). In the source meta-analysis the association held in studies with 20 or more years of follow-up, which argues against reverse causation, yet exercise trials have not shown that activity prevents dementia, and publication bias is possible. |
| Quoted sentence | Physical inactivity | 1·4 (1·2–1·7) | 17·7% | 55·2% | 9·6% | 1·6% | A new systematic review and meta-analysis of 58 studies studying the link between physical activity and dementia, in adu…A new systematic review and meta-analysis of 58 studies studying the link between physical activity and dementia, in adults aged 20 and over, found that higher versus lowest physical activity was associated with a decreased risk of all-cause dementia (RR 0.80, 0.77 to 0.84, n=257 983) so corresponding RR for inactivity would be 1.25, 1.19-1.29. |
| Sources | lancet_dementia2020 lancet_dementia | lancet_dementia isomarkku_pa_dementia_2022 |
Re-checked on 18 Sep 2026. Updated from the 2020 Lancet Commission figure, 1.4 (1.2–1.7), to the 2024 figure, the inverse of a 58-study meta-analysis (Iso-Markku et al. 2022). review_note
Also changed in: 2.0 (23 Oct 2026)
Social isolation and loneliness → Dementia (all-cause)
isolation|dementia
| Field | Before | After |
| Estimate | 1.6 | 1.57 |
| Interval, lower | 1.3 | 1.32 |
| Interval, upper | 1.9 | 1.85 |
| Comparison | social isolation vs not isolated | less vs more frequent social contact |
| Score (ESS) | 8.7 | 8.5 |
| Caveat | empty | Most contributing studies followed older people for under four years, so withdrawal from social contact may be an early…Most contributing studies followed older people for under four years, so withdrawal from social contact may be an early sign of dementia. Loneliness is a separate exposure and is outside this estimate. |
| Quoted sentence | Social isolation | 1·6 (1·3–1·9) | 11·0% | 28·1% | 4·2% | 3·5% | We have continued to use the meta-analysis of relative risk used in our previous commission as it is the only such paper…We have continued to use the meta-analysis of relative risk used in our previous commission as it is the only such paper we could find which considers frequency of contacts and dementia (RR 1.57, 1.32-1.85). |
| Sources | lancet_dementia2020 lancet_dementia | lancet_dementia kuiper_social_dementia_2015 |
Re-checked on 18 Sep 2026. The 2024 Lancet Commission keeps the meta-analysis it used in 2020 (Kuiper et al. 2015) and prints it as 1.57 (1.32–1.85), for less frequent social contact. review_note
Also changed in: 2.0 (23 Oct 2026)
Depression (as a risk factor) → Dementia (all-cause)
depression_exposure|dementia
| Field | Before | After |
| Estimate | 1.9 | 2.25 |
| Interval, lower | 1.6 | 1.69 |
| Interval, upper | 2.3 | 2.98 |
| Comparison | depression vs no depression | depression vs no depression, in cohorts followed for 10 to 14 years |
| Score (ESS) | 10.4 | 11.7 |
| Caveat | Late-life depression is frequently a prodromal symptom of dementia rather than a cause. The Commission counts it as a ri…Late-life depression is frequently a prodromal symptom of dementia rather than a cause. The Commission counts it as a risk factor, but the direction of causation is genuinely unresolved. | This estimate pools only the seven cohorts followed for 10 to 14 years, which lowers the chance that depression was an e…This estimate pools only the seven cohorts followed for 10 to 14 years, which lowers the chance that depression was an early symptom of dementia. Results varied widely between studies, and the Commission notes that in late life some of the association is caused by preclinical dementia. |
| Quoted sentence | Depression | 1·9 (1·6–2·3) | 13·2% | 69·8% | 10·6% | 3·9% | For this commission, we performed a new random effects meta-analysis using the seven studies with a 10-to-14-year follow…For this commission, we performed a new random effects meta-analysis using the seven studies with a 10-to-14-year follow-up in the systematic review by Stafford et al. We found an increased risk of dementia (RR 2.25, 1.69- 2.98 I2= 82.8%). |
| Sources | lancet_dementia2020 lancet_dementia | lancet_dementia |
Re-checked on 18 Sep 2026. Updated from the 2020 Lancet Commission figure, 1.9 (1.6–2.3), to the 2024 Commission's own meta-analysis of seven cohorts with 10 to 14 years of follow-up. review_note
Also changed in: 2.0 (23 Oct 2026)
Traumatic brain injury → Dementia (all-cause)
tbi|dementia
| Field | Before | After |
| Estimate | 1.84 | 1.66 |
| Interval, lower | 1.54 | 1.42 |
| Interval, upper | 2.2 | 1.93 |
| Score (ESS) | 23.7 | 21.4 |
| Caveat | empty | Results vary greatly between studies. In the three studies that required at least a year between injury and dementia dia…Results vary greatly between studies. In the three studies that required at least a year between injury and dementia diagnosis, the pooled risk ratio was lower (1.24). |
| Quoted sentence | The pooled RR was 1.84 (95% CI 1.54-2.20) for all cause dementia from all severities of TBI | A meta-analysis of 32 studies (n= 7,634,844), which included 17 studies from the other meta-analysis, found a RR for dem…A meta-analysis of 32 studies (n= 7,634,844), which included 17 studies from the other meta-analysis, found a RR for dementia after TBI of 1.66 (1.42-1.93). |
| Sources | lancet_dementia2020 lancet_dementia headinjury_dementia_meta_2017 | lancet_dementia gardner_tbi_dementia_2023 headinjury_dementia_meta_2017 |
Re-checked on 18 Sep 2026. Updated from the 2020 Lancet Commission figure, 1.84 (1.54–2.20), to the pooled estimate the 2024 Commission reports from a 32-study meta-analysis (Gardner et al. 2023). The Commission's own calculation used 1.72, for which it gives no interval. review_note
Also changed in: 2.0 (23 Oct 2026)
Heavy alcohol use → Dementia (all-cause)
alcohol_heavy|dementia
| Field | Before | After |
| Estimate | 1.18 | 1.21 |
| Interval, lower | 1.06 | 1.01 |
| Interval, upper | 1.31 | 1.46 |
| Comparison | >21 units (168 g) of alcohol per week vs lighter drinking | more than 21 UK units (168 g) of alcohol a week in midlife vs 1–21 units, current drinkers |
| Score (ESS) | 4.2 | 4.7 |
| Caveat | empty | The comparison group is lighter drinkers (1–21 units a week). Non-drinkers were excluded, so the estimate compares heavier with lighter drinking only. |
| Quoted sentence | The RR associated with drinking—more than 21 units (168 g) of alcohol weekly—compared with lighter drinking was 1.18 (95% Cl 1.06–1.31) | …heavier drinking of > 21 units per week in midlife compared to lighter drinking was associated with an increased risk o……heavier drinking of > 21 units per week in midlife compared to lighter drinking was associated with an increased risk of dementia (HR 1.22, 1.01-1.48). We converted this to RR using published formulae […] to give RR 1.21, 95% CI 1.01-1.46. |
| Sources | lancet_dementia2020 lancet_dementia | lancet_dementia kivimaki_alcohol_dementia_2020 |
Re-checked on 18 Sep 2026. Updated from the 2020 Lancet Commission figure, 1.18 (1.06–1.31), to the 2024 figure: an individual-participant analysis of seven cohorts, converted by the Commission from a hazard ratio of 1.22 (1.01–1.48). review_note
Also changed in: 2.0 (23 Oct 2026)
Fine particulate air pollution → Dementia (all-cause)
pm25|dementia
| Field | Before | After |
| Caveat | empty | The Commission's estimate rests on a single Canadian cohort in a low-pollution setting, which the Commission expects to underestimate the effect. |
| Quoted sentence | We calculated the RR of dementia for those in the three highest quartiles compared to the lowest was 1.09 (1.07–1.11). | We therefore used our previous method of calculating the RR of dementia for those in the three highest quartiles compare…We therefore used our previous method of calculating the RR of dementia for those in the three highest quartiles compared to the lowest from a cohort study including 2,066,639 people, with a mean baseline age of 67 year. The RR was 1·09 (1·07–1·11) and prevalence of higher levels of pollution was 75%. |
| Sources | lancet_dementia2020 lancet_dementia who_air | lancet_dementia |
| Review status | adjust | confirmed |
Re-checked on 18 Sep 2026: the 2024 Lancet Commission keeps this estimate from a single Ontario cohort of 2,066,639 people, because no meta-analysis was possible. The citation moves from the 2020 to the 2024 report. review_note
Also changed in: 2.0 (23 Oct 2026)
Short sleep → Dementia (all-cause)
short_sleep|dementia
| Field | Before | After |
| Comparison | short sleep duration vs normal (7-8 h/night) | short vs normal sleep duration, as each cohort defined them |
| Caveat | Sleep changes are also an early symptom of neurodegeneration, so reverse causation is hard to exclude. The confidence interval includes no effect. | Sleep changes are also an early symptom of neurodegeneration, so reverse causation is hard to exclude. The confidence in…Sleep changes are also an early symptom of neurodegeneration, so reverse causation is hard to exclude. The confidence interval includes no effect. The 2024 Lancet Commission judged the evidence too inconsistent to count short sleep as a modifiable risk factor. |
| Sources | fan_sleep_dementia_2019 lancet_dementia2020 | fan_sleep_dementia_2019 lancet_dementia |
Re-checked on 18 Sep 2026: the estimate matches its source. The contrast now states that each cohort defined short sleep in its own way, and the 2024 Lancet Commission replaces the 2020 citation. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)1.3 (9 Sep 2026)
High LDL cholesterol → Dementia (all-cause)
high_ldl|dementia
| Field | Before | After |
| Estimate | 1.15 | 1.32 |
| Interval, lower | 1.06 | 1.25 |
| Interval, upper | 1.25 | 1.38 |
| Comparison | midlife high LDL vs normal | LDL cholesterol above 3 mmol/L vs lower, adults under 65 at baseline |
| Score (ESS) | 7.2 | 12.2 |
| Caveat | empty | The estimate comes from one large study of English primary-care records, where who gets their cholesterol tested is not…The estimate comes from one large study of English primary-care records, where who gets their cholesterol tested is not random, and applies to people under 65 at baseline. A meta-analysis of three UK cohorts found 1.08 (1.03 to 1.14) per 1 mmol/L higher LDL. |
| Quoted sentence | empty | We considered a study of 1,189,090 participants which found high LDL (>3mmol/l) was associated with an increased risk of…We considered a study of 1,189,090 participants which found high LDL (>3mmol/l) was associated with an increased risk of dementia – HR 1.33, 95% CI 1.26-1.40. We converted this to RR using published formulae […] to give RR 1.32, 95% CI 1.25-1.38. |
| Review status | suspect | adjust |
Re-checked on 18 Sep 2026. Updated to the 2024 Lancet Commission figure, 1.32 (1.25–1.38), which the Commission converted from a hazard ratio of 1.33 in a study of 1,189,090 people. The earlier 1.15 (1.06–1.25) appears in neither Commission report. review_note
Also changed in: 2.0 (23 Oct 2026)
Long-term benzodiazepines → Dementia (all-cause)
benzodiazepines|dementia
| Field | Before | After |
| Estimate | 1.25 | 1.49 |
| Interval, lower | 1.12 | 1.3 |
| Interval, upper | 1.4 | 1.72 |
| Comparison | long-term use vs none | ever vs never benzodiazepine use |
| Grade | Suggestive | Limited |
| Score (ESS) | 10.4 | 8.5 |
| Caveat | Likely inflated by prodromal prescribing for anxiety and insomnia in the years before diagnosis. | Anxiety and insomnia, the usual reasons for prescribing, can be early signs of dementia. Studies that allowed at least f…Anxiety and insomnia, the usual reasons for prescribing, can be early signs of dementia. Studies that allowed at least five years between use and diagnosis found a smaller association (odds ratio 1.30, 1.14 to 1.48), and the dose-response evidence comes from only two studies. An umbrella review rates the evidence from all five meta-analyses as weak. |
| Quoted sentence | Our review included five meta-analyses encompassing 30 studies, and the effect size of the association between benzodiaz…Our review included five meta-analyses encompassing 30 studies, and the effect size of the association between benzodiazepine use and dementia risk ranged from 1.38 to 1.78. | Compared with never users, pooled adjusted risk ratios (RRs) for dementia were 1.49 (95% confidence interval (CI) 1.30-1…Compared with never users, pooled adjusted risk ratios (RRs) for dementia were 1.49 (95% confidence interval (CI) 1.30-1.72) for ever users, 1.55 (95% CI 1.31-1.83) for recent users, and 1.55 (95% CI 1.17-2.03) for past users. |
| Sources | benzo_dementia_umbrella_2023 | zhong_bzd_dementia_2015 penninkilampi_bzd_dementia_2018 benzo_dementia_umbrella_2023 |
| Review status | suspect | adjust |
Re-checked on 18 Sep 2026. The filed 1.25 (1.12–1.40) for long-term use matches no published pooled estimate, and no meta-analysis compares long-term use with no use. The estimate now comes from the meta-analysis restricted to nested case-control and cohort studies (Zhong et al. 2015), for ever versus never use, graded Limited. review_note
Also changed in: 2.0 (23 Oct 2026)
High blood pressure → Alzheimer's disease
high_sbp|alzheimers
| Field | Before | After |
| Estimate | 1.45 | 1.18 |
| Interval, lower | 1.28 | 1.02 |
| Interval, upper | 1.64 | 1.35 |
| Comparison | midlife hypertension vs normotension | midlife systolic hypertension (above 140 mmHg) vs lower systolic pressure |
| Grade | Probable | Suggestive |
| Score (ESS) | 24.1 | 9.2 |
| Caveat | empty | Blood pressure was measured in midlife in cohorts with long follow-up. Late-life blood pressure shows no consistent link…Blood pressure was measured in midlife in cohorts with long follow-up. Late-life blood pressure shows no consistent link with Alzheimer's disease, partly because blood pressure falls in the years before diagnosis. Diastolic hypertension showed no association in the four studies that reported it. |
| Quoted sentence | Moderate-quality evidence indicated that midlife hypertension was related to a 1.19- to 1.55-fold excess risk of cognitive disorders. | There was a significant association between systolic hypertension (>160 mm Hg) and AD (HR 1.25, 95CI 1.06 - 1.47, p = 0.…There was a significant association between systolic hypertension (>160 mm Hg) and AD (HR 1.25, 95CI 1.06 - 1.47, p = 0.0065). Similarly, for systolic hypertension > 140 mm Hg, there was a smaller but still significant association (HR 1.18, 95CI 1.02 - 1.35, p = 0.021). |
| Sources | ou_bp_cognition_2020 lancet_dementia2020 | lennon_htn_ad_2019 ou_bp_cognition_2020 |
| Review status | new_citation | adjust |
Re-checked on 18 Sep 2026. The filed 1.45 (1.28–1.64) appears in no cited source. The estimate now comes from a meta-analysis of midlife systolic hypertension and Alzheimer's disease (Lennon et al. 2019). The grade moves to Suggestive because the association is modest and genetic studies conflict. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Low educational attainment → Alzheimer's disease
low_education|alzheimers
| Field | Before | After |
| Quoted sentence | Dichotomous operationalisations indicated an increased risk for low education of 45% (95% CI:29-63%) for any dementia an…Dichotomous operationalisations indicated an increased risk for low education of 45% (95% CI:29-63%) for any dementia and 85% (95% CI:56-118%) for AD, however definitions of low education were heterogeneous, ranging from zero to 12 years. | The dichotomous association for low education from six prospective cohort and two case control studies was represented i…The dichotomous association for low education from six prospective cohort and two case control studies was represented in a summary odds ratio of 1.85 (95% CI: 1.56–2.18), as shown in GOfER 2 |
| Review status | adjust | confirmed |
Re-checked on 18 Sep 2026: the estimate matches the summary odds ratio of Maccora et al. 2020, from six cohort and two case-control studies. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Low socioeconomic position → Major depression
low_sep|depression
| Field | Before | After |
| Comparison | lowest vs highest socioeconomic position | poorer vs better neighbourhood socioeconomic conditions (longitudinal studies, high-income countries) |
| Comparison type | quantile | category |
| Caveat | Cash-transfer trials in low-income settings improve mental health, which supports causality unusually directly for a soc…Cash-transfer trials in low-income settings improve mental health, which supports causality unusually directly for a social exposure. Pooled across 14 longitudinal studies. Among studies with at least five years of follow-up the association disappears (OR 1.00, 0.95-1.06); the authors describe the evidence as inconsistent. | This estimate describes the socioeconomic conditions of the neighbourhood; a person's own income or education may carry…This estimate describes the socioeconomic conditions of the neighbourhood; a person's own income or education may carry a different risk. Among studies with at least five years of follow-up the association disappears (OR 1.00, 0.95 to 1.06). Randomised cash-transfer programmes in low- and middle-income countries reduced depression and anxiety slightly, and the benefit may fade after payments stop. |
Re-checked on 18 Sep 2026: the estimate matches its source, which pools longitudinal studies of neighbourhood socioeconomic conditions. The contrast is relabelled to that measure, because no eligible pooled estimate with an interval exists for a person's own socioeconomic position. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)1.3 (9 Sep 2026)
Low physical activity → Major depression
low_pa|depression
| Field | Before | After |
| Quoted sentence | Adults accumulating the recommended volume of 8.8 mMET hours per week had 25% (95% CI, 18%-32%) lower risk with diminish…Adults accumulating the recommended volume of 8.8 mMET hours per week had 25% (95% CI, 18%-32%) lower risk with diminishing potential benefits and higher uncertainty observed beyond that exposure level. | Depression | 0.82 (0.77-0.87) | 0.75 (0.68-0.82) | 0.72 (0.64-0.81) | 6.38 (4.25-8.63) | 11.53 (7.69-15.43) | 13.89 (8.44-19.25) |
| Review status | adjust | confirmed |
Re-checked on 18 Sep 2026: the estimate is the inverse of the published risk ratio at the recommended activity volume, 0.75 (0.68–0.82) (Pearce et al. 2022, Table 2, second column). review_note
Also changed in: 2.0 (23 Oct 2026)
Access to green space → Major depression
green_space|depression
| Field | Before | After |
| Caveat | empty | Greener neighbourhoods differ from others in income and in other ways that are hard to adjust for. Among cohort studies…Greener neighbourhoods differ from others in income and in other ways that are hard to adjust for. Among cohort studies pooled by a second meta-analysis the association was similar (odds ratio 0.91, 0.84 to 0.98), with substantial heterogeneity. |
| Quoted sentence | According to this meta-analysis, a 10% increase in the proportion of green space was linked to a lower risk of depressio…According to this meta-analysis, a 10% increase in the proportion of green space was linked to a lower risk of depression (merged OR (95% CI) = 0.963 (0.948, 0.979)) and anxiety (merged OR (95% CI) = 0.938 (0.858, 1.025)) and a 0.1 unit increase in NDVI was linked to a lower risk of depression (merged OR (95% CI) = 0.931 (0.887, 0.977)). | According to this meta-analysis, a 10% increase in the proportion of green space was linked to a lower risk of depressio…According to this meta-analysis, a 10% increase in the proportion of green space was linked to a lower risk of depression (merged OR (95% CI) = 0.963 (0.948, 0.979)) and anxiety (merged OR (95% CI) = 0.938 (0.858, 1.025)) and a 0.1 unit increase in NDVI was linked to a lower risk of depression (merged OR (95% CI) = 0.931 (0.887, 0.977)). |
| Sources | greenspace_depression_yang | greenspace_depression_yang zhang_green_psych_2024 |
| Review status | adjust | confirmed |
Re-checked on 18 Sep 2026: the displayed 0.93 (0.89–0.98) rounds the published 0.931 (0.887–0.977), and the quote now contains it. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Low physical activity → Osteoporotic fracture
low_pa|fracture
| Field | Before | After |
| Review status | adjust | confirmed |
Re-checked on 18 Sep 2026: the estimate is the inverse of the published 38% (31% to 44%) lower hip-fracture risk in active women, from 13 prospective cohorts: 1/0.62 = 1.61, 1/0.69 = 1.45, 1/0.56 = 1.79. review_note
Also changed in: 2.0 (23 Oct 2026)
Menopausal hormone therapy → Osteoporotic fracture
mht|fracture
| Field | Before | After |
| Estimate | 0.76 | 0.74 |
| Interval, upper | 0.83 | 0.8 |
| Comparison | combined oestrogen-progestogen vs placebo | hormone therapy (oestrogen with or without progestogen) vs control in randomised trials, all fractures |
| Grade | Convincing | Probable |
| Score (ESS) | 22.0 | 18.8 |
| Caveat | One of the few clear benefits confirmed by the WHI trial, though it does not outweigh the harms for most women taking it purely for prevention. | One of the few clear benefits of hormone therapy, though it does not outweigh the harms for most women taking it purely…One of the few clear benefits of hormone therapy, though it does not outweigh the harms for most women taking it purely for prevention. The protection may fade after treatment stops and appears smaller when treatment starts after age 60. In the largest trial, oestrogen plus progestogen reduced all clinical fractures (0.78, 0.71 to 0.86, moderate certainty) but raised the risks of breast cancer, stroke and blood clots. |
| Quoted sentence | Seven hundred thirty-three women (8.6%) in the estrogen-plus-progestin group and 896 women (11.1%) in the placebo group…Seven hundred thirty-three women (8.6%) in the estrogen-plus-progestin group and 896 women (11.1%) in the placebo group experienced a fracture (hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.69-0.83). | The overall relative risk of HT was 0.74 (95% confidence interval [CI] 0.69-0.80) for total fractures, 0.72 (95% CI 0.53…The overall relative risk of HT was 0.74 (95% confidence interval [CI] 0.69-0.80) for total fractures, 0.72 (95% CI 0.53-0.98) for hip fractures, and 0.63 (95% CI 0.44-0.91) for vertebral fractures. |
| Sources | whi whi_fracture | mht_fracture_zhu mht_cochrane2026 whi_fracture |
| Review status | confirmed | adjust |
Re-checked on 18 Sep 2026. The filed 0.76 (0.69–0.83) is correct for the WHI trial but rests on that single trial. A meta-analysis of 28 randomised trials gives 0.74 (0.69–0.80) for all fractures (Zhu et al. 2016). The current Cochrane review rates the fracture evidence moderate certainty, so the grade moves from Convincing to Probable. review_note
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Rheumatoid arthritis
smoking|ra
| Field | Before | After |
| Interval, lower | 1.28 | 1.2 |
| Interval, upper | 1.53 | 1.66 |
| Comparison | current smoker vs never smoker | current smoking of 10 cigarettes a day vs non-smokers |
| Comparison type | binary | category |
| Grade | Convincing | Probable |
| Score (ESS) | 31.1 | 24.8 |
| Caveat | Interacts strongly with HLA-DRB1 shared-epitope genotype for seropositive disease; a well-characterised gene-environment interaction. | The Burden of Proof analysis rates this pair at three stars, from six studies, and flags possible publication bias. Risk…The Burden of Proof analysis rates this pair at three stars, from six studies, and flags possible publication bias. Risk is higher in men and for rheumatoid-factor-positive disease: in one meta-analysis, current smokers had 1.87 times the odds of rheumatoid arthritis among men and 1.31 times among women. Smoking interacts strongly with the HLA-DRB1 shared-epitope genotype for seropositive disease. |
| Quoted sentence | For men, summary OR for ever, current and past smokers were 1.89 (95% CI 1.56 to 2.28), 1.87 (1.49 to 2.34) and 1.76 (1.…For men, summary OR for ever, current and past smokers were 1.89 (95% CI 1.56 to 2.28), 1.87 (1.49 to 2.34) and 1.76 (1.33 to 2.31), respectively. ... For women, summary OR for ever, current and past smokers were 1.27 (1.12 to 1.44), 1.31 (1.12 to 1.54) and 1.22 (1.06 to 1.40), respectively. | Rheumatoid arthritis | Cigarettes per day | 1.20 (1.10, 1.31) | 1.40 (1.20, 1.66) | 1.67 (1.31, 2.14) | 1.73 (1.34, 2.26…Rheumatoid arthritis | Cigarettes per day | 1.20 (1.10, 1.31) | 1.40 (1.20, 1.66) | 1.67 (1.31, 2.14) | 1.73 (1.34, 2.26) | 26.25 | 1.72 (1.34, 2.25) | 0.21 | 1.23 | 23.32 | 3 | 1 | 6 |
| Sources | smoke_ra_ma smoke_ra_dose_ma | bprf_smoking smoke_ra_ma smoke_ra_dose_ma |
| Review status | new_citation | adjust |
Re-checked on 18 Sep 2026. The filed 1.40 (1.28–1.53) matches no published estimate. The Burden of Proof smoking study, the only eligible source with an estimate for both sexes, gives 1.40 (1.20–1.66) at 10 cigarettes a day against non-smokers (Table 2; 1.67 at 20 a day) and rates the evidence three stars, so the grade moves from Convincing to Probable. review_note
Also changed in: 2.0 (23 Oct 2026)
Low seafood omega-3 intake → Age-related macular degeneration
low_omega3|amd
| Field | Before | After |
| Estimate | 1.2 | 1.41 |
| Interval, lower | 1.08 | 1.1 |
| Interval, upper | 1.33 | 1.82 |
| Comparison | lowest vs highest intake | lowest vs highest dietary omega-3 intake, late age-related macular degeneration |
| Score (ESS) | 8.9 | 14.2 |
| Caveat | The AREDS2 trial found no benefit from adding omega-3 to the antioxidant formulation. | The figure shown is for late AMD, the stage that threatens sight; for early AMD the equivalent figure is 1.16 (1.04 to 1…The figure shown is for late AMD, the stage that threatens sight; for early AMD the equivalent figure is 1.16 (1.04 to 1.30). The AREDS2 trial and a Cochrane review of supplement trials in people who already had AMD found no slowing of progression to advanced disease, and no trial has tested diet for prevention. |
| Review status | new_citation | adjust |
Re-checked on 18 Sep 2026. The filed 1.20 (1.08–1.33) matched neither stage in the meta-analysis. The estimate is now the inverse of its late AMD figure, 0.71 (0.55–0.91): 1/0.71 = 1.41, 1/0.91 = 1.10, 1/0.55 = 1.82. review_note
Also changed in: 2.0 (23 Oct 2026)
Type 2 diabetes (as a risk factor) → Cataract
t2d_exposure|cataract
| Field | Before | After |
| Estimate | 2.0 | 1.97 |
| Interval, lower | 1.75 | 1.45 |
| Interval, upper | 2.29 | 2.67 |
| Comparison | diabetes vs no diabetes | type 2 diabetes vs no diabetes, any cataract (mostly cross-sectional studies) |
| Grade | Probable | Limited |
| Score (ESS) | 34.6 | 12.8 |
| Caveat | empty | Most of the pooled studies compared how common cataract was in people with and without diabetes at one point in time, so…Most of the pooled studies compared how common cataract was in people with and without diabetes at one point in time, so the timing of the two conditions is unclear. People with diabetes also have more frequent eye examinations, which finds more cataracts. Cortical (1.68, 1.47 to 1.91) and posterior subcapsular (1.55, 1.27 to 1.90) cataract were raised, nuclear cataract less clearly (1.36, 0.97 to 1.90). |
| Review status | new_citation | adjust |
Re-checked on 18 Sep 2026. The published interval is 1.45–2.67 (1.75–2.29 was on file). Six of the eight pooled studies are cross-sectional, a design the framework does not accept as a source of estimates, and no meta-analysis of prospective studies was found, so the grade moves to Limited. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Nitrogen dioxide → Coronary heart disease
no2|chd
| Field | Before | After |
| Estimate | 1.11 | 1.05 |
| Interval, lower | 1.07 | 1.03 |
| Interval, upper | 1.16 | 1.08 |
| Comparison | per 10 ppb higher annual NO2, cardiovascular mortality | per 10 µg/m³ higher long-term NO2, death from ischaemic heart disease |
| Score (ESS) | 2.8 | 1.4 |
| Caveat | Hard to separate from PM2.5 and traffic noise, which share the same spatial pattern. | The estimate is for death from ischaemic heart disease. NO2 marks traffic pollution and tracks PM2.5 and road-traffic no…The estimate is for death from ischaemic heart disease. NO2 marks traffic pollution and tracks PM2.5 and road-traffic noise; in multi-pollutant models the association shrinks and is mostly non-significant. |
| Quoted sentence | The pooled HRs for cardiovascular and respiratory mortality per 10 ppb increment were 1.11 (95%CI: 1.07-1.16, n = 20 stu…The pooled HRs for cardiovascular and respiratory mortality per 10 ppb increment were 1.11 (95%CI: 1.07-1.16, n = 20 studies, I = 99.2%) and 1.05 (95%CI: 1.02-1.08, n = 17 studies, I = 94.6%), respectively. | Thirty-one studies reported results regarding exposure to NO2 and IHD mortality from which 20 were included in the meta-…Thirty-one studies reported results regarding exposure to NO2 and IHD mortality from which 20 were included in the meta-analysis estimating, a pooled RR 1.05 (95% CI: 1.03, 1.08) (Table 1). |
| Sources | no2_mortality who_air | who_aqg_o3_kasdagli no2_mortality_stieb |
Re-checked on 18 Sep 2026. The filed 1.11 (1.07–1.16) per 10 ppb was for all cardiovascular deaths. The review for the WHO air quality guidelines gives 1.05 (1.03–1.08) per 10 µg/m³ for ischaemic heart disease deaths, from 20 cohort studies (Kasdagli et al. 2024, Table 1). review_note
Also changed in: 2.0 (23 Oct 2026)
Gum disease → Type 2 diabetes
periodontitis|t2d
| Field | Before | After |
| Interval, lower | 1.14 | 1.13 |
| Interval, upper | 1.37 | 1.38 |
| Comparison | periodontitis vs healthy gums | periodontitis vs no periodontitis at baseline |
| Caveat | Periodontal treatment produces small improvements in HbA1c in trials, supporting a bidirectional relationship. | Periodontal treatment produces small improvements in HbA1c in trials. The relationship runs both ways: diabetes also rai…Periodontal treatment produces small improvements in HbA1c in trials. The relationship runs both ways: diabetes also raises the risk of periodontitis, and shared causes such as smoking and obesity may explain part of the link. |
| Quoted sentence | Severe periodontitis increased the incidence of T2DM by 53% (p = 0.000), and this result was stable. In contrast, the im…Severe periodontitis increased the incidence of T2DM by 53% (p = 0.000), and this result was stable. In contrast, the impact of mild periodontitis on T2DM incidence (RR = 1.28, p = 0.007) was less robust. | Across for 29 265 participants, pooled HR estimates indicated a 18–25% higher occurrence of newly incident type 2 diabet…Across for 29 265 participants, pooled HR estimates indicated a 18–25% higher occurrence of newly incident type 2 diabetes cases among individuals with periodontitis compared with those without periodontitis (figure 2A; appendix 2 p 14). |
| Sources | perio_t2d_wu oral_diabetes_lancet | oral_diabetes_lancet perio_t2d_wu |
| Review status | new_citation | adjust |
Re-checked on 18 Sep 2026: the pooled hazard ratio across five cohorts in the Lancet Public Health meta-analysis (Figure 2A) is 1.25 (1.13–1.38); the interval on file was 1.14–1.37. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Long-term NSAID use → Coronary heart disease
nsaids|chd
| Field | Before | After |
| Estimate | 1.3 | 1.76 |
| Interval, lower | 1.18 | 1.31 |
| Interval, upper | 1.43 | 2.37 |
| Comparison | regular non-aspirin NSAID use vs none | high-dose coxib vs placebo in randomised trials, major coronary events |
| Grade | Convincing | Probable |
| Score (ESS) | 23.7 | 31.1 |
| Caveat | Established by randomised trials and regulatory review; risk differs between agents, being highest for diclofenac and ro…Established by randomised trials and regulatory review; risk differs between agents, being highest for diclofenac and rofecoxib-type drugs and lowest for naproxen. | Risk depends on the drug and dose. In the same trials, high-dose diclofenac (1.70) and ibuprofen (2.22) also raised majo…Risk depends on the drug and dose. In the same trials, high-dose diclofenac (1.70) and ibuprofen (2.22) also raised major coronary events, while high-dose naproxen did not raise major vascular events (0.93). No trial synthesis gives a single figure for all NSAIDs. |
| Quoted sentence | The corresponding odds ratios (95% credible intervals) were 1.24 (0.91 to 1.82) for celecoxib, 1.48 (1.00 to 2.26) for i…The corresponding odds ratios (95% credible intervals) were 1.24 (0.91 to 1.82) for celecoxib, 1.48 (1.00 to 2.26) for ibuprofen, 1.50 (1.06 to 2.04) for diclofenac, 1.53 (1.07 to 2.33) for naproxen, and 1.58 (1.07 to 2.17) for rofecoxib. | Major vascular events were increased by about a third by a coxib (rate ratio [RR] 1·37, 95% CI 1·14-1·66; p=0·0009) or d…Major vascular events were increased by about a third by a coxib (rate ratio [RR] 1·37, 95% CI 1·14-1·66; p=0·0009) or diclofenac (1·41, 1·12-1·78; p=0·0036), chiefly due to an increase in major coronary events (coxibs 1·76, 1·31-2·37; p=0·0001; diclofenac 1·70, 1·19-2·41; p=0·0032). |
| Sources | nsaids_bally nsaids_trelle | nsaids_cnt2013 nsaids_bally nsaids_trelle |
| Review status | suspect | adjust |
Re-checked on 18 Sep 2026. The filed 1.30 (1.18–1.43) for all non-aspirin NSAIDs has no published source. The individual-participant meta-analysis of randomised trials gives 1.76 (1.31–2.37) for high-dose coxibs (CNT Collaboration 2013). For coxibs the trial evidence is conclusive; the link is graded Probable because the effect differs between drugs. review_note
Also changed in: 2.0 (23 Oct 2026)
Blood pressure treatment → Dementia (all-cause)
antihypertensives|dementia
| Field | Before | After |
| Caveat | empty | Among people with normal blood pressure, the same analysis found no association between antihypertensive use and dementi…Among people with normal blood pressure, the same analysis found no association between antihypertensive use and dementia, so the benefit applies to treating raised blood pressure. |
| Sources | ding_ahm_dementia_2020 lancet_dementia2020 | ding_ahm_dementia_2020 lancet_dementia |
| Review status | new_citation | confirmed |
Re-checked on 18 Sep 2026: the estimate matches the individual-participant analysis of six cohorts (Ding et al. 2020), which the 2024 Lancet Commission also reports. The citation moves from the 2020 to the 2024 Commission. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Statin treatment → Peripheral artery disease
statins|pad
| Field | Before | After |
| Estimate | 0.82 | 0.7 |
| Interval, lower | 0.76 | 0.6 |
| Interval, upper | 0.89 | 0.82 |
| Comparison | per 1 mmol/L LDL reduction | statin use vs none in people who already have PAD, major adverse limb events (amputation, graft occlusion or revascularisation) |
| Comparison type | per-unit | binary |
| Grade | Convincing | Probable |
| Score (ESS) | 17.3 | 21.1 |
| Trial and genetic evidence | Trial supportive; Genetic (MR) none; dose-response yes | Trial supportive; Genetic (MR) none; dose-response no |
| Caveat | empty | This concerns limb complications in people who already have PAD. Most of the 51 pooled studies compared statin users wit…This concerns limb complications in people who already have PAD. Most of the 51 pooled studies compared statin users with non-users; the 39% lower all-cause mortality they report is far larger than the 10% per 1 mmol/L seen in statin trials, a sign of healthy-user bias. A meta-analysis of five randomised trials of lipid-lowering therapy in PAD found fewer major adverse limb events (odds ratio 0.76, 0.66 to 0.87). |
| Quoted sentence | When both types of trial were combined, similar proportional reductions in major vascular events per 1·0 mmol/L LDL chol…When both types of trial were combined, similar proportional reductions in major vascular events per 1·0 mmol/L LDL cholesterol reduction were found in all types of patient studied (rate ratio [RR] 0·78, 95% CI 0·76-0·80; p<0·0001), including those with LDL cholesterol lower than 2 mmol/L on the less intensive or control regimen. | Statins reduced MALE incidence by 30% (pooled hazard ratio [HR]: 0.702; 95% confidence interval [CI]: 0.605-0.815) and a…Statins reduced MALE incidence by 30% (pooled hazard ratio [HR]: 0.702; 95% confidence interval [CI]: 0.605-0.815) and amputations by 35% (HR: 0.654; 95% CI: 0.522-0.819), all-cause mortality by 39% (pooled HR: 0.608, 95% CI: 0.543-0.680), CV death by 41% (HR: 0.594; 95% CI: 0.455-0.777), composite CV endpoints by 34% (pooled HR: 0.662; 95% CI: 0.591-0.741) and ischemic stroke by 28% (pooled HR: 0.718; 95% CI: 0.620-0.831). |
| Sources | ctt pad_statin_pastori pad_statin_sofat | pad_statin_pastori pad_statin_sofat lipid_male_rct_ma |
| Review status | suspect | adjust |
Re-checked on 18 Sep 2026. The filed 0.82 (0.76–0.89) per 1 mmol/L has no source, and the cholesterol trialists' analysis reports no PAD outcome. No eligible estimate exists for statins and new PAD, so the link now shows the pooled statin estimate for limb events in people with PAD, 0.702 (0.605–0.815) (Pastori et al. 2020), rounded outward to 0.70 (0.60–0.82). Randomised trials of lipid lowering point the same way. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Chronic psychological stress → Coronary heart disease
chronic_stress|chd
| Field | Before | After |
| Interval, lower | 1.15 | 1.12 |
| Interval, upper | 1.4 | 1.45 |
| Comparison | high vs low chronic stress exposure | high vs low perceived stress (self-reported) |
| Comparison type | quantile | category |
| Caveat | empty | Pools six prospective cohort studies that measured stress in different ways. Most did not account for depression or anxi…Pools six prospective cohort studies that measured stress in different ways. Most did not account for depression or anxiety, which often accompany stress and also raise heart risk. |
| Quoted sentence | Smoking (odds ratio 2.87 for current vs never, PAR 35.7% for current and former vs never), raised ApoB/ApoA1 ratio (3.25…Smoking (odds ratio 2.87 for current vs never, PAR 35.7% for current and former vs never), raised ApoB/ApoA1 ratio (3.25 for top vs lowest quintile), history of hypertension (1.91), diabetes (2.37), abdominal obesity (1.12 for top vs lowest tertile and 1.62 for middle vs lowest tertile), psychosocial factors (2.67, PAR 32.5%), daily consumption of fruits and vegetables (0.70), regular alcohol consumption (0.91), and regular physical activity (0.86), were all significantly related to acute myocardial infarction. | Meta-analysis yielded an aggregate risk ratio of 1.27 (95% confidence interval 1.12 to 1.45) for the magnitude of the re…Meta-analysis yielded an aggregate risk ratio of 1.27 (95% confidence interval 1.12 to 1.45) for the magnitude of the relation between high perceived stress and incident CHD. |
| Sources | interheart ipd_work | stress_chd_richardson |
| Review status | suspect | adjust |
Re-checked on 18 Sep 2026. The filed 1.27 (1.15–1.40) matched neither cited source: INTERHEART is a case-control study of a combined psychosocial index, and IPD-Work measures job strain, which has its own link. The estimate now comes from a meta-analysis of six prospective cohorts on perceived stress and incident coronary heart disease (118,696 people). review_note
Also changed in: 2.0 (23 Oct 2026)
Low educational attainment → Major depression
low_education|depression
| Field | Before | After |
| Estimate | 1.3 | 1.49 |
| Interval, lower | 1.18 | 1.16 |
| Interval, upper | 1.43 | 1.91 |
| Comparison | lowest vs highest education | less vs more education, older adults, new depression in later life |
| Score (ESS) | 11.7 | 15.6 |
| Caveat | empty | The relative risk comes from 12 prospective studies of older adults and applies to depression arising in later life. The…The relative risk comes from 12 prospective studies of older adults and applies to depression arising in later life. The odds ratio in the same sentence comes from cross-sectional studies. |
| Quoted sentence | Results indicated that low-SES individuals had higher odds of being depressed (odds ratio = 1.81, p < 0.001), but the od…Results indicated that low-SES individuals had higher odds of being depressed (odds ratio = 1.81, p < 0.001), but the odds of a new episode (odds ratio = 1.24, p = 0.004) were lower than the odds of persisting depression (odds ratio = 2.06, p < 0.001). A dose-response relation was observed for education and income. | The qualitative meta-analysis showed that, compared with old people with more education, those with less education had h…The qualitative meta-analysis showed that, compared with old people with more education, those with less education had higher risk for depression (odds risk (OR): 1.58, 95% confidence intervals (95% CI): 1.38-1.82; Relative risk (RR): 1.49, 95% CI: 1.16-1.91). |
| Sources | lorant_ses_depression | chang_education_depression_2010 lorant_ses_depression |
| Review status | new_citation | adjust |
Re-checked on 18 Sep 2026. The filed 1.30 (1.18–1.43) has no located source. The estimate now comes from the 12 prospective studies in a meta-analysis of education and late-life depression (Chang-Quan et al. 2010). review_note
Also changed in: 2.0 (23 Oct 2026)
High triglycerides → Type 2 diabetes
high_tg|t2d
| Field | Before | After |
| Estimate | 1.55 | 1.73 |
| Interval, lower | 1.4 | 1.31 |
| Interval, upper | 1.72 | 2.29 |
| Comparison | per 1 mmol/L higher triglycerides | fasting triglycerides above 1.7 mmol/L vs below |
| Comparison type | per-unit | category |
| Grade | Probable | Contested |
| Score (ESS) | 24.1 | 8.6 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) contradicts; dose-response yes |
| Caveat | empty | Raised triglycerides travel with insulin resistance and excess weight, and genetic studies suggest they are largely a co…Raised triglycerides travel with insulin resistance and excess weight, and genetic studies suggest they are largely a consequence of the processes leading to diabetes. Risk was higher above 2.3 mmol/L (1.82, 1.18 to 2.87) than at 1.7 to 2.3 mmol/L (1.42, 1.13 to 1.79). |
| Quoted sentence | Significant positive correlations were also confirmed for the lipid accumulation product (LAP) (RR = 2.94, 95% CI: 2.31,…Significant positive correlations were also confirmed for the lipid accumulation product (LAP) (RR = 2.94, 95% CI: 2.31, 3.73), the triglyceride glucose (TyG) index (RR = 2.51, 95% CI: 2.13, 2.95), the atherogenic index of plasma (AIP) (RR = 1.97, 95% CI: 1.54, 2.52), the visceral adiposity index (VAI) (RR = 1.77, 95% CI: 1.61, 1.94), the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio (RR = 1.51, 95% CI: 1.36, 1.69), and non-high-density lipoprotein cholesterol (non-HDL-C) (RR = 1.27, 95% CI: 1.07, 1.52). | We found that people with HTG had more than a 1.5-fold higher risk (HR: 1.73 [1.31; 2.29]) of developing T2DM. |
| Sources | lipid_t2d_umbrella mets_t2d_ford | htg_t2d_ma tg_t2d_mr_desilva |
| Review status | suspect | adjust |
Re-checked on 18 Sep 2026. The filed 1.55 (1.40–1.72) per 1 mmol/L has no source, and neither cited paper reports triglycerides alone. A 2025 meta-analysis of eight cohorts gives 1.73 (1.31–2.29) for triglycerides above 1.7 mmol/L. Mendelian randomisation finds genetically raised triglycerides do not increase diabetes risk, so the link is graded Contested. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Occupational silica dust → Chronic kidney disease
silica|ckd
| Field | Before | After |
| Estimate | 1.45 | 1.52 |
| Interval, lower | 1.22 | 1.16 |
| Interval, upper | 1.72 | 1.98 |
| Comparison | occupationally exposed vs not | workers in silica-exposed industries vs the general population, death from kidney disease (standardised mortality ratio) |
| Grade | Probable | Limited |
| Score (ESS) | 17.6 | 7.1 |
| Caveat | empty | The outcome is death from kidney disease compared with the general population, which death certificates record unreliabl…The outcome is death from kidney disease compared with the general population, which death certificates record unreliably. The excess differed between industries (pottery 2.15, 1.13 to 4.08; coal and iron-ore mining 0.99, 0.78 to 1.25) and did not rise clearly with dose. The review's authors say it may reflect diagnostic and methodological problems. |
| Quoted sentence | While the studies of cohorts exposed to silica found elevated SMRs for renal disease, no clear evidence of a dose-respon…While the studies of cohorts exposed to silica found elevated SMRs for renal disease, no clear evidence of a dose-response relationship emerged. The elevated risk may be attributed to diagnostic and methodological issues. | The combined analysis of the industry-based cohorts resulted in SMR = 1.52 (95% CI 1.16–1.98) (Fig. 3). |
| Review status | suspect | adjust |
Re-checked on 18 Sep 2026. The filed 1.45 (1.22–1.72) appears nowhere in the cited meta-analysis. It pools industrial cohorts into a standardised mortality ratio for kidney disease of 1.52 (1.16–1.98) (Möhner et al. 2017). The link now names that outcome and is graded Limited. review_note
Also changed in: 2.0 (23 Oct 2026)
Low cardiorespiratory fitness → Type 2 diabetes
low_fitness|t2d
| Field | Before | After |
| Comparison | per 1 MET lower cardiorespiratory fitness | per 1 MET lower cardiorespiratory fitness, adjusted for adiposity |
| Review status | adjust | confirmed |
Re-checked on 18 Sep 2026: the estimate is the inverse of the published 8% (6% to 10%) lower risk per 1 MET higher fitness, adjusted for adiposity (Tarp et al. 2019): 1/0.92 = 1.09, 1/0.94 = 1.06, 1/0.90 = 1.11. review_note
Also changed in: 2.0 (23 Oct 2026)
Current cigarette smoking → Multiple sclerosis
smoking|multiple_sclerosis
| Field | Before | After |
| Comparison | ever smoker vs never smoker | smokers vs non-smokers (ever or current smoking, as each study reported it) |
| Grade | Probable | Contested |
| Score (ESS) | 11.9 | 3.7 |
| Trial and genetic evidence | Trial none; Genetic (MR) none; dose-response yes | Trial none; Genetic (MR) null; dose-response yes |
| Caveat | empty | Observational studies consistently link smoking with a higher risk of multiple sclerosis, and the Burden of Proof analys…Observational studies consistently link smoking with a higher risk of multiple sclerosis, and the Burden of Proof analysis rates the evidence at three stars. Two Mendelian randomisation studies using genetic markers of smoking found no clear causal effect (lifetime smoking 1.10, 0.87 to 1.40). The pooled figure also includes studies that recorded smoking status after diagnosis. |
| Quoted sentence | Only three of the 11 significant meta-analyses (p<0·001) included more than 1000 cases, had 95% prediction intervals exc…Only three of the 11 significant meta-analyses (p<0·001) included more than 1000 cases, had 95% prediction intervals excluding the null value, and were not suggestive of large heterogeneity (I(2)<50%), small-study effects (p for Egger's test >0·10), or excess significance (p>0·05). | These were IgG seropositivity to Epstein-Barr virus nuclear antigen (EBNA) (random effects odds ratio [OR] 4·46, 95% CI…These were IgG seropositivity to Epstein-Barr virus nuclear antigen (EBNA) (random effects odds ratio [OR] 4·46, 95% CI 3·26-6·09; p for effect size=1·5 × 10(-19); I(2)=43%), infectious mononucleosis (2·17, 1·97-2·39; p=3·1 × 10(-50); I(2)=0%), and smoking (1·52, 1·39-1·66; p=1·7 × 10(-18;)I(2)=0%). |
| Sources | ms_umbrella_belbasis | ms_umbrella_belbasis bprf_smoking smoking_ms_mr_mitchell smoking_ms_mr_vandebergh |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026: the estimate matches the umbrella review, and the quote now carries the number. The grade moves from Probable to Contested because two independent Mendelian randomisation studies found no causal effect. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
H. pylori eradication therapy → Peptic ulcer
hp_eradication|peptic_ulcer
| Field | Before | After |
| Grade | Convincing | Probable |
| Score (ESS) | 27.5 | 22.0 |
| Caveat | Cochrane graded the trial evidence very low quality despite the large effect. This is the effect of treatment; carrying…Cochrane graded the trial evidence very low quality despite the large effect. This is the effect of treatment; carrying H. pylori raises ulcer risk, roughly doubling it among people taking NSAIDs (odds ratio 2.12, 1.68-2.67). | Cochrane graded this trial evidence very low quality despite the size of the effect. The outcome is the return of a duod…Cochrane graded this trial evidence very low quality despite the size of the effect. The outcome is the return of a duodenal ulcer in people who have already had one; eradication also prevented gastric ulcer recurrence (0.31, 0.22 to 0.45). This is the effect of treatment; carrying H. pylori raises ulcer risk, roughly doubling it among people taking NSAIDs (odds ratio 2.12, 1.68 to 2.67). |
Re-checked on 18 Sep 2026: the estimate matches the Cochrane review (27 trials). Cochrane rates the certainty of this comparison very low, so the grade moves from Convincing to Probable. review_note
Also changed in: 2.0 (23 Oct 2026)1.3 (9 Sep 2026)
Tight blood sugar control → Diabetic retinopathy
glucose_control|diabetic_retinopathy
| Field | Before | After |
| Estimate | 0.79 | 0.85 |
| Interval, lower | 0.68 | 0.78 |
| Interval, upper | 0.92 | 0.93 |
| Comparison | intensive glucose-lowering targets vs conventional targets in type 2 diabetes | intensive vs standard glucose lowering in type 2 diabetes, retinopathy as each trial defined it |
| Grade | Convincing | Probable |
| Score (ESS) | 10.0 | 6.0 |
| Caveat | The same trials show the cost of tight targets: severe hypoglycaemia more than doubled (2.18, 1.53 to 3.11) and serious…The same trials show the cost of tight targets: severe hypoglycaemia more than doubled (2.18, 1.53 to 3.11) and serious adverse events rose (1.06, 1.02 to 1.10), with no effect on death from any cause. | Retinopathy was counted as each trial defined it. All trials were open-label, and the review rated its evidence moderate…Retinopathy was counted as each trial defined it. All trials were open-label, and the review rated its evidence moderate certainty at best. Severe hypoglycaemia rose (1.88, 1.24 to 2.84). Some pooled trials, such as Steno-2 and Look AHEAD, also intensified blood pressure, lipid or lifestyle treatment alongside glucose lowering. Servier funded the meta-analysis. |
| Quoted sentence | Targeting intensive versus conventional glycaemic control seemed to reduce the risks of non-fatal myocardial infarction…Targeting intensive versus conventional glycaemic control seemed to reduce the risks of non-fatal myocardial infarction (RR 0.87, 95% CI 0.77 to 0.98; P = 0.02; 30,417 participants, 14 trials), amputation of a lower extremity (RR 0.65, 95% CI 0.45 to 0.94; P = 0.02; 11,200 participants, 11 trials), as well as the risk of developing a composite outcome of microvascular diseases (RR 0.88, 95% CI 0.82 to 0.95; P = 0.0008; 25,927 participants, 6 trials), nephropathy (RR 0.75, 95% CI 0.59 to 0.95; P = 0.02; 28,096 participants, 11 trials), retinopathy (RR 0.79, 95% CI 0.68 to 0.92; P = 0.002; 10,300 participants, 9 trials), and the risk of retinal photocoagulation (RR 0.77, 95% CI 0.61 to 0.97; P = 0.03; 11,212 participants, 8 trials). | Intensive versus standard therapy reduced the risk of retinopathy (HR 0.85; 0.78-0.93), nephropathy (HR 0.71; 0.58-0.87)…Intensive versus standard therapy reduced the risk of retinopathy (HR 0.85; 0.78-0.93), nephropathy (HR 0.71; 0.58-0.87) and composite microvascular outcomes (HR 0.88; 0.77-1.00). |
| Sources | cochrane_glycaemic | glucose_intensive_kunutsor |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026. The Cochrane review behind this link (2013) was withdrawn in 2015. It is replaced by a 2024 meta-analysis of 11 trials of intensive glucose lowering (Kunutsor et al.): 0.85 (0.78–0.93) for retinopathy. The grade moves from Convincing to Probable because the review rates the certainty moderate at best. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Tight blood sugar control → Chronic kidney disease
glucose_control|ckd
| Field | Before | After |
| Estimate | 0.75 | 0.71 |
| Interval, lower | 0.59 | 0.58 |
| Interval, upper | 0.95 | 0.87 |
| Comparison | intensive glucose-lowering targets vs conventional targets in type 2 diabetes | intensive vs standard glucose lowering in type 2 diabetes, nephropathy as each trial defined it |
| Score (ESS) | 9.2 | 10.4 |
| Caveat | The pooled outcome is nephropathy as each trial defined it, most often new or worsening protein in the urine rather than…The pooled outcome is nephropathy as each trial defined it, most often new or worsening protein in the urine rather than kidney failure, and the trial sequential analysis could not confirm a 10% reduction. | Nephropathy was counted as each trial defined it, and only three trials reported it. Doubling of serum creatinine, a har…Nephropathy was counted as each trial defined it, and only three trials reported it. Doubling of serum creatinine, a harder kidney endpoint, did not fall significantly (0.92, 0.70 to 1.21). Some pooled trials, such as Steno-2, also intensified blood pressure and lipid treatment, which could account for part of the benefit. Servier funded the meta-analysis. |
| Quoted sentence | nephropathy (RR 0.75, 95% CI 0.59 to 0.95; P = 0.02; 28,096 participants, 11 trials) | Intensive versus standard therapy reduced the risk of retinopathy (HR 0.85; 0.78-0.93), nephropathy (HR 0.71; 0.58-0.87)…Intensive versus standard therapy reduced the risk of retinopathy (HR 0.85; 0.78-0.93), nephropathy (HR 0.71; 0.58-0.87) and composite microvascular outcomes (HR 0.88; 0.77-1.00). |
| Sources | cochrane_glycaemic | glucose_intensive_kunutsor |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026. The Cochrane review behind this link (2013) was withdrawn in 2015. It is replaced by a 2024 meta-analysis of 11 trials of intensive glucose lowering (Kunutsor et al.): 0.71 (0.58–0.87) for nephropathy. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
High blood pressure → Erectile dysfunction
high_sbp|erectile_dysfunction
| Field | Before | After |
| Comparison | people with high blood pressure vs people without, adjusted for obesity, lipids, alcohol, activity, smoking and education | people with high blood pressure vs people without, adjusted for obesity, lipids, alcohol, activity, smoking and education (cross-sectional studies) |
| Grade | Probable | Limited |
| Score (ESS) | 12.5 | 4.7 |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026: the estimate matches its source, a meta-analysis of 18 cross-sectional studies. The framework does not accept cross-sectional pooling as a source of estimates, and no meta-analysis of prospective studies was found, so the grade moves to Limited. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Binge drinking → Coronary heart disease
binge_drinking|chd
| Field | Before | After |
| Grade | Suggestive | Limited |
| Score (ESS) | 3.0 | 1.7 |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026: the estimate matches its source. The interval includes no effect, so the link is graded Limited under the dataset's rule for null results. review_note
Also changed in: 2.0 (23 Oct 2026)1.3 (18 Sep 2026)1.3 (9 Sep 2026)
Cold weather and cold spells → COPD
cold_spells|copd
| Field | Before | After |
| Estimate | 1.21 | 1.35 |
| Interval, lower | 0.97 | 1.22 |
| Interval, upper | 1.51 | 1.5 |
| Comparison | respiratory deaths during cold spells vs other days | extreme cold, as each study defined it, vs other temperatures; COPD illness or death |
| Score (ESS) | 4.7 | 6.5 |
| Caveat | The interval crosses no effect and rests on only four studies. The outcome is respiratory death during cold spells, whic…The interval crosses no effect and rests on only four studies. The outcome is respiratory death during cold spells, which includes pneumonia and other conditions as well as COPD. | The outcome is COPD illness or death during or shortly after extreme cold, which mainly reflects flare-ups in people who…The outcome is COPD illness or death during or shortly after extreme cold, which mainly reflects flare-ups in people who already have COPD. The figures come from the authors' published correction; for deaths alone the figure is 1.28 (1.12 to 1.45), and for illness alone 1.47 (1.26 to 1.71). |
| Quoted sentence | respiratory diseases (1.21; 95% CI: 0.97, 1.51; 8 estimates from four studies) | We observed that extreme heat increased the relative risk (RR) for COPD morbimortality by 1.19-fold (95 % CI: 1.09-1.29;…We observed that extreme heat increased the relative risk (RR) for COPD morbimortality by 1.19-fold (95 % CI: 1.09-1.29; p < 0.05), and extreme cold increased the RR by 1.35-fold (95 % CI: 1.22-1.50; p < 0.05). |
| Sources | coldspells_ryti | extreme_temp_copd_tran extreme_temp_copd_tran_corr gbd2021rf |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026. The filed 1.21 (0.97–1.51) was for all respiratory deaths during cold spells. A 2025 meta-analysis gives a COPD-specific estimate, 1.35 (1.22–1.50) in its published correction. review_note
Also changed in: 2.0 (23 Oct 2026)1.3 (18 Sep 2026)1.3 (9 Sep 2026)
Non-sugar sweeteners → Type 2 diabetes
nonsugar_sweeteners|t2d
| Field | Before | After |
| Review status | empty | confirmed |
Re-checked on 18 Sep 2026: the estimate matches Table 2 of the meta-analysis (Imamura et al. 2015), 1.08 (1.02–1.15) per daily serving after adjustment for adiposity; the abstract gives it as 8% (2% to 15%). review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (21 Oct 2026)
Having been born preterm → Chronic kidney disease
preterm_birth|ckd
| Field | Before | After |
| Comparison | born before 37 weeks vs at full term | born before 37 weeks vs at full term (one national cohort) |
| Grade | Probable | Limited |
| Score (ESS) | 15.4 | 5.8 |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026: the estimate matches its source, a single national cohort of 4.19 million Swedish births. No pooled estimate exists, and the framework admits a single study only as supporting evidence, so the grade moves to Limited. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Having been born preterm → Type 2 diabetes
preterm_birth|t2d
| Field | Before | After |
| Estimate | 1.49 | 1.51 |
| Interval, lower | 1.31 | 1.32 |
| Interval, upper | 1.68 | 1.72 |
| Comparison | born before 37 weeks vs at full term, diagnosed between ages 18 and 43 | born preterm (before 37 weeks) vs at term |
| Grade | Probable | Suggestive |
| Score (ESS) | 11.5 | 8.1 |
| Caveat | From the same Swedish cohort of 4.19 million births. The association was stronger in women (1.75, 1.47 to 2.09) than men…From the same Swedish cohort of 4.19 million births. The association was stronger in women (1.75, 1.47 to 2.09) than men (1.28, 1.08 to 1.53), and sibling comparisons suggested shared family factors explain only part of it. | Only five studies with 1,898 cases contributed. The largest single study, a Swedish national cohort, found a similar ris…Only five studies with 1,898 cases contributed. The largest single study, a Swedish national cohort, found a similar risk at ages 18 to 43 (1.49, 1.31 to 1.68), stronger in women (1.75) than in men (1.28), and sibling comparisons suggested that shared family factors explain only part of it. |
| Quoted sentence | Adjusted HRs for type 1 and type 2 diabetes at age <18 years associated with preterm birth were 1.21 (95% CI, 1.14, 1.28…Adjusted HRs for type 1 and type 2 diabetes at age <18 years associated with preterm birth were 1.21 (95% CI, 1.14, 1.28) and 1.26 (95% CI, 1.01, 1.58), respectively, and at age 18-43 years were 1.24 (95% CI, 1.13, 1.37) and 1.49 (95% CI, 1.31, 1.68), respectively, compared with full-term birth. | Preterm birth was also significantly associated with increased risk of type 2 diabetes (OR = 1.51, 95% CI = 1.32-1.72),…Preterm birth was also significantly associated with increased risk of type 2 diabetes (OR = 1.51, 95% CI = 1.32-1.72), with no evidence of (I(2) = 0.0%, P = 0.557). |
| Sources | preterm_diabetes_crump | preterm_t2d_li preterm_diabetes_crump |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026. The link rested on a single national cohort, which the framework admits only as supporting evidence. A meta-analysis of five studies gives 1.51 (1.32–1.72) (Li et al. 2014). Confounding by maternal and family factors is only partly addressed, so the grade is Suggestive. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Low cardiorespiratory fitness → Anxiety disorders
low_fitness|anxiety_disorders
| Field | Before | After |
| Comparison | lowest vs highest third of cardiorespiratory fitness | lowest vs highest third of cardiorespiratory fitness; outcome is depression or anxiety disorder, pooled together |
| Grade | Probable | Limited |
| Score (ESS) | 11.2 | 4.2 |
| Caveat | The outcome pooled was common mental health disorders, which combines anxiety and depression rather than separating them…The outcome pooled was common mental health disorders, which combines anxiety and depression rather than separating them. Four studies contributed and heterogeneity was 85%. Low fitness can also be a consequence of early symptoms. | The source pooled anxiety and depression together because too few studies reported anxiety alone; four studies contribut…The source pooled anxiety and depression together because too few studies reported anxiety alone; four studies contributed and heterogeneity was 85%. The largest single study of anxiety, in Swedish male conscripts, reported a similar hazard ratio (1.48, 1.36 to 1.60) for low compared with high fitness. Low fitness can also follow early symptoms. |
| Quoted sentence | We found that low CRF (HR = 1.47, [95% CI 1.23 - 1.76] p < 0.001 I = 85.1) and medium CRF (HR = 1.23, [95% CI 1.09 - 1.3…We found that low CRF (HR = 1.47, [95% CI 1.23 - 1.76] p < 0.001 I = 85.1) and medium CRF (HR = 1.23, [95% CI 1.09 - 1.38] p < 0.001 I = 87.20) CRF are associated with a 47% and 23% greater risk of a common mental health disorders respectively, compared with high CRF. | We found that low CRF (HR = 1.47, [95% CI 1.23 - 1.76] p < 0.001 I2 = 85.1) and medium CRF (HR = 1.23, [95% CI 1.09 - 1.…We found that low CRF (HR = 1.47, [95% CI 1.23 - 1.76] p < 0.001 I2 = 85.1) and medium CRF (HR = 1.23, [95% CI 1.09 - 1.38] p < 0.001 I2 = 87.20) CRF are associated with a 47% and 23% greater risk of a common mental health disorders respectively, compared with high CRF. |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026. No pooled estimate exists for anxiety disorders alone: the source had too few studies to pool them. The link keeps its combined depression-or-anxiety estimate, now labelled as such, and is graded Limited. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Type 2 diabetes (as a risk factor) → Erectile dysfunction
t2d_exposure|erectile_dysfunction
| Field | Before | After |
| Comparison | men with diabetes vs healthy controls | men with diabetes vs healthy controls, prevalence of erectile dysfunction |
| Grade | Probable | Limited |
| Score (ESS) | 20.5 | 7.7 |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026: the estimate matches its source. It compares how common erectile dysfunction is in men with and without diabetes, from eight comparisons within a prevalence meta-analysis. No meta-analysis of prospective studies was found, so the grade moves to Limited. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
DASH eating pattern → Coronary heart disease
dash_diet|chd
| Field | Before | After |
| Estimate | 0.8 | 0.82 |
| Interval, upper | 0.82 | 0.87 |
| Comparison | highest vs lowest adherence to a DASH-style healthy eating pattern | higher vs lower adherence to the DASH diet |
| Score (ESS) | 7.7 | 7.0 |
| Caveat | This pooled three closely related diet-quality scores rather than DASH alone, and the outcome combined cardiovascular in…This pooled three closely related diet-quality scores rather than DASH alone, and the outcome combined cardiovascular incidence with cardiovascular death. People who score well on these diets differ in many other ways; the authors rated the credibility of the evidence moderate. | The estimate comes from seven cohort studies. People whose diet is closest to the DASH pattern differ from others in man…The estimate comes from seven cohort studies. People whose diet is closest to the DASH pattern differ from others in many ways the studies could only partly adjust for. |
| Quoted sentence | Diets of the highest quality, as assessed by the Healthy Eating Index, Alternate Healthy Eating Index, and Dietary Appro…Diets of the highest quality, as assessed by the Healthy Eating Index, Alternate Healthy Eating Index, and Dietary Approaches to Stop Hypertension scores, were inversely associated with risk of all-cause mortality (RR 0.80, 95% CI 0.79 to 0.82, I= 68%, n= 23), cardiovascular disease incidence or mortality (RR 0.80, 95% CI 0.78 to 0.82, I= 59%, n= 45), cancer incidence or mortality (RR 0.86, 95% CI 0.84 to 0.89, I= 73%, n= 45), incidence of type 2 diabetes (RR 0.81, 95% CI 0.78 to 0.85, I= 76%, n= 16), and incidence of neurodegenerative diseases (RR 0.82, 95% CI 0.75 to 0.89, I= 71%, n= 12). | Compared to lower adherence, higher adherence to the DASH diet was associated a decreased risk of CAD (RR 0.82, 95% conf…Compared to lower adherence, higher adherence to the DASH diet was associated a decreased risk of CAD (RR 0.82, 95% confidence interval [CI]: 0.78-0.87). |
| Sources | dietquality_morze dash_htn_ma | dash_cad_yang dash_cvd_meta |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026. The filed 0.80 (0.78–0.82) pooled three diet-quality scores for all cardiovascular disease, and the cited DASH meta-analysis on blood pressure did not study coronary disease. The estimate now comes from a meta-analysis of the DASH diet and coronary artery disease in seven prospective cohorts; an earlier meta-analysis gives 0.79 (0.71–0.88). review_note
Also changed in: 2.0 (23 Oct 2026)
DASH eating pattern → Dementia (all-cause)
dash_diet|dementia
| Field | Before | After |
| Estimate | 0.82 | 0.8 |
| Interval, lower | 0.75 | 0.6 |
| Interval, upper | 0.89 | 1.06 |
| Comparison | highest vs lowest adherence to a DASH-style healthy eating pattern | highest vs lowest adherence to the DASH diet, older adults |
| Grade | Suggestive | Limited |
| Score (ESS) | 4.8 | 2.9 |
| Caveat | The outcome pooled neurodegenerative diseases broadly rather than dementia alone, twelve studies contributed, and hetero…The outcome pooled neurodegenerative diseases broadly rather than dementia alone, twelve studies contributed, and heterogeneity was 71%. Diet is recorded years before diagnosis, but early brain changes can alter eating long before dementia is recognised. | The confidence interval includes no effect. Diet was recorded in older adults, and early brain changes can alter eating…The confidence interval includes no effect. Diet was recorded in older adults, and early brain changes can alter eating before dementia is recognised. The 2024 Lancet Commission judged the evidence on unhealthy diet too inconsistent to list it as a modifiable risk factor. |
| Quoted sentence | incidence of neurodegenerative diseases (RR 0.82, 95% CI 0.75 to 0.89, I= 71%, n= 12) | The pooled HR in the MED diet was 0.85 (95% CI: 0.71-1.03) based on 51 581 participants, while in the DASH diet and the…The pooled HR in the MED diet was 0.85 (95% CI: 0.71-1.03) based on 51 581 participants, while in the DASH diet and the MIND diet with 36 123 and 18 328 participants, the pooled HRs were 0.80 (95% CI: 0.60-1.06) and 0.78 (95% CI: 0.68-0.89), respectively. |
| Sources | dietquality_morze | wang_diet_dementia_2026 |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026. The filed 0.82 (0.75–0.89) pooled three diet-quality scores against neurodegenerative diseases in general. The DASH-specific estimate for dementia, from a 2026 meta-analysis of cohort studies, is 0.80 (0.60–1.06); the interval includes no effect, so the grade is Limited. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Tight blood sugar control → Coronary heart disease
glucose_control|chd
| Field | Before | After |
| Estimate | 0.87 | 0.84 |
| Interval, lower | 0.77 | 0.75 |
| Interval, upper | 0.98 | 0.94 |
| Comparison | intensive glucose-lowering targets vs conventional targets in type 2 diabetes, outcome non-fatal heart attack | intensive vs standard glucose lowering in type 2 diabetes, outcome non-fatal heart attack |
| Score (ESS) | 5.3 | 6.3 |
| Caveat | Trial sequential analysis could not confirm this reduction, there was no effect on cardiovascular death (1.06, 0.94 to 1…Trial sequential analysis could not confirm this reduction, there was no effect on cardiovascular death (1.06, 0.94 to 1.21) or death from any cause, and severe hypoglycaemia more than doubled. | The benefit is confined to non-fatal heart attacks: all heart attacks combined (0.92, 0.80 to 1.05), cardiovascular deat…The benefit is confined to non-fatal heart attacks: all heart attacks combined (0.92, 0.80 to 1.05), cardiovascular death (1.03, 0.89 to 1.19) and major cardiovascular events (0.97, 0.92 to 1.03) did not fall. Severe hypoglycaemia rose (1.88, 1.24 to 2.84). All 11 trials were open-label, and some, such as Steno-2 and Look AHEAD, also intensified blood pressure, lipid or lifestyle treatment alongside glucose lowering. Servier funded the meta-analysis. |
| Quoted sentence | Targeting intensive versus conventional glycaemic control seemed to reduce the risks of non-fatal myocardial infarction…Targeting intensive versus conventional glycaemic control seemed to reduce the risks of non-fatal myocardial infarction (RR 0.87, 95% CI 0.77 to 0.98; P = 0.02; 30,417 participants, 14 trials) | Intensive versus standard therapy reduced the risk of non-fatal myocardial infarction (MI) (HR 0.84; 95% CI 0.75-0.94) w…Intensive versus standard therapy reduced the risk of non-fatal myocardial infarction (MI) (HR 0.84; 95% CI 0.75-0.94) with no difference in the risk of major adverse cardiovascular events (HR 0.97; 95% CI 0.92-1.03) and other adverse cardiovascular outcomes. |
| Sources | cochrane_glycaemic | glucose_intensive_kunutsor |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026. The Cochrane review behind this link (2013) was withdrawn in 2015. It is replaced by a 2024 meta-analysis of 11 trials of intensive glucose lowering (Kunutsor et al.), which gives 0.84 (0.75–0.94) for non-fatal heart attack. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Tight blood sugar control → Peripheral artery disease
glucose_control|pad
| Field | Before | After |
| Estimate | 0.65 | 0.91 |
| Interval, lower | 0.45 | 0.8 |
| Interval, upper | 0.94 | 1.05 |
| Comparison | intensive glucose-lowering targets vs conventional targets in type 2 diabetes, outcome lower-limb amputation | intensive vs standard glucose lowering in type 2 diabetes, outcome peripheral vascular disease |
| Grade | Probable | Limited |
| Score (ESS) | 12.1 | 1.4 |
| Caveat | The outcome counted is amputation, an end consequence of peripheral artery disease and foot ulceration in diabetes, rath…The outcome counted is amputation, an end consequence of peripheral artery disease and foot ulceration in diabetes, rather than the artery disease itself. Eleven trials and a modest number of events, so the interval is wide. | The interval includes no effect. Amputations were not clearly reduced either (0.89, 0.63 to 1.26). The earlier figure of…The interval includes no effect. Amputations were not clearly reduced either (0.89, 0.63 to 1.26). The earlier figure of 0.65 for amputation came from a review that has since been withdrawn. Servier funded the meta-analysis. |
| Quoted sentence | amputation of a lower extremity (RR 0.65, 95% CI 0.45 to 0.94; P = 0.02; 11,200 participants, 11 trials) | (g) no strong evidence of a reduction in the risk of peripheral vascular disease and amputations [HRs (95% CIs) of 0.91…(g) no strong evidence of a reduction in the risk of peripheral vascular disease and amputations [HRs (95% CIs) of 0.91 (0.80-1.05) and 0.89 (0.63-1.26), respectively] (Figure 2; Appendix S9) |
| Sources | cochrane_glycaemic | glucose_intensive_kunutsor |
| Review status | empty | adjust |
Re-checked on 18 Sep 2026. The Cochrane review behind this link (2013) was withdrawn in 2015. Its replacement, a 2024 meta-analysis of 11 trials (Kunutsor et al.), reports peripheral vascular disease directly: 0.91 (0.80–1.05). The interval includes no effect, so the grade moves from Probable to Limited. review_note
Also changed in: 2.0 (23 Oct 2026)1.4 (9 Oct 2026)
Heavy alcohol use → Fatty liver disease (MASLD)
alcohol_heavy|masld
Link removed (rr 1.18 grade Contested).
Batch 4 of the 18 Sep 2026 audit follow-up: No estimate can exist for this pair: heavy drinking excludes a diagnosis of MASLD, and the only pooled estimate attached was for light drinking. Re-checked against the source. corrections.json remove_links
Hepatitis C virus → Liver cirrhosis
hcv|cirrhosis
Link removed (rr 12.0 grade Convincing).
Batch 4 of the 18 Sep 2026 audit follow-up: Uncited; no eligible source reports a relative risk of cirrhosis for chronic hepatitis C infection against no infection. Hepatitis C causes cirrhosis; the literature measures it as incidence among infected people and attributable fractions, which do not fit this dataset's relative-risk format. Re-checked against the source. corrections.json remove_links
Also changed in: 1.3 (9 Sep 2026)
Hepatitis B virus → Liver cirrhosis
hbv|cirrhosis
Link removed (rr 8.5 grade Convincing).
Batch 4 of the 18 Sep 2026 audit follow-up: Uncited; no eligible source reports a relative risk of cirrhosis for chronic hepatitis B infection against no infection. Hepatitis B causes cirrhosis; the literature measures it as incidence among infected people and attributable fractions, which do not fit this dataset's relative-risk format. Re-checked against the source. corrections.json remove_links
Also changed in: 1.3 (9 Sep 2026)
Current cigarette smoking → Liver cirrhosis
smoking|cirrhosis
Link removed (rr 1.4 grade Probable).
Batch 4 of the 18 Sep 2026 audit follow-up: No meta-analysis, pooled consortium or credible Mendelian randomisation estimate exists, and the filed 1.40 (1.25–1.57) appears in neither cited cohort. Re-checked against the source. corrections.json remove_links
Diesel engine exhaust → COPD
diesel|copd
Link removed (rr 1.3 grade Probable).
Batch 4 of the 18 Sep 2026 audit follow-up: No meta-analysis, pooled consortium or adjudicating synthesis gives an estimate for diesel exhaust and COPD, and the filed 1.30 (1.15–1.47) appears in none of the four cited sources. Re-checked against the source. corrections.json remove_links
Occupational solvents → Asthma (adult)
occ_solvents|asthma
Link removed (rr 1.45 grade Probable).
Batch 4 of the 18 Sep 2026 audit follow-up: Uncited, and no eligible pooled estimate exists for occupational organic solvents and adult asthma. Re-checked against the source. corrections.json remove_links
Also changed in: 1.3 (9 Sep 2026)
Long-term NSAID use → Inflammatory bowel disease
nsaids|ibd
Link removed (rr 1.42 grade Limited).
Batch 4 of the 18 Sep 2026 audit follow-up: No pooled estimate exists for NSAID use and developing inflammatory bowel disease; the only meta-analysis concerns flares of existing disease and is null. Re-checked against the source. corrections.json remove_links
Also changed in: 1.3 (18 Sep 2026)1.3 (9 Sep 2026)
Low socioeconomic position → COPD
low_sep|copd
Link removed (rr 1.6 grade Probable).
Uncited, and no eligible pooled estimate exists for socioeconomic position and COPD. Batch 4 of the 18 Sep 2026 audit follow-up (DECISIONS-2026-09-18.md): re-checked against the source. corrections.json remove_links
Also changed in: 1.3 (9 Sep 2026)